Conditions: Anthrax
Keywords: Antibiotics Pharmacokinetics Vaccine Ciprofloxacin Doxycycline CPG 7909 Bacillus anthracis Anthrax Vaccine Adsorbed Post-exposure Prophylaxis Adjuvant
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 210
Healthy volunteers: yes

Brief summary:
This study is designed to evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose schedule of AV7909 administered two weeks apart.

Detailed description:
This is a Phase 2, open-label, multicenter, randomized trial designed to evaluate the pharmacokinetic profile, immunogenicity, and safety of AV7909 and ciprofloxacin or doxycycline when administered concomitantly in healthy adults for an indication of post-exposure prophylaxis (PEP) of anthrax.

Healthy adults between 18 to 45 years of age (inclusive) will sign and date an informed consent form and then be screened for eligibility for participation in the study 2 to 28 days prior to randomization. Participants meeting the entry criteria will be randomized 1:1:1 to one of the three study groups (AV7909 + ciprofloxacin, AV7909 + doxycycline and AV7909 only) on Day 1.

Subjects randomized into Groups 1 \& 2 will be assigned to subgroups. Subgroup A will be assigned to the antibiotic PK treatment group first, while subgroup B will be assigned to the antibiotic non-PK treatment group.

Participants will be evaluated for safety through Day 51 \[or the early withdrawal visit (EWV)\], as assessed by clinical laboratory tests (hematology, serum chemistry, and urinalysis), monitoring of Adverse Events (AEs) including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs), vital signs, and physical examinations. Adverse Events of Special Interest are adverse events associated with autoimmune disease as defined by the Center for Biologics Evaluation and Research, and might represent a safety signal for vaccine-associated autoimmunity. Reactogenicity (solicited systemic and injection site reactions) will be assessed daily by the participants using electronic diaries (e-diaries) after each vaccination. The e-diary will also be used to record self-administration of antibiotics for applicable study groups.

Information on the use of medications will be collected at each study visit. In addition, blood samples for auto-antibody assessment will be taken at Day 1 pre-dose and Day 51 (or Early Withdrawal Visit).

Participants who receive at least one dose of vaccine will also be asked to participate in safety follow-up phone calls occurring on Month 3, Month 6, Month 9, and Month 12 (nominally 3, 6, 9, and 12 months after the last vaccination) to collect information on AEs, SAEs and any potential AESIs. Based on responses at these phone contacts, participants may be asked to return to the clinic for an unscheduled visit to provide blood samples for auto-antibody testing to investigate reports of potential AESIs.

Independent safety oversight will be provided by a Data Safety Monitoring Board, which will be notified of significant AEs, potential AEsIs, or any other events as determined by the Medical Monitor, on an ongoing basis.

Arms:
arm 1: Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.

Group 1 will concomitantly receive ciprofloxacin. arm 2: Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.

Group 2 will concomitantly receive doxycycline. arm 3: Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.

Interventions: intervention 1: Ciprofloxacin 500Mg Tablet intervention 2: Doxycycline 100Mg Tablet intervention 3: AV7909
Intervention descriptions: intervention 1: Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37. intervention 2: Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38. intervention 3: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.

Protocol document:
ICF_002.pdf: 
Informed Consent Form to Take Part in a Clinical Research Study 
and Authorization to Disclose Health Information 
 
Study No. / Title:  
EBS.AVA.210 / A Phase 2 Drug-Vaccine Interaction Study to Examine 
Whether Co-administering AV7909 with Ciprofloxacin or Doxycycline 
Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy 
Adults 
 
Study Sponsor:  
 
 
 
Site Code: 
<Site Code> 
Principal Investigator: <Name> 
Site Address: 
<Address> 
Site Telephone: 
<Phone Number> 
 
You are being asked to take part in a research study.  This Informed Consent Form will tell you 
about: 
 
The study and what will happen to you as a participant in the study, 
 
Possible benefits and risks to you if you choose to take part in the study, and  
 
Your rights as a participant in the study.  
Before you agree to take part in the study, you must read, sign, and date this Informed Consent Form. 
Please read this form and ask as many questions as you need to be sure that you understand what will 
happen to you in this study. You should only sign and date this form if the study doctor or study staff 
have answered all your questions and you decide that you want to be part of this study. The study 
doctor or a member of the study staff will also sign and date this form. You will be given a copy of 
this signed and dated Informed Consent Form to keep.  It is your choice to take part in this study 
because joining this study is voluntary. There will be no penalty or changes to your medical treatment 
if you choose not to take part in this study. Signature and date on this form does not mean you will 
automatically get in the study. Only after you sign and date this form can the study doctor do any tests 
to see if you meet all the requirements to join the study.  
Participating in a research study is not the same as getting regular medical care.  The purpose of 
regular medical care is to improve or monitor your health.  The purpose of a research study is to 
gather information about how safe the study drug is and how well it works.  Being in this study does 
not replace your regular medical care. 
 
 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 2 of 27 
 
 
 
 
INFORMATION ABOUT THIS RESEARCH STUDY 
1 
INTRODUCTION 
This study is being paid for by the Biomedical Advanced Research and Development Authority 
(BARDA; part of the United States [U.S.] Department of Health & Human Services) together with a 
company called Emergent Product Development Gaithersburg, Inc, hereafter called “Emergent.” 
Emergent is the sponsor of this study and makes the study drug being tested, a study vaccine called 
AV7909. The AV7909 study vaccine is being developed to see if it can prevent anthrax disease. This 
study is being conducted to determine whether giving the vaccine interferes with how your body 
processes the antibiotics that are also recommended to prevent anthrax disease in exposed individuals.  
No one will be exposed to anthrax in this study. 
1.1 
What are Vaccines?  
Vaccines are given to people to prevent them from getting a specific infection or disease by helping 
their immune system to fight off the bacteria or virus that causes the infection or disease.  The 
immune system is the body’s natural defense against germs and other invaders.  Through a series of 
steps called the immune response, the immune system attacks germs that invade your body and cause 
disease.  Vaccines help the immune system make special proteins called antibodies that can help fight 
an infection at a later point in time.  This may result in a milder infection (you get better sooner) or 
even keep you from getting sick at all after being exposed to the bacteria or virus at a later point in 
time.   
1.2 
What is Anthrax Disease? 
Anthrax is a disease that can affect both animals and humans.  It is caused by the bacteria called 
Bacillus anthracis (also written as B. anthracis).  Though very rare, people can get anthrax from 
direct skin contact from infected animals, wool, meat, or hides; breathing or ingesting the bacteria, or 
by injection (through a shot). It was also used in the US nearly 20 years ago as a bioterrorist agent. 
Anthrax is usually a skin disease that results in open sores on the skin often associated with fever and 
tiredness. Two out of ten people who catch the skin type of anthrax die if they do not receive 
treatment.  When B. anthracis is breathed in, the resulting disease (inhalation anthrax) is much more 
serious than the skin disease.  The first symptoms may include a sore throat, mild fever and muscle 
aches.  Within several days, these symptoms are followed by severe breathing problems, shock, and 
often meningitis (inflammation of the membrane that covers the brain and spinal cord). Once 
symptoms appear, most people who catch this form of anthrax die even if they are treated with 
antibiotics. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 3 of 27 
During the 2001 US terrorist attack, which spread anthrax through the mail system, 22 people were 
diagnosed with anthrax disease; 11 with the skin type and 11 with inhalation type. All were treated 
with antibiotics. There were five deaths, all of which occurred in those with inhalation anthrax. 
1.3 
What is AV7909 Study Vaccine? 
AV7909 study vaccine is made up of the same drug substance found in an approved vaccine called 
BioThrax®.  BioThrax vaccine, which is also made by Emergent, is a Food and Drug Administration 
(FDA)-approved vaccine used to prevent anthrax infection in adults who are at high risk of getting 
anthrax (such as certain people in the military).  BioThrax vaccine helps people make antibodies 
against the bacteria that cause anthrax. AV7909 study vaccine also contains another substance called 
CPG 7909 (not found in BioThrax) that works by boosting the vaccine’s effects to increase the body’s 
immune response.  Being a combination of BioThrax plus CPG 7909, it is believed that AV7909 
study vaccine can work just as well if not better than BioThrax vaccine to help the body make 
antibodies against the bacteria that cause anthrax. 
The use of AV7909 study vaccine is “investigational,” meaning the study vaccine has not been 
approved for sale in the U.S. by the Food and Drug Administration (FDA). The study doctor is being 
paid to conduct this study.  
1.4 
What is Ciprofloxacin and Doxycycline? 
Ciprofloxacin and doxycycline are both antibiotics, which are oral medicines that fight bacteria in the 
body. These medicines have been FDA-approved for treating different types of infections, including 
the treatment of post-exposure inhalation anthrax. For the purposes of this study, the ciprofloxacin 
will be provided as tablets at a strength of 500 mg, taken twice per day, every 12 hours. For the 
purposes of this study, doxycycline will be provided as tablets at a strength of 100 mg, taken twice 
per day, every 12 hours.  
1.5 
What is the Purpose of this Study? 
The purpose of this study is to understand whether vaccination with AV7909 affects the levels of 
ciprofloxacin or doxycycline (antibiotics) in the blood when the vaccine and antibiotics are given 
together.  Similarly, researchers want to know if taking these antibiotics will affect the immune 
response that your body makes when given the AV7909 vaccine.  
The current treatment for suspected exposure to anthrax is 60 days with an approved antibiotic such 
as ciprofloxacin or doxycycline and 3 shots with the currently approved vaccine, BioThrax. An earlier 
study showed that the two treatments (BioThrax vaccine plus ciprofloxacin antibiotic) when given 
together were as safe as when given separately. This earlier study also showed that both the 
ciprofloxacin levels in the blood and the immune response to BioThrax were essentially the same 
when the two treatments were given together as when they were given separately. In the currently 
planned study, which is the subject of this consent form, researchers want to find out if the same 
results can be obtained with the AV7909 study vaccine in combination with ciprofloxacin or 
doxycycline. They will test the AV7909 study vaccine with and without one of the two antibiotics to 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 4 of 27 
 
determine whether either the levels of antibiotic in the blood or the body’s immune response to the 
vaccine are affected when the vaccine and an antibiotic are given together. You will NOT come into 
contact with the anthrax bacteria as part of this research study; therefore, you will NOT be at risk of 
anthrax infection.  
1.6 
What is this Study About? 
Approximately two hundred and ten (210) healthy participants who are between 18 and 45 years old 
will be enrolled in this study at up to 4 medical clinics across the U.S.  All eligible participants (210) 
will receive the AV7909 study vaccine (investigational vaccine). All eligible participants will receive 
the AV7909 study drug (investigational vaccine) and may receive ciprofloxacin or doxycycline study 
drug (investigational antibiotics). Approximately 70 subjects will be assigned to each study drug 
(AV7909, ciprofloxacin or doxycycline). No participants will receive both ciprofloxacin and 
doxycycline.   
This study is “open-label,” which means that you and the study doctor will know what treatment you 
are receiving (AV7909 study vaccine, or AV7909 and ciprofloxacin, or AV7909 and doxycycline). 
The AV7909 study vaccine is given as two shots separated by two weeks.  
Two shots of AV7909, in combination with antibiotics will be given on various study days to 
establish peak antibiotic levels in the blood, to evaluate if there is an effect of the antibiotics on the 
immune system to the vaccine. 
1.7 
What are the Risks of Being in this Study? 
The main risks in this study are associated with the use of antibiotics, vaccines and general blood 
collection procedures.  With the use of the vaccine the main risks to you, if you choose to participate, 
are side affects you may experience when a vaccine is given into your muscle such as pain, swelling  
and redness at the injection site, dizziness, fainting, bruising or infection. A very rare but potential risk 
when receiving a vaccine can also result in having a serious reaction to the study drug, which can lead 
to death. The main risks associated with the use of ciprofloxacin are common side effects such as 
diarrhea, dizziness, headache, drowsiness, nausea, vomiting and an upset stomach, however, 
ciprofloxacin carries rare potential risks such as tendon rupture (cords), increased or worsening of 
rupture tears in the aorta blood vessel, damage to nerves of your body and uncontrolled movements of 
the body (seizures). The most common side effects that you may experience with the use of doxycycline 
antibiotics may include problems with your liver, watery or bloody stools and excessive sunlight 
sensitivity such as sunburns and rashes. Lastly, during the process of collecting your blood for study 
requirements, you may feel faint, experience bruising and/or swelling at the site where blood was 
drawn.  Please see section 5, risks and benefits for a detailed list of potential risks. 
1.8 
Are there any benefits to being in the study? 
This study is for research purposes only.  There is no direct benefit to you from your participation in 
the study. Information from this study might help researchers develop a new vaccine to prevent 
anthrax, new tests, or other medications that could help others in the future. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 5 of 27 
2 
ELIGIBILITY  
2.1 
Who can participate in the study? 
People who served in the U.S. military after 1990 cannot participate in this study because they may 
have already received the BioThrax vaccine.  In addition, if you plan to enlist in the military from 
Screening through the Final Study Contact, approximately 14.5 months, you cannot participate in this 
study.  If you are considering enlisting in the military, please tell the study doctor. 
To be in this study, you must additionally meet the following requirements: 
 
Read, sign and date the study Informed Consent Form 
 
Be 18 to 45 years old at the time of this consent and considered to be in good health, with no 
signs of illness (within the past five years), drug or alcohol abuse 
 
Have a Body Mass Index (BMI) less than or equal to 35.0 kg/m2 (the study doctor will 
measure your height and weight to determine your BMI)  
 
Be able to have blood drawn without too much difficulty 
 
For women able to have children:  
 
Have negative pregnancy tests before enrolling in the study and before getting your first 
study shot  
 
Not be currently breast-feeding  
 
Have no intention to become pregnant at any time while participating in the study   
 
Must use an acceptable form of birth control to prevent pregnancy at least one (1) month 
prior to Study Day 1 through Month 12 
An acceptable form of birth control for women is any of the following: 
1) No sexual intercourse; 
2) Previous bilateral tubal ligation procedure (both tubes tied); 
3) Monogamous relationship with a vasectomized partner (vasectomy performed at least six 
months ago); or 
4) Any of these forms of birth control: pills, intrauterine device/system (IUD/S), implantable 
or injectable contraceptive (for example, Norplant® or Depo-Provera®), removable 
device (for example, NuvaRing® or Evra® patch), or double-barrier method (condom 
with spermicide, diaphragm with spermicide). 
The study doctor or study staff will ask you about your preferred birth control method along 
with the use of a second method of birth control and review it with you at every study visit or 
phone call. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 6 of 27 
 
 
Have no plans to receive a vaccine shot (for example, flu vaccine, tetanus vaccine) from 
seven days before your first scheduled study shot through two (2) weeks after receiving your 
final study shot 
 
Take no medications before or during the study that your study doctor determines could 
affect your body’s immune response 
 
Have not previously had anthrax disease, or been exposed to anthrax, or previously received a 
shot of anthrax vaccine 
 
Has not given blood within one month prior to signing the study informed consent form and 
does not plan to give blood at any time during the study until after the final safety phone 
contact 
 
Have not previously had a severe allergic reaction to a vaccine, and have no known allergy to 
synthetic oligonucleotides, aluminum, formaldehyde, benzethonium chloride (also called 
phemerol), or latex 
 
Have no plan for elective surgery at any time while participating in study  
 
Have no tattoo/scar/birthmark or any other skin condition affecting the upper arm areas where 
the study shot will be given 
 
Not be participating in any other research study in which you receive an investigational 
product (meaning it is not FDA-approved) at the same time as this study 
Tell the study doctor if you don’t meet one or more of these study requirements. Before you can be 
enrolled in the study, the study doctor will perform a physical examination, run some laboratory tests, 
and ask you some questions about your health and medical history (refer to Section 4 of this Informed 
Consent Form).  Based on the results, the study doctor will decide if you qualify for participation in 
the study.   
3 
PARTICIPANT RESPONSIBILITIES 
3.1 
What will happen while on the study? 
You will be expected to attend all planned visits and accept all study-related phone calls as listed in 
the study treatment schedule described in Section 4 of this Informed Consent Form.  You must 
additionally:  
 
Show up on time for all scheduled study visits, which may include overnight visits depending 
on the study group you are assigned to. Alert the study doctor/study staff as soon as possible 
if you must reschedule a visit for any reason. 
 
Allow the study doctor/study staff to draw blood and take urine samples on the study days 
listed in this Informed Consent Form.  
 
Tell the study doctor/study staff about all past and current health concerns/conditions for 
which you have received medical care or treatment. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 7 of 27 
 
Tell the study doctor/study staff about any past [within thirty (30) days before your first study 
visit] or new medications you are taking. 
 
Tell the study doctor/study staff if you do not feel well or notice unusual changes in your 
mind or body while in the study. 
 
Allow the study staff to give you a study shot in one arm on Study Day 8 and in the opposite 
arm on Study Day 23.  
 
When at home, complete an electronic diary (e-diary) once a day for at least one week after 
each study shot to describe your study shot-related symptoms. If you are selected to Group 1 
and 2, you will also enter the times you take your antibiotic and your temperature once a day. 
If you don’t have a personal smartphone, tablet, or computer with internet access to do this, 
the study staff will loan you a mobile device, to be used only for purposes of this study and to 
be returned to study staff when directed.  
 
If you are a woman able to have children, continuously use an acceptable method of birth 
control (refer to Section 2) for the duration of the study and let the study doctor/staff know 
immediately if you know or think you may be pregnant or when there has been a change in 
your method of birth control. 
 
Agree not to receive any commercially available shot such as a flu shot, until at least two (2) 
weeks after the last study shot.  
 
Agree to lifestyle and dietary restrictions such as avoiding dairy products at certain times, 
limited caffeine use, avoiding the sun, and strenuous physical activity.  
 
Agree not to take certain medications because these medications may hide the side effects of 
the study shot or interact with the antibiotics. This includes any aspirin- or Tylenol-
containing medications and any non-steroidal anti-inflammatory medications such as 
ibuprofen, naproxen, diclofenac and celecoxib.   
 
Respond to the study doctor/study staff when they call you 3, 6, 9, and 12 months after the 
last planned study shot to find out about any changes to your general health since the last 
study visit or phone call. 
 
Agree to come to the study doctor’s office when requested by the study doctor or study staff 
outside of a scheduled study visit or phone call to undergo a medical evaluation and 
blood/urine tests if necessary. 
4 
STUDY TREATMENT SCHEDULE 
If the study doctor says you can be in the study and you agree to participate, your time in the study 
will last about fourteen and a half months.  Depending on the study group you are chosen to 
participate in, you will have to come to the study doctor’s office at a minimum of six visits but no 
more than nineteen visits, during the first one and a half month of the study.  The study staff will tell 
you when to come in for your study visits and the amount of time you are expected to stay during 
your visit.  At the end of all the study visits, you will receive phone calls from the study doctor/staff 
spaced several months apart over 12 months, so they can check up on your health and well-being.  
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 8 of 27 
 
See below for more information about which tests and procedures will be done at each study visit or 
phone call and be sure to ask the study doctor or study staff if you have any questions. 
4.1 
Visit 1: Screening Visit (Day -28 to -2) 
If you agree to participate in the study, you will sign and date this Informed Consent Form before any 
study procedures are done. 
First, a screening visit will be conducted.  During this first study visit, the study doctor and/or study 
staff will collect some information about you and do some tests to find out if you can be in the study.  
They will: 
 
Assign you a subject code number that will identify you for the study purposes so that 
information collected about you is kept private (also see Section 7). 
 
Ask questions about you (age, sex, race and ethnicity) and your medical history, including 
medicines you take and shots you have had.  You will need to tell study staff if you take any 
over-the-counter or prescription medicines and any vitamins or herbs. 
 
Review the conditions for being in the study with you.  
 
Perform a complete physical exam, including an electrocardiogram (ECG) to check the health 
of your heart.  
 
Measure your height, weight, and vital signs (blood pressure, temperature, heart and 
breathing rates). 
 
Draw blood for some tests (about 3 teaspoons of blood will be collected).  You will be tested 
for signs of illness or infection, including for HIV (human immunodeficiency virus), hepatitis 
B and hepatitis C.  If you test positive for HIV, hepatitis B, hepatitis C or certain other 
illnesses or infections, you cannot be in the study. Depending on state law, you may have to 
sign and date a separate Informed Consent Form before this testing can start.  The study 
doctor or study staff will tell you if the test results are positive.  If required by state law, the 
study doctor or study staff may report a positive test result to the local health department.  
 
Collect a urine sample to test for signs of illness or infection and for illegal drugs.  If your 
urine test shows illness, infection or illegal drugs, you will be told the results and you will not 
qualify to be in the study. 
 
If you are a woman who is not surgically sterile, draw blood for a pregnancy test (less than a 
teaspoon of blood will be collected). The study doctor or study staff will tell you if the 
pregnancy test results are positive; results of the pregnancy testing must be negative for you 
to be in the study.  Pregnant women and women who are not using two forms of acceptable 
birth control cannot be in the study. If you have not had a period for more than twelve (12) 
months in a row, blood will be drawn and tested to verify if you are postmenopausal. Once 
you are confirmed to be postmenopausal, you will not need to have any more pregnancy tests 
for the rest of the study. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 9 of 27 
If you meet the conditions to be in the study, the study doctor/staff will tell you when to come back 
for your second visit. 
Females who are of child-bearing potential must agree to use a form of birth control that the study 
doctor considers “adequate” and agree to use it thirty (30) days before receiving the study drug 
(vaccine or antibiotic or both) until the study is complete (Study Days 374 to 402). If you are assigned 
to Groups 1 or 2 and receive ciprofloxacin and/or doxycycline, the antibiotics can decrease the 
effectiveness of birth control pills or implantable or injectable contraceptives. Therefore, you will be 
required to add a second form of birth control: 
 
add a double-barrier method (condoms in combination with contraceptive jelly, cream or 
foam or a diaphragm in combination with contraceptive jelly) or 
 
use an intrauterine device (IUD), or 
 
practice abstinence 
4.2 
Visit 2: Randomization Visit 
At your second visit, the study doctor will review with you the conditions for being in the study.  
Additionally, the following procedures will be done: 
 
Perform a physical exam if needed. 
 
Measure your vital signs (blood pressure, temperature, heart and breathing rates). 
 
Review your medication(s) and update your medical history, including any side effects you 
may have experienced. 
 
If you are a woman able to have children, a urine pregnancy test will be performed.  If the test 
is positive, a blood test will be required to confirm the result. 
 
If you are a woman able to have children, study staff will confirm that you are on birth 
control and decide if the type you are taking is acceptable. 
 
Review your health concern/condition. 
If you meet all requirements, the study doctor will assign you to one of the three study groups on a 
random basis, that is you could just as easily be assigned to Group 1 or to Group 2 or Group 3, all of 
which are described below:   
 
Group 1: AV7909 vaccine and ciprofloxacin antibiotic (with or without blood draw testing 
for ciprofloxacin blood levels) 
 
Group 2: AV7909 vaccine and doxycycline antibiotic (with or without blood draw testing for 
doxycycline blood levels) 
 
Group 3: AV7909 vaccine; no antibiotics given  
If you are in Group 1 or Group 2, you may be randomly selected as part of a sub group for blood draw 
testing of ciprofloxacin blood levels (Group 1A) or doxycycline levels (Group 2A). If you are not 
selected as part of either sub group, you will be part of Group 1B or 2B where you do not participate 
in the blood draw testing for ciprofloxacin or doxycycline blood levels. 
Upon your Group assignment, the following activities will occur: 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 10 of 27 
 
 
Blood will be drawn and tested for antibodies. 
 
You will be instructed when to return to the clinic for your overnight visit OR be provided 
your antibiotic and medication schedule, based on your Group assignment. 
 
You will be told by the study staff when to return to clinic for your shot. 
 
Study staff will talk to you about your diet and daily routine limitations to follow when taking 
antibiotics. 
 
You will be given instructions on how to complete an electronic diary on the internet. 
Your chances of being assigned to one of the three AV7909 study groups will be equal, that is 1:1:1.   
4.3 
Vaccination (AV7909 Shot) Visits: Study Days 8 and 23 
Regardless of which group you are in (Group 1, Group 2 or Group 3), you will receive two study 
shots in the upper arm during the study, each shot will be given two weeks apart. The first study shot 
will be given during your Study Day 8 visit (also called Vaccination # 1). The second study shot will 
be given during your Study Day 23 visit, about two (2) weeks after the first study shot (called 
Vaccination #2).  At the Study Day 23 visit, you will get the shot in the opposite arm from the one 
used the last time you got a shot.  
During your visit at Study Days 8 and 23, the study doctor or study staff will perform the following 
procedures: 
 
Review the conditions for being able to receive a study shot on that day (for example, you 
can’t have a fever or be pregnant).  
 
Collect urine for a pregnancy test and confirm your method of birth control, if you are a 
woman who could become pregnant.  If this test is positive, blood will be drawn for a more 
accurate pregnancy test.  You will be told the results of this test.  
 
Review how you have been feeling since your last visit. 
 
May perform a physical exam related to your symptoms, if you have any, and measure your 
vital signs (blood pressure, temperature, heart and breathing rates).   
 
Review any medicines you have taken since the last visit. 
If you still qualify for receiving the study shot after all of these tests and examinations, you will be 
given a study shot.  
 
After the study shot: 
 
The study doctor and study staff will check up on you in the study clinic for at least 30 
minutes after the study shot to see if you have any reaction to it and also measure your vital 
signs about 30 minutes after the study shot. 
 
On Study Days 8 and 23, you will be given instructions on how to complete an e-diary on the 
internet.  The e-diary is used to record some types of side effects related to the study shot you 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 11 of 27 
may have over the next seven days and any medications you are taking.  You will complete 
an e-diary once a day for seven days after each study shot.  If you still have side effects 
related to the study shot after seven days, you will continue to complete the e-diary until 
you’ve had no more symptoms for at least two days in a row. To help you complete the e-
diary, you will be given a thermometer to record your temperature.  You will also be given a 
measuring tool and shown how to measure the size of any redness or swelling on your arm 
where you recently received your study shot. If you need a mobile device in order to access 
the e-diary, one will be loaned to you by the study staff to be used for the purposes of this 
study. 
 
If you previously completed an e-diary, the study doctor or study staff will review it with 
you. 
 
 The next study visit will be scheduled. 
4.4 
Group 1 and 2 Clinic Visits: 
If you are assigned to Group 1 (A or B) or 2 (A or B), you will be required to take your antibiotic on 
certain study days, whether you are at the clinic or at home. For those in Group 1 (A or B), 
ciprofloxacin will be provided as tablets at a strength of 500 mg and will be taken every 12 hours in 3 
courses on Study Days 4-9, 22-24 and 31-37. For those in Group 2 (A or B), doxycycline will be 
provided as tablets at a strength of 100 mg and will be taken every 12 hours on Study Days 2-9, 22-24 
and 32-38.    
For Groups 1 and 2, you will be given instructions on how to complete an electronic diary when you 
receive your first antibiotic course. For those in Group 1 (A or B) , you will receive instruction on 
Study Day 4 and those in Group 2 (A or B) will receive instruction on Study Day 2. 
In addition to items described in sections 4.2, 4.3 and 4.5, participants in Group 1 (A or B) and 2 (A 
or B) will be required to attend the following study visits:   
 
Group 1A will have four overnight stays on Study Days 3, 7, 30, and 34. Starting in the 
mornings after your overnight stays (Study Days 4, 8, 31 and 35), you will have 
approximately fifteen (15) blood samples taken to measure your ciprofloxacin levels over 
a period of twelve (12) hours. During your clinic visits on Study Days 4, 5, 6, 7, 8, 23, 
31, 32, 33, 34 and 35, you will receive your antibiotic.  On Study Days 9, 22, 24 and 36 
you will be taking your antibiotic at home. On Study Day 37 you will take your morning 
antibiotic at home and return to the clinic for a blood draw to test for antibodies to the 
vaccine. During this visit, you will be required to return any leftover antibiotic 
medication to the clinic staff. 
 
Group 1B will be instructed to take your ciprofloxacin at home on Study Days 4, 5, 6, 7, 
8, 9, 22, 23, 24, 31, 32, 33, 34, 35, 36 and 37. You will come to the study clinic on the 
morning of Study Days 8 and 23 to receive your shot and morning antibiotic. On Study 
Day 37 you will take your morning antibiotic at home and return to the clinic for a blood 
draw to test for antibodies to the vaccine. During this visit, you will be required to return 
any leftover antibiotic medication to the clinic staff. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 12 of 27 
 
 
Group 2A will have four overnight stays on Study Days 1, 7, 31 and 37. Starting in the 
mornings after your overnight stays (Study Days 2, 8, 32 and 38), you will have 
approximately fifteen (15) blood samples taken to measure your doxycycline levels over 
a period of twelve (12) hours. During your clinic visits on Study Days 2, 3, 4, 5, 6, 7, 8, 
23, 32, 33, 34, 35, 36 and 37, you will receive your antibiotic.  On Study Days 9, 22 and 
24 you will be taking your antibiotic at home. On Study Day 38 you will take your 
morning antibiotic in the clinic and have blood drawn to test for antibodies to the vaccine. 
During this visit, you will be required to return any leftover antibiotic medication to the 
clinic staff.   
 
Group 2B will be instructed to take your doxycycline at home on Study Days 2, 3, 4, 5, 6, 
7, 8, 9, 22, 23, 24, 31, 32, 33, 34 , 35 , 36 , 37 and 38.  You will return to the study clinic 
on the morning of Study Days 8 and 23 to receive your shot and  morning antibiotic. On 
Study Day 37 you will take your morning antibiotic at home and have blood drawn to test 
for antibodies to the vaccine. During this visit, you will be required to return any leftover 
antibiotic medication to the clinic staff. 
4.5 
      Group 3 Clinic Visits 
In addition to items described in sections 4.2 and 4.3, participants in Group 3 will return to the clinic 
on Day 37 for a blood draw to test for antibodies to the vaccine. 
4.6 
Last Clinic Visit (Study Day 51) 
Regardless of which group you are in (Group 1, Group 2 or Group 3) at the last study visit (Study 
Day 50, 51 or 52), you will return to the clinic and the study doctor or study staff will do some or all 
of the following: 
 
Review how you have been feeling since the previous visit. Any side effects will be recorded 
by the study doctor. 
 
Perform a complete physical exam and measure your vital signs (blood pressure, temperature, 
heart and breathing rates).  
 
Collect a urine sample to test for signs of illness or infection. 
 
Draw blood [about three and a half (3½) teaspoons of blood will be collected] for laboratory 
testing. Your blood will be tested for signs of illness or infection. Your blood will also be 
checked for substances made by your immune system called antibodies.  
 
 If you are a woman able to have children, a urine pregnancy test will be performed.  If the 
test is positive, a blood test will be required to confirm the result. 
 
Review any medicines you have taken since the last visit. 
 
Review your diary entries and collect the mobile device provided to you for e-diary entry (if 
not already returned to the study staff). 
 
Collect any remaining antibiotic medication for Groups 1 and 2 if needed. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 13 of 27 
4.7 
Early Withdrawal Visit  
You can withdraw from the study at any time without penalty.  The study doctor may also decide you 
can’t receive any more study shots, antibiotics or both, if applicable (for example, if you have an 
allergic reaction to the study shot, or you have a fever on a day when you were supposed to receive a 
study shot, or you become pregnant). Once you’ve received at least one study shot and either you or 
the study doctor decides you can’t receive any more study shots, you will continue with your 
scheduled study visits and study follow-up phone calls.  You will have the tests and procedures 
described in Section 4. However, you won’t have any more study shots, antibiotics or both, if 
applicable and may not have any more blood samples collected to test the amount of antibodies that 
could protect you against anthrax. This will allow the study doctor and study staff to check up on your 
health and well-being for the entire study length. 
If, however, you choose not to participate in the study anymore and have not yet reached your last 
study visit (Study Day 51), the study doctor/study staff will ask you to come to the doctor’s office for 
an Early Withdrawal Visit to check your health one last time.  
At the Early Withdrawal Visit, the study doctor or study staff will do some or all of the following: 
 
Review how you have been feeling since the previous visit. Any side effects will be recorded 
by the study doctor. 
 
Perform a complete physical exam and measure your vital signs (blood pressure, temperature, 
heart and breathing rates).  
 
Review any medicines you have taken since the last visit. 
 
In women who are able to have children, draw blood (less than a teaspoon) for a pregnancy 
test and confirm your method of birth control.  You will be told the results of this test. 
 
Draw blood (about two (2) teaspoons of blood will be collected) and collect urine for 
laboratory testing. Your blood and urine will be tested for signs of illness or infection. 
 
If you withdraw close to study Day 37, you may be asked for blood sample to check for 
substances made by your immune system called antibodies [about one and a half (1½) 
teaspoons of blood will be collected].   
 
Review e-diary entries.  
 
Collect and count left-over antibiotic supply for Groups 1 and 2 to document medication 
compliance. 
 
Collect the mobile device provided to you for e-diary entry (if not already returned to the 
study staff). 
4.8 
Phone Calls at Study Days 100-128, 191-219, 282-310 and 374-402 (Months 3, 6, 9, and 
12) 
Regardless of what group you are in (Group 1, Group 2 or Group 3), you will receive phone calls 
from the study doctor or study staff at Study Days 100-128, 191-219, 282-310 and 374-402, which 
will occur, at 3 months, 6 months, 9 months, and 12 months respectively, after you receive your last 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 14 of 27 
 
scheduled study shot. You will also be asked about your health since your last visit or the last time 
you received a phone call.  If you are a woman who could have children, you will be asked to confirm 
your method of birth control. You may also be asked about any medications you have taken.  The 
study doctor may ask you more detailed questions about any side effects and possibly refer you to a 
specialist if more tests are needed. The study doctor may ask you to come to the study doctor’s office 
to collect blood in order to test it for antibodies that may indicate an autoimmune response. 
4.9 
What will happen to any samples you give? 
Samples collected for safety: 
Blood and urine samples will be collected from you for safety testing.  These samples will be kept 
until testing is completed or until the sample is no longer usable. The samples will then be destroyed. 
These samples will be labeled with your subject code number and will not contain your name or any 
other personal information. 
Samples collected for future use: 
If you agree, samples of your blood will be stored for possible future re-testing as part of continued 
research on the anthrax vaccine.  Your blood samples will not be tested for gene sequencing 
(structure). Any blood samples left over from the immune response testing will be stored frozen at a 
long-term storage facility.  You will not be asked to provide additional blood samples. 
Samples may be stored until at least 2 years after the last marketing application is approved (AV7909 
is not approved for sale), or is no longer pending, or the investigation of AV7909 is discontinued. 
These samples will only be used for research purposes and will not be sold or used directly for the 
production of commercial products.   
Allowing retention of your leftover blood samples for future research is optional.  You will be asked 
to agree or decline to the retention of your leftover blood samples at the end of this form. 
Identifiers will be removed from your private information (personal and health information collected 
as part of this study) and any biospecimens (blood samples).  These samples will be labeled with your 
subject code number and will not contain your name or any other personal information. After the 
information or biospecimens can no longer be readily identified as yours, it may be used for future 
research studies or sent to another investigator for future research studies.  You will not be asked to 
provide additional informed consent for such use. 
Medical research from your subject coded blood samples, may result in new products or discoveries.  
These may have value to others, but you will not share in any financial or other benefits from the use 
of your blood samples. 
You will not be informed if clinically relevant information (information that can be used to support 
the health care of people) is discovered during research using your samples. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 15 of 27 
5 
RISKS AND BENEFITS 
5.1 
What are the Risks of Being in this Study? 
All medicines may cause side effects. There may be side effects of the AV7909 vaccine or 
ciprofloxacin or doxycycline that are not yet known. AV7909 has been previously studied in people. 
AV7909 has already been given to about 241 people in 3 completed studies.   
The known side effects for the vaccine and antibiotics in this study are listed below. By agreeing to 
take part in this study, you should know that you might experience any of the problems listed below 
or other side effects that are not known yet. 
5.2 
What are the possible side effects with AV7909 Vaccine? 
The potential side effects listed below, whether related or not to AV7909 were reported during 3 
completed clinical studies. These potential side effects may include but are not limited to: 
 
Reactions on your upper arm where you got the study shot, such as swelling, tenderness, 
redness, warmth, itching, bruising, bleeding, darker skin color, a hardened bump or lump, 
rash, limited arm movement, pain, burning sensation, or numbness/tingling 
 
Feeling very tired all over 
 
Headache, migraine 
 
Flu-like symptoms such as fever, chills, and muscle aches 
 
Decrease or increase in cell blood numbers, such as in the number of white blood cells 
 
Cold with stuffy nose 
 
Rapid or fast breathing 
 
Nausea 
 
Diarrhea 
 
Excess gassiness or flatulence 
 
Toothache 
 
Vomiting 
 
Flushing 
 
Night sweats 
 
Cough 
 
Nasal congestion or sore throat 
 
Upper respiratory tract infection 
 
Urinary tract infection 
 
Vaginal infection 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 16 of 27 
 
 
Increased level in liver function tests 
 
Changes in blood pressure 
 
Decreased appetite 
 
High or low blood sugar levels 
 
High or low potassium levels 
 
High or low magnesium blood levels 
 
Difficulty sleeping 
 
Blood, protein, or white blood cells in the urine 
 
Inflammation of voice box 
 
Slow or fast heart beat (pulse) 
 
Decreased hemoglobin (e.g., anemia) 
 
Increased level of bilirubin in the blood 
 
Decreased kidney function 
 
Abnormal size or change in shape or feel of lymph nodes  
 
Feeling of body temperature change 
 
Feeling unwell  
 
Stomach flu 
 
Hives 
 
Numbness and tingling 
 
Pain [e.g., in muscles, joints, jaw, back, neck, chest (non-cardiac), abdomen, ear] 
 
Skin mole 
 
Muscle cramps  
 
Discomfort in the armpit area 
 
Indigestion 
Sometimes people may have allergic reactions to the AV7909 vaccine. If you have a very bad allergic 
reaction, you could die.  Some things you may have during an allergic reaction are: 
 
A rash  
 
Having a hard time breathing 
 
Wheezing  
 
Sudden drop in blood pressure (making you feel dizzy or lightheaded) 
 
Swelling around the mouth, throat, or eyes 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 17 of 27 
 
Fast pulse 
 
Sweating 
 
Nausea and cramps 
 
Hard or fast heart beat or skipping heart beat(s) 
Possible risks associated with getting any shot are:    
 
Dizziness/fainting 
 
Pain associated with the needle stick 
 
Nerve or blood vessel damage  
 
Infection 
 
Sterile abscess, which is a sore at the point of injection, can be painful and warm to the touch  
You should get medical help and contact the study doctor or study staff if you have any of these or 
any other side effects during the study. Contact information for the study staff can be found on page 
one of this Informed Consent Form. 
The AV7909 vaccine and ciprofloxacin or doxycycline are not recommended for anyone who 
previously had a severe allergic reaction.  If you have had a bad allergic reaction to a vaccine or 
antibiotic in the past, please tell the study doctor.  If you are allergic to latex, you cannot participate in 
this study because the lid on the vaccine container contains a dry natural rubber that could cause an 
allergic reaction.  If you are allergic to latex, please tell the study doctor.  
One of the possible risks from one of the substances in the AV7909 study vaccine is overstimulation 
of your body’s immune response, which could result in a chronic autoimmune disease. Chronic 
means a disease that continues for a long time. An autoimmune disease develops when your immune 
system, which defends your body against disease, decides your healthy cells are foreign. As a result, 
your immune system attacks healthy cells. Depending on the type, an autoimmune disease can affect 
one or many different parts of your body. Because of this possible risk, the study doctor and study 
staff will check up on your medical condition throughout this study up through 12 months after the 
last scheduled study shot.  
During this study you will be observed for any bad or harmful effects.  The study doctor will decide if 
it is safe for you to keep taking part in the study. Tell the study doctor or study staff right away if you 
have any problems with your health or the way you feel during the study, whether or not you think 
these problems are related to the study shots.  
It is possible that you could have side effects to AV7909 study vaccine, ciprofloxacin or doxycycline 
antibiotics that nobody knows about yet, which could even include death.  If the study doctor learns 
any new information about AV7909, ciprofloxacin or doxycycline that might change your mind about 
continuing in the study, the study doctor or study staff will tell you about it in a timely manner.  
It is possible that receiving AV7909, ciprofloxacin or doxycycline  with your regular medications or 
supplements may change how AV7909, your regular medications, or your regular supplements work.  
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 18 of 27 
 
It is very important that you tell the study doctor about all medications or supplements you are taking 
during the study and any changes in your overall health. 
5.3 
What are the possible side effects with ciprofloxacin? 
Ciprofloxacin is an antibiotic medication that has already been approved by the Food and Drug 
Administration (FDA) and is not investigational as defined in section 1.3. Ciprofloxacin can cause 
serious side effects which could result in death. The list below includes, some, but not all, of the side 
effects you may experience when taking ciprofloxacin: 
 
Increased risk or worsening of ruptures or tears in the main blood vessel of the body: this is a 
rare but serious side effect that affects the main artery of the body called aorta. These tears 
can lead to dangerous bleeding or even death. 
 
Damage of nerves to your body resulting in altered sensations (peripheric neuropathy) 
 
Central Nervous System side effects: seizures (uncontrolled movement/shaking of the body) 
 
Peripheral neuropathy (damage to nerves of your body resulting in altered sensations 
including pain, burning, tingling, numbness and/or weakness)  
 
Worsening of Myasthenia Gravis (a muscular disease the produces muscular weakness) 
 
Tendon Rupture (tendons are tough cords of tissue that connect muscles to bones):Symptoms 
associated with tendon rupture include pain, tears, and inflammation at the tendon sites 
 
Photosensitivity (excessive skin reactions such as sunburns and rashes when you go into the 
sunlight)  
 
Skin rashes 
 
Allergic reactions, even after a single swallow 
 
Diarrhea 
 
Dizziness and lightheadedness  
 
Nausea 
 
Liver injury/failure and abnormal liver function (lab values) 
 
Prolongation of the QT Interval (irregular heartbeats) 
5.4 
What are the possible side effects with doxycycline? 
Doxycycline is an antibiotic medication that has already been approved by the Food and Drug 
Administration (FDA) and is not investigational as defined in section 1.3. Listed below include, 
but is not limited to, some of the side effects you may experience when taking doxycycline: 
 
Serious liver problems 
 
Diarrhea 
 
Watery and bloody stools 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 19 of 27 
 
Tooth discoloration 
 
Photosensitivity (excessive reactions such as sunburns and rashes when you go into the 
sunlight) 
 
Rash 
5.5 
What are the Possible Risks to Reproduction or to the Unborn Baby (Fetus or Embryo) 
or Nursing Infant? 
If you are pregnant or nursing a child while receiving AV7909 study vaccine, there may be risks to 
your unborn baby or nursing child. It is not known what these risks are right now.   
AV7909 study vaccine has not been tested in pregnant women or women who are breast-feeding. As 
a result, pregnant or breast-feeding women are not allowed to join the study. Also, women who want 
to become pregnant at any time while on the study will not be allowed to join the study. Women who 
join the study but are able to have children must use an acceptable and adequate form of birth control 
to prevent pregnancy at least one (1) month prior to Study Day 1 through Month 12 (after the last 
study phone call). See Section 2 of this Informed Consent Form for what is considered an acceptable 
form of birth control. Be aware that you can still become pregnant even if you use an acceptable birth 
control method. 
If you join the study and are a woman who could get pregnant: The study doctor will ask about your 
method of contraception and also give you a pregnancy test before you join the study and during 
every study visit. If you become pregnant during the study or think you may be pregnant, you must 
immediately tell the study doctor/ study staff so that the pregnancy can be confirmed with a blood test 
and the study doctor knows to stop giving you any more study shots and stop antibiotic treatments as 
well. The study doctor will check up on your health and well-being for the length of the study, and, 
after the birth, also confirm the health and well-being of your child. If you choose to leave the study 
early, or even if you complete the study as scheduled but have not yet given birth, the study 
doctor/staff will contact you at the time of your labor/delivery to check up on your health and also 28 
days later to check up on the health of your child.  
5.6 
Are there any other risks? 
Are there any risks from blood collection? 
Some people have discomfort or pain when blood is collected.  Some people feel faint or pass out 
during or shortly after blood is drawn.  If you feel faint, lie down right away so you don’t get hurt 
from a fall and tell the study personnel right away.  There is a risk of infection, bleeding, swelling, 
and/or bruising at the spot where blood was taken, or a clot may form when blood is collected. 
You will give approximately a total of about 13 teaspoons (~64 mL) of blood, or less than 1 cup 
(~236.5 mL) throughout the duration of the study.  For comparison, this is less than half the standard 
blood donation of about 2 cups (473 mL). 
Are there any risks of injury that could result from participating in the study? 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 20 of 27 
 
All forms of medical health diagnosis and treatment – whether routine or experimental – involve 
some risk of injury.  There may also be risks in this study that we do not know about.  Even with all 
the care that is taken, you may still develop medical complications from being in this study.  If during 
this study you get hurt or sick or have any side effect to the vaccine or study procedure, please contact 
the study doctor.  If such complications happen, the study doctor will help you get the proper medical 
treatment.  
In the event of an injury that occurs to you as a result of receiving AV7909 vaccine, ciprofloxacin or 
doxycycline or undergoing study procedures, you will receive the necessary medical treatment. In the 
event that you suffer injury as a direct result of participating in this study, Emergent will cover the 
costs of reasonably necessary medical treatment not covered by your medical or hospital insurance or 
by third-party or governmental programs providing such coverage. Emergent or the study doctor will 
not cover costs for medical care for injuries or illnesses that are not a direct result of study activities. 
There are no plans to provide other compensation from Emergent or the study doctor.    
You are not prevented from seeking to collect compensation for injury related to malpractice, fault, or 
blame on the part of those involved in the study, including the study clinic or Emergent.  
By signing and dating this Informed Consent Form, you do not give up your legal right to look for 
and receive required medical treatment. You do not give up any rights to seek payment for personal 
injury by signing and dating this form. 
6 
ALTERNATIVE COURSES OF TREATMENT AVAILABLE (OR ALTERNATIVES TO 
BEING IN THE STUDY) 
The medication given to you in this study is not intended to treat or prevent anthrax or any disease. 
The only option available to you is not to be in this study. 
7 
USE OF STUDY RESULTS AND CONFIDENTIALITY OF MEDICAL RECORDS 
Your medical and treatment history will be recorded for study purposes.  Any information learned 
about you in this study will be kept private.  The study doctor, study sponsor (Emergent), third parties 
working on behalf of the study sponsor (including BARDA), the ethics board also known as the 
Institutional Review Board (IRB), and the proper national and international regulatory authorities 
such as FDA will be able to see your health records and test results to confirm the study data and the 
safety of study participants. They may copy information from your health records. Your records will 
be protected and kept as private as possible under local/national/international regulations. By signing 
and dating this Informed Consent Form, you are granting direct access to these records and test 
results.  Subject to applicable laws, any report that is written about this study will not reveal your 
identity. If the results of this study are given to medical journals, your identity will not be revealed. 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov,  as required by 
U.S. Law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 21 of 27 
8 
AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH 
INFORMATION 
Privacy rights of people participating in clinical research studies are protected under the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA). Your rights as a subject under this act 
include deciding who has access to your personal health information (called “Protected Health 
Information”). 
Protected Health Information is medical information about you that includes your entire historical 
medical records, all study doctor visits, evaluations, biospecimens (for example, blood samples), 
laboratory tests, diagnostic tests, procedures, treatments, medications taken, hospitalizations, etc. The 
study doctor may also get information about your past, present and/or future physical or mental health 
and/or condition from your primary care doctor. Protected Health Information contains identifiers that 
can link your medical records specifically to you, such as: 
 
Your name, 
 
Your address, 
 
Date of birth, 
 
Social security/insurance number, 
 
Dates and results of various tests and procedures, 
 
Basic demographic information (such as age, gender, ethnicity/race). 
The study information sent to the sponsor and their representative(s) by your study doctor and/or 
study clinic will not include your name, address or social security/insurance number. As a safety 
measure to help keep confidentiality, a subject code number will be used to identify you. 
The study doctor will keep this personal health information in your study-related medical records 
(that we will refer to as “your records”) during the study and for two (2) years after the last marketing 
application is approved, is no longer pending, or investigation of AV7909 is discontinued.  
By signing and dating this authorization form, you are allowing the study doctor and/or study clinic to 
have direct access to your Protected Health Information collected in this study, and to receive your 
Protected Health Information from either your physician or the facilities where you have received 
health care.  
Information collected about you during this study will be used to confirm the safety and effectiveness 
of AV7909 study vaccine, and the study information may be published in a scientific article. You will 
not be personally identified in these instances. In addition, the sponsor may re-analyze the results at a 
later date and combine them with results of other studies. 
Your signature and date on this Informed Consent Form authorizes: 
 
The researchers, study doctors, and/or institution to have access to your Protected Health 
Information collected as part of this study; 
 
The study doctor and/or institution to receive your Protected Health Information from your 
physician and/or facilities where you have received any health care; 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 22 of 27 
 
 
Your Protected Health Information to be shared with other persons or organizations involved 
in the conduct or oversight of this research study, including but not limited to: U.S. Food and 
Drug Administration (FDA); Biomedical Advanced Research and Development Authority 
(BARDA); Centers for Disease Control & Prevention (CDC); the IRB used by your study 
doctor’s office; regulatory agencies in other countries; the sponsor and third parties working 
on behalf of the sponsor; and the laboratory(ies) handling the lab specimens for this study. 
The other persons and/or organizations need to see your personal health information, so they 
can review the data and to confirm the quality of the study conduct and/or the data collected. 
These other persons and/or organizations may or may not have the same obligations as the 
study doctor or institution to protect your Protected Health Information. 
The IRB used by your study doctor’s office may review your Protected Health Information.  
Your Protected Health Information will not be used or given to any other person or entity, except as 
required by law, or for authorized oversight of this research study. Your Protected Health Information 
will be used for as long as the sponsor reports study information to the FDA or other countries’ 
regulatory agencies. 
You may cancel this authorization in writing at any time by contacting the study doctor listed on the 
first page of this Informed Consent Form. If you cancel the authorization, continued use is permitted 
for the Protected Health Information obtained before the cancellation, if its use is necessary in 
completing the research, including samples collected for future research, if you have agreed to the 
storage of your leftover blood samples. 
If you refuse to provide this authorization, you will not be able to participate in the research study. If 
you cancel the authorization, then you will be withdrawn from the study. 
Finally, federal regulations allow you to obtain access to your Protected Health Information collected 
or used in this study. However, in order to complete the research study, your access to this Protected 
Health Information may be temporarily suspended while the research study is in progress. When the 
study is completed, your right of access to this information will be reinstated. 
This authorization will expire once there is no longer a need to review and analyze the information 
related to this study. Your authorization for the use of your Protected Health Information will not 
expire, but once the study is over there will be no access or link to your Protected Health Information 
for anything other than this study. In California and any other state that requires an expiration date, 
the Authorization will expire 50 years after you sign this authorization document. 
 
________________________ 
 
_____/_____/___ 
 
 
_____:_____ 
Signature of Participant  
 
YYYY   MMM   DD 
 
 
Time (24h clock) 
 
________________________ 
Print Name of Participant Here 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 23 of 27 
9 
COSTS AND SUBJECT COMPENSATION 
Study shots will be provided by the sponsor.  There is no cost to you for any of the study visits or 
tests.   
While you are in the study, you still need to get regular medical care as you normally would seek that 
care.  You (and/or your health care payer) will still have to pay for the costs of your regular medical 
care that are not a part of this study.   
If you are assigned to either Groups 1 or 2, you may receive up to $ _____ if you complete the whole 
study. If you do not complete the whole study, you may receive $_____ for each visit completed. This 
includes reimbursement for your time and also covers any reasonable travel expenses that are directly 
related to the study visits. The study staff can tell you more about when you will get paid. 
If you are assigned to Group 3, you may receive up to $ _____ if you complete the whole study. If 
you do not complete the whole study, you may receive  $_____ for each visit completed. This 
includes reimbursement for your time and also covers any reasonable travel expenses that are directly 
related to the study visits. The study staff can tell you more about when you will get paid. 
10 RIGHT TO ASK QUESTIONS AND/OR WITHDRAW FROM THE STUDY 
Your participation in this study is completely voluntary.  You may drop out of this study at any time.  
Your choice to drop out of this study will not in any way affect your medical treatment from your 
doctor.   
Please ask questions about any and every part of this study that you do not understand before you sign 
and date this Informed Consent Form.  If you drop out of the study you cannot re-enter, but this will 
not affect you in any other way. 
If you decide to leave this study after you receive a study shot, antibiotics or both, or are asked to 
leave by your study doctor once you have already received a study shot, antibiotics or both you will 
be asked to stay in the study to take part in only the safety tests for all remaining study visits and 
phone calls, or, if you refuse that, to come back to the study doctor’s office one last time for safety 
tests (see Section 4 of this Informed Consent Form).  These safety tests and follow up phone calls are 
to identify any unexpected side effects.  Your study doctor will make sure your regular medicines are 
working if you were on previous medicines.  Your study doctor will record your medical condition at 
the time you leave the study. 
11 NEW INFORMATION 
You will be told in a timely manner by your study doctor of any new important information about this 
study, AV7909 study vaccine, ciprofloxacin and doxycycline, and other therapies that may affect 
your health, welfare, or willingness to stay in the study. You may be asked to sign and date a new 
(revised) Informed Consent Form to show that you have been told of this new information.  You may 
contact the study doctor at any time after your participation ends to find out if any new information 
about this study has become available. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 24 of 27 
 
12 STUDY DISCONTINUATION 
Your study doctor, the study sponsor (Emergent), or FDA may decide to take you out of the study, 
without your consent, if it is in your best interest, if the IRB suspends/terminates study approval, if 
you are unable to meet the requirements of the study, or if the study is cancelled. You may be asked 
to leave the study if you do not follow study requirements or if the study shows signs of causing 
medical harm to you.  Also, the study sponsor may decide to end the study at any time for any reason.   
13 WHOM TO CONTACT ABOUT THIS STUDY 
During the study, if you experience any medical problems, whether or not you think they are related 
to this study, suffer a research-related injury, or have questions, concerns or complaints about the 
study, please contact the Principal Investigator at the telephone number listed on the first page of this 
consent document and below.  If you seek urgent/emergency care, or hospitalization is required, alert 
the treating physician that you are participating in this research study.   
An institutional review board (IRB) is an independent committee established to help protect the rights 
of research subjects.  If you have any questions about your rights as a research subject, and/or 
concerns or complaints regarding this research study, you may contact the IRB below: 
Name:       _________________________________Telephone: _______________________ 
This Informed Consent Form contains important information that will enable you to decide if you 
want to participate in this study.  If you have any questions that are not answered in this form, please 
ask the research personnel.  With your consent, your primary physician will be told of your 
participation in the study.  
 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 25 of 27 
STATEMENT OF INFORMED CONSENT 
NOTE: This informed consent with the “original” signatures must be retained in the subject’s file by 
the clinical study doctor. A signed and dated copy must be given to the subject for his/her records. 
Site Code:                                              Subject Identification Number: _____________ 
Study Number: __________________ Name of Investigator: _____________________ 
You (the participant) must complete the following: 
Please Tick Boxes 
1. I confirm that I have read this Informed Consent Form for the above study. 
 
2.  I confirm that the study has been explained to my satisfaction and I have had the 
time and opportunity to ask any questions. I know whom to contact if I think of 
more questions later.                                                                                                         
 
3.  I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving a reason and without my medical care or legal rights 
being affected. 
 
4.  I understand that sections of my medical notes may be looked at by responsible 
individuals appointed by the study sponsor (Emergent), ethics boards, such as the 
IRB, and regulatory authorities such as the FDA where it is relevant to my taking 
part in the study. I give permission for these individuals to have direct access to 
my records. 
 
5. By taking part in this study I agree to the transfer of my personal data to Emergent 
and to regulatory authorities both within and outside the U.S. 
 
6.   I have been given the information about the use and disclosure of my protected 
health information from this research. 
 
7.   By signing and dating this authorization form, I have not given up any of my legal 
rights. 
 
8.   I authorize the use and disclosures of my health information for the purposes 
described above to the parties listed in this Informed Consent Form for this study. 
 
9. I understand and agree to my primary physician being notified of my participation 
in the study (if applicable). 
 
10. All my questions have been answered. 
 
11. I agree to take part in the above study. 
 
 
A copy of the signed and dated Informed Consent Form will be given to you to keep. 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 26 of 27 
 
 
 
________________________ 
 
_____/_____/___ 
 
 
_____:_____ 
Signature of Participant  
 
YYYY   MMM   DD 
 
 
Time (24h clock) 
 
___________________________ 
Print Name of Participant Here 
 
 
_____________________________ 
Address of Participant 
 
 
______________________________ 
Telephone No. of Participant 
 
 
_______________________________ 
E-mail address of Participant (if applicable) 
 
 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


 
Master ICF Version 1.0 (13 May 2019), Protocol Version 2.0 
Study EBS.AVA.210 
Participant’s Initials _______  
 
 
 
Page 27 of 27 
Retention of blood samples for future use (choose one): 
I agree to the storage of my leftover blood samples for future re-testing as part of continued research 
on the AV7909 vaccine. Please note these samples will not be tested for gene sequencing (structure). 
YES, I agree to allow my 
blood samples to be 
retained for future 
analysis. 
Participant’s Signature 
Date of 
signature 
____________ 
(YYYY/MMM/DD) 
NO, I decline to allow 
my blood samples to be 
retained for future 
analysis. 
Participant’s Signature  
Date of 
signature 
____________ 
(YYYY/MMM/DD) 
 
_________________________  
 
_____/_____/___ 
 
_____:_____ 
Signature of Witness (if applicable) 
 
YYYY   MMM   DD 
 
Time (24h clock) 
_________________________ 
Print Name of Witness Here 
_________________________  
 
_____/_____/___ 
 
_____:_____ 
Signature Person Explaining Consent 
 
YYYY   MMM   DD 
 
Time (24h clock) 
______________________________________ 
Print Name of Person Explaining Consent Here 
INVESTIGATOR’S STATEMENT 
I, the undersigned, certify that to the best of my knowledge, the individual/participant signing and 
dating this consent has had the study fully and carefully explained and clearly understands the nature, 
risks and benefits of participating in this research project. 
 
__________________________ 
 
_____/_____/___ 
 
_____:_____ 
Signature of Investigator 
  
               YYYY   MMM   DD  
 Time (24h clock) 
________________________________ 
Print Name of Investigator Here 
 
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019


Document Approvals
Approved Date: 5/15/2019
Approval Task
Verdict:  Approve
14-May-2019 20:57:46 GMT+0000
Approval Task
Verdict:  Approve
14-May-2019 21:27:51 GMT+0000
QA Approval Task
Verdict:  Approve
15-May-2019 12:51:13 GMT+0000
Number: CLIN040070  Version: 1.0                    Effective Date: 15 May 2019

Prot_000.pdf: 
AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 1 of 139 
 
TITLE PAGE 
A Phase 2 Drug-Vaccine Interaction Study to Examine Whether 
Co-administering AV7909 with Ciprofloxacin or Doxycycline Affects 
Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults  
Clinical Protocol EBS.AVA.210  
 
 
 
Sponsor: 
 
 
 
 
 
Sponsor Representatives: 
 
 
 
VP, Clinical Development: 
 
  
  
 
 
 
Clinical Project Manager: 
 
 
 
 
 
 
 
Medical Monitor (IQVIA): 
 
 
  
 
 
 
Medical Monitor (Emergent): 
 
 
 
 
 
 
Immediately Reportable Serious 
Event(s): 
 
  
  
 
 
Protocol Version / Issue Date: 
 
 
Version 3.0 / 28 October 2019 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 2 of 139 
 
 
SPONSOR’S SIGNATURE PAGE 
 
Protocol Title: 
A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-
administering AV7909 with Ciprofloxacin or Doxycycline Affects 
Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy 
Adults 
 
Protocol Number: 
 
EBS.AVA.210 
Protocol Version 
(Issue Date): 
3.0 
(28 October 2019) 
 
 
 
  
  
 
 
 
Date 
 
 
 
 
 
 
 
 
Date 
  
 
 
 
 
 
 
 
Date 
 
 
 
 
Date 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 3 of 139 
 
 
INVESTIGATOR’S AGREEMENT 
 
The signature below constitutes the approval of this protocol and the attachments and provides 
the necessary assurances that the study will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable U.S. State and federal regulations and International 
Council for Harmonisation (ICH) guidelines. 
I will provide copies of the protocol and all pertinent information to all individuals responsible to 
me who assist in the conduct of this study. I will discuss this material with them to ensure that 
they are fully informed regarding the product and the conduct of the study. 
I agree that all information pertaining to the study, including protocols, electronic case report 
forms (eCRFs), and verbal and written consent information will be kept strictly confidential. 
Distribution of such information or information on the conduct, progress, or results of the study 
will be restricted to the clinical personnel involved with the conduct of the study, members of the 
Institutional Review Board/Independent Ethics Committee (IRB/IEC), and/or regulatory 
authorities. 
I understand that Emergent Product Development Gaithersburg Inc. (Emergent), its 
representatives, representatives from the Biomedical Advanced Research and Development 
Authority (BARDA) and regulatory agencies shall have access to any documents relevant to the 
study, including documents that demonstrate protocol and regulatory compliance. 
 
 
Printed Name of Principal Investigator 
 
 
 
 
Signature of Principal Investigator 
 
 
 
Date 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 4 of 139 
 
 
TABLE OF CONTENTS 
TITLE PAGE ...................................................................................................................................1 
SPONSOR’S SIGNATURE PAGE .................................................................................................2 
INVESTIGATOR’S AGREEMENT ...............................................................................................3 
TABLE OF CONTENTS .................................................................................................................4 
LIST OF TABLES .........................................................................................................................12 
LIST OF FIGURES .......................................................................................................................13 
LIST OF ABBREVIATIONS/SPECIALIST TERMS ..................................................................14 
1. 
SYNOPSIS .................................................................................................................19 
2. 
INTRODUCTION ......................................................................................................29 
2.1. 
Study Rationale ...........................................................................................................29 
2.2. 
Background .................................................................................................................29 
2.3. 
Benefit/Risk Assessment ............................................................................................31 
2.3.1. 
Benefits .......................................................................................................................31 
2.3.2. 
Risks ...........................................................................................................................31 
2.3.2.1. 
BioThrax .....................................................................................................................31 
2.3.2.2. 
CPG 7909....................................................................................................................31 
2.3.2.3. 
AV7909 .......................................................................................................................32 
2.3.2.4. 
Study Procedures (IM injections and Venipuncture) ..................................................33 
2.3.2.5. 
Ciprofloxacin ..............................................................................................................33 
2.3.2.6. 
Doxycycline ................................................................................................................33 
3. 
STUDY OBJECTIVES & ENDPOINTS ...................................................................34 
3.1. 
Study Objectives .........................................................................................................34 
3.1.1. 
Primary Objective .......................................................................................................34 
3.1.2. 
Secondary Objectives .................................................................................................34 
3.2. 
Study Endpoints ..........................................................................................................34 
3.2.1. 
Primary Endpoints ......................................................................................................34 
3.2.2. 
Secondary Endpoints ..................................................................................................34 
4. 
STUDY DESIGN .......................................................................................................35 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 5 of 139 
 
 
4.1. 
Overall Study Design ..................................................................................................35 
4.1.1. 
Group 1A Schedule .....................................................................................................39 
4.1.2. 
Group 1B Schedule .....................................................................................................39 
4.1.3. 
Group 2A Schedule .....................................................................................................39 
4.1.4. 
Group 2B Schedule .....................................................................................................40 
4.1.5. 
Group 3 Schedule .......................................................................................................40 
4.2. 
Scientific Rationale for Study Design ........................................................................40 
4.3. 
Justification of the Dose and Schedule .......................................................................41 
4.3.1. 
AV7909 .......................................................................................................................41 
4.3.2. 
Ciprofloxacin ..............................................................................................................41 
4.3.3. 
Doxycycline ................................................................................................................42 
4.4. 
End of Study Definition ..............................................................................................42 
5. 
STUDY POPULATION .............................................................................................43 
5.1. 
Inclusion Criteria ........................................................................................................43 
5.2. 
Exclusion Criteria .......................................................................................................44 
5.3. 
Lifestyle Restrictions ..................................................................................................46 
5.3.1. 
Meals and Dietary Restrictions ...................................................................................46 
5.3.1.1. 
Precautions for Participants Taking Ciprofloxacin or Doxycycline ...........................46 
5.3.1.2. 
Special Meals for Participants on Days with PK Sessions .........................................46 
5.3.2. 
Activity Restrictions ...................................................................................................46 
5.4. 
Screen Failures ............................................................................................................47 
6. 
TREATMENTS ..........................................................................................................48 
6.1. 
Treatment Administration ...........................................................................................48 
6.1.1. 
AV7909 Description ...................................................................................................48 
6.1.2. 
Ciprofloxacin Description ..........................................................................................48 
6.1.3. 
Doxycycline Description ............................................................................................48 
6.1.4. 
Administration of AV7909 .........................................................................................49 
6.1.5. 
Administration of Ciprofloxacin .................................................................................49 
6.1.6. 
Administration of Doxycycline ..................................................................................50 
6.2. 
Acquisition/Preparation/Handling/Storage/Accountability ........................................51 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 6 of 139 
 
 
6.2.1. 
Acquisition ..................................................................................................................51 
6.2.2. 
Preparation of Investigational Product for Injection ..................................................51 
6.2.3. 
Handling .....................................................................................................................51 
6.2.4. 
Product Storage and Stability .....................................................................................52 
6.2.4.1. 
AV7909 .......................................................................................................................52 
6.2.4.2. 
Ciprofloxacin ..............................................................................................................52 
6.2.4.3. 
Doxycycline ................................................................................................................52 
6.2.5. 
Investigational Product Experiencing Any Temperature Excursions .........................52 
6.2.6. 
Accountability .............................................................................................................52 
6.3. 
Measures to Minimize Bias ........................................................................................53 
6.3.1. 
Method of Treatment Assignment ..............................................................................53 
6.3.2. 
Blinding ......................................................................................................................53 
6.4. 
Treatment Compliance ................................................................................................54 
6.5. 
Concomitant Therapy .................................................................................................54 
6.5.1. 
Prohibited Medications ...............................................................................................55 
6.5.1.1. 
Medications Prohibited Due to Effects on Inflammation or the Immune 
System.........................................................................................................................55 
6.5.1.2. 
Medications Known to Interact with Ciprofloxacin ...................................................56 
6.5.1.3. 
Medications Known to Interact with Doxycycline .....................................................56 
7. 
STOPPING RULES, DISCONTINUATION/WITHDRAWAL CRITERIA 
AND PROCEDURES .................................................................................................57 
7.1. 
Entire Study ................................................................................................................57 
7.2. 
Individual Site .............................................................................................................57 
7.3. 
Individual Participants ................................................................................................57 
7.3.1. 
Discontinuation of Study Treatment ...........................................................................58 
7.3.2. 
Withdrawal from the Study ........................................................................................59 
7.4. 
Lost to Follow-up .......................................................................................................60 
8. 
STUDY ASSESSMENTS AND PROCEDURES ......................................................61 
8.1. 
Schedule of Assessments ............................................................................................61 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 7 of 139 
 
 
8.1.1. 
Screening, Randomization/Enrollment and Initial Blood Draws for TNA and 
Autoantibodies ............................................................................................................61 
8.1.1.1. 
Screening (Days -28 to -2) ..........................................................................................61 
8.1.1.2. 
Randomization/Enrollment and Initial Blood Draws for TNA and 
Autoantibodies: Day 1 ................................................................................................62 
8.1.2. 
Group 1A: Ciprofloxacin + AV7909 with Ciprofloxacin PK Sessions ......................63 
8.1.2.1. 
Group 1A: Day 3 – Overnight Stay # 1 ......................................................................65 
8.1.2.2. 
Group 1A: Day 4 – Pre-vaccine Single Dose Ciprofloxacin PK Session ...................65 
8.1.2.3. 
Group 1A: Days 5, 6 and 7 – Morning .......................................................................66 
8.1.2.4. 
Group 1A: Day 7 – Evening & Overnight Stay # 2 ....................................................67 
8.1.2.5. 
Group 1A: Day 8 – Pre-vaccine Steady-State Ciprofloxacin PK Session & 
Vaccination #1 ............................................................................................................67 
8.1.2.6. 
Group 1A: Days 9, 22 and 24 (At home) ....................................................................68 
8.1.2.7. 
Group 1A: Day 23 (± 1d) – Vaccination # 2 ..............................................................68 
8.1.2.8. 
Group 1A: Day 30 – Evening & Overnight Stay # 3 ..................................................69 
8.1.2.9. 
Group 1A: Day 31 – Post-vaccine Single Dose Ciprofloxacin PK Session ...............69 
8.1.2.10. 
Group 1A: Days 32, 33 and 34 – Morning .................................................................70 
8.1.2.11. 
Group 1A: Day 34 – Evening & Overnight Stay # 4 ..................................................70 
8.1.2.12. 
Group 1A: Day 35: – Post-vaccine Steady-State Ciprofloxacin PK Session .............71 
8.1.2.13. 
Group 1A: Day 36 (At home) .....................................................................................71 
8.1.2.14. 
Group 1A: Day 37 (± 1d) – Blood Draw for TNA .....................................................71 
8.1.2.15. 
Group 1A: Day 51 (± 1d) – Final In-Clinic Study Visit .............................................72 
8.1.3. 
Group 1B: Ciprofloxacin + AV7909 without Ciprofloxacin PK................................72 
8.1.3.1. 
Group 1B: Days 4 to 7 (At home) ..............................................................................74 
8.1.3.2. 
Group 1B: Day 8 – Vaccination #1 ............................................................................74 
8.1.3.3. 
Group 1B:Days 9, 22 and 24 (At home) .....................................................................75 
8.1.3.4. 
Group 1B: Day 23 (± 1 d) – Vaccination #2 ...............................................................75 
8.1.3.5. 
Group 1B: Days 31 to 36 (At home) ..........................................................................76 
8.1.3.6. 
Group 1B: Day 37 (± 1 d) – Blood Draw for TNA ....................................................76 
8.1.3.7. 
Group 1B: Day 51 (± 1 d) – Final In-Clinic Study Visit ............................................77 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 8 of 139 
 
 
8.1.4. 
Group 2A: Doxycycline + AV7909 with Doxycycline PK Sessions .........................77 
8.1.4.1. 
Group 2A: Day 1 – Overnight Stay # 1 ......................................................................79 
8.1.4.2. 
Group 2A: Day 2 – Pre-vaccine Single Dose Doxycycline PK Session ....................79 
8.1.4.3. 
Group 2A: Days 3, 4, 5, 6 and 7 – Morning ...............................................................80 
8.1.4.4. 
Group 2A: Day 7 – Evening & Overnight Stay # 2 ....................................................80 
8.1.4.5. 
Group 2A: Day 8 – Pre-vaccine Steady-State Doxycycline PK Session & 
Vaccination #1 ............................................................................................................81 
8.1.4.6. 
Group 2A: Days 9, 22 and 24 (At home) ....................................................................82 
8.1.4.7. 
Group 2A: Day 23 (± 1d) – Vaccination # 2 ..............................................................82 
8.1.4.8. 
Group 2A: Day 31 (+ 1d) – Evening & Overnight Stay # 3 .......................................83 
8.1.4.9. 
Group 2A: Day 32 – Post-vaccine Single Dose Doxycycline PK Session .................83 
8.1.4.10. 
Group 2A: Days 33, 34, 35, and 36 – Morning ..........................................................84 
8.1.4.11. 
Group 2A: Day 37 – Blood Draw for TNA ................................................................84 
8.1.4.12. 
Group 2A: Day 37 – Evening & Overnight Stay # 4 ..................................................84 
8.1.4.13. 
Group 2A: Day 38: – Post-vaccine Steady-State Doxycycline PK Session ...............85 
8.1.4.14. 
Group 2A: Day 51 (± 1d) – Final In-Clinic Study Visit .............................................85 
8.1.5. 
Group 2B: Doxycycline + AV7909 without Doxycycline PK Sessions ....................86 
8.1.5.1. 
Group 2B: Days 2 to 7 (At home) ..............................................................................87 
8.1.5.2. 
Group 2B: Day 8 – Vaccination #1 ............................................................................87 
8.1.5.3. 
Group 2B: Days 9, 22 and 24 (At home) ....................................................................88 
8.1.5.4. 
Group 2B: Day 23 (± 1 day) – Vaccination #2 ...........................................................88 
8.1.5.5. 
Group 2B: Days 32 to 37 (At home) ..........................................................................89 
8.1.5.6. 
Group 2B: Day 37 (± 1) – Blood Draw for TNA .......................................................89 
8.1.5.7. 
Group 2B: Day 51 (± 1d) – Final Study Visit .............................................................90 
8.1.6. 
Group 3: AV7909 Alone ............................................................................................90 
8.1.6.1. 
Group 3: Day 8 – Vaccination #1 ...............................................................................92 
8.1.6.2. 
Group 3: Day 23 (± 1 d) Vaccination #2 ....................................................................92 
8.1.6.3. 
Group 3: Day 37 (± 1 d) – Blood Draw for TNA .......................................................93 
8.1.6.4. 
Group 3: Day 51 (± 1 d) – Final In-Clinic Study Visit ...............................................93 
8.1.7. 
Quarterly Safety Follow-up Phone Calls ....................................................................94 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 9 of 139 
 
 
8.1.8. 
Early Withdrawal Visit ...............................................................................................95 
8.1.9. 
Unscheduled Visits .....................................................................................................95 
8.2. 
Immunogenicity/Efficacy Assessments ......................................................................96 
8.3. 
Safety Assessments .....................................................................................................96 
8.3.1. 
Adverse Events ...........................................................................................................96 
8.3.2. 
Clinical Laboratory Tests ...........................................................................................96 
8.3.3. 
Physical Examination .................................................................................................99 
8.3.4. 
Vital Signs ..................................................................................................................99 
8.3.5. 
Other Safety Assessments ...........................................................................................99 
8.3.5.1. 
E-diary Records ..........................................................................................................99 
8.4. 
Pharmacokinetics Sessions and Trough Concentrations of Antibiotics ...................102 
8.4.1. 
Ciprofloxacin ............................................................................................................102 
8.4.2. 
Doxycycline ..............................................................................................................102 
8.4.3. 
Specimen Collection, Preparation, Handling, and Shipping ....................................102 
8.5. 
Data Safety Monitoring Board ..................................................................................102 
9. 
REPORTING ADVERSE EVENTS ........................................................................104 
9.1. 
Definitions ................................................................................................................104 
9.1.1. 
Adverse Event ...........................................................................................................104 
9.1.2. 
Serious Adverse Event ..............................................................................................104 
9.1.3. 
Adverse Events of Special Interest ...........................................................................104 
9.2. 
Eliciting and Reporting Adverse Events ...................................................................104 
9.2.1. 
Rating the Severity of Adverse Events .....................................................................105 
9.2.2. 
Rating the Causality of Adverse Events ...................................................................105 
9.2.3. 
Eliciting Adverse Events from Other Safety Assessments .......................................106 
9.3. 
Immediately Reportable Events ................................................................................107 
9.3.1. 
Principal Investigator’s Responsibilities ..................................................................107 
9.3.2. 
Sponsor’s Reporting Requirements ..........................................................................107 
9.4. 
Pregnancy .................................................................................................................108 
9.5. 
Reporting of Other Information – Unanticipated Problems .....................................109 
9.6. 
Procedure for Breaking the Blind for Individual Participants ..................................109 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 10 of 139 
 
 
9.7. 
Follow-up of Adverse Events ...................................................................................109 
9.7.1. 
Follow-up of Nonserious Adverse Events ................................................................109 
9.7.2. 
Follow-up of Serious Adverse Events or Adverse Events of Special Interest .........110 
10. 
STATISTICAL ANALYSIS ....................................................................................111 
10.1. 
Study Endpoints and Statistical Hypotheses .............................................................111 
10.1.1. 
Primary Endpoints ....................................................................................................111 
10.1.2. 
Secondary Endpoints ................................................................................................111 
10.1.2.1. 
Secondary Safety Endpoints .....................................................................................111 
10.1.2.2. 
Secondary Pharmacokinetic Endpoints ....................................................................112 
10.1.2.3. 
Secondary Immunogenicity Endpoints .....................................................................112 
10.2. 
Sample Size and Power ............................................................................................112 
10.3. 
Analysis Populations ................................................................................................113 
10.4. 
Handling of Outliers and Missing Data ....................................................................114 
10.5. 
Statistical Methods ....................................................................................................114 
10.5.1. 
PK Analyses ..............................................................................................................114 
10.5.1.1. 
Summary of Concentrations and PK Parameters ......................................................114 
10.5.1.2. 
Equivalence Testing for Primary PK Endpoints .......................................................115 
10.5.1.3. 
Equivalence Testing for Secondary PK Endpoints ...................................................115 
10.5.2. 
Non-Inferiority Testing for Secondary Immunogenicity Endpoints ........................115 
10.5.3. 
Exploratory Analysis for Immunogenicity ...............................................................115 
10.6. 
Safety Analysis .........................................................................................................116 
10.6.1. 
Adverse Events .........................................................................................................116 
10.6.2. 
Clinical Laboratory Data ..........................................................................................116 
10.6.3. 
Physical Examination ...............................................................................................117 
10.6.4. 
Vital Signs ................................................................................................................117 
10.6.5. 
Prior and Concomitant Medications .........................................................................117 
10.6.6. 
Other Safety Variables ..............................................................................................117 
10.6.6.1. 
Reactogenicity ..........................................................................................................117 
10.6.6.2. 
Autoantibody Testing and TSH Assessment ............................................................117 
10.7. 
Interim Analysis ........................................................................................................118 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 11 of 139 
 
 
10.8. 
Multiplicity ...............................................................................................................118 
10.9. 
Final Analysis Plan ...................................................................................................118 
11. 
DATA HANDLING AND RECORDKEEPING .....................................................119 
11.1. 
Source Documents and Access .................................................................................119 
11.2. 
Data Management .....................................................................................................119 
11.3. 
Data Collection and Discrepancy Management .......................................................119 
11.4. 
File Management at the Investigational Site ............................................................119 
11.5. 
Record Retention at the Investigational Site ............................................................120 
11.6. 
Protocol Deviations ..................................................................................................120 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE .......................................122 
12.1. 
Monitoring ................................................................................................................122 
12.2. 
Auditing ....................................................................................................................123 
13. 
ETHICS ....................................................................................................................124 
13.1. 
Informed Consent .....................................................................................................124 
13.2. 
Institutional Review Board .......................................................................................124 
13.3. 
Future Use of Stored Specimens ...............................................................................125 
13.4. 
Confidentiality ..........................................................................................................125 
14. 
AMENDMENT POLICY .........................................................................................126 
15. 
PUBLICATION POLICY ........................................................................................127 
16. 
LIST OF REFERENCES ..........................................................................................128 
17. 
APPENDICES ..........................................................................................................132 
APPENDIX A. TOXICITY GRADING SCALE FOR HEALTHY ADULT AND 
ADOLESCENT VOLUNTEERS ENROLLED IN PREVENTIVE 
VACCINE CLINICAL TRIALS .....................................................................133 
APPENDIX B. ADVERSE EVENTS OF SPECIAL INTEREST ...........................................137 
APPENDIX C. SPONSOR’S GUIDANCE ON CHRONIC CONDITIONS FOR 
INVESTIGATORS ..........................................................................................139 
 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 12 of 139 
 
 
LIST OF TABLES 
Table 1: 
Abbreviations/Specialist Terms ..................................................................................14 
Table 2: 
Study Groups ..............................................................................................................35 
Table 3: 
Medications Prohibited for all Participants ................................................................55 
Table 4: 
Criteria for Discontinuation of Treatment in Individual Participants .........................58 
Table 5 
Schedule of Events for Group 1A: Ciprofloxacin + AV7909 with 
Ciprofloxacin PK ........................................................................................................63 
Table 6: 
Schedule of Events for Group 1B: Ciprofloxacin + AV7909 without 
Ciprofloxacin PK ........................................................................................................73 
Table 7: 
Schedule of Events for Group 2A: Doxycycline + AV7909 with 
Doxycycline PK ..........................................................................................................77 
Table 8: 
Schedule of Events for Group 2B: Doxycycline + AV7909 without 
Doxycycline PK ..........................................................................................................86 
Table 9: 
Schedule of Events for Group 3: AV7909 Alone .......................................................90 
Table 10: Screening/Safety Clinical Laboratory Tests ...............................................................98 
Table 11 
Antibiotic Pharmacokinetic Parameters ...................................................................114 
Table 12: Toxicity Grading Scale for Clinical Abnormalities in Healthy Adult and 
Adolescent Volunteers ..............................................................................................133 
Table 13: Toxicity Grading of Laboratory Abnormalities ........................................................135 
Table 14: List of Adverse Events of Special Interest* .............................................................137 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 13 of 139 
 
 
LIST OF FIGURES 
Figure 1: 
 Study Design for EBS.AVA.210 ...............................................................................37 
Figure 2: 
 Event Schematic for EBS.AVA.210 Groups 1 to 3 ...................................................38 
 
  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 14 of 139 
 
 
LIST OF ABBREVIATIONS/SPECIALIST TERMS 
The following abbreviations and specialist terms are used in this study protocol. 
Table 1: 
Abbreviations/Specialist Terms  
Abbreviation/Specialist 
Term  
Definition 
ACC 
American College of Cardiologists 
ACIP 
Advisory Committee on Immunization Practices 
ADHD 
Attention Deficit Hyperactivity Disorder 
AE 
Adverse event 
AESI  
Adverse event of special interest 
AHA 
American Heart Association 
aIG 
Animal derived immune globulin 
ALP 
Alkaline phosphatase 
ALT 
Alanine aminotransferase 
ANA 
Antinuclear antibody 
ANCA 
Anti-neutrophil cytoplasmic antibody 
ANOVA 
Analysis of variance 
AST  
Aspartate aminotransferase 
AUC0-12h 
Area under the concentration-time curve from t=0 to 12 hours 
AUC0-inf 
Area under the concentration-time curve from t=0 to infinity 
AUC0-t 
Area under the concentration-time curve from t=0 to last measurable 
concentration 
AUMC 
Area under the first moment curve 
AVA 
Anthrax vaccine adsorbed, BioThrax. 
AV7909 
AVA plus CPG 7909, an investigational product 
B. anthracis 
Bacillus anthracis 
BARDA 
Biomedical Advanced Research and Development Authority 
BioThrax 
BioThrax® (Anthrax Vaccine Adsorbed) 
BMI 
Body mass index 
BUN 
Blood urea nitrogen 
CBC 
Complete blood cell count 
CBER 
Center for Biologics Evaluation and Research 
CDC 
Centers for Disease Control and Prevention 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 15 of 139 
 
 
Abbreviation/Specialist 
Term  
Definition 
CFR 
Code of Federal Regulations 
CI 
Confidence interval 
Cipro 
Ciprofloxacin  
Cmax 
Maximum concentration 
CNS 
Central nervous system 
CPG 7909 
A synthetic oligonucleotide used as an adjuvant 
CRO 
Contract research organization 
Ct 
Last measurable concentration 
CV 
Coefficient of variation 
d 
Day(s) 
dL 
Deciliter 
DM 
Diabetes mellitus 
DMP 
Data Management Plan 
Doxy 
Doxycycline  
DRESS 
Drug reaction with eosinophilia and systemic symptoms 
dsDNA 
Double-stranded deoxyribonucleic acid 
DSMB 
Data Safety Monitoring Board 
 
 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
e-diary 
Electronic diary 
 
 
ER 
Emergency room 
EWV 
Early withdrawal visit 
FDA 
Food and Drug Administration 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practices 
GERD 
Gastroesophageal reflux disease 
GLP 
Good Laboratory Practices 
GMC 
Geometric mean concentration 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 16 of 139 
 
 
Abbreviation/Specialist 
Term  
Definition 
GMT 
Geometric mean titer 
GUP 
General use prophylaxis 
HBsAg 
Hepatitis B virus surface antigen 
HCVAb 
Hepatitis C virus antibody 
hhIG 
Human hyperimmune globulins 
h/hr 
Hour(s) 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human Immunodeficiency Virus 
HIVAb 
Antibody to human immunodeficiency virus  
ICF  
Informed consent form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IgG 
Immunoglobulin G 
IGIM 
Human immunoglobulins for intravenous injection 
IGIV 
Human immunoglobulins for intravenous injection 
IGSC 
Human immunoglobulins for subcutaneous injection 
IH 
Intracranial hypertension 
IM 
Intramuscular 
IND 
Investigational New Drug (application) 
IP 
Investigational product 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IUD  
Intrauterine device 
IUS 
Intrauterine system 
IV 
Intravenous 
IXRS 
Interactive voice/web response system 
kDa 
Kilodalton 
Kel 
Elimination rate constant 
LD50 
Dose at which 50% mortality is observed 
LLOQ 
Lower limit of quantification 
MedDRA 
Medical Dictionary for Regulatory Activities 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 17 of 139 
 
 
Abbreviation/Specialist 
Term  
Definition 
mEq 
MilliEquivalents 
mg 
Milligram 
min 
Minute(s) 
mIU/mL 
Milli-international units per milliliter 
MM 
Medical Monitor 
MRT 
Mean residence time 
NB 
Note well (nota bene) 
NF50 
50% neutralization factor 
NHP 
Nonhuman primate 
NOSTASOT  
No statistical significance of trend 
NSAID 
Non-steroidal anti-inflammatory drug 
ODN 
Oligodeoxynucleotide 
OHRP 
Office of Human Research Protection 
PA 
Protective antigen 
PE 
Physical examination 
PEP 
Post-exposure prophylaxis 
PI 
Principal Investigator 
PK 
Pharmacokinetic(s) 
po 
Per os (orally) 
PRBC 
Packed red blood cells 
PT 
Preferred term (MedDRA) 
PV  
Pharmacovigilance 
q 12 hr 
Every 12 hours 
QA 
Quality Assurance 
QC 
Quality Control 
RBC/hpf 
Red blood cells/high powered field 
RF 
Rheumatoid factor 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SAS 
Statistical Analysis Software 
SC 
Subcutaneous 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 18 of 139 
 
 
Abbreviation/Specialist 
Term  
Definition 
SOC 
System Organ Class level of MedDRA 
SOP 
Standard operating procedure 
Subject ID 
A unique identifier assigned to each study participant 
SUSAR 
Suspected unexpected serious adverse reaction 
SV 
Study visit 
t1/2 
Elimination half-life 
TBD 
To be determined 
TEAE 
Treatment emergent adverse event 
tmax 
Time to maximum concentration 
TNA 
Toxin neutralizing antibody 
TOST 
Two one-sided t-tests  
TSH 
Thyroid stimulating hormone 
UAT 
User acceptability testing 
ULN 
Upper limit of normal 
UPT 
Urine pregnancy test 
USP 
United States Pharmacopeia 
USV 
Unscheduled Visit 
UVA/UVB 
Ultraviolet radiation A/B 
Vac 
Vaccination 
WBC 
White blood cell count 
WHO 
World Health Organization 
WOCBP 
Woman of childbearing potential 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 19 of 139 
 
 
1. 
SYNOPSIS 
Name of Sponsor/Company: 
 
Name of Investigational Product: AV7909 
Name of Active Ingredient: AVA drug substance and CPG 7909 as adjuvant 
Name of Co-Administered Products: Ciprofloxacin hydrochloride; Doxycycline hyclate 
Title of Study: A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co-
administering AV7909 with Ciprofloxacin or Doxycycline Affects Antibiotic 
Pharmacokinetics or AV7909 Immunogenicity in Healthy Adults 
Short Title: PEP Antibiotic-AV7909 Interaction Study 
Study center(s): Up to five sites in the United States (US) 
Studied period (months): 
Individual participants enrollment in the study 
from the screening visit to the last visit and all 
safety follow-up calls will be approximately 14.5 
months. Screening will be from Day -28 to Day -2 
followed by either 19 (Group 2A), 17 (Group 1A) 
or 6 (Groups 1B, 2B and 3) in-clinic visits 
occurring over six weeks. Safety follow-up phone 
calls will be conducted 3, 6, 9 and 12 months after 
the last vaccination. 
Overall study duration from the first participant 
first visit to last participant last visit is anticipated 
to be approximately 18 months. 
Phase of Development: Phase 2 
 
Objectives: 
Primary: 
 To evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when 
administered orally, prior to, and following, the intramuscular (IM) administration of 
a two-dose schedule of AV7909 administered two weeks apart. 
Secondary: 
 To assess the safety of concurrent administration of oral ciprofloxacin or doxycycline 
and two doses of AV7909 administered IM. 
 To evaluate the Day 37 immune response using the toxin-neutralizing antibody 
(TNA) assay following two IM doses of AV7909 with and without the concurrent 
oral administration of ciprofloxacin or doxycycline. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 20 of 139 
 
 
Study Design: 
This is a randomized, open-label, phase 2, multicenter trial to investigate the potential 
interactions of AV7909 and ciprofloxacin or doxycycline when administered concomitantly. 
Healthy males and females between 18 and 45 years of age, inclusive, will read, sign and 
date an informed consent form and then be screened for eligibility for participation in the 
study. Participants (N=210) meeting the entry criteria on Day 1 will be randomized 1:1:1 into 
one of three investigational product (IP) groups as shown in the table below.  
IP Group 
Treatment 
Group 
Treatment 
Sample 
Size 
 (N) 
1 Cipro 
1A 
AV7909 + ciprofloxacin (with PK assessment) 
≈40 
≈70 
1B 
AV7909 + ciprofloxacin (without PK assessment) 
30 
2 Doxy 
2A 
AV7909 + doxycycline (with PK assessment) 
≈40 
≈70 
2B 
AV7909 + doxycycline (without PK assessment) 
30 
3 AV7909 
3 
AV7909 only 
70 
 
 
TOTAL 
≈210 
Approximately the first 40 participants who are randomized for either IP Groups 1 and 2, ie, 
the first 80 participants randomized across all sites to either antibiotic group, will be assigned 
to Treatment Groups 1A or 2A while those randomized into IP Groups 1 and 2 thereafter will 
be assigned to Treatment Groups 1B or 2B. Randomization will be stratified by site. A 
representative racial distribution will be sought among recruited participants and sites will be 
asked to recruit populations that are gender- and age-balanced (ie, between 40-60% male 
with 40-60% of participants in the two age ranges of 18 to 30 years of age and 31 to 45 years 
of age). 
Figure 1 displays the overall design used for this study. 
Ciprofloxacin (500 mg by mouth [per os] every 12 hours [po q 12 hr]) will be administered to 
Group 1 on Days 4-9, Days 22-24 and Days 31-37, and doxycycline (100 mg by mouth [per 
os] every 12 hours [po q 12 hr]) will be administered to Group 2 on Days 2-9, Days 22-24, 
and Days 32-38. Antibiotics will be administered in three courses that will be used both by 
site staff for in-clinic visits and by participants when they are at home. The exact format of 
the courses in terms of number of tablets and when participants will receive each course will 
be described in the Pharmacy Manual. 
The 40 participants in Group 1A will self-administer approximately half (14/31) of the 
ciprofloxacin doses; the remainder will be administered by site staff during clinic visits. The 
30 participants in Group 1B, with far fewer clinic visits than Group 1A due to the lack of PK 
sampling, will self-administer more than 90% (29/31) of ciprofloxacin doses. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 21 of 139 
 
 
For the doxycycline groups, the distributions of self-administered doses are similar to those 
planned for the two ciprofloxacin groups with Group 2A self-administering 15/35 doses and 
Group 2B self-administering 33/35 doses. 
An event schematic for this study is provided in Figure 2. 
Ciprofloxacin PK sessions in Group 1A will be conducted on Days 4, 8, 31 and 35.  
Ciprofloxacin pre-dose or trough values will be measured prior to the morning doses of 
ciprofloxacin on Days 4, 5, 6, 7 and 8 and again on Days 31, 32, 33, 34 and 35. On the days 
with PK sessions, blood samples for measurement of ciprofloxacin concentrations will be 
collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter). The Schedules of Events for Group 1A and Group 1B 
are provided in Table 5 and Table 6, respectively.   
Doxycycline PK sessions in Group 2A will be conducted on Days 2, 8, 32 and 38.  
Doxycycline pre-dose or trough values will be measured prior to the morning doses of 
doxycycline on Days 2, 3, 4, 5, 6, 7 and 8 and again on Days 32, 33, 34, 35, 36, 37 and 38.  
On the days with PK sessions, blood samples for measurement of doxycycline concentrations 
will be collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose 
(± 5 min through hr 4, then ± 15 min thereafter). The Schedules of Events for Group 2A and 
Group 2B are provided in Table 7 and Table 8, respectively. 
All participants, including the 70 participants in Group 3, will receive AV7909 IM in the 
deltoid muscle of alternate arms on Days 8 and 23.  For Groups 1A and 2A, the first 
vaccination will occur following completion of the PK sessions and after administration of 
the evening antibiotic (ciprofloxacin or doxycycline) dose. The Schedule of Events for Group 
3 is provided in Table 9. 
Blood draws for TNA assessments will be performed for all participants at randomization 
(Day 1) and on Day 37 (two weeks following the second and final vaccination). 
Safety in all groups will be assessed up to Day 51 (or the early withdrawal visit [EWV]) by 
physical examinations, vital signs, clinical laboratories (hematology, serum chemistry, and 
urinalysis), monitoring of adverse events (AEs), serious AEs (SAEs), AEs of special interest 
(AESIs; ie, of autoimmune etiology; see Table 14), concomitant medications, and injection 
site and systemic reactions as reported in participant electronic diaries (e-diaries). The 
severity of AEs, laboratory test results for select analytes, and vital sign results will be 
assessed based on the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Reactogenicity 
(solicited systemic and local injection site reactions) will be assessed daily by the participants 
using e-diaries for at least seven days after each vaccination. If local injection site or 
systemic reactions continue beyond seven days (d), participants will be prompted to continue 
e-diary entries until resolved for at least two consecutive days. Participants in Groups 1 and 2 
will also use the e-diary to record their self-administration of antibiotics. Site staff will 
review e-diary entries on a routine basis and will review the e-diary record with each 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 22 of 139 
 
 
participant at each study visit. Safety follow-up phone contacts to collect information on 
AEs, SAEs and AESIs will occur at 3 months (Day 114 ± 14 d), 6 months (Day 205 ± 14 d), 9 
months (Day 296 ± 14 d) and 12 months (Day 388 ± 14 d) after the last scheduled 
vaccination. 
Blood samples will be taken at randomization (Day 1) and Day 51 (or the EWV) to test (if 
medically indicated as per principal investigator’s discretion based on a report of potential 
AESI) for thyroid stimulating hormone (TSH) levels, antinuclear antibodies (ANA), 
rheumatoid factor (RF) and anti-double stranded deoxyribonucleic acid (dsDNA) antibodies. 
Samples may also be collected at unscheduled visits following the safety follow-up phone 
contact(s) to investigate potential AESI reports. 
Independent safety oversight will be provided by a Data Safety Monitoring Board (DSMB), 
which will be notified of significant AEs [eg, SAEs, severe AEs recorded on an electronic 
case report form (eCRF), potential AESIs of autoimmune etiology, or any other events the 
medical monitor deems medically relevant] as determined by the medical monitor on an 
ongoing basis. The DSMB will comprise at least three voting members, to include one expert 
in immunology to specifically support the evaluation of potential AESIs for autoimmune 
etiology, if pre-existing or new onset, and relationship to the study product. The DSMB will 
make recommendations regarding the safety of continuing enrollment and dosing. Study 
enrollment and dosing may be interrupted at the request of the DSMB Chair if it is believed 
that an AE represents a significant safety concern requiring suspension of dosing pending full 
DSMB evaluation. The operations of the DSMB will be detailed in a DSMB Charter which 
will be finalized prior to screening the first participant. 
Number of Participants (Planned): 
Approximately 210 
Diagnosis and Main Criteria for Study Participation 
Healthy males and females aged 18 to 45 years (inclusive) with no prior history of anthrax 
disease, suspected exposure to anthrax, or vaccination with anthrax vaccine and no history of 
allergic reaction or intolerance to quinolone or tetracycline antimicrobials and as determined 
by inclusion and exclusion criteria listed below. 
Inclusion Criteria 
Individuals must meet all of the following inclusion criteria for study participation: 
1. Written informed consent obtained from the participant (dated, signed, and captured 
in the medical chart at the site). 
2. A male or female, aged 18 to 45 years of age, inclusive, at the time of informed 
consent. 
3. Healthy condition as established by medical history and clinical examination before 
entering into the study. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 23 of 139 
 
 
4. Have a body mass index (BMI) less than or equal to 35.0 kg/m2 at the Screening visit. 
5. Have adequate venous access for phlebotomies.  
6. For a woman of childbearing potential (WOCBP), negative pregnancy test at 
Screening and pre-randomization on Day 1, not currently breastfeeding, and no 
intention to become pregnant during the study period through 12 months after last 
receipt of any investigational product (IP).  
Every female participant is considered to be a WOCBP unless she is surgically sterile 
(ie, has had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or 
postmenopausal [which is defined as >12 consecutive months without menses and a 
Screening FSH of >30 mIU/mL]. Adequate birth control (as defined here) must be 
initiated at least one month prior to randomization on Day 1 and used throughout the 
trial.  Adequate birth control methods are sexual abstinence, intrauterine 
device/system (IUD/IUS), birth control pills, implantable or injectable contraceptives 
(eg, Norplant® or Depo-Provera®), removable birth control device (eg, NuvaRing® 
or Evra® patches) or double-barrier method of birth control (diaphragm in 
combination with contraceptive jelly or condoms in conjunction with contraceptive 
jelly, cream or foam), tubal ligation, or have a monogamous relationship with 
vasectomized partner who has been vasectomized for 6 months or more prior to the 
participant’s trial entry.  
Female participants randomized to Groups 1 or 2: be willing to add a double-barrier 
method, IUD, or abstinence as back-up forms of birth control since ciprofloxacin and 
doxycycline may decrease the effectiveness of birth control pills, implantable or 
injectable contraceptives. 
Exclusion Criteria 
Individuals meeting any of the following exclusion criteria will be excluded from study 
participation: 
1. A Screening clinical laboratory test result greater than the central laboratory’s upper 
limit of normal (ULN) for aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), random glucose, total bilirubin, blood urea nitrogen (BUN), 
or creatinine. Other serum chemistry parameters that are not within the reference 
range will not be considered exclusionary, unless deemed clinically significant by the 
principal investigator. 
2. History of allergic reaction or intolerance to quinolone antimicrobials or  any medical 
condition that would contraindicate the use of ciprofloxacin, including and not limited 
to vascular disorders, tendon disorders, certain genetic connective tissue disorders 
(eg, Marfan and Ehlers–Danlos syndrome), prolongation of QT interval, seizures, 
peripheral neuropathy, increased risk of C. difficile infection  (see ciprofloxacin 
prescribing information in the Pharmacy Manual). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 24 of 139 
 
 
3. History of allergic reaction or intolerance to tetracycline antibiotics or any medical 
condition that would contraindicate the use of doxycycline including an increased risk 
of C. difficile infection, increases in BUN or an increased sensitivity to direct sunlight 
or ultraviolet radiation resulting in erythema (see doxycycline prescribing information 
in the Pharmacy Manual).   
4. Has a need for any of the prohibited medications in Section 6.5.1 or requires the 
medications/foods within the prohibited times in Section 5.3.1.1.  
5. Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area that 
may interfere with injection site assessments. 
6. History of anthrax disease, suspected exposure to anthrax, or previous vaccination 
with any anthrax vaccine.  
7. Have previously served in the military any time after 1990 or plan to enlist in the 
military any time from Screening through the final telephone contact.  
8. Previous anaphylactic reaction, severe systemic response, or serious hypersensitivity 
to a prior immunization or a known allergy to synthetic ODNs, aluminum, 
formaldehyde, benzethonium chloride (phemerol). 
9. Plan to have an elective surgery at any point during the study until after the final 
safety phone contact. 
10. Have donated or plan to donate blood within one month prior to enrollment or at any 
point during the study until after the final safety phone contact. 
11. Use of any investigational or non-registered product (drug, vaccine or biologic) 
within 30 days preceding the dose of study vaccine, or planned use during the study 
until after the final safety phone contact.  
12. Planned administration of any commercially-available vaccine from one week prior to 
the first study vaccination through two weeks after the last vaccination.  
13. Have experienced chronic dosing (defined as more than 14 days) with any immune-
modifying drugs within six months of study enrollment. This includes oral, 
intramuscular, intra-articular, intravenous, or inhalation corticosteroids except in the 
case of inhaled or intranasal medications for seasonal allergies (see Table 3).  
14. Receipt of immunoglobulins and/or any blood products within the three months 
preceding study enrollment or at any point during the study period until after the final 
safety visit on Day 51. 
15. An abnormal electrocardiogram (ECG) at screening interpreted as ‘Abnormal, 
Significant’. Inclusion of participants with ‘Abnormal, Insignificant’ ECGs will be 
based on the principal investigator’s discretion. 
16. Have an active malignancy or history of metastatic or hematologic malignancy.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 25 of 139 
 
 
17. Have a history of an autoimmune, inflammatory, vasculitic or rheumaticor rheumatic 
disease including but not limited to systemic lupus erythematosus, Guillain-Barré 
syndrome, myasthenia gravis, polymyalgia rheumatica, diabetes mellitus type I, 
rheumatoid arthritis or scleroderma. 
18. A positive laboratory evidence of hepatitis B, hepatitis C, or human 
immunodeficiency virus (HIV) HIV-1 or HIV-2 infection. 
19. Positive result on urine drug screen, any evidence of ongoing drug abuse or 
dependence (including alcohol), or recent history (over the past five years) of 
treatment for alcohol or drug abuse.  
20. Has an acute disease at the time of enrollment. 
Note that screening lab tests may be delayed to allow the resolution of a transient 
acute condition or the subject may be rescreened according to procedures under 
Section 5.4.  
21. Any medical condition that, in the opinion of the investigator, could adversely impact 
the participant’s involvement or the conduct of the study. 
22. Have a significant chronic condition (see Sponsor’s guidance on significant chronic 
conditions in Appendix C), eg, serious cardiovascular, pulmonary, hepatic, type II 
diabetes mellitus or renal disease that, in the opinion of the investigator, would render 
treatment unsafe or would interfere with trial evaluations or completion of the study. 
23. An opinion of the investigator that it would be unwise to allow the participant to be 
randomized into the study. 
24. Member or immediate family member of an investigator site team. 
Investigational Products (IP), Dosage, Schedule and Mode of Administration: 
 AV7909 (containing 0.5 mL AVA + 0.25 mg CPG 7909 adjuvant per dose) will be 
administered IM in the deltoid muscle of alternating arms to all (Groups 1 to 3) on Day 
8 and Day 23. 
 Ciprofloxacin (500 mg po q 12 hr) will be administered to participants in Group 1 on 
Days 4-9, Days 22-24, and Days 31-37. 
 Doxycycline (100 mg po q 12 hr) will be administered to participants in Group 2 on 
Days 2-9, Days 22-24, and Days 32-38. 
Duration of Treatment: 
All participants will receive two vaccinations with AV7909 two weeks apart. 
Participants in Group 1 will be intermittently dosed with ciprofloxacin over 33 days and 
participants in Group 2 will be intermittently dosed with doxycycline over 36 days.  
Endpoints 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 26 of 139 
 
 
Primary Endpoints: 
 Area under the curve from 0 to 12 hours (AUC0-12h) and maximum concentration 
(Cmax) for ciprofloxacin on Days 8 and 35 
 Area under the curve from 0 to 12 hours (AUC0-12h) and maximum concentration 
(Cmax) for doxycycline on Days 8 and 38  
Secondary Endpoints: 
Safety 
 Incidence of AEs from the first dose of any IP through the Final Study Visit 
(Day 51 ± 1 d) 
 Incidence of serious AEs (SAEs) from the first dose of any IP until the 12-month 
follow-up (Day 388 ± 14d) 
 Incidence of solicited systemic and injection site reactions reported in participant e-
diaries following each vaccination 
 Incidence of AESIs from the first dose of any IP until the 12-month follow-up 
(Day 388 ± 14 d) 
 Incidence of clinical laboratory abnormalities 
Pharmacokinetics and Immunogenicity 
 AUC0-12h and Cmax for ciprofloxacin on Days 4 and 31 and for doxycycline on 
Days 2 and 32 
 Geometric mean TNA 50% neutralizing factor (NF50) values 2 weeks after the 
second vaccination (Day 37 ± 1 d) 
Statistical Methods: 
Statistical Analysis 
To characterize the PK profiles of ciprofloxacin and doxycycline, the following PK 
parameters will be calculated using noncompartmental analytic methods: 
 Maximum observed concentration: Cmax 
 Time of Cmax: tmax  
 Elimination half-life: t1/2 
 Elimination rate constant: Kel 
 Area under the serum concentration-time curve (12 hours): AUC0-12h 
 Area under the first moment curve: AUMC 
  Mean residence time: MRT  
 Area under the serum concentration-time curve extrapolated to infinity: AUC0-inf  
Effect of AV7909 on Ciprofloxacin Pharmacokinetics 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 27 of 139 
 
 
To examine the effect of AV7909 vaccination on the steady state pharmacokinetics of 
ciprofloxacin, the trough values for Days 4 through 8 and Days 31 through 35 will be 
analyzed to demonstrate that ciprofloxacin concentrations have achieved steady state on Day 
8 and Day 35. Then the Cmax and AUC0-12h values for ciprofloxacin determined for Group 1A 
participants on Day 35 (following two doses of AV7909) will be compared to those 
determined on Day 8 (prior to AV7909 vaccination).  Point estimates and 90% confidence 
intervals (CIs) will be calculated for the geometric mean ratios. If the CIs are all within 0.80 
and 1.25, then it can be concluded that AV7909 vaccination does not significantly influence 
the steady state Cmax and AUC0-12h values of ciprofloxacin. 
Effect of AV7909 on Doxycycline Pharmacokinetics 
To examine the effect of AV7909 vaccination on the steady state pharmacokinetics of 
doxycycline, the trough values for Days 2 through 8 and Days 32 through 38 will be analyzed 
to demonstrate that doxycycline concentrations have achieved steady state on Day 8 and 
Day 38. Then the Cmax and AUC0-12h values for doxycycline determined for Group 2A 
participants on Day 38 (following two doses of AV7909) will be compared to those 
determined on Day 8 (prior to AV7909 vaccination).  Point estimates and 90% CIs will be 
calculated for the geometric mean ratios. If the CIs are all within 0.80 and 1.25, then it can be 
concluded that AV7909 vaccination does not significantly influence the steady state Cmax and 
AUC0-12h values of doxycycline.  
For the secondary endpoints, a similar comparison will be conducted for the Cmax and 
AUC0-12h values for ciprofloxacin from Day 31 vs Day 4 to determine if these single-dose PK 
values of ciprofloxacin are affected by AV7909 vaccination and a similar comparison will be 
conducted for the Cmax and AUC0-12h values for doxycycline from Day 32 vs Day 2 to 
determine if these single-dose PK values of doxycycline are affected by AV7909 vaccination. 
Effect of Ciprofloxacin or Doxycycline on AV7909 Immunogenicity 
To evaluate whether the administration of ciprofloxacin affects the immunogenicity of 
AV7909, TNA NF50 values two weeks after the second dose of AV7909 will be compared 
between the cohort of participants that received both ciprofloxacin and AV7909, ie, Group 1, 
also known as the ciprofloxacin test cohort, and the cohort who received AV7909 only, ie, 
Group 3 or the reference cohort. Point estimates and two-sided 95% lower CIs will be 
constructed for the ratio (test: reference) of geometric means. If the lower bound of the two-
sided 95% lower CI is greater than 0.5 (the non-inferiority margin) it can be concluded that 
the immune response in the cohort who received AV7909 plus ciprofloxacin is non-inferior 
to the cohort which received AV7909 alone and thus that ciprofloxacin did not demonstrably 
affect the immunogenicity of AV7909. 
The same evaluation will be conducted to determine if the administration of doxycycline 
affects the immunogenicity of AV7909 in that TNA NF50 values two weeks after the second 
dose of AV7909 will be compared between the cohort of participants that received both 
doxycycline and AV7909, ie, Group 2, the doxycycline test cohort, and the cohort who 
received AV7909 only (ie, Group 3 or the reference cohort). Point estimates and two-sided 
95% lower CIs will be constructed for the ratio (test: reference) of geometric means. If the 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 28 of 139 
 
 
lower bound of the two-sided 95% lower CI is greater than 0.5 (the non-inferiority margin) it 
can be concluded that the immune response in the cohort who received AV7909 plus 
doxycycline is non-inferior to the cohort which received AV7909 alone and thus that 
doxycycline did not demonstrably affect the immunogenicity of AV7909. 
Sample Size Considerations 
Antibiotic PK: Assessment of the effect of vaccination with AV7909 on the PK of either 
antibiotic will be made using the geometric mean of the within-participant ratio of Cmax and 
AUC0-12h for either ciprofloxacin or doxycycline before (Day 8) vs after (Day 35 or Day 38) 
AV7909 vaccination. The equivalence (no interaction) margin for the ratio is [0.80, 1.25], 
which will be compared with the 90% CI for the geometric mean ratio. Assuming that the 
coefficient of variation (CV) with the within-participant ratio is 30% and the true ratio is 
0.95, 27 participants allows for 90% power at significance level 0.05 while 34 participants 
would provide 95% power. A group size of 40 participants in each of the antibiotic PK 
groups (Group 1A and Group 2A) is planned to allow for up to 30% participants being 
excluded from the PK population. 
Immunogenicity: Sample sizes of 53 in each cohort (AV7909 alone vs AV7909 + antibiotic 
[either ciprofloxacin or doxycycline]) provide 90% power at the 2.5% one-sided significance 
level for the non-inferiority test (defined as the lower bound of the two-sided 95% CI of the 
ratio greater than 0.5), if the true ratio of geometric means is 0.85 and the CV of NF50 values 
between participants in the same group is 100%. A cohort size of 70 is planned to allow for 
up to 25% of participants to be excluded from the immunogenicity population. 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 29 of 139 
 
 
2. 
INTRODUCTION 
2.1. 
Study Rationale 
Antimicrobial therapy is an important component of post-exposure prophylaxis (PEP) following 
exposure to aerosolized Bacillus anthracis spores.  According to the Centers for Disease Control 
and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) 
recommendations for PEP of inhalation anthrax, BioThrax® (Anthrax Vaccine Adsorbed; AVA) 
administered subcutaneously at 0, 2, and 4 weeks, combined with appropriate antimicrobial 
therapy, is currently licensed for this indication in previously unvaccinated adults {Wright et al, 
2010}.  While a two-dose vaccination schedule with AV7909 for PEP would have clear logistical 
advantages over the three-dose schedule with BioThrax, antimicrobial therapy would still be a 
required component of the PEP schedule. The purpose of this study is to identify any potential 
effects of AV7909 vaccination on the PK of the antibiotics ciprofloxacin or doxycycline and any 
potential effects of ciprofloxacin or doxycycline therapy on the immunogenicity of AV7909. 
Both ciprofloxacin and doxycycline have been chosen for use in this study because they are first-
line therapies recommended by the ACIP for PEP {Wright et al, 2010}.   
2.2. 
Background 
Anthrax is an acute non-communicable infectious disease caused by B. anthracis, a spore-
forming, gram-positive bacterium that occurs globally {Brachman et al, 2008; WHO, 2008}. 
While human cases are rare in the United States (US), the bioterrorist use of B. anthracis spores 
as a biological weapon resulted in the exposure of tens of thousands of individuals across six 
states and the District of Columbia in 2001 {CDC, 2001}. The CDC considers B. anthracis to be 
one of the most likely biological agents to be used in any future terrorism activities {CDC, 
2014}.  
While vaccination prior to exposure offers the optimal protection against anthrax, mass 
vaccination is neither practical nor feasible as a defense against bioterrorism {CDC, 2000}. At 
the time of the bioterrorist events in 2001, the only Food and Drug Administration (FDA)-
approved post-exposure treatments for anthrax were the antimicrobials: ciprofloxacin, ofloxacin, 
doxycycline, penicillin VK and amoxicillin {CDC, 2000}. In the event of an aerosol exposure, 
the CDC’s ACIP recommended at the time that PEP consist of a minimum of 30 days of 
antibiotics and possibly a longer course of 42-60 days. The ACIP recommendations from 2000 
also stated that if a vaccine was available, three doses of vaccine should be administered (at 0, 2, 
and 4 weeks) with discontinuation of antibiotic after the third vaccination {CDC, 2000}.   
In response to the 2001 attacks, approximately 9300 individuals were initially prescribed 
antimicrobial prophylaxis for at least 60 days; however, a subsequent study determined that 
compliance with this schedule was poor. Based on interviews with 6178 persons, 86% (n=5343) 
took at least one dose of antimicrobial prophylaxis but fewer than half (44%, n=2712) reported 
taking antimicrobial prophylaxis for at least 60 days {Shepard et al, 2002}.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 30 of 139 
 
 
The CDC subsequently offered an additional antimicrobial treatment in a voluntary treatment 
continuation program with or without three doses of the BioThrax vaccine; about 200 opted to 
receive the supply of antimicrobials plus three doses of BioThrax {Tierney et al, 2003}.  
Ultimately, the attacks resulted in 22 cases of anthrax; 11 cutaneous and 11 inhalation, five of 
which (all inhalation cases) resulted in mortality {Jernigan et al, 2002}. No cases of anthrax were 
identified among persons recommended to take antimicrobial prophylaxis after the bioterrorist 
attacks of 2001 {Tierney et al, 2003}. 
In November of 2015, the FDA approved BioThrax for PEP given in three doses (administered at 
0, 2, and 4 weeks) along with a post-exposure regimen of appropriate antimicrobial prophylaxis. 
{Wright et al, 2010} However, in contrast to the ACIP’s earlier recommendation, which 
indicated that antimicrobial prophylaxis could cease after the third dose of vaccine 
{CDC, 2002}, the ACIP updated their recommendations to reflect a 60-day antimicrobial 
treatment period and to continue with the antimicrobial for 14 days following the third dose of 
vaccine, which could result in the antimicrobial being used for more than 60 days, if the 
initiation of the vaccination series was delayed.   
Given the poor compliance with an antimicrobial regimen of 60 days as observed in 2001, there 
is a demonstrated medical need for a vaccine that can induce a rapid and robust immune 
response. AV7909, a vaccine consisting of AVA plus the adjuvant CPG 7909, is under 
development to meet this need.  CPG 7909 is a synthetic immunostimulatory oligonucleotide 
(short DNA sequence). It has been shown to be a toll-like receptor 9 (TLR9) agonist that induces 
both an enhanced antigen-specific antibody response and a natural killer (NK) T-cell immune 
response when used in combination with prophylactic (preventative) or therapeutic vaccines 
{Krieg, 1996; Pisetsky, 1996; Kim et al, 1999; Stewart et al, 2008}. 
By combining AVA with CPG 7909, the AV7909 product development program aims to create a 
new vaccine that will accelerate the development of the immune response to the B. anthracis 
antigens, reducing the number of doses required to induce full protection, thereby reducing the 
amount of antigen required to establish protective immunity. From the three clinical studies 
conducted to date, Study V011, Study EBS.AVA.201 and Study EBS.AVA.208 {Rynkiewicz et 
al, 2011; Hopkins et al, 2013; Hopkins et al, 2016}, a formulation consisting of 0.5 mL of AVA 
plus 0.25 mg CPG 7909 administered intramuscularly (IM) on a 0, 2 week schedule has been 
selected as the candidate formulation for Phase 3.  
Based on the results of the last study, vaccination of healthy adults with 2 doses of AV7909 can 
potentially accelerate the development of a protective level of immunity by one or two weeks (in 
comparison to the time required with the 3-dose schedule of BioThrax) depending on whether 
AV7909 doses are administered four weeks or two weeks apart {Hopkins et al, 2016}. This 
study also demonstrated that AV7909 given in a 3-dose schedule (as per the BioThrax label) 
resulted in a greater percentage of individuals achieving a potentially protective antibody level 
one week after the last vaccination and at all subsequent time points evaluated.   
A clinical trial conducted with BioThrax and ciprofloxacin {EPDG, 2014} as part of the process 
of PEP licensure found no evidence of any interaction between vaccination with BioThrax and 
the pharmacokinetics (PK) of ciprofloxacin or between dosing with ciprofloxacin and the 
immunogenicity of BioThrax. It is the goal of this trial to demonstrate that vaccination with 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 31 of 139 
 
 
AV7909 does not affect the PK profiles of either ciprofloxacin or doxycycline and that neither 
ciprofloxacin nor doxycycline impair the immunogenicity of AV7909.  
2.3. 
Benefit/Risk Assessment 
2.3.1. 
Benefits 
No benefits can be guaranteed to individuals participating in this study. However, by joining this 
study, participants will be contributing to research that may result in the licensure of the next 
generation anthrax vaccine for PEP (ie, AV7909).   
2.3.2. 
Risks 
2.3.2.1. 
BioThrax 
More than 14 million doses of BioThrax have been administered to over 3.3 million people since 
it was approved in the U.S. in 1970 for pre-exposure prophylaxis {BioThrax.com }. BioThrax is 
approved by the Food and Drug Administration (FDA) and indicated for active immunization for 
the prevention of disease caused by B. anthracis in persons 18 through 65 years of age.  Details 
with respect to the potential risks of administration of BioThrax can be found in the BioThrax 
prescribing information {BioThrax® Prescribing Information, 2015}. The most common 
injection-site reactions observed in clinical studies included tenderness, pain, erythema/redness, 
edema/swelling, and arm motion limitation.  The most common systemic reactions were muscle 
aches, fatigue, and headache.  Other side effects included bruising, warmth, itching, or nodules at 
the injection site, nasopharyngitis, back pain, nausea and diarrhea. See the AV7909 
Investigator’s Brochure for more information. 
In a 200-person trial designed to evaluate the BioThrax PEP schedule, the most common 
solicited injection site reactions were lump, tenderness and erythema, and the common systemic 
reactions were fatigue, headache and myalgia. Of those individuals who reported solicited 
reactions, ≥ 98% percent required minimal to no treatment and reported little to no interference 
with activities of daily living {BioThrax® Prescribing Information, 2015}. 
2.3.2.2. 
CPG 7909 
CPG 7909 has been investigated clinically since the mid-1990s for indications that have included 
cancer monotherapy, combination use with anti-cancer therapies, and as an adjuvant in vaccines 
against infectious diseases and cancers. The most relevant risk data for this trial come from 
clinical studies of CPG 7909 used as an adjuvant in vaccine trials for hepatitis B, influenza, 
anthrax, malaria, gram negative sepsis, pneumococcal disease, and cytomegalovirus in normal 
participants. Safety data from such trials indicated that the most commonly reported 
reactogenicities were increases in the frequency and severity of injection site reactions and 
systemic AEs including fatigue, headache, flu-like symptoms, transient decreases in neutrophil 
and lymphocyte counts, and myalgia have been reported with the addition of CPG 7909 to 
vaccine antigens {Coley, 2006; Cooper et al, 2004; Sagara et al, 2009; Mullen et al, 2008}. 
While immune activation by CPG 7909 is designed to be transient and localized to vaccine-
exposed draining lymphatics, the possibility exists for pathologic and sustained non-specific 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 32 of 139 
 
 
activation of either T or B lymphocytes. Because of the potential for CpG ODN adjuvants to 
trigger autoimmune disease in susceptible individuals {Segal et al, 2000}, all participants should 
be monitored for a minimum of 12 months after the last vaccination. Participants who 
discontinue study treatment should be encouraged to attend all subsequent clinic visits and safety 
follow-up contacts to facilitate this monitoring. See the Investigator’s Brochure for additional 
details on the relationship of CPG 7909 to adverse events of special interest (AESIs; events with 
autoimmune etiology).  
2.3.2.3. 
AV7909 
The risks associated with AV7909 are similar to those described for BioThrax and CPG 7909 
since AV7909 is a combination of the two products. In the three clinical trials completed to date 
as a part of the AV7909 clinical development program, 241 healthy participants were immunized 
with the combination of AVA + CPG 7909. Across these three trials, most participants have 
experienced mild to moderate injection site reactions following vaccination with between 40% 
and 90% of participants reporting tenderness, pain, and arm motion limitation in their diary 
responses. Participants reporting these latter reactions experienced predominantly mild reactions, 
with generally less than 10% experiencing moderate or severe reactions. The most common 
systemic adverse reactions (observed in ≥5% of participants) were muscle aches, fatigue, and 
headache.  See the AV7909 Investigator’s Brochure for more information. 
Hypersensitivity and Anaphylactic/Anaphylactoid Reactions 
Acute allergic reactions have occurred in the AV7909 program with a report of urticaria after the 
second of two 0.5 mL doses of AV7909 (AV7909 Arm 1; Study EBS.AVA.208) that resolved 
with diphenhydramine hydrochloride. This arm received two doses of AV7909 containing 
0.5 mL AVA +0.25 mg CPG 7909 given 2 weeks apart {Hopkins et al, 2016}. The participant 
had a history of urticaria and this event was considered by the investigator as unrelated to the 
study product administration. In Study EBS.AVA.201, urticaria was reported in a participant in 
the AV7909 Formulation 1 arm, which was treated and resolved after 2 days and considered 
possibly related to study product administration. The Formulation 1 arm participants received 
two 0.5 mL doses formulated to contain 0.5 mL AVA + 0.5 mg CPG 7909 that were delivered 
IM two weeks apart. 
Two participants in Study EBS.AVA.208 discontinued vaccination because of mild generalized 
pruritus and rash (AV7909 Arm 2) and moderate rash (AV7909 Arm 1), all events considered to 
be related to study product administration. Both Arm 1 and Arm 2 received two doses of 
AV7909 containing 0.5 mL AVA + 0.25 mg CPG 7909; however, for Arm 1, the doses were 
delivered two weeks apart and for Arm 2, the doses were delivered 4 weeks apart {Hopkins et al, 
2016}. In Study V011, which consisted of three treatment groups [AVA (0.5 mL) alone, CPG 
7909 (1.0 mg)-alone and AVA (0.5 mL) + CPG 7909 (1.0 mg)] all administered as three doses 
two weeks apart, two participants in the AVA + CPG 7909 arm had hypersensitivity reactions. 
Both of these were considered by the investigator to be unlikely related to study product 
administration. An additional participant in the AVA + CPG 7909 group discontinued 
vaccination after the second injection due to the development of moderate generalized rash 
(accompanied by pruritus) that was considered to be related to study product administration 
{Coley, 2006}. Appropriate medical treatment and supervision must be available to manage 
possible anaphylactic reactions following administration of the vaccine.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 33 of 139 
 
 
AV7909 is not to be administered to participants with known sensitivity to any of the vaccine 
components, eg, synthetic ODNs, formaldehyde, benzethonium chloride (phemerol), or 
aluminum, or a sensitivity to latex. 
No participants in the completed AV7909 clinical trials or in CPG 7909-adjuvanted infectious 
disease trials have reported AEs related to autoimmune disorders, although several have reported 
positive, transient and/or non-symptomatic findings for clinical laboratory markers of disease 
such as anti-nuclear antibodies (ANA), anti-double-stranded deoxyribonucleic acid 
(anti-dsDNA) antibodies, and rheumatoid factor (RF). In oncology trials of CPG 7909 (reviewed 
in the AV7909 Investigator’s Brochure) that typically use higher doses and treatment durations 
than expected with AV7909 vaccine exposure, autoimmune disease has been reported in multiple 
participants, although causal attribution to the study product is complicated by comorbidities and 
concomitant products/therapies. Autoimmune conditions have included polyarthralgia, arthritis, 
Sjögren’s syndrome, autoimmune thyroiditis, vitiligo, Guillain-Barré syndrome, and ulcerative 
colitis.  
2.3.2.4. 
Study Procedures (IM injections and Venipuncture) 
Potential risks associated with IM injections include accidental injection of a vein instead of 
muscle, dizziness, fainting, or infection, as well as pain associated with a needle stick. Potential 
risks associated with venipuncture include pain, bruising, dizziness, and infection. 
2.3.2.5. 
Ciprofloxacin 
Ciprofloxacin, a fluoroquinolone antimicrobial agent, belongs to the class of quinolone 
antibiotics which target bacterial DNA gyrase and topoisomerase IV. The fluoroquinolones 
including ciprofloxacin have potent bactericidal activities against a broad range of gram-negative 
and gram-positive bacteria including B. anthracis {MacDougall, 2018}.  
Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially 
irreversible serious adverse reactions that have occurred together including: 
 Tendinitis and tendon rupture  
 Peripheral neuropathy  
 Central nervous system effects  
For additional safety information on ciprofloxacin, please refer to the prescribing information 
provided in the Pharmacy Manual. 
2.3.2.6. 
Doxycycline  
Doxycycline hyclate is a broad-spectrum antibiotic synthetically derived from oxytetracycline. 
As a member of the tetracycline class of antibiotics, doxycycline functions primarily through a 
bacteriostatic mechanism which is thought to occur via the inhibition of protein synthesis. The 
tetracyclines, including doxycycline, are active across a broad range of gram negative and gram-
positive bacteria including B. anthracis. Details with respect to the potential risks associated with 
the administration of doxycycline hyclate can be found in the prescribing information provided 
in the Pharmacy Manual.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 34 of 139 
 
 
3. 
STUDY OBJECTIVES & ENDPOINTS 
3.1. 
Study Objectives 
3.1.1. 
Primary Objective 
To evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when 
administered orally, prior to, and following, the intramuscular (IM) administration of a two-dose 
schedule of AV7909 administered two weeks apart. 
3.1.2. 
Secondary Objectives 
 To assess the safety of concurrent administration of oral ciprofloxacin or doxycycline and 
two doses of AV7909 administered IM.  
 To evaluate the Day 37 immune response using the toxin-neutralizing antibody (TNA) 
assay following two IM doses of AV7909 with and without the concurrent oral 
administration of ciprofloxacin or doxycycline. 
3.2. 
Study Endpoints 
3.2.1. 
Primary Endpoints 
 Area under the curve from 0 to 12 hours (AUC0-12h) and maximum concentration (Cmax) 
for ciprofloxacin on Days 8 and 35 
 
Area under the curve from 0 to 12 hours (AUC0-12h) and maximum concentration (Cmax) 
for doxycycline on Days 8 and 38  
3.2.2. 
Secondary Endpoints 
Safety 
 Incidence of AEs from the first dose of any IP through the Final Study Visit (Day 
51 ± 1 d)  
 Incidence of serious AEs (SAEs) from the first dose of any IP until the 12-month follow-
up (Day 388 ± 14 d) 
 Incidence of solicited systemic and injection site reactions reported in participant e-
diaries following each vaccination 
 Incidence of AESIs from the first dose of any IP until the 12-month follow-up 
(Day 388 ± 14 d) 
 Incidence of clinical laboratory abnormalities 
Pharmacokinetics and Immunogenicity 
 AUC0-12h and Cmax for ciprofloxacin on Days 4 and 31 and for doxycycline on Days 2 and 
32 
 
Geometric mean TNA 50% neutralizing factor (NF50) values 2 weeks after the second 
vaccination (Day 37 ± 1 d) 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 35 of 139 
 
 
4. 
STUDY DESIGN 
4.1. 
Overall Study Design 
This is a randomized, open-label, phase 2, multicenter trial to investigate the potential 
interactions of AV7909 and ciprofloxacin or doxycycline when administered concomitantly. The 
potential effect of AV7909 vaccination on ciprofloxacin or doxycycline serum levels will be 
investigated by evaluating the changes in the single dose and steady-state PK profiles of 
ciprofloxacin or doxycycline before and after vaccination with a two-dose series of AV7909.  
The effect of ciprofloxacin or doxycycline dosing on the immunogenicity of AV7909 will be 
investigated by evaluating whether TNA levels two weeks following the final dose of a two-dose 
vaccination series is affected by concomitant dosing with oral ciprofloxacin or doxycycline. 
Healthy males and females 18 to 45 years of age, inclusive, will read, sign and date an informed 
consent form (ICF) explaining the study and then be screened (2 to 28 days prior to 
randomization) for eligibility to participate in the study.  Participants (N=210) meeting the entry 
criteria will be evenly randomized 1:1:1 to one of the three investigational product (IP) groups 
shown in Table 2. Approximately the first 40 participants who are randomized into IP Groups 1 
and 2 will be assigned to Treatment Groups 1A or 2A while the remaining 30 participants 
randomized into IP Groups 1 and 2 thereafter will be assigned to Treatment Groups 1B or 2B.   
Randomization will be stratified by site. A representative racial distribution will be sought 
among participants and sites will be asked to recruit populations that are gender- and age-
balanced (ie, between 40-60% male with 40-60% of participants in the two age ranges of 18-30 
years of age and 31-45 years of age). 
Table 2: 
Study Groups 
IP Group 
Treatment 
Group 
Treatment 
Sample Size 
 (N) 
1 Cipro 
1A 
AV7909 + ciprofloxacin (with PK assessment) 
≈40 
≈70 
1B 
AV7909 + ciprofloxacin (without PK assessment) 
30 
2 Doxy 
2A 
AV7909 + doxycycline (with PK assessment) 
≈40 
≈70 
2B 
AV7909 + doxycycline (without PK assessment) 
30 
3 AV7909 
3 
AV7909 only 
70 
 
 
TOTAL 
≈210 
Figure 1 shows the design for this study, with an event schematic for the entire study being 
presented in Figure 2 followed by brief discussions of each group’s schedule. Detailed schedules 
are presented in Section 8.1.2 through Section 8.1.6.   
Safety in all groups will be assessed up to Day 51 by in-clinic recording of vital signs, adverse 
events (AEs, SAEs, and potential AESIs), concomitant medications, physical examination 
results, and by clinical laboratory outcomes recorded at screening and at Day 51 or the Early 
Withdrawal Visit (EWV), if applicable. Adverse events of special interest are AEs associated 
with autoimmune disease as defined by the Center for Biologics Evaluation and Research 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
 
Page 36 of 139 
 
 
(CBER); refer to Appendix B; these may represent a safety signal for vaccine-associated 
autoimmunity. The severity of AEs, laboratory test results for select analytes, and vital sign 
results will be assessed based on the FDA Guidance for Industry: Toxicity Grading Scale for 
Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (refer to 
Appendix A). 
Additionally, an electronic diary (e-diary) will be used following each vaccination to collect 
daily information on reactogenicity events including systemic and local (injection site) reactions 
and any changes in concomitant medications. For participants in Group 1 and 2, a separate 
antibiotic compliance e-diary will be used to record the dates and times of self-administered 
ciprofloxacin or doxycycline doses. This information will be evaluated on a routine basis and 
used by the site staff to identify additional AEs, SAEs, potential AESIs, and changes in 
concomitant medications as well as to document ciprofloxacin or doxycycline compliance. Blood 
samples for autoimmunity assessment will be taken at randomization (Day 1) and Day 51 (or 
EWV) for testing (if medically indicated as per PI’s discretion based on report of potential AESI) 
of TSH levels, and RF, ANA and anti-dsDNA autoantibodies.   
Safety follow-up phone contacts to collect information on SAEs and any potential AESIs will 
occur 3 months (Day 114 ± 14 d), 6 months (Day 205 ± 14 d), 9 months (Day 296 ± 14 d) and 12 
months (Day 388 ± 14 d) after the second vaccination. Samples may also be collected at 
unscheduled visits following the safety follow-up phone contact(s) to investigate reports of 
potential AESIs. 
Independent safety oversight will be provided by a Data Safety Monitoring Board (DSMB), 
which will be notified of significant AEs (refer to Section 8.5) as determined by the medical 
monitor (MM) on an ongoing basis. The DSMB will comprise at least three voting members, to 
include one expert in immunology to specifically support the evaluation of potential AESIs for 
autoimmune etiology, if pre-existing or new onset, and relationship to the study product. The 
DSMB will make recommendations regarding the safety of continuing enrollment and dosing. 
Study enrollment and dosing may be interrupted at the request of the DSMB Chair if it is 
believed that an AE represents a significant safety concern requiring suspension of dosing 
pending full DSMB evaluation. The operations of the DSMB will be detailed in a DSMB 
Charter.
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 Oct 2019) 
 
 
 
 
Confidential & Proprietary  
 
Page 37 of 139 
 
 
Figure 1: 
 Study Design for EBS.AVA.210 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 Oct 2019) 
 
 
 
 
Confidential & Proprietary  
 
Page 38 of 139 
 
 
Figure 2: 
 Event Schematic for EBS.AVA.210 Groups 1 to 3 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 39 of 139 
 
 
4.1.1. 
Group 1A Schedule 
The 40 participants in Group 1A will have blood drawn at randomization (Day 1) for TNA 
testing, and TSH and autoantibody testing. These participants will receive both ciprofloxacin and 
AV7909 and undergo four ciprofloxacin PK sessions. They will have a final blood draw for TNA 
on Day 37 and will complete their final visit for safety including a blood draw for TSH and 
autoantibodies on Day 51. Note: testing of samples for TSH levels and autoantibodies will be 
performed only if medically indicated (ie, as per PI’s discretion based on a report of a potential 
AESI).  
Ciprofloxacin (500 mg by mouth [per os] every 12 hours [q 12 hr]) will be administered 
intermittently, ie, on Days 4-9, Days 22-24 and Days 31-37. Participants will use the same 
supply of ciprofloxacin in the clinic and for self-administration at home. 
AV7909 (0.5 mL) will be administered by IM injection delivered on:  
 Day 8 (Note: this will be administered in the evening following completion of the PK 
session and administration of the evening antibiotic)  
 Day 23 
Ciprofloxacin PK sessions will be performed on Days 4, 8, 31, and 35. On days with PK 
sessions, blood samples for measurement of ciprofloxacin concentrations will be collected at 
0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min through hr 4, 
then ± 15 min thereafter). Ciprofloxacin pre-dose or trough values (all samples collected prior to 
the morning dose of ciprofloxacin) will be measured on Days, 4, 5, 6, 7 and 8; and again on Days 
31, 32, 33, 34 and 35. The ciprofloxacin pre-dose values on Days 4, 8, 31 and 35 serve as the t=0 
values for the PK sessions on those days as well as contributing to the two trough value analyses 
used to evaluate achievement of steady state before and after vaccination.  
4.1.2. 
Group 1B Schedule 
As shown in Figure 2 except for clinic visits for PK and trough value sampling, the 30 
participants in Group 1B will receive otherwise identical treatment to those in Group 1A. They 
will have blood drawn at randomization (Day 1) for TNA, TSH and autoantibody testing and will 
receive a supply of ciprofloxacin after they have been randomized into Group 1. They will begin 
taking ciprofloxacin on Day 4, self-administering the antibiotic intermittently on Days 4-9, Days 
22-24, and Days 31-37. Following randomization, they will have four scheduled clinic visits. 
The first two will be on Day 8 and Day 23, when they receive their first and second vaccinations 
with AV7909. Their third clinic visit will be on Day 37 when they will have a final blood draw 
for TNA and their fourth and final planned clinic visit will occur on Day 51 and includes a blood 
draw for TSH and autoantibodies.  
4.1.3. 
Group 2A Schedule 
The 40 participants in Group 2A will have blood drawn at randomization (Day 1) for TNA, TSH 
and autoantibody testing. These participants will receive both doxycycline and AV7909 and will 
undergo four PK sessions. They will have a blood draw for TNA on Day 37 and will complete 
their final visit for safety including a blood draw for TSH and autoantibodies on Day 51.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 40 of 139 
 
 
Doxycycline (100 mg by mouth [per os] every 12 hours [po q 12 hr]) will be administered 
intermittently ie, on Days 2-9, Days 22-24 and Days 32-38, in three courses, the exact format for 
which will be provided in the Pharmacy Manual. Participants will use the same supply of 
doxycycline in the clinic and for self-administration at home. 
AV7909 (0.5 mL) will be administered by IM injection on:  
 Day 8 (Note: this will be administered in the evening following completion of the PK 
session)  
 Day 23 
Doxycycline PK sessions will be performed on Days 2, 8, 32 and 38. On days with PK sessions, 
blood samples for measurement of doxycycline concentrations will be collected at 0.25, 0.5, 
0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min through hr 4, then ± 15 min 
thereafter).  Doxycycline pre-dose or trough values (all samples collected prior to the morning 
dose of doxycycline) will be measured on Days 2, 3, 4, 5, 6, 7 and 8; and again on Days 32, 33, 
34, 35, 36, 37 and 38. The doxycycline pre-dose values on Days 2, 8, 32 and 38 serve as the t=0 
values for the PK sessions on those days as well as contributing to the two trough analyses used 
to evaluate achievement of steady state before and after vaccination.  
4.1.4. 
Group 2B Schedule 
As shown in Figure 2 except for clinic visits for PK and trough value sampling, the 30 
participants in Group 2B will receive otherwise identical treatment to those in Group 2A. They 
will have blood drawn at randomization (Day 1) for TNA, TSH and autoantibody testing and will 
receive a supply of doxycycline after they have been randomized into Group 2. They will begin 
taking doxycycline on Day 2, self-administering the antibiotic intermittently on Days 2-9, Days 
22-24 and Days 32-38. Following randomization, they will have four scheduled clinic visits. The 
first two will be on Day 8 and Day 23, when they receive their first and second vaccinations with 
AV7909. Their third clinic visit will be on Day 37 when they will have a final blood draw for 
TNA and their fourth and final planned clinic visit will occur on Day 51 and includes a blood 
draw for TSH and autoantibodies. 
4.1.5. 
Group 3 Schedule 
The 70 participants in Group 3 will have blood drawn at randomization (Day 1) for TNA, TSH 
and autoantibody testing. They receive two doses of AV7909, the first on Day 8 and the second 
on Day 23. They will have a final blood draw for TNA on Day 37 and will complete their final 
visit for safety including a blood draw for TSH and autoantibodies on Day 51. 
4.2. 
Scientific Rationale for Study Design 
The study design is similar to that of an earlier trial (EBS.AVA.009: NCT01753115; Longstreth 
et al, 2018) conducted with the predecessor anthrax vaccine, BioThrax.  As was done in that trial, 
antibiotic administration will be intermittent rather than continuous in order to reduce antibiotic 
exposure thereby presumably reducing the risks of adverse effects from these antibiotics in these 
healthy participants.  In this trial, as in the previous trial, the aim is to characterize the single 
dose and steady state PK profiles of ciprofloxacin or doxycycline before and after vaccination to 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 41 of 139 
 
 
determine whether vaccination affects antibiotic PK. Additionally, a second aim is to evaluate 
whether administration of either of these antibiotics affects the immunogenicity of AV7909 
when evaluated with the TNA assay two weeks after the last vaccination of a 0-, 2-week 
schedule.  
4.3. 
Justification of the Dose and Schedule 
4.3.1. 
AV7909 
The AV7909 formulation, dose, route of administration and dosing schedule being used in this 
study are the same as those being used in the licensure-enabling clinical trial being conducted 
concurrently (Study EBS.AVA.212). The formulation of 0.5 mL AVA and 0.25 mg CPG 7909, 
administered IM as two 0.5 mL doses, 2 weeks apart, was selected for further development based 
on the following observations in two previously conducted AV7909 clinical trials {Hopkins et al, 
2013; Hopkins et al, 2016}. 
 Keeping the AVA content at 0.5 mL (compared to 0.25 mL) maintained 
immunogenicity 
 Increasing the CPG 7909 content beyond 0.25 mg to 0.5 mg increased the incidence 
and severity of both local and systemic reactions as assessed with a participant 
e-diary without enhancing immunogenicity 
 Injection site reactogenicity was similar to that observed for BioThrax 
 At 0.25 mg CPG 7909, a lower amount of unbound CPG could potentially reduce the 
risk of off-target immune activation 
4.3.2. 
Ciprofloxacin 
The ciprofloxacin dose (500 mg), dosing schedule [twice a day (q 12 hr)] and route of 
administration [by mouth (po)] being used in this study are those that would be used for PEP in 
the event of anthrax exposure and similar to those that were used in the prior PEP study 
conducted with ciprofloxacin and BioThrax {EPDG, 2014}.  In this study and the prior BioThrax 
study (Study EBS.AVA.009), ciprofloxacin administration occurs on an intermittent daily rather 
than a continuous daily dosing schedule, with the assumption that intermittent dosing would 
achieve the required single dose and steady state concentrations needed prior to and following 
the vaccination schedule, as well as the immunogenicity endpoints while restricting the 
antibiotics administered to the minimum to achieve these ends. 
Ciprofloxacin will be administered intermittently in three courses that will be used both by site 
staff for in-clinic visits and by participants when they are at home. The course format in terms of 
number of tablets and when participants will receive each course will be described in the 
Pharmacy Manual.  
In addition to ensuring the achievement of steady state concentrations before and after the 
complete two-dose series of the vaccine, the selected ciprofloxacin dosing periods reflect the 
time when the inflammatory and immunosuppressive effects of ciprofloxacin are most likely to  
affect the antibody response to AV7909 {Takahashi et al, 2005; Kaminski et al, 2010}. The 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 42 of 139 
 
 
intermittent dosing schedule was chosen in the hopes of minimizing any adverse effects from 
ciprofloxacin. This strategy appeared to have been successful in the BioThrax plus ciprofloxacin 
study in that ciprofloxacin-related AEs were low in number, frequently reported as related to 
both ciprofloxacin and BioThrax, generally mild in severity and resolved without sequelae by the 
end of the study {EPDG, 2014}.  
4.3.3. 
Doxycycline 
The doxycycline dose (100 mg), dosing schedule [twice a day (q 12 hr)] and route of 
administration [by mouth (po)] being used in this study are those that would be used for PEP in 
the event of inhalation exposure to anthrax. As with ciprofloxacin, doxycycline administration 
will occur on an intermittent daily rather than a continuous daily dosing schedule for the same 
reason this approach is used for ciprofloxacin.  This schedule will provide the required single 
dose and steady state PK dosing regimens needed and, in addition to achieving the needed 
steady-state concentrations before and after vaccination, is designed to achieve the 
immunogenicity end-points while restricting the antibiotics administered to the minimum 
required to achieve these ends.  
However, since the half-life of doxycycline is considerably longer than that of ciprofloxacin (15-
16 hours after a single dose and 22 or more hours after multiple doses compared to 3-7 hours for 
ciprofloxacin), participants in Group 2 will receive a few more doses of antibiotic than those in 
Group 1. This is because we believe more days of dosing will be required to achieve steady state. 
Thus, Group 2 will receive seven days of dosing with doxycycline compared to five days used 
for ciprofloxacin before tests for steady state are applied. 
Doxycycline will also be administered in three courses that will be used both by site staff for in-
clinic visits and by participants when they are at home. The format of the courses in terms of 
number of tablets and when participants will receive each course will be described in the 
Pharmacy Manual. 
The doxycycline dosing periods were chosen because they have been shown to have an effect on 
humoral immunity in mice {Woo et al, 1999} and to affect post-vaccination cell-mediated 
immunity in swine {Pomorska-Mól et al. 2014}, suggesting it could also affect the antibody 
response to AV7909. The intermittent dosing schedule was chosen in the hopes of minimizing 
any adverse effects from doxycycline.  
4.4. 
End of Study Definition 
A participant is considered to have completed the study if he or she has completed all phases of 
this study through the 12-month final safety follow-up phone contact (ie, Day 388 ± 14 d). 
Participants who do not complete the study are considered to have been withdrawn from the trial 
(refer to Section 7.3). 
The End of Study Date is defined as the date of the last participant’s final safety follow-up call, 
or earlier if the participant’s last follow-up contact occurs before this time point. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 43 of 139 
 
 
5. 
STUDY POPULATION 
Participants will be recruited at up to five clinical research centers in the United States. At least 
210 healthy adults meeting the eligibility criteria will be randomized 1:1:1 to one of the three IP 
groups: 70 in Group 1 (AV7909 + ciprofloxacin), 70 in Group 2 (AV7909 + doxycycline) and 70 
in Group 3 (AV7909 alone). Groups 1 and 2 will each have two subgroups; the A subgroup 
(N=40) will undergo PK sessions while the B subgroup (N = 30) will not. Approximately the 
first 40 participants who are randomized into Groups 1 and 2 will be assigned to Treatment 
Group 1A or Group 2A, while those who are randomized into Groups 1 and 2 thereafter will be 
assigned to Groups 1B or 2B.   
No waivers of inclusion and/or exclusion criteria will be permitted in the trial. The sites will be 
asked to implement procedures that will ensure a representative racial distribution among 
recruited participants and result in populations that are gender- and age-balanced (ie, between 
40-60% male with 40-60% of participants in the two age ranges of 18-30 years of age and 31-45 
years of age). 
5.1. 
Inclusion Criteria 
Individuals must meet all of the following inclusion criteria for study participation: 
1. Written informed consent obtained from the participant (dated, signed, and captured in 
the medical chart at the site). 
2. A male or female, aged 18 to 45 years of age, inclusive, at the time of informed consent. 
3. Healthy condition as established by medical history and clinical examination before 
entering into the study. 
4. Have a body mass index (BMI) less than or equal to 35.0 kg/m2 at the Screening visit. 
5. Have adequate venous access for phlebotomies.  
6. For a woman of childbearing potential (WOCBP), negative pregnancy test at Screening 
and pre-randomization on Day 1, not currently breastfeeding, and no intention to become 
pregnant during the study period through 12 months after last receipt of any 
investigational product (IP).  
Every female participant is considered to be a WOCBP unless she is surgically sterile (ie, 
has had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or 
postmenopausal [which is defined as >12 consecutive months without menses and a 
Screening FSH of >30 mIU/mL].  Adequate birth control (as defined here) must be 
initiated at least one month prior to randomization on Day 1 and used throughout the trial.  
Adequate birth control methods are sexual abstinence, intrauterine device/system 
(IUD/IUS), birth control pills, implantable or injectable contraceptives (eg, Norplant® or 
Depo-Provera®), removable birth control device (eg, NuvaRing® or Evra® patches) or 
double-barrier method of birth control (diaphragm in combination with contraceptive 
jelly or condoms in conjunction with contraceptive jelly, cream or foam), tubal ligation, 
or have a monogamous relationship with vasectomized partner who has been 
vasectomized for 6 months or more prior to the participant’s trial entry.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 44 of 139 
 
 
Female participants randomized to Groups 1 or 2: be willing to add a double-barrier 
method, IUD, or abstinence as back-up forms of birth control since ciprofloxacin and 
doxycycline may decrease the effectiveness of birth control pills, implantable or 
injectable contraceptives.  
5.2. 
Exclusion Criteria 
Individuals meeting any of the following exclusion criteria will be excluded from study 
participation: 
1. A Screening clinical laboratory test result greater than the central laboratory’s upper limit 
of normal (ULN) for aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
random glucose, total bilirubin, blood urea nitrogen (BUN), or creatinine. Other serum 
chemistry parameters that are not within the reference range will not be considered 
exclusionary unless deemed clinically significant by the principal investigator. 
2. History of allergic reaction or intolerance to quinolone antimicrobials or any medical 
condition that would contraindicate the use of ciprofloxacin, including and not limited to 
vascular disorders, tendon disorders, certain genetic connective tissue disorders (eg, 
Marfan and Ehlers–Danlos syndrome), prolongation of QT interval, seizures, peripheral 
neuropathy, increased risk of C. difficile infection (see ciprofloxacin prescribing 
information in the Pharmacy Manual). 
3. History of allergic reaction or intolerance to tetracycline antibiotics or any medical 
condition that would contraindicate the use of doxycycline including an increased risk of 
C. difficile infection, increases in BUN or an increased sensitivity to direct sunlight or 
ultraviolet radiation resulting in erythema (see doxycycline prescribing information in the 
Pharmacy Manual).   
4. Has a need for any of the prohibited medications in Section 6.5.1 or requires the 
medications/foods within the prohibited times in Section 5.3.1.1.  
5. Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area that 
may interfere with injection site assessments. 
6. History of anthrax disease, suspected exposure to anthrax, or previous vaccination with 
any anthrax vaccine.  
7. Have previously served in the military any time after 1990 or plan to enlist in the military 
any time from Screening through the final telephone contact.  
8. Previous anaphylactic reaction, severe systemic response, or serious hypersensitivity to a 
prior immunization or a known allergy to synthetic ODNs, aluminum, formaldehyde, 
benzethonium chloride (phemerol). 
9. Plan to have an elective surgery at any point during the study until after the final safety 
phone contact. 
10. Have donated or plan to donate blood within one month prior to enrollment or at any 
point during the study until after the final safety phone contact. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 45 of 139 
 
 
11. Use of any investigational or non-registered product (drug, vaccine or biologic) within 30 
days preceding the dose of study vaccine, or planned use during the study until after the 
final safety phone contact.  
12. Planned administration of any commercially-available vaccine from one week prior to the 
first study vaccination through two weeks after the last vaccination.  
13. Have experienced chronic dosing (defined as more than 14 days) with any immune-
modifying drugs within six months of study enrollment. This includes oral, 
intramuscular, intra-articular, intravenous, or inhalation corticosteroids except in the case 
of inhaled or intranasal medications for seasonal allergies (see Table 3).  
14. Receipt of immunoglobulins and/or any blood products within the three months 
preceding study enrollment or at any point during the study period until after the final 
safety visit on Day 51. 
15. An abnormal electrocardiogram (ECG) at screening interpreted as ‘Abnormal, 
Significant’. Inclusion of participants with ‘Abnormal, Insignificant’ ECGs will be based 
on the principal investigator’s discretion. 
16. Have an active malignancy or history of metastatic or hematologic malignancy.  
17. Have a history of an autoimmune, inflammatory, vasculitic or rheumaticor rheumatic 
disease including but not limited to systemic lupus erythematosus, Guillain-Barré 
syndrome, myasthenia gravis, polymyalgia rheumatica, diabetes mellitus type I, 
rheumatoid arthritis or scleroderma. 
18. A positive laboratory evidence of hepatitis B, hepatitis C, or human immunodeficiency 
virus (HIV) HIV-1 or HIV-2 infection. 
19. Positive result on urine drug screen, any evidence of ongoing drug abuse or dependence 
(including alcohol), or recent history (over the past five years) of treatment for alcohol or 
drug abuse.  
20. Has an acute disease at the time of enrollment. 
Note that screening lab tests may be delayed to allow the resolution of a transient acute 
condition or the subject may be rescreened according to procedures under Section 5.4.  
21. Any medical condition that, in the opinion of the investigator, could adversely impact the 
participant’s involvement or the conduct of the study. 
22. Have a significant chronic condition (see Sponsor’s guidance on significant chronic 
conditions in Appendix C), eg, serious cardiovascular, pulmonary, hepatic, type II 
diabetes mellitus or renal disease that, in the opinion of the investigator, would render 
treatment unsafe or would interfere with trial evaluations or completion of the study. 
23. An opinion of the investigator that it would be unwise to allow the participant to be 
randomized into the study. 
24. Member or immediate family member of an investigator site team. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 46 of 139 
 
 
5.3. 
Lifestyle Restrictions 
Participants in the two antibiotic groups will have certain lifestyle restrictions with which they 
will need to comply and that the site staff will need to remind them on an on-going basis.  In 
addition, for Group 1A and 2A participants, meals served during PK sessions need to observe 
these same limitations. Details of these restrictions are provided below. 
5.3.1. 
Meals and Dietary Restrictions 
5.3.1.1. 
Precautions for Participants Taking Ciprofloxacin or Doxycycline 
Participants in Groups 1 and 2 should be informed that these antibiotics may be taken with or 
without food, but antacids containing magnesium or aluminum and multivitamin/supplement 
preparations with calcium, zinc or other metals, eg, iron, should be taken at least two hours 
before or six hours after antibiotic administration. Furthermore, the same schedule should be 
used for the consumption of dairy products (like milk or yogurt) or calcium-fortified juices and 
the timing of antibiotic dosing since absorption of antibiotic may be significantly reduced by 
consumption of dairy products. However, these antibiotics may be taken with a meal that 
contains these products. In addition, participants in Group 2 should avoid taking bismuth 
subsalicylate (Pepto Bismol®) within 2-3 hours of their doxycycline dose. 
Participants should also be asked to limit their consumption of caffeine to 400 mg/day 
(equivalent to about 4 cups of coffee).   
5.3.1.2. 
Special Meals for Participants on Days with PK Sessions 
On their PK session days [Days 4, 8, 31 and 35 for Group 1A (ciprofloxacin) and Days 2, 8, 32 
and 38 for Group 2A (doxycycline)], participants are to be provided a non-dairy breakfast, 30 to 
60 min prior to dosing. This is to be followed over the course of the day with a light lunch and a 
light dinner/snack. 
5.3.2. 
Activity Restrictions 
Participants should be asked to limit their time in the sun and to avoid the use of sunlamps and 
tanning beds. Ciprofloxacin and doxycycline increase the sensitivity of the skin to the ultraviolet 
radiation both from the sun and from artificial sources such as sunlamps and tanning beds. All 
such exposures while on these medications can result in severe sunburns, blisters or swelling of 
the skin.  
Participants should be reminded to avoid sun exposure but if they must go out to avoid the high 
UV hours of 10 am to 2 pm, to wear sunscreen and protective gear (hats, sunglasses and 
protective clothes) when they do go outside. If they develop any of the signs or symptoms of 
sunburn while on antibiotic, participants must be instructed to notify the site staff.  
Participants in Group 1should be advised against engaging in strenuous physical activity as this 
may independently increase the risk of tendon rupture from ciprofloxacin. 
During each PK session, participants should remain in a seated or semi-recumbent position for 2 
hours post-dose and then maintain a light activity level throughout the course of the day. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 47 of 139 
 
 
5.4. 
Screen Failures 
A screen failure is a participant from whom informed consent is obtained and documented in 
writing, but who is not subsequently randomized to study treatment. Reasons for screen failure 
are to be recorded in the electronic case report forms (eCRFs). 
All screening procedures must occur 2 to 28 days before the Day 1 study visit, at which time 
participants are allocated to a treatment group. During the initial Screening visit, the Principal 
Investigator (PI) or designee will confirm, by documentation of the evaluation, any transient 
acute condition that may affect the participant’s Screening clinical laboratory results (which 
should meet the criteria specified in Exclusion criterion 1). The clinical laboratory assessment 
can be performed at the same visit or delayed, allowing time for resolution of the transient acute 
condition (eg, delayed screening until resolution of febrile illness, delayed urine occult blood in a 
menstruating woman). The clinical laboratory testing for Screening will not be performed more 
than twice (one initial and one repeat test for a total of two times). If the laboratory results are 
abnormal due to a processing or handling error, the test will be repeated without counting 
towards the not-to-exceed total of twice performed.  
Participants who are screen failures are permitted to be rescreened one time (only) according to 
the PI’s discretion. In the event that the participant is rescreened for trial participation, a new 
informed consent form (ICF) must be signed. For example, if there are any delays between 
Screening and enrollment that cause eligible participants to fall outside the Screening window, 
these participants may be re-consented and rescreened. Participants who complete the 
rescreening and are randomized in the study will not be considered screen failures. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 48 of 139 
 
 
6. 
TREATMENTS 
6.1. 
Treatment Administration 
6.1.1. 
AV7909 Description 
AV7909 is a preformulated, sterile, milky-white suspension for IM injection consisting of the 
AVA drug substance (AVA) and CPG 7909 adjuvant. All participants will receive one dose of 
AV7909 0.5 mL IM, consisting of 0.5 mL AVA and 0.25 mg CPG 7909, on Day 8 and one dose 
IM on Day 23. 
The AV7909 vaccine, manufactured by 
 
, will be supplied in 6 mL (nominal fill volume) clear borosilicate glass multi-dose 
vials with rubber stoppers and flip-top aluminum seals for storage. A single vial is filled with 
approximately 6.1 mL. For purposes of this trial, only a single dose (0.5 mL) will be used from 
each vial. 
Each vial will be labeled with the name, main constituents and volume of study product; route of 
administration; manufacturer name; characterization as “sterile” product and “multi-dose vial”; 
storage conditions; manufacturing (fill) date and lot number; and appropriate federal caution 
statement for investigational use product. 
6.1.2. 
Ciprofloxacin Description 
Ciprofloxacin hydrochloride, USP, a fluoroquinolone, is a synthetic broad-spectrum 
antimicrobial agent for oral administration. It is the monohydrochloride monohydrate salt of 1-
cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. It is a 
faintly yellowish to light yellow crystalline substance with a molecular weight of 385.8. Its 
empirical formula is C17H18FN3O3•HCl•H2O.  
Ciprofloxacin will be provided as tablets of ciprofloxacin hydrochloride at strength of 500 mg 
ciprofloxacin equivalent. The manufacturer and exact formulation, ie, excipients, and format for 
the tablets will be specified in the Pharmacy Manual. 
6.1.3. 
Doxycycline Description 
Doxycycline hyclate, USP, is a broad-spectrum antibiotic synthetically derived from 
oxytetracycline. The chemical designation is 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro- 
3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide 
monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline is a light-
yellow crystalline powder. The hyclate has a molecular weight 1025.9 with an empiric formula 
of (C22H24N2O8•HCl)2 • C2H6O • H20. 
Doxycycline will be provided as tablets of doxycycline hyclate at strength of 100 mg 
doxycycline equivalent. The manufacturer and exact formulation, ie, excipients, and format for 
the tablets will be specified in the Pharmacy Manual. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 49 of 139 
 
 
6.1.4. 
Administration of AV7909 
AV7909 will be administered to all participants in all groups as a 0.5 mL IM vaccination in 
alternate arms on Days 8 and 23. Vaccinations will be administered in the clinic by authorized 
personnel once AEs have been assessed, vitals have been taken and a symptom-directed PE 
conducted.  Females who have not demonstrated an FSH level >30 mIU/mL must also pass a 
urine pregnancy test (see Section 8.3.2).   
Participants in Groups 1A and 2A will receive their first vaccination after the 12-hour PK sample 
in the evening of Day 8, and their second vaccination on Day 23. Site personnel who administer 
the vaccine should be trained in the early recognition of symptoms of anaphylactic reactions, a 
rare but potentially serious reaction to parenteral injections.   
Sites should be prepared to treat participants experiencing clinically significant dyspnea or 
hypotension, wheezing or generalized urticarial reactions.  Appropriate medical therapy for 
anaphylaxis should be administered, if indicated, which should include IM or subcutaneous 
epinephrine 1:1000, and may include corticosteroids, diphenhydramine, bronchodilators, 
intravenous volume expansion, and/or oxygen.  Participants will be evaluated and carefully 
monitored until complete resolution of any signs and symptoms, should they occur. 
If a participant in Groups 1or 2 has a moderate or severe illness and/or an oral temperature 
greater than 100.4°F within three days before vaccination 1, or any condition that, in the opinion 
of the Investigator, would render vaccination unsafe or would interfere with evaluations, these 
participants will be withdrawn from the study and will be considered ineligible for rescreening. 
These participants will be instructed to cease taking antibiotics but to continue with their e-diary 
for an additional 7 days beyond the day they ceased taking antibiotics at which point they will be 
asked to return to the site and complete the EWV procedures. If the reason for not receiving 
vaccine is an AE/SAE/AESI, the participants will be followed until the event has resolved, 
stabilized or the participant has been referred to another physician. These participants, having not 
received any vaccine, will not be included in the long-term follow-up nor will they have 
additional blood samples taken for TNA, TSH or autoantibodies.   
Any participant in Group 3 who has a moderate or severe illness and/or an oral temperature 
greater than 100.4°F within three days before vaccination 1, or any condition that, in the opinion 
of the Investigator, would render vaccination unsafe or that would interfere with evaluations may 
be re-screened and re-randomized with the event which precluded vaccination being added to 
that participant’s medical history. If such an event were to occur within three days of vaccination 
2, the vaccination must be delayed but should still occur within the 1-day study window. 
Participants unable to receive vaccination 2 within the allowed study visit window will remain in 
the study and be followed for safety. 
6.1.5. 
Administration of Ciprofloxacin 
Ciprofloxacin (500 mg po q 12 hr) will be administered only to participants in Group 1. A total 
of 31 ± 2 doses will be administered in three courses, the exact format for which will be 
presented in the Pharmacy Manual.  
Group 1A participants will nominally receive 17 of their 31 ciprofloxacin doses in the clinic 
whereas Group 1B will nominally receive two of their 31 ciprofloxacin doses in the clinic.  The 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 50 of 139 
 
 
remaining doses will be taken at home. Doses should be taken at the same times ± 30 min each 
day. Doses administered in the clinic will be recorded by the staff with the date and time of 
administration in each participant’s source documents and eCRF. Doses self-administered at 
home will be recorded by the participant with time of administration in their e-diary. Refer to 
Section 8.3.5.1 for additional details on the e-diary. If a participant misses a dose, they should be 
instructed to take the dose as soon as remembered, but no later than within 4 hours of its 
scheduled time. The participant should then wait until the next scheduled dose. The participant 
should not take two doses at the same time. 
Exact details regarding the format in which the doses will be provided to the participants will be 
provided in the Pharmacy Manual.   
Certain foods and over-the-counter products can interfere with the absorption of ciprofloxacin so 
prior to administration of doses in the clinic, site staff should ask each participant if they have 
eaten certain dairy products (such as milk or yogurt) or taken magnesium/aluminum antacids, 
other highly buffered drugs, or other products containing calcium, iron or zinc since their last 
dose and if so record this information along with the timing of intake, eg, 6 hours since their last 
dose. This information along with other precautions that need to be followed when taking 
ciprofloxacin will be provided to participants when they are given their supplies of ciprofloxacin 
for self-administration (see Section 5.3.1). 
6.1.6. 
Administration of Doxycycline 
Doxycycline (100 mg po q 12 hr) will be administered only to participants in Group 2. A total of 
35 ± 2 doses will be administered in three courses as shown in Figure 2.  
Group 2A participants will nominally receive 20 of their 35 doxycycline doses in the clinic 
whereas Group 2B will nominally receive two of their 35 doxycycline doses in the clinic.  The 
remaining doses will be taken at home. Doses should be taken at the same times ± 30 min each 
day. Doses administered in the clinic will be recorded by the staff with the date and time of 
administration in each participant’s source documents and eCRF. Doses self-administered at 
home will be recorded by the participant with the time of administration in their e-diary. Refer to 
Section 8.3.5.1 for additional details on the e-diary. If a participant misses a dose, they should be 
instructed to take the dose as soon as remembered, but no later than 4 hours of its scheduled 
time. The participant should then wait until the next scheduled dose. The participant should not 
take two doses at the same time. 
Exact details regarding the format in which the doses will be provided to the participants will be 
provided in the Pharmacy Manual.   
Certain foods and over-the-counter products can interfere with the absorption of doxycycline so 
prior to administration of doses in the clinic, site staff should ask each participant if they have 
eaten certain dairy products (such as milk or yogurt) or taken magnesium/aluminum antacids, 
other highly buffered drugs, or other products containing calcium, iron or zinc since their last 
dose and if so record this information along with the timing of intake (eg, 6 hours since their last 
dose). This information along with other precautions that need to be followed when taking 
doxycycline will be provided to participants when they are given their supplies of doxycycline 
for self-administration (see Section 5.3.1). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 51 of 139 
 
 
6.2. 
Acquisition/Preparation/Handling/Storage/Accountability 
6.2.1. 
Acquisition 
AV7909 liquid suspension for injection and oral antibiotics [ciprofloxacin and doxycycline 
(exact formats will be specified in the Pharmacy Manual)] will be shipped to investigational sites 
from the drug depot following institutional review board/independent ethics committee 
(IRB/IEC) and Emergent approval. All shipments will be accompanied by TempTale® 
temperature monitors to record any excursions outside of required storage conditions, ie, 
refrigerated storage [36 to 46ºF (2-8 ºC)] for the vaccine and room temperature [68° to 77°F (20-
25 ºC)] for the antibiotics (ciprofloxacin or doxycycline). Detailed instructions for inventory 
receipt, temperature excursions, and IP resupply will be provided in the Pharmacy Manual. 
6.2.2. 
Preparation of Investigational Product for Injection 
Vaccine vials should be removed from the storage unit and allowed to sit at room temperature for 
approximately 15 minutes before administration. Vaccine doses should be drawn into a syringe 
only when administration is eminent. The stability of the vaccine stored in the syringes has not 
been determined. A site staff member, licensed to administer medication/vaccination, will 
prepare each dose of AV7909 into a syringe according to the following instructions: 
 A separate 1- or 1½-inch 23- or 25-gauge sterile needle and separate 1.0 mL syringe will 
be used for each participant. 
 Gently roll the vial of AV7909 between the hands to ensure that the suspension is 
homogeneous.   
 Visually inspect the product for particulate matter and discoloration prior to preparing 
into the syringe. If the product appears discolored or has visible particulate matter, DO 
NOT USE the contents of the vial.  THE VIAL SHOULD BE QUARANTINED and 
reported to the CRO according to the instructions in the Pharmacy Manual.  
 Wipe the rubber stopper with an alcohol swab and allow to air dry before inserting the 
needle.   
 Withdraw 0.5 mL of investigational product from the vial into a sterile syringe for 
administration.  The volume and contents of the syringe will be verified by a second 
person before administration.  
 Reseal the vial and cover it with tamper-evident tape to indicate no additional doses may 
be withdrawn from the vial. 
AV7909 should not be mixed with any other product in the syringe. 
6.2.3. 
Handling  
Detailed instructions for packaging, labeling, and shipping as well as inventory receipt, and IP 
resupply will be provided in the Pharmacy Manual.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 52 of 139 
 
 
6.2.4. 
Product Storage and Stability 
6.2.4.1. 
AV7909 
Each shipment of AV7909 will arrive in a refrigerated carton containing vaccine and a 
TempTale™ temperature recorder that will be reviewed before use of the vaccine.  Immediately 
upon receipt of each shipment of vaccine, vials are to be refrigerated at 36 to 46ºF (2 to 8ºC).  
AV7909 should not be frozen. Storage temperature must be continuously monitored and 
recorded. To guarantee proper storage conditions, the minimum, actual and maximum 
temperature in the storage refrigerator shall be continuously monitored for correct temperature. 
A back-up power source for the refrigerator is required. The study vaccine should be stored in a 
locked room, with access restricted to necessary site personnel. 
6.2.4.2. 
Ciprofloxacin 
Each shipment of ciprofloxacin will arrive in an insulated container with a temperature 
monitoring device which at a minimum displays the minimum and maximum temperature 
encountered while in transit. Ciprofloxacin is to be stored at room temperature [68° to 77°F (20° 
to 25°C)]. The ciprofloxacin should be stored with access restricted to necessary site personnel 
with temperature log for recording ambient temperature daily. 
6.2.4.3. 
Doxycycline 
Each shipment of doxycycline will arrive in an insulated container with a temperature 
monitoring device that at a minimum displays the minimum and maximum temperature 
encountered while in transit. Doxycycline is to be stored at room temperature [68° to 77°F (20° 
to 25°C)]. The doxycycline should be stored with access restricted to necessary site personnel 
with a temperature log for recording ambient temperature daily. 
6.2.5. 
Investigational Product Experiencing Any Temperature Excursions 
AV7909, ciprofloxacin or doxycycline which have been delivered/received at the site with 
temperature recorders indicating temperature excursions above or below their storage ranges will 
be immediately quarantined and not used by the site until the CRO study monitor has been 
informed and can determine an appropriate path forward. Similarly, if any IP is subjected to such 
temperature excursions while held at the site, the CRO study monitor must be contacted for 
further instructions. 
6.2.6. 
Accountability 
The Investigator will maintain complete records of receipt, storage and administration of 
investigational products at the investigator site. For the AV7909 vaccine, this will include lot 
number, the dose/volume administered, and the time, date, and site of administration. The latter 
information will be recorded in the participant’s source documents along with the initials of the 
administering individual. NO VIALS OF VACCINE, including empty, damaged or partially 
used vials are to be destroyed or discarded during the conduct of the study.  At the completion of 
the study, once all vaccine accountability is complete and queries resolved, the site will be 
responsible for discarding all remaining vials of IP per the instructions in the site Pharmacy 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 53 of 139 
 
 
Manual. For ciprofloxacin and doxycycline, the Investigator will record number of tablets 
received, lot number(s), and the number of tablets dispensed. For those tablets administered on 
site, the site will also record the date and time of administration on the appropriate eCRF page. 
The latter information will be recorded in the participant’s source documents along with the 
initials of the administering individual. For antibiotic tablets dispensed to participants, 
participants will record in an e-diary the time of self-administration of these antibiotics at home 
and the sites will check e-diary records regularly as well as collect the antibiotic supplies at each 
applicable in-clinic visit and do a tablet count to check compliance. At the completion of the 
treatment period, once all antibiotic dose accountability is complete and queries resolved, the site 
will be responsible for discarding all remaining antibiotic doses per the instructions in the 
Pharmacy Manual. 
6.3. 
Measures to Minimize Bias 
6.3.1. 
Method of Treatment Assignment 
After the ICF has been signed and dated by the participant and PI/designee but before any 
screening procedures are performed, the participant will be assigned a unique subject 
identification (ID) number by the site. To maintain confidentiality, the subject ID will be used to 
identify the participant for data collected in eCRFs throughout the trial and for all clinical 
laboratory samples. The investigational site will retain a master list linking the subject ID with 
the name, date of birth, and contact information of the participant. The master list is to be 
retained by the site only and is not to be collected by Emergent or its agents. 
If a participant is rescreened, a new subject ID will be assigned. To link records to the same 
participant, the participant’s previous subject ID will be recorded in the eCRF along with the 
new subject ID. 
At the Randomization visit (Day 1), after the PI has confirmed that the participant meets all the 
inclusion criteria and none of the exclusion criteria, a central randomization process will be used 
to assign each participant to one of the three open-label IP groups. The sites will be asked to the 
extent possible to execute a recruitment process that achieves a representative racial/ethnic 
distribution in populations that are reasonably gender- and age-balanced (ie, at least 40% male 
with 40% of participants in the two age ranges of 18-30 years of age and 31-45 years of age).  
A randomization plan will be prepared and finalized prior to randomization of the first 
participant. The specific instructions for randomizing participants will be provided in the 
Pharmacy Manual. 
If a participant signs and dates the ICF but is not randomized within the screening period 
window, that participant is considered a screen failure unless he or she signs a new ICF, is re-
screened and is randomized within the allowable window (refer to Section 5.4). 
6.3.2. 
Blinding 
Not applicable; this is an open-label study. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 54 of 139 
 
 
6.4. 
Treatment Compliance 
Each dose of AV7909 vaccine will be administered by site personnel at the investigator site.  The 
date and time of the vaccine administration will be recorded in the participant’s source 
documents and on the eCRFs. 
The antibiotics, ciprofloxacin or doxycycline, will be administered in-clinic by staff and self-
administered by participants at home.  Each dose of ciprofloxacin or doxycycline administered 
by the site personnel will be recorded in the participant’s source documents and the eCRF with 
the date and time of administration.  
Each dose of ciprofloxacin or doxycycline self-administered at home will be recorded by the 
participant in the e-diary along with the date.  The investigator site personnel will review the 
compliance data recorded in the e-diary on a routine basis and will call or talk to any participants 
who fail to record their antibiotic doses on two or more occasions. Repeated non-compliance 
may warrant discontinuation although such participants will be followed for safety.  
If a participant misses a dose of antibiotic (ciprofloxacin or doxycycline) at home, the missed 
dose should be documented in the e-diary. Participants missing an at-home dose of antibiotic will 
remain in the study. Participants will be reminded that they have a 4-hour window within which 
to take a forgotten dose and that the time they record in the e-diary should be the time the dose is 
actually taken rather than the time it should be taken.  They will also be reminded that a late dose 
should not reset the schedule, ie, that even if they take one dose late, their next dose should be 
taken on their original dosing schedule, and that they should continue to maintain 12 hours 
between doses thereafter and never take two doses at the same time. Thus, if a participant 
normally takes doses at 7 am and 7 pm but forgets to take the 7 am dose until 10 am, he or she 
should still take the second dose at 7 pm. 
Participants will be asked to bring their antibiotic supplies with them to the clinic at each visit so 
that staff can confirm the remaining number of doses to document compliance. Site staff will 
collect any doses remaining once a course is complete and supply the next course when it is 
needed.  
Additionally, for Groups 1A and 2A, compliance will also be tracked via the individual 
ciprofloxacin or doxycycline serum concentrations that will be recorded in the pre-dose and 
trough values, which are being collected to demonstrate achievement of the steady state 
concentrations of these antibiotics before and after vaccination with AV7909. 
6.5. 
Concomitant Therapy 
Prior and concomitant medication information (medications used 30 days prior to Screening or 
medications used since the last study visit) will be recorded in the eCRF at screening, 
randomization and at each study visit when applicable.  
The medication name, dose, route, frequency, indication, and stop and start days/times for each 
new medication will be recorded. For the purposes of this trial, concomitant medications will be 
defined to include prescription drugs and biologics, over-the-counter drugs as well as herbal and 
nutritional supplements. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 55 of 139 
 
 
6.5.1. 
Prohibited Medications 
Prohibited and restricted medications for this study fall into two categories: those that are 
restricted because of their effect on inflammation, immunity and vaccination and those known to 
interact with either ciprofloxacin or doxycycline.    
6.5.1.1. 
Medications Prohibited Due to Effects on Inflammation or the Immune System 
Prohibited and restricted medications for all participants include anti-inflammatory or antipyretic 
medications, topical antihistamine eye drops, nasal steroids, vaccines, immunosuppressive 
therapy, cytotoxic therapy and any experimental treatments (see Table 3). 
Table 3: 
Medications Prohibited for all Participants 
Category 
Generic Name and Examples of Associated Brand Names 
Anti-inflammatory or 
antipyretic medication: 
prohibited within 24 
hours prior to or after 
vaccination 
Glucocorticoids, aspirin-containing medication, NSAIDs, acetaminophen-
containing medication 
Motrin, Advil®, Co-Advil®, Bayer®, Tylenol® Excedrin® 
Topical hydrocortisone 
Note: NSAIDs should be used (if medically indicated) with caution 
(outside 24 hours prior to or after vaccination) by participants in Group 1, 
because in pre-clinical studies and post-marketing the combination of high 
doses of quinolones with NSAIDs has been shown to provoke convulsions 
(see ciprofloxacin prescribing information in the Pharmacy Manual). 
Aspirin withheld on 
each day of vaccination, 
but may be resumed the 
following day 
Low-dose aspirin (≤ 81 mg/day) 
Any commercially-
available vaccine 
(except that for anthrax) 
through two weeks after 
the last vaccination 
Including but not limited to vaccines for influenza, shingles, hepatitis B, 
pneumococcal, tetanus, yellow fever, pertussis, cholera, adenovirus, 
diphtheria, rabies virus haemophilus b, hepatitis A, human papillomavirus, 
measles, mumps, Japanese encephalitis virus, meningococcal vaccine, polio 
virus, plague, rotavirus, zoster vaccine, smallpox  
Immunomodulatory 
agents through the final 
follow-up phone call. 
Note: inhalation use (eg, 
for seasonal allergies) is 
permitted.  
Any systemic corticosteroids including, but not limited to, generic and 
brand names of: betamethasone, budesonide, cortisone acetate, 
dexamethasone, hydrocortisone, methylprednisolone, prednisolone, 
prednisone, triamcinolone. 
Cytotoxic Therapy 
Any of the alkylating agents, platinum coordinating complexes, 
antimetabolites or natural products used in current therapeutic regimens for 
cancer or rheumatic diseases including but not limited to generic and brand 
names of: methotrexate, cyclophosphamide, azathioprine, methotrexate, 
mercaptopurine, bendamustine, streptozocin, cisplatin, chlorambucil and 
hydroxyurea. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 56 of 139 
 
 
Category 
Generic Name and Examples of Associated Brand Names 
Investigational 
Medicinal Product 
Product that is used in a clinical investigation. 
Blood thinners and anti-
coagulants (Groups 1A 
and 2A)  
Any medication that might increase the risk of bleeding including but not 
limited to heparin and its derivatives, warfarin and other vitamin K 
antagonists, oral factor Ax inhibitors, any reversible or irreversible inhibitor 
of coagulation receptor P2Y12, any glycoprotein IIa/IIIa antagonist, or any 
PAR-1 antagonist 
Parenteral 
Immunoglobulins or 
Blood Products 
Any of the approved intravenous (IV), subcutaneous (SC), or intramuscular 
(IM) human immune globulins (IG) or the human hyperimmune globulins 
(hhIG) or animal derived immune globulin (aIG) products including but not 
limited to: any IGIV, IGIM or IGSC; any anthrax hhIG, botulism hhIG, 
cytomegalovirus hhIG, hepatitis B hhIG, Rho(D) hIG, vaccinia hIG, or 
rabies hhIG; or any anti-thymocyte aIG, anti-scorpion venom aIG, anti-
snake venom aIG, anti-spider venom aIG, anti-digoxin aIG, anti-botulinum 
toxin aIG, or anti-thymoglobulin aIG. 
6.5.1.2. 
Medications Known to Interact with Ciprofloxacin 
Prohibited and restricted medications for participants in Group 1 include those that are primarily 
metabolized by human cytochrome 450P1A2 (CYP1A2), but also those that are metabolized by 
CYP3A4 since ciprofloxacin is a strong inhibitor of CYP1A2 and a moderate inhibitor of 
CYP3A4, as well as products that can affect the absorption of ciprofloxacin such as antacids, 
multivitamins, or supplements that contain magnesium, aluminum, calcium, iron or zinc. If 
required, the latter medications should be taken 2 hours before or 6 hours after a ciprofloxacin 
dose. Refer to the ciprofloxacin prescribing information (in the Pharmacy Manual) where 
medications which are known to interact with ciprofloxacin are listed and should not be taken by 
participants in Group 1 of this study.  
A more extensive list of medications is provided at the following URL: 
https://online.epocrates.com/drugs/50110/ciprofloxacin/Monograph {Athenahealth 2019a}. With 
the exception of those indicated to be contraceptives and those which may be components of 
antacids, multivitamins, or supplements that contain magnesium, aluminum, calcium, iron, or 
zinc, all medications, vaccines and supplements found at the above URL are also prohibited for 
participants in Group 1 of this study. 
6.5.1.3. 
Medications Known to Interact with Doxycycline 
Prohibited and restricted medications for participants in Group 2 can be found in the doxycycline 
prescribing information (provided in the Pharmacy Manual)Error! Reference source not 
found.. A more extensive list of medications is provided at the following URL: 
https://online.epocrates.com/drugs/20310/doxycycline/Monograph {Athenahealth 2019b}. With 
the exception of those indicated to be contraceptives and those which may be components of 
antacids, multivitamins, or supplements that contain magnesium, aluminum, calcium, iron, or 
zinc, all medications, vaccines and supplements found at the above URL are also prohibited for 
participants in Group 2 of this study. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 57 of 139 
 
 
7. 
STOPPING RULES, DISCONTINUATION/WITHDRAWAL 
CRITERIA AND PROCEDURES 
7.1. 
Entire Study 
Study enrollment and vaccinations may be temporarily halted by the DSMB or the Sponsor if 
any of the following occur, pending further evaluation: 
 three or more dosed participants having the same Grade 3 or higher AE 
 three suspected unexpected serious adverse reactions (SUSARs) within the same 
body system as assessed by the Sponsor 
 five potential AESIs considered related to the IP, as assessed by the Sponsor 
 a single DSMB-assessed AESI, considered to be related to the IP by the PI  
These events will be reviewed by the DSMB and a recommendation will be made regarding 
vaccinations, continuation of study, or study termination. The procedures for DSMB notification 
and review of SUSARs, AESIs, and other significant events will be outlined in the DSMB 
Charter (refer to Section 8.5).  
Emergent, BARDA, the IRB/IEC and/or FDA reserve the right to terminate the study at any time 
for clinical or administrative reasons. This study may be terminated due to safety concerns, 
failure to meet expected enrollment goals, administrative reasons or at Emergent’s discretion. If 
the study is terminated prematurely, Emergent will provide written notification to all 
investigators and regulatory authorities and will specify the reason(s) for early termination.  The 
investigator must inform the IRB/IEC promptly and provide the reason(s) for the termination. 
7.2. 
Individual Site 
The CRO will promptly notify Emergent if the trial is terminated by the PI or the IRB/IEC at the 
site.  
Any particular site may be terminated from the trial at the discretion of the PI, Emergent, or 
IRB/IEC, eg, for non-enrollment of participants or non-compliance with the protocol. Emergent 
may decide to replace a terminated site. 
7.3. 
Individual Participants 
All participants have the right to withdraw at any point during treatment without prejudice. The 
PI can also discontinue a participant from a trial at any time if medically necessary or for reasons 
of noncompliance.  
Every attempt will be made to follow participants for safety for the entire duration of the trial 
through the Month 12 safety follow-up providing they have received at least one vaccination. 
Participants in Groups 1 and 2 who discontinue treatment prematurely for any reason after 
receiving the first dose of antibiotic but prior to receipt of the first vaccination will be 
encouraged to return to the clinic for the Early Withdrawal procedures minus the blood draws for 
autoantibodies, TSH and TNA. Participants who discontinue treatment prematurely for any 
reason after receiving the first vaccination will be encouraged to continue in the study for any 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 58 of 139 
 
 
remaining study visits (for safety assessments only) and the safety follow-up phone calls at 
Months 3, 6, 9 and 12 (post-vaccination).  
If a participant discontinues treatment and/or involvement in the study, the reason(s) must be 
fully evaluated and recorded appropriately in source documents and eCRFs. Reason for 
discontinuation of treatment and reason for withdrawal from the study are to be recorded 
separately on eCRFs. If the participant is being discontinued because of an AE, that AE will be 
indicated as the reason for discontinuation and/or study withdrawal. 
Randomized participants who withdraw for any reason will not be replaced in this trial. 
7.3.1. 
Discontinuation of Study Treatment 
Study treatment, either administration of antibiotic (ciprofloxacin or doxycycline) or vaccination 
with AV7909, will be permanently discontinued in any participants if they meet any of the 
individual participant halting rules described in Table 4. The date when the event occurred or 
was detected and the specific reason, ie, which criterion was met, for discontinuation of 
treatment, is to be recorded on the eCRF. 
Table 4: 
Criteria for Discontinuation of Treatment in Individual Participants 
No. 
Item 
1.  
Participants experiencing any of the AEs described in the WARNINGS AND 
PRECAUTIONS sections of the ciprofloxacin and doxycycline package inserts (provided 
in the Pharmacy Manual) will be discontinued.  
In the case of ciprofloxacin, these include, but are not limited to, tendinitis and tendon 
rupture, hypersensitivity reactions (including rash and jaundice), peripheral neuropathy, 
central nervous system effects, exacerbation of myasthenia gravis, hepatotoxicity, 
Clostridium difficile-associated diarrhea, prolongation of the QT interval, and a variety of 
other serious adverse reactions including severe dermatologic reactions, eg, toxic 
epidermal necrolysis, Stevens-Johnson syndrome; anemia, including hemolytic and 
aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; 
agranulocytosis; pancytopenia; and/or other hematologic abnormalities and inflammatory 
responses, eg, interstitial nephritis; acute renal insufficiency or failure; allergic 
pneumonitis; hepatitis; jaundice; acute hepatic necrosis or failure. 
In the case of doxycycline, these include, but are not limited to, Clostridium difficile-
associated diarrhea, photosensitivity manifesting as an exaggerated sunburn reaction; super 
infection and overgrowth of non-susceptible organisms including fungi; severe skin 
reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, 
toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms 
(DRESS); intracranial hypertension (IH, pseudotumor cerebri) manifesting as headache, 
blurred vision, diplopia, and vision loss has been observed with papilledema detectable on 
fundoscopy; delayed skeletal development in the fetuses of pregnant women [tetracyclines/ 
however, data for doxycycline are limited]. NB: Pregnancy would require discontinuation 
from the trial (refer to Section 9.4).  
2.  
Grade 2 or greater hypersensitivity, ie, anaphylaxis, allergic reaction (such as, but not 
limited to difficulty breathing, rapid increase in heart rate, dizziness, nausea, evidence of 
rash, or periorbital swelling) believed by the PI to be associated with receipt of any of the 
IPs  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 59 of 139 
 
 
No. 
Item 
3.  
Any Grade 3 or higher systemic reactogenicity symptom assessed by e-diary and 
confirmed by the PI  
4.  
Any AE that would pose a risk to the participant as determined by the PI if continued 
administration of IP were to occur. 
5.  
Any violation of eligibility criteria discovered after randomization that would pose a risk to 
the participant, as determined by the PI and agreed to by the Medical Monitor (MM) 
6.  
Febrile illness (fever > 100.4 °F) within three days prior to either vaccination (Exception: 
For the second vaccination, the visit may be rescheduled to another day outside this three-
day period providing it will not fall outside the required visit window for vaccination two 
[Section 8.1].) 
7.  
Receipt of AV7909 associated with loss of cold chain 
8.  
Suspected or confirmed pregnancy (refer to Section 9.4). (Exception: In the case of 
suspected pregnancy, if the subsequent serum pregnancy test is negative, the antibiotic 
dosing may be resumed and the vaccination visit (second vaccination only) may be 
rescheduled to another day providing it does not fall outside the required visit window for 
the visit [Refer to Section 8.1].) 
9.  
Scheduling or other conflict results in the second vaccination visit falling outside the 
required window 
10.  
Receipt of prohibited medication (see Section 6.5.1) as determined by the PI and agreed by 
the MM 
11.  
Causally-related Grade 3 or higher unsolicited AE as assessed by the PIa 
12.  
Causally-related SAE or potential AESI as assessed by the Sponsor 
AE=adverse event; AESI = adverse event of special interest; IP=investigational product; MM = medical monitor; PI=principal 
investigator, SAE = serious adverse event, 
aAny AE is considered to be related to the vaccine administration if assessed by the PI as being “possibly” or “probably” or 
“definitely” related.  
All participants who have received at least one vaccination will be encouraged to continue with 
the scheduled study safety evaluations, including any remaining study visits (safety assessments 
only), collection of samples for TSH and autoantibodies (only if medically indicated) and the 
safety follow-up calls.  Participants who decline will be encouraged to complete the EWV (see 
Section 8.1.8) and followed for safety through the 12-Month (Day 388 ± 14d) Safety Follow-up 
phone call. If the discontinuation was due to an AE, participants will be followed until the event 
has resolved or stabilized or the participant has been referred to an outside physician.  
7.3.2. 
Withdrawal from the Study  
A participant may withdraw from the study at any time, for any reason.  The PI may withdraw a 
participant from the study for the following reasons: 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 60 of 139 
 
 
1. Occurrence of an AE that in the opinion of the PI, warrants the participant’s permanent 
discontinuation from treatment (if having received at least one vaccination, the 
participant will be encouraged to continue in the study for safety follow-up only). 
2. Death. 
3. Lost to follow-up.  
4. Non-compliance with IP. 
5. Physician decision. 
6. Withdrawal of consent by participant.  
7. Study terminated by Sponsor. 
8. Other (eg, if Sponsor requests withdrawal of a participant, ceases dosing due to 
unacceptable toxicity). 
If the PI determines a participant has been noncompliant with study procedures, the PI will 
document the reason for noncompliance, and the participant will be withdrawn from the study. 
Reason(s) for study withdrawal will be recorded on the End of Study eCRF page. Participants 
who withdraw from the study treatment will be asked to continue with the scheduled study safety 
evaluations, including any remaining study visits (safety assessments only), collection of 
samples for autoantibodies and the safety follow-up calls details of which are provided in 
Section 8.1.6.3, Section 8.1.6.4, and Section 8.1.7.  Participants who decline will be encouraged 
to complete the EWV.  The EWV procedures are discussed in Section 8.1.8.  
7.4. 
Lost to Follow-up 
Participants who cannot be contacted during the in-clinic evaluation period through the Day 51 
(Final In-clinic Visit) or at the final 12-month (388 ± 14 d) safety follow-up phone contacts and 
who do not have a known reason for study withdrawal (eg, withdrew consent or AE) will be 
classified as “lost to follow-up” as the reason for study discontinuation in the eCRFs. The site 
will make three attempts to contact the participant by telephone. In the event the site is unable to 
reach the participant by telephone, the site will attempt to contact the participant via certified 
mail or an alternative similar method where appropriate. The time-period between contact 
attempts will be greater than one week apart. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 61 of 139 
 
 
8. 
STUDY ASSESSMENTS AND PROCEDURES 
8.1. 
Schedule of Assessments  
Involvement for the individual participant in this study from first visit to last visit inclusive of the 
screening visit and the safety follow-up phone calls will be approximately 14.5 months. 
Screening will occur within approximately one month (Day -28 to Day -2) of study start. Eligible 
participants will be randomized into one of the three groups shown in Table 2. All participants 
undergo the same assessments and procedures during screening and immediately following 
randomization; however, thereafter each group has its own schedule of assessments. The 
following sections provide detailed lists of assessments to be performed by visit, first starting 
with a section on the Screening and Randomization visits which are common to all participants 
and then followed with sections for each of the five groups. 
8.1.1. 
Screening, Randomization/Enrollment and Initial Blood Draws for TNA and 
Autoantibodies 
8.1.1.1. 
Screening (Days -28 to -2) 
Participants will be screened for participation in the trial from 2 to 28 days prior to the Day 1 
(randomization) visit. The Screening period begins once the participant signs and dates the ICF. 
The following activities will occur during the Screening visit or period: 
1. Ensure review and completion of all required information on the ICF and capture in site 
source documentation and eCRF. 
2. Assign subject ID number.  
3. Record demographics. 
4. Record complete medical history including current signs and symptoms which will be 
recorded as AEs only if they result from a study-related procedure(s). 
5. (For WOCBP only) document in the participant’s chart about counsel received for the 
requirements around type and timing of an adequate method of contraception, including 
the participant’s preferred method. 
6. Perform complete physical examination including an ECG. 
7. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature), height and weight and determine BMI. 
8. Record medications taken in last 30 days. 
9. Collect blood and urine samples for clinical laboratory tests (see Section 8.3.2) 
a. Depending on a woman’s fertility status conduct a serum pregnancy test (for 
WOCBP) or an FSH test (for postmenopausal women). Any female participant whose 
FSH test returns a value ≤30 mIU/mL will need to take a serum pregnancy test.  
b. Hematology. 
c. Serum chemistry.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 62 of 139 
 
 
d. Viral serology (human immunodeficiency virus [HIV] antibodies, hepatitis B surface 
antigen [HBsAg], and hepatitis C antibody). 
e. Urinalysis. 
f. Urine drug screen.  
10. Review for study eligibility against inclusion/exclusion criteria.  
8.1.1.2. Randomization/Enrollment and Initial Blood Draws for TNA and Autoantibodies: 
Day 1 
Day 1: Morning 
The following will occur on Day 1 prior to randomization: 
1. Update medical history including signs and symptoms, which will be recorded as AEs 
only if the event results from a study-related procedure. 
2. Assess vital signs. 
3. Conduct symptom-directed PE. 
5. Record medications taken since screening visit.  
6. Confirm continued use of an adequate method of contraception and collect urine sample 
for pregnancy test for WOCBP (if positive, the participant must not be randomized; upon 
receipt of a confirmatory negative serum pregnant test result, the participant may be 
rescheduled for the Day 1 visit, providing the visit falls within the required window of the 
screening procedures). 
7. Review for study eligibility against inclusion/exclusion criteria, to include a review of all 
safety and screening laboratory test results and status of ongoing AEs since the prior 
visit. 
After the PI has confirmed that the participant meets all the inclusion criteria and none of the 
exclusion criteria, the participant will be randomized into one of the three IP groups.  
1. Randomize eligible participants. 
2. For participants who are WOCBP and randomized to Group 1 or 2: Re-educate 
participants that ciprofloxacin and doxycycline may decrease the effectiveness of birth 
control pills, implantable or injectable contraceptives. Instruct the participant to add a 
double-barrier method, IUD, or abstinence as back-up forms of birth control.   
3. All randomized participants will have blood samples taken for TNA, TSH and 
autoantibodies. 
4. Participants randomized to Group 2A will be instructed to return the same evening so that 
they can enter the first doxycycline PK session the following morning (See 
Section 8.1.4). 
5. Participants randomized to Group 1A will be instructed to return to the site the evening of 
Day 3 so that they can enter the first ciprofloxacin PK session on Day 4 (See 
Section 8.1.2). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 63 of 139 
 
 
6. Participants randomized to Group 1B or 2B will be: 
 provided their antibiotics [ciprofloxacin (Group 1B) or doxycycline (Group 2B)],  
 provided instructions on the dosing regimen (twice daily at 12-hour intervals), 
beginning on the following day (Day 2) for those taking doxycycline (Group 2B) and 
beginning on Day 4 for those taking ciprofloxacin (Group 1B). 
 informed about the dietary and lifestyle precautions required when taking each 
antibiotic (see Section 5.3).  
 introduced to the e-diary for antibiotic compliance (see Section 8.3.5.1) and give 
instructions on how the e-diary should be used to record self-administered antibiotic 
doses.  
 instructed to return on Day 8 to receive their first vaccination (See Sections 8.1.3 and 
Section 8.1.5).  
Any participant who does not have or who does not wish to use their own personal device 
to access the e-diary will at this time be supplied a hand-held device by the site. 
7. Participants randomized to Group 3 will be instructed to return on Day 8 to receive their 
first vaccination (Section 8.1.6). 
8.1.2. 
Group 1A: Ciprofloxacin + AV7909 with Ciprofloxacin PK Sessions 
Shown in Table 5 is a schedule of events for Group 1A participants from screening until the end 
of the study. Following the table are detailed descriptions of the daily activities that the sites are 
expected to conduct for each of the column headings identified in the table. Note that this detail 
starts with PM Admit (Evening Admission) as the detailed activities during Screening and Group 
Assign (Randomization) were covered previously in Section 8.1.1.  
Table 5 Schedule of Events for Group 1A: Ciprofloxacin + AV7909 with Ciprofloxacin 
PK  
 
Screening Group 
Assign 
PMa 
Admit 
PKb  AMa 
Visits Vac  
At 
 Home† TNA Final 
Visit 
Safety 
Calls 
EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
3, 7, 
30, 34 
4, 8, 
31, 35 
5-7 
32-34 
8 
23* 
9, 22, 24, 
36, 37 
37 
51 
114, 205, 
 296, 388 
NA 
Visit Window  
NA 
 
§TBD 
NA 
NA ± 1 d* 
 
± 1 d ± 1 d 
± 14 d 
 
Sign, date ICF & assign ID 
X 
 
 
 
 
 
 
 
 
 
 
Review eligibility c 
X 
X 
X 
 
 
X 
 
 
 
 
 
Medical history & 
demographics 
X 
X 
 
 
 
 
 
 
 
 
 
Physical examinationd  
X 
 
 
 
 
 
 
 
X 
 
X 
ECGe 
X 
 
 
 
 
 
 
 
 
 
 
Vital signsf 
X 
X 
 
X 
 
X 
 
 
X 
 
X 
Pregnancy testg 
X 
X 
X  
(D3&D7 
only) 
 
 
X 
 
 
X 
 
X 
FSH testg 
X 
 
 
 
 
 
 
 
 
 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 64 of 139 
 
 
 
Screening Group 
Assign 
PMa 
Admit 
PKb  AMa 
Visits Vac  
At 
 Home† TNA Final 
Visit 
Safety 
Calls 
EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
3, 7, 
30, 34 
4, 8, 
31, 35 
5-7 
32-34 
8 
23* 
9, 22, 24, 
36, 37 
37 
51 
114, 205, 
 296, 388 
NA 
Visit Window  
NA 
 
§TBD 
NA 
NA ± 1 d* 
 
± 1 d ± 1 d 
± 14 d 
 
Collect sample for hematologyh 
X 
 
 
 
 
 
 
 
X 
 
X 
Collect sample for serum 
chemistryi 
X 
 
 
 
 
 
 
 
X 
 
X 
Collect sample for urinalysisj 
X 
 
 
 
 
 
 
 
X 
 
X 
Urine drug screenk 
X 
 
 
 
 
 
 
 
 
 
 
HIVAb/HBsAg/HCVAb 
X 
 
 
 
 
 
 
 
 
 
 
Concomitant medicationsl 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Randomize eligible participants 
 
X 
 
 
 
 
 
 
 
 
 
Symptom-directed PEm 
 
X 
 
 
 
X 
 
 
X 
 
X 
Blood draws for TNAn  
 
X 
 
 
 
 
 
X 
 
 
 
Cipro dosing & complianceo,p  
 
 
X 
X 
X 
X 
X 
X 
 
 
X p 
Cipro pre-dose or trough  
 
 
 
X 
X 
 
 
 
 
 
 
Cipro PKq 
 
 
 
X 
 
 
 
 
 
 
 
AV7909 vaccinationr 
 
 
 
 
 
X 
 
 
 
 
 
Participant e-diary + toolss 
 
x 
 
X 
X 
X 
X 
X 
X 
 
X 
Staff review of e-diariest 
 
 
Xs 
X 
X 
X 
X 
X 
X 
 
X 
AEsu, SAEs, AESIsv  
X 
X 
X 
X 
 
X 
 
 
X 
X 
X 
Collect TSH & autoantibody 
samplesw  
 
X 
 
 
 
 
 
 
X 
 
X w 
For the abbreviations used above please refer to Table 1 of the protocol. *The ± 1 d window applies only to the second 
vaccination on Day 23 (note: the second course of antibiotic treatment will have to shift accordingly) and needs discussion with 
CRO. †At Home Days are only those days where both doses of ciprofloxacin are taken at home. § The TBD window only applies 
to Day 30 and can at best be +1 d but needs discussion with sites and CRO because it will require a 1 day forward shift for all 
activities thereafter until Day 37 which may not need to shift because of its window. ‡For EWV occurring within the visit 
window of Day 37, a blood sample for TNA will be drawn. 
aPM and AM admissions must be timed so that ciprofloxacin can be administered in the clinic within a 12 hr ± 30 min window of 
the prior AM or PM dose.  
b For each PK session, the sites will manage the meals and activity of participants as detailed in Protocol Section 5.3.1 and 
Protocol Section 5.3.2. 
c Eligibility will be reviewed before each vaccination, either the evening before (ie, on Day 7) or the morning of vaccination (ie, 
on Day 23). 
d Physical examinations (PE) will be conducted as described in Protocol Section 8.3.3.  
e Electrocardiograms (ECGs) will be conducted and interpreted at screening as described in Section 8.3.3. 
f  Vital signs will be administered as described in Protocol Section 8.3.4.  
g Pregnancy tests (serum and/or urine) will be administered to all WOCBP as described in Protocol Section 8.3.2. Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP required before each 
vaccination will be administered either the evening before (ie, on Day 7) or the morning (ie, on Day 23) of vaccination. Note: 
for WOCBP in group 1A, UPT is required at Day 3 and Day 7 only (during overnight stay visit); it is not required at Day 30 or 
34. FSH test will be performed at Screenining visit only for postmenopausal women.    
h Hematology tests will be conducted as described in Protocol Section 8.3.2.  
i Serum chemistry tests will be conducted as described Protocol Section 8.3.2.   
j Urinalyses will be conducted as described in Protocol Section 8.3.2.    
k Urine drug screens will be conducted as described in Protocol Section 8.3.2.  
l Concomitant medications will be identified and recorded along with their indication as described in Protocol Section 6.5.    
m Symptom-directed PEs will be conducted as described in Protocol Section 8.3.3. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 65 of 139 
 
 
n Blood samples for TNA assessment on Day 1 will be collected in the morning following randomization. Those on Day 37 will 
be collected after the final dose of ciprofloxacin has been administered. A TNA sample will also be collected if EWV occurs 
within the visit window of Day 37 as described in Protocol Section 8.1.8.  
o Ciprofloxacin doses (500 mg po q 12 hr) will be administered as described in Protocol Section 6.1.5 with the first dose being 
administered on Day 4 when the cipro PK group enters their first PK session. 
p Ciprofloxacin dose compliance will be managed as described in Protocol Section 6.4. 
q Blood samples for assessment of ciprofloxacin concentrations will be collected as detailed in Protocol Section 8.4. 
r Vaccinations with AV7909 will be administered as described in Protocol Section 6.1.4. 
s All Participants will be provided with an e-diary for post vaccination follow up along with a thermometer and an injection site 
reaction measurement tool. Participants in Group 1 and 2 will be provided with an e-dairy for antibiotic compliance. All 
participants will be trained on the use of these tools and the e-diaries as described in Protocol Section 8.3.5.1. 
t Staff will begin reviewing the e-diaries on Day 6 and will review them at regular intervals thereafter. 
u AEs will be collected at all clinic visits through Day 51/EWV as described in detail in Protocol Section 9. 
v AEs, SAEs and potential AESIs will be collected during the Safety Follow-up Telephone Calls (see Protocol Section 8.1.7). 
w Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section 8.3.2 (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination).  Additional samples for TSH & 
autoantibody testing may be requested (eg, based on participant report(s) of a potential AESI); blood draws for additional TSH 
and/or autoantibody testing should be performed as part of an unscheduled visit. 
8.1.2.1. 
Group 1A: Day 3 – Overnight Stay # 1 
1. Admit to the clinic for overnight stay #1. 
2. Review and record AE assessments and changes in medications in participant’s medical 
history unless they are related to study procedures in which case they are recorded as 
AEs. 
3. For WOCBP, collect urine and perform a UPT.  Positive UPTs will be confirmed with a 
serum pregnancy test. All confirmed pregnancies in participants who have received at 
least one dose of any IP and where conception occurs prior to 12 months after last receipt 
of that IP will be followed to outcome.  
8.1.2.2. Group 1A: Day 4 – Pre-vaccine Single Dose Ciprofloxacin PK Session  
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Collect blood sample for ciprofloxacin t=0 concentration determination prior to 
administration of AM dose of ciprofloxacin. 
4. Administer AM ciprofloxacin dose following blood sample collection for t=0 antibiotic 
concentration determination and record time of administration in the source document 
and eCRF; ensure the participant remains semi-recumbent for two hours after dosing and 
continues with a light activity level throughout the day.  
5. Blood samples for ciprofloxacin PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr, 4 then ± 15 min thereafter). The exact time of sample collection is to be 
recorded in the source document and eCRF. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 66 of 139 
 
 
6. Administer ciprofloxacin dose (500 mg po) in the clinic after the final 12-hour 
ciprofloxacin PK sample has been collected and 12 hours after morning dose (± 30 min), 
record exact time of administration in the source document and eCRF. 
7. Record anyAEs reported. 
8. Conduct a symptom-directed PE (if required).  
9. Prior to being discharged from the clinic, participants will be:  
 informed about the dietary and lifestyle precautions required when taking 
ciprofloxacin (see Section 5.3)  
 Review the e-diary instructions on how the e-diary should be used to record 
compliance for the antibiotic doses (see Section 8.3.5.1 e-diary).  
Any participant who does not have or who does not wish to use their own personal 
device to access the e-diary will at this time be supplied a hand-held device by the 
site;  
8.1.2.3. Group 1A: Days 5, 6 and 7 – Morning 
1. Review e-diary, confirm compliance with ciprofloxacin dosing (Days 6 and 7), and ask if 
there were any associated changes in concomitant medications. 
2. Collect blood samples for determination of ciprofloxacin trough concentrations prior to 
administering the AM dose of ciprofloxacin on Days 5, 6 and 7; record times of 
administration of ciprofloxacin in source document and eCRF. 
3. Prior to discharge from the clinic on Day 5, participants will 
 receive a ciprofloxacin supply to take with them 
 be reminded to take their evening dose of ciprofloxacin approximately 12 hours 
(± 30 min) from the time their morning dose was provided and to bring their 
supply of ciprofloxacin with them when they return the following morning.  
 be reminded of the dietary and activity precautions associated with the use of 
ciprofloxacin (see Section 5.3).  
4. On Days 5 and 6, the evening dose (q 12 hr) of ciprofloxacin is to be self-administered at 
home (at about the same times [± 30 min] each day).  The participant will to be 
instructed/reminded to record the date and time of administration of ciprofloxacin in the 
e-diary  
5. On the mornings of Days 5, 6 and 7, staff will review the e-diary entries with the 
participant, confirm compliance with ciprofloxacin dosing (Days 5 and 6), review and 
record any changes in concomitant medications, and will remind participants on Days 5 
and 6 to return the next morning for another clinic visit. 
6. At the end of each clinic visit, participants will be reminded to take their evening dose of 
ciprofloxacin and to be aware of the dietary and activity precautions associated with the 
use of ciprofloxacin (see Section 5.3). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 67 of 139 
 
 
7. Prior to discharge on morning of Day 7, participants will be reminded to return to clinic 
that evening for the second overnight admission.   
8.1.2.4. Group 1A: Day 7 – Evening & Overnight Stay # 2  
1. Admit to clinic for overnight stay #2. 
2. For WOCBP, collect urine and perform a UPT. Positive UPTs will be confirmed with a 
serum pregnancy test. All confirmed pregnancies in participants who have received at 
least one dose of any IP and where conception occurs prior to 12 months after last receipt 
of that IP will be followed to outcome.  
3. Staff will review ciprofloxacin supply with participant, checking the remaining content 
against the dosing records in the e-diary to document compliance and using this supply to 
provide the evening ciprofloxacin dose which is to be administered 12 hours (± 30 min) 
after morning dose; record time of administration of ciprofloxacin in source document 
and the eCRF. 
8.1.2.5. Group 1A: Day 8 – Pre-vaccine Steady-State Ciprofloxacin PK Session & 
Vaccination #1 
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day. 
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Review eligibility for vaccination. 
4. Review and record AEs. 
5. Reassess concomitant medications. 
6. Perform symptom-directed PE, if required. 
7. Collect blood sample for ciprofloxacin t=0 concentration determination prior to 
administration of AM dose of ciprofloxacin. 
8. Administer AM dose of ciprofloxacin following blood sample collection for t=0 
antibiotic concentration determination and record time of administration in the source 
document and the eCRF; ensure the participant remains semi-recumbent for two hours 
after dosing and continues with a light activity level throughout the day. 
9. Blood samples for ciprofloxacin PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter).  
10. Administer ciprofloxacin 500 mg po in the clinic after the final 12-hour ciprofloxacin PK 
sample has been collected and 12 hours after morning dose (± 30 min). 
11. Administer AV7909 vaccination #1 after the 12 hr blood sample for ciprofloxacin PK has 
been collected and after the PM dose of ciprofloxacin has been administered. Participants 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 68 of 139 
 
 
will be monitored for at least 30 minutes following vaccine administration for any 
adverse effects especially anaphylaxis. 
12. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature) at 30 ± 5 minutes post-vaccination. 
13. At some point during the day but prior to being discharged from the clinic, the 
participant’s ciprofloxacin supply will be reviewed, checking the remaining content 
against the dosing records.   
14.  Prior to discharge from the clinic, the participant will be provided and trained on an e-
diary to capture local and systemic reactogenicity events (ie, reactogenicity e-diary) and 
to record daily for at least seven days following each vaccination. If a reaction is not 
resolved at seven days postvaccination, the participant is to continue completing the e-
diary daily until they are symptom free for two consecutive days. Participants will be 
provided with an injection site reaction measurement tool and shown how to use it to 
measure the size of certain reactogenicity events associated with vaccination, rate the 
intensity and where to enter this information in the e-diary (see Section 8.3.5.1).  
15. When the participants are discharged from the clinic, they will be reminded: 
 about the diet and activity precautions that must be followed when taking 
ciprofloxacin (see Section 5.3).  
 to continue to use the antibiotic e-diary to record the times they take their 
ciprofloxacin doses each day, and to use their reactogenicity e-diary to record any 
vaccination reactions, if applicable. 
8.1.2.6. Group 1A: Days 9, 22 and 24 (At home) 
On Days 9, 22 and 24, the participant is to self-administer ciprofloxacin (500 mg po q 12 hr) at 
home [at about the same times (± 30 min) each day]. The participant will continue with the e-
diary as described in Section 8.3.5.1.  
It is required that participants self-administer ciprofloxacin on the day before (morning and 
evening, the day of (evening), and the day after vaccination (morning and evening). The site 
must contact the participant to remind them to begin their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccination date).Any participant who 
needs to shift the day they come for their second vaccination must be reminded by the site to 
start their ciprofloxacin dosing on the appropriate day, eg, if the second vaccination shifts to Day 
22, then the participant will need to be reminded to start taking ciprofloxacin on the morning and 
evening of Day 21 in order to meet the dosing requirement.   
8.1.2.7. Group 1A: Day 23 (± 1d) – Vaccination # 2 
1. Review e-diary entries with the participant, recording of ciprofloxacin dosing, reminding 
the participant of the precautions in Section 5.3. 
2. Review and record AEs, including any ongoing since the prior visit. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 69 of 139 
 
 
3. Reassess concomitant medications. 
4. Perform symptom-directed PE, if required. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect urine and perform a UPT (prior to AV7909 vaccination).  Positive 
UPTs will be confirmed with a serum pregnancy test. All confirmed pregnancies in 
participants who receive at least one dose of any IP and where conception occurs prior to 
12 months after last receipt of any IP will be followed to outcome. 
7. Review eligibility for continuing vaccination. 
8. Administer AM ciprofloxacin dose; record time of administration in source document 
and the eCRF.  
9. Administer AV7909 vaccination #2; this should occur after ciprofloxacin dosing. 
Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis. 
10. Assess vital signs at 30 ± 5 min post-vaccination (seated/semi-recumbent blood pressure, 
heart rate, respiratory rate, and temperature). 
11. After vaccination, participants will be reminded to continue to use the e-diary and 
injection site reaction measurement tool to capture the adverse events associated with 
vaccination, and to record the dates and times they take their self-administered 
ciprofloxacin doses.  (See Section 8.3.5.1 e-diary). 
12. Prior to discharge on Day 23 ± 1d, participants will be reminded to continue to take their 
ciprofloxacin on the following day (Day 24) and to return to clinic in seven days for the 
third overnight admission.    
8.1.2.8. Group 1A: Day 30 – Evening & Overnight Stay # 3 
1. Admit to the clinic for overnight stay #3.  
2. Staff will review e-diary entries with participant, discussing the use of concomitant 
medication as well as any vaccination reactions.  
3. Staff will review ciprofloxacin supply from participant, cross-referencing the content 
against the dosing records in the e-diary to document compliance.  
8.1.2.9. Group 1A: Day 31 – Post-vaccine Single Dose Ciprofloxacin PK Session 
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.  
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Collect blood sample for ciprofloxacin t=0 concentration determination prior to 
administration of AM dose of ciprofloxacin.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 70 of 139 
 
 
4. Administer AM dose of ciprofloxacin following blood sample collection for t=0 
concentration determination and record time of administration in the source document 
and the eCRF; ensure the participant remains semi-recumbent for two hours after dosing 
and continues with a light activity level throughout the day. 
5. Blood samples for ciprofloxacin PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter). 
6. Administer ciprofloxacin 500 mg po in the clinic after the final 12-hour ciprofloxacin PK 
sample has been collected and 12 hours after morning dose (± 30 min). 
7. Following the PK session, staff will review any changes in concomitant medications. 
8. When the participants are discharged from the clinic, they will be reminded: 
 about the diet and activity precautions that must be followed when taking 
ciprofloxacin (see Section 5.3).  
 to continue to use the antibiotic e-diary to record their ciprofloxacin doses each 
day, and to use the reactogenicity e-diary to record any vaccination reactions, if 
applicable, see Section 8.3.5.1 (Participant e-diary). 
8.1.2.10. Group 1A: Days 32, 33 and 34 – Morning  
1. Review e-diary, confirm compliance with ciprofloxacin dosing to document compliance, 
discuss any changes in  concomitant medications, as well as any vaccination reactions if 
still ongoing and remind participants about the dietary and activity precautions that must 
be followed when taking ciprofloxacin (see Section 5.3).  
2. Collect blood samples for determination of ciprofloxacin trough concentrations prior to 
the in-clinic administration of the AM dose of ciprofloxacin on Days 32, 33 and 34; 
record times of administration of ciprofloxacin in source document and the eCRF. 
3. On Days 32 and 33, the evening dose (q 12 hr) of ciprofloxacin is to be self-administered 
at home (at about the same times [± 30 min] each day). 
4. Prior to discharge on the morning of Day 34, participants will be reminded to return to 
clinic that evening for the fourth overnight admission.    
8.1.2.11. Group 1A: Day 34 – Evening & Overnight Stay # 4 
1. Admit to clinic for overnight stay #4. 
2. Staff will review the participant’s ciprofloxacin supply and review e-diary entries, 
conducting a compliance check of the remaining doses compared to the e-diary record. 
Staff will also ask if the participant required the use of concomitant medication as well as 
any vaccination reactions if still ongoing.  
3. Administer ciprofloxacin 500 mg po 12 hours after morning dose (± 30 min). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 71 of 139 
 
 
8.1.2.12. Group 1A: Day 35: – Post-vaccine Steady-State Ciprofloxacin PK Session 
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Collect blood sample for ciprofloxacin t=0 concentration determination prior to 
administration of AM dose of ciprofloxacin. 
4. Administer AM dose of ciprofloxacin (500 mg po) following blood sample collection for 
t=0 concentration determination and record time of administration in the source 
document and the eCRF; ensure the participant remains semi-recumbent for two hours 
after dosing and continues with a light activity level throughout the day. 
5. Blood samples for ciprofloxacin PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter).  
6. Administer ciprofloxacin 500 mg po in the clinic after the final 12-hour ciprofloxacin PK 
sample has been collected and 12 hours after the morning dose (± 30 min). 
7. Record concomitant medications. 
8. Return ciprofloxacin supply to participant 
9. When the participants are discharged from the clinic, they will be reminded: 
 about the diet and activity precautions that must be followed when taking 
ciprofloxacin (see Section 5.3).  
 to continue to use the antibiotic e-diary to record the times they take their 
ciprofloxacin doses each day and to use the reactogenicity e-diary to record any 
vaccination reactions, if applicable, see Section 8.3.5.1  (Participant e-diary). 
8.1.2.13. Group 1A: Day 36 (At home) 
Two ciprofloxacin doses (500 mg po morning and evening, q 12 hr) are to be self-administered 
at home on Day 36. The participant will continue with the e-diary as described in Section 8.3.5.1. 
8.1.2.14. Group 1A: Day 37 (± 1d) – Blood Draw for TNA 
The Day 37 visit to draw blood for immunogenicity may shift by ± 1 d.  If such a shift in visit 
day occurs, the participant must remain on ciprofloxacin 500 mg po every 12 hours until the 
morning of that visit.  In the event of such a shift, the participant’s required number of doses of 
ciprofloxacin will vary. The Pharmacy Manual will contain a table detailing the dosing options 
for the final course of ciprofloxacin given a one-day shift from Day 37. 
1. Participants will report to the clinic having taken their morning dose of ciprofloxacin at 
home. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 72 of 139 
 
 
2. Review participant’s ciprofloxacin supply; count the number of remaining doses and 
compare to the e-diary record to document compliance; record total remaining in source 
document and eCRF. 
3. Review other e-diary entries with participant. Discuss any changes in the use of 
concomitant medication as well as any vaccination reactions if still ongoing. Remind 
participants that they should still use sunscreen and avoid excessive sun exposure and 
strenuous sports until the Day 51 Final Study Visit. 
4. Record concomitant medications. 
5. Collect blood sample for TNA assessment. 
8.1.2.15. Group 1A: Day 51 (± 1d) – Final In-Clinic Study Visit  
1. Perform complete PE. 
2. Review e-diary entries with participant and collect hand-held device if study provided.  
3. Review and record AEs. 
4. Record concomitant medications. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform a UPT.  Positive UPTs will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participants who receive at least one dose of 
AV7909 or ciprofloxacin and where conception occurs prior to 12 months after last 
receipt of either IP will be followed to outcome. 
7. Collect blood samples for hematology and serum chemistry.  
8. Collect blood samples for TSH & autoantibodies. 
9. Collect urine sample for urinalysis. 
8.1.3. 
Group 1B: Ciprofloxacin + AV7909 without Ciprofloxacin PK 
Shown in Table 6 is a schedule of events for Group 1B participants from screening until the end 
of the study. Following the table are detailed descriptions of the activities that the sites are 
expected to conduct for each of the column headings identified in the table once each participant 
has received his or her group assignment. Note that this detail starts following randomization for 
Group 1B which is when they receive their first course of ciprofloxacin although the actual 
activities for the trial do not begin until Day 4 when participants self-administer their first dose 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 73 of 139 
 
 
of ciprofloxacin. The detailed activities during Screening and Group Assign (Randomization) 
were covered previously in Section 8.1.1.  
Table 6: Schedule of Events for Group 1B: Ciprofloxacin + AV7909 without Ciprofloxacin 
PK 
 
Screening 
Group 
Assign 
At 
Home† 
Vac 
At Home† TNA Final 
Visit 
Safety 
Calls 
EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
4-7 
8 
23* 
9, 22, 24, 
31-37 
37 
51 
114, 205, 
 296, 388 
NA 
Visit Window  
NA 
NA 
 
*± 1 d 
 
± 1 d ± 1 d 
± 14 d 
 
Sign, date ICF & assign ID 
X 
 
 
 
 
 
 
 
 
Review eligibility a 
X 
X 
 
X 
 
 
 
 
 
Medical history & demographics 
X 
X 
 
 
 
 
 
 
 
Physical examinationb  
X 
 
 
 
 
 
X 
 
X 
ECGc 
X 
 
 
 
 
 
 
 
 
Vital signsd 
X 
X 
 
X 
 
 
X 
 
X 
Pregnancy teste 
X 
X 
 
X 
 
 
X 
 
X 
FSH teste 
X 
 
 
 
 
 
 
 
 
Collect sample for hematologyf 
X 
 
 
 
 
 
X 
 
X 
Collect sample for serum chemistryg 
X 
 
 
 
 
 
X 
 
X 
Collect sample for urinalysish 
X 
 
 
 
 
 
X 
 
X 
Urine drug screeni 
X 
 
 
 
 
 
 
 
 
HIVAb/HBsAg/HCVAb 
X 
 
 
 
 
 
 
 
 
Concomitant medicationsj 
X 
X 
 
X 
 
X 
X 
X 
X 
Randomize eligible participants 
 
X 
 
 
 
 
 
 
 
Symptom-directed PEk 
 
X 
 
X 
 
 
 
 
 
Blood draws for TNAl 
 
X 
 
 
 
X 
 
 
 
Cipro dosing & compliancem,,n 
 
X 
X 
X 
X 
X 
 
 
Xn 
AV7909 vaccinationo 
 
 
 
X 
 
 
 
 
 
Participant e-diary + toolsp 
 
X 
X 
X 
X 
X 
X 
 
X 
Staff review of e-diariesq 
 
 
X 
X 
X 
X 
X 
 
X 
AEsr, SAEs & AESIss 
X 
X 
 
X 
 
 
X 
X 
X 
Collect TSH & autoantibody samplest 
 
X 
 
 
 
 
X 
 
X 
For the abbreviations used above please refer to Table 1 of the protocol. *The ± 1 d window applies only to the second 
vaccination on Day 23 (note: the second course of antibiotic treatment will have to shift accordingly). †At Home Days are only 
those days where both doses of ciprofloxacin are taken at home. ‡For EWV occurring within the visit window of Day 37, a blood 
sample for TNA will be drawn. 
a Eligibility will be reviewed before each vaccination, ie, on Day 8 and Day 23. 
b Physical examinations (PE) will be conducted as described in Protocol Section 8.3.3. 
c ECGs will be conducted and interpreted at screening as described in Protocol Section 8.3.3.   
d Vital signs will be administered as described in Protocol Section 8.3.4.   
e Pregnancy tests (serum and/or urine) will be administered to all WOCBP as described in Protocol Section 8.3.2. Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP will be required 
before each vaccination. At Screening visit only, FSH test will be performed for postmenopausal women.     
f Hematology will be conducted as described in Protocol Section 8.3.2.   
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 74 of 139 
 
 
g Serum chemistry will be conducted as described Protocol Section 8.3.2.   
h Urinalysis will be conducted as described in Protocol Section 8.3.2. 
i Urine drug screens will be conducted as described in Protocol Section 8.3.2. 
j Concomitant medications will be identified and recorded as described in Protocol Section 6.5.     
k Symptom-directed PEs will be conducted as described in Protocol Section 8.3.3. 
l Blood samples for TNA assessment on Day 1 will be collected in the morning following randomization. Those on Day 37 will 
be collected after the final dose of ciprofloxacin has been administered. A TNA sample will also be collected if EWV occurs 
within the visit window of Day 37 as described in Protocol Section 8.1.8. 
m Participants receive their first course of ciprofloxacin following randomization. Format of the doses and distribution of 
subsequent courses will be described in the Pharmacy manual. Self-administration of ciprofloxacin starts on Day 4. Ciprofloxacin 
dose compliance will be managed as described in Protocol Section 6.4.   
n Ciprofloxacin doses (500 mg po q 12 hr) will be administered as described in Protocol Section 6.1.2.   
o Vaccinations with AV7909 will be administered as described Protocol Section 6.1.4.  
p All participants will be provided with an e-diary for post vaccination follow up along with a thermometer and an injection site 
reaction measurement tool. Participants in Group 1 and 2 will be provided with an e-dairy for antibiotic compliance. All 
participants will be trained on the use of these tools and the e-diaries as described in Protocol Section 8.3.5.1. 
q Staff will begin reviewing the e-diaries on Day 5 and will review them at regular intervals thereafter. 
r AEs will be collected at all clinic visits through Day 51/EWV as described in detail in Protocol Section 9.  
s AEs, SAEs and potential AESIs will be collected during the Safety Follow-Up Telephone Calls (see Protocol Section 8.1.7). 
t Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section 8.3.2 (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination). Additional samples for TSH & 
autoantibody testing may be requested (ie, based on the participant’s report(s) of a potential AESI); blood draws for additional 
TSH and/or autoantibody testing should be performed as part of an unscheduled visit. 
8.1.3.1. Group 1B: Days 4 to 7 (At home) 
1. On Days 4 to 7, the participant will self-administer ciprofloxacin 500 mg po every 12 
hours at home at about the same times (± 30 min) each day.   
2. Participant will use the antibiotic e-diary to record the date and time of administration of 
ciprofloxacin.  
8.1.3.2. Group 1B: Day 8 – Vaccination #1 
1. Review eligibility. 
2. Staff will review the ciprofloxacin supply and review the e-diary entries, conducting a 
compliance check of the remaining doses compared to the e-diary record. Staff will 
record ciprofloxacin doses to document compliance. Staff will also discuss any changes 
in the use of concomitant medication while reminding the participant of the precautions 
in Section 5.3. 
3. Review and record AEs. 
4. Conduct a symptom-directed PE, if required. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 or ciprofloxacin and where conception occurs 
prior to 12 months after last receipt of either IP will be followed to outcome. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 75 of 139 
 
 
7. Administer ciprofloxacin 500 mg po in AM prior to vaccination; the evening dose of 
ciprofloxacin 500 mg po will be self-administered at home 12 hours after the AM dose 
[and at approximately the same time (± 30 min) each day]. 
8. Administer AV7909 vaccination #1. Participants should be monitored for at least 30 
minutes following vaccine administration for any adverse effects especially anaphylaxis. 
9. Assess vital signs at 30 ± 5 min postvaccination. 
10. Prior to being discharged from the clinic, the participant will be given and trained on an 
e-diary to capture local and systemic reactogenicity events (ie, reactogenicity e-diary) and 
to record daily for at least seven days following each vaccination. If a reaction is not 
resolved at seven days postvaccination, the participant is to continue completing the e-
diary daily until they are symptom free for two consecutive days. Participants will be 
given aninjection site reaction measurement tool and shown how to use it to measure the 
size and assess the severity of certain reactogenicity events associated with vaccination. 
See Section 8.3.5.1 (e-diary) and remind participants about the diet and activity 
precautions that must be followed when taking ciprofloxacin (see Section 5.3). 
8.1.3.3. 
Group 1B:Days 9, 22 and 24 (At home) 
On Days 9, 22 and 24, the participant is to self-administer ciprofloxacin (500 mg po q 12 hr) at 
home [at about the same times (± 30 min) each day]. The participant will continue with the e-
diary as described in Section 8.3.5.1.  
It is required that participants self-administer ciprofloxacin on the day before (morning and 
evening), the day of (evening), and the day after (morning and evening) vaccination. The site 
must contact the participant to remind them to begin their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccination date). Any participant who 
schedules vaccination 2 (on Day 23) to shift within the allowable window (± 1 d) will be 
reminded to start their ciprofloxacin dosing on the appropriate day, eg, if the second vaccination 
shifts to Day 22 then the participant will be reminded to start taking ciprofloxacin on the 
morning and evening of Day 21 in order to meet the dosing requirement. 
8.1.3.4. Group 1B: Day 23 (± 1 d) – Vaccination #2 
1. Staff will review ciprofloxacin supply and review against e-diary entries conducting a 
compliance check of the remaining doses compared to the e-diary record. Staff will 
record ciprofloxacin doses to document compliance. Staff will discuss changes in the use 
of concomitant medication as well as any vaccination reactions if still ongoing while 
reminding the participant of the precautions in Section 5.3.  
2. Review and record AEs. 
3. Perform symptom-directed PE, if required. 
4. Record concomitant medications.  
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate, and 
temperature). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 76 of 139 
 
 
6. Review eligibility for continuing vaccination. 
7. For female participants not exempted due to a screening FSH >30 mIU/mL, collect and 
perform UPT (prior to AV7909 vaccination).  Positive UPTs will be confirmed with a 
serum pregnancy test.  All confirmed pregnancies in participants who receive at least one 
dose of any IP and where conception occurs prior to 12 months after last receipt of any IP 
will be followed to outcome. 
8. Administer ciprofloxacin 500 mg po in AM; the evening dose will be self-administered at 
home. 
9. Administer AV7909 vaccination #2; this should occur after ciprofloxacin dosing. 
Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis.  
10. Following the 30 (± 5) minutes of observation, repeat vital signs (seated/semi-recumbent 
blood pressure, heart rate, respiratory rate, and temperature) measurement. 
11. After e-diary review, participants will be reminded to continue to use the reactogenicity 
e-diary and injection site reaction measurement tool to capture the adverse events 
associated with vaccination, and to record the dates and times they self-administer their 
ciprofloxacin doses in the antibiotic e-diary. See Section 8.3.5.1 (e-diary). 
12. Prior to discharge on Day 23, participants will be reminded to return to clinic in two 
weeks (± 1 d) on Day 37 ± 1 d for the final blood draws for TNA. Again, participants are 
to continue dosing with ciprofloxacin through the evening of Day 24 and discontinue 
dosing until Day 31. Their ciprofloxacin supply will be returned to them before they are 
discharged from the clinic.  
8.1.3.5. Group 1B: Days 31 to 36 (At home) 
On Days 31 to 37, the participant is to self-administer ciprofloxacin 500 mg po every 12 hours at 
home [at about the same times (± 30 min) each day].  The participant will continue with the e-
diary as described in Section 8.3.5.1. The site must contact the participant to remind them to start 
their third course of ciprofloxacin within 24 hours of Day 31. 
8.1.3.6. Group 1B: Day 37 (± 1 d) – Blood Draw for TNA  
The Day 37 Visit may shift by ± 1 d. If such a shift occurs, the participant must remain on 
ciprofloxacin 500 mg po every 12 hours until the morning before the blood draw.  In the event of 
such a shift, the participant’s required number of doses of ciprofloxacin will vary. The Pharmacy 
Manual will contain a table detailing the dosing options for the final course of ciprofloxacin 
given a one-day shift from Day 37. 
1. Participants will report to the clinic having taken their morning dose of ciprofloxacin at 
home. 
2. Review participant’s ciprofloxacin supply; count the number of remaining doses and 
compare to the e-diary record to document compliance; record total remaining in source 
document. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 77 of 139 
 
 
3. Review other e-diary entries with participant. Discuss any changes in the use of 
concomitant medication as well as any vaccination reactions if still ongoing. Remind 
participants that they should still use sunscreens and avoid excessive sun exposure and 
strenuous sports until the Day 51 Final Study Visit.  
4. Record concomitant medications. 
5. Collect blood sample for TNA assessment 
8.1.3.7. Group 1B: Day 51 (± 1 d) – Final In-Clinic Study Visit  
1. Perform complete PE.  
2. Review e-diary entries with participant and collect hand-held device if study provided.  
3. Review and record AEs. 
4. Record concomitant medications. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform UPT.  Positive UPTs will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participants who receive at least one dose of 
AV7909 or ciprofloxacin and where conception occurs prior to 12 months after last 
receipt of either IP will be followed to outcome. 
7. Collect blood sample for hematology. 
8. Collect blood sample for serum chemistry. 
9. Collect blood sample for TSH and autantibodies. 
10. Collect urine sample for urinalysis.  
8.1.4. 
Group 2A: Doxycycline + AV7909 with Doxycycline PK Sessions 
Shown in Table 7 is a schedule of events for Group 2A participants from screening until the end 
of the study. Following the table are detailed descriptions of the activities that the sites are 
expected to conduct for each of the column headings identified in the Table. Note that this detail 
starts with PM Admit (Evening Admission) as the detailed activities during Screening and Group 
Assign (Randomization) were covered previously in Section 8.1.1. 
Table 7: 
Schedule of Events for Group 2A: Doxycycline + AV7909 with Doxycycline 
PK 
 
Screening Group 
Assign 
PMa 
Admit 
PKb  
AMa 
Visits Vac  
At 
 Home† TNA  Final 
Visit 
Safety 
Calls 
EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
1r, 7c,e, 
31, 37 
2r, 8, 
32, 38 
3-7 
33-37 
8 
23e* 9, 22, 24,  37 
51 
114, 205, 
 296, 388 
NA 
Visit Window ±  
NA 
 
§+ 1 d 
NA 
 
*± 1 d 
 
 
± 1 d 
± 14 d 
 
Read, sign, date ICF & receive ID 
X 
 
 
 
 
 
 
 
 
 
 
Review eligibility  
X 
X 
X 
 
 
Xc 
 
 
 
 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 78 of 139 
 
 
 
Screening Group 
Assign 
PMa 
Admit 
PKb  
AMa 
Visits Vac  
At 
 Home† TNA  Final 
Visit 
Safety 
Calls 
EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
1r, 7c,e, 
31, 37 
2r, 8, 
32, 38 
3-7 
33-37 
8 
23e* 9, 22, 24,  37 
51 
114, 205, 
 296, 388 
NA 
Visit Window ±  
NA 
 
§+ 1 d 
NA 
 
*± 1 d 
 
 
± 1 d 
± 14 d 
 
Medical history & demographics 
X 
X 
 
 
 
 
 
 
 
 
 
Physical examinationd  
X 
 
 
 
 
 
 
 
X 
 
X 
ECGe 
X 
 
 
 
 
 
 
 
 
 
 
Vital signsf 
X 
X 
 
X 
 
X 
 
 
X 
 
X 
Pregnancy testg 
X 
X 
X  
(D7 only) 
 
 
X 
 
 
X 
 
X 
FSH testg 
X 
 
 
 
 
 
 
 
 
 
 
Collect sample for hematologyh 
X 
 
 
 
 
 
 
 
X 
 
X 
Collect sample for serum 
chemistryi 
X 
 
 
 
 
 
 
 
X 
 
X 
Collect sample for urinalysisj 
X 
 
 
 
 
 
 
 
X 
 
X 
Urine drug screenk 
X 
 
 
 
 
 
 
 
 
 
 
HIVAb/HBsAg/HCVAb 
X 
 
 
 
 
 
 
 
 
 
 
Concomitant medicationsj 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Randomize eligible participants 
 
X 
 
 
 
 
 
 
 
 
 
Symptom-directed PEm 
 
X 
 
 
 
X 
 
 
X 
 
 
Blood draws for TNAn  
 
X 
 
 
 
 
 
X 
 
 
 
Doxy dosing & complianceo,p  
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
Doxy pre-dose or trough  
 
 
 
X 
X 
 
 
 
 
 
 
Doxy PKq 
 
 
 
X 
 
 
 
 
 
 
 
AV7909 vaccinationr 
 
 
 
 
 
X 
 
 
 
 
 
Participant e-diary + toolsx 
 
X 
 
X 
X 
X 
X 
X 
X 
 
X 
Staff review of e-diariest 
 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
AEsu, SAEs, AESIsv  
X 
X 
X 
X 
 
X 
 
 
X 
X 
X 
Collect TSH & autoantibody 
samplesw  
 
X 
 
 
 
 
 
 
X 
 
X 
For the abbreviations used above please refer to Table 1 of the protocol. *The ± 1 d window applies only to the second 
vaccination on Day 23 (note: the second course of antibiotic treatment will have to shift accordingly). †At Home Days are only 
those days where both doses of doxycycline are taken at home.  § The +1 d window only applies to Day 31. ‡For EWV occurring 
within the visit window of Day 37, a blood sample for TNA will be drawn. 
a PM and AM admissions must be timed so that doxycycline can be administered in the clinic within a 12 hr ± 30 min window of 
the prior AM or PM dose.  
b For each PK session, the sites will manage the meals and activity of participants as detailed in Protocol Section 5.3.1 and 
Protocol Section 5.3.2. 
c Eligibility will be reviewed before each vaccination, either the evening before (ie, on Day 7) or the morning of vaccination (ie, 
on Day 23).  
d Physical examinations (PE) will be conducted as described in Protocol Section 8.3.3. 
e ECGs will be conducted and interpreted at screening as described in Protocol Section 8.3.3.  
f Vital signs will be administered as described in Protocol Section 8.3.4.  
g Pregnancy tests (serum and/or urine) will be administered to all WOCBP as described in Protocol Section 8.3.2. Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP required before each 
vaccination will be performed either the evening before (ie, on Day 7) or the morning of vaccination (ie, on Day 23). Note: for 
WOCBP in group 2A, UPT is required only at Day 7 (at the evening admission); it is not required at evening admissions at Day 
1, 31 or 37. FSH test will be performed at Screenining visit only for postmenopausal women.     
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 79 of 139 
 
 
h Hematology tests will be conducted as described in Protocol Section 8.3.2.   
i Serum chemistry tests will be conducted as described Protocol Section 8.3.2. 
j Urinalysis will be conducted as described in Protocol Section 8.3.2.  
k Urine drug screens will be conducted as described in Protocol Section 8.3.2. 
l Concomitant medications will be identified and recorded as described in Protocol Section 6.5. 
m Symptom-directed PEs will be conducted as described in Protocol Section 8.3.3. 
n Blood samples for TNA assessment on Day 1 will be collected in the morning following randomization. Those on Day 37 will 
be collected after the morning dose of doxycycline has been administered. A TNA sample will also be collected if the EWV 
occurs within the visit window of Day 37 as described in Protocol Section 8.1.8.  
n Symptom-directed PEs will be conducted as described in Protocol Section 8.3.3. 
o Doxycycline dose compliance will be managed as described in Protocol Section 6.4.   
p Doxycycline doses (100 mg po q 12 hr) will be administered as described in Protocol Section 6.1.6.  
q Blood samples for assessment of doxycycline concentrations will be collected as detailed in Protocol Section 8.4. 
r Vaccinations with AV7909 will be administered as described Protocol Section 6.1.4.  
s All participants will be provided with an e-diary for post vaccination follow up along with a thermometer and an injection site 
reaction measurement tool. Participants in Group 1 and 2 will be provided with an e-dairy for antibiotic compliance. All 
participants will be trained on the use of these tools and the e-diaries as described in Protocol Section 8.3.5.1. 
t Staff will begin reviewing the e-diaries on Day 3 and will review them at routine intervals thereafter. 
u AEs will be collected at all clinic visits through Day 51/EWV as described in detail in Protocol Section 9.  
v AEs, SAEs and potential AESIs will be collected during the Safety Follow-Up Telephone Calls (see Protocol Section 8.1.7). 
w Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section 8.3.2 (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination). Additional TSH & autoantibody 
testing may be requested (ie, based on the participant’s report(s) of a potential AESI); additional TSH and/or autoantibody testing 
should be performed as part of an unscheduled visit. 
8.1.4.1. 
Group 2A: Day 1 – Overnight Stay # 1 
1. Admit to the clinic for overnight stay #1. 
2. Review eligibility.  
3. Review and record AE assessments and changes in concomitant medications in 
participant’s medical history unless they are related to study procedures in which case 
they are recorded as AEs. 
8.1.4.2. Group 2A: Day 2 – Pre-vaccine Single Dose Doxycycline PK Session  
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Collect blood sample for doxycycline t=0 concentration determination prior to 
administration of AM dose of doxycycline. 
4. Administer AM dose of doxycycline following blood sample collection for t=0 antibiotic 
concentration determination and record time of administration in the source document 
and the eCRF; ensure the participant remains semi-recumbent for two hours after dosing 
and continues with a light activity level throughout the day.  
5. Blood samples for doxycycline PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter). The exact time of sample collection is to be 
recorded in the source document and eCRF. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 80 of 139 
 
 
6. Administer doxycycline dose (100 mg po) in the clinic after the final 12-hour 
doxycycline PK sample has been collected and 12 hours after morning dose (± 30 min), 
record exact time of administration in the source document and the eCRF. 
7. Record any AEs reported. 
8. Conduct a symptom-directed PE in response to any AEs reported.  
9. Prior to being discharged from the clinic, participants will:  
 Be informed about the dietary and lifestyle precautions required when taking 
doxycycline (see Section 5.3). 
 Review the instructions on the use of the antibiotic e-diary to record compliance for 
the antibiotic doses (see Section 8.3.5.1 e-diary).  
Any participant who does not have or who does not wish to use their own personal device 
to access the e-diary will at this time be supplied a hand-held device by the site. 
8.1.4.3. Group 2A: Days 3, 4, 5, 6 and 7 – Morning 
1. Review e-diary, confirm compliance with doxycycline dosing (Days 6 and 7) and ask if 
there were any associated changes in concomitant medications. 
2. Collect blood samples for determination of doxycycline trough concentrations prior to 
administering the AM dose of doxycycline on Days 3, 4, 5, 6 and 7; record times of 
administration of doxycycline in the source documents and eCRF. 
3. Prior to discharge from the clinic on Day 3, participants will receive their first course of 
doxycycline and will be introduced to the dietary and activity precautions associated with 
the use of doxycycline (see Section 5.3).  
4. On Days 3, 4, 5 and 6, the evening dose (q 12 hr) of doxycycline is to be self-
administered at home [at about the same time (± 30 min) each day].  The participant will 
to be instructed/reminded to record the date and time of administration of doxycycline in 
the e-diary. 
5. On the mornings of Days 4, 5, 6 and 7, staff will review the e-diary entries with the 
participant and confirm compliance with doxycycline dosing (Days 3, 4, 5 and 6).  
6. At the end of each clinic visit, participants will be reminded to take their evening dose of 
doxycycline and to be aware of the dietary and activity precautions associated with the 
use of doxycycline (see Section 5.3). 
7. Prior to discharge on morning of Day 7, participants will be reminded to return to clinic 
that evening for the second overnight admission and to bring their doxycycline supply 
with them.   
8.1.4.4. Group 2A: Day 7 – Evening & Overnight Stay # 2  
1. Admit to clinic for overnight stay #2. 
2. Review eligibility for vaccination. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 81 of 139 
 
 
3. Staff will review the e-diary entries with participant, confirming antibiotic dosing 
compliance. Staff will then record AEs and any changes in concomitant medications. 
4. For WOCBP, collect urine and perform a UPT.  Positive UPTs will be confirmed with a 
serum pregnancy test. All confirmed pregnancies in participants who have received at 
least one dose of any IP and where conception occurs prior to 12 months after last receipt 
of that IP will be followed to outcome.  
5. Administer doxycycline 12 hours after morning dose (± 30 min); record time of 
administration of doxycycline in source document and in eCRF 
8.1.4.5. Group 2A: Day 8 – Pre-vaccine Steady-State Doxycycline PK Session & 
Vaccination #1 
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day. 
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Review and record AEs. 
4. Reassess concomitant medications. 
5. Perform symptom-directed PE, if required. 
6. Collect blood sample for doxycycline t=0 concentration determination prior to 
administration of AM dose of doxycycline. 
7. Administer AM dose of doxycycline following blood sample collection for t=0 antibiotic 
concentration determination; ensure the participant remains semi-recumbent for two 
hours after dosing and continues with a light activity level throughout the day.  
8. Blood samples for doxycycline PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter).  
9. Administer doxycycline 100 mg po in the clinic after the final 12-hour doxycycline PK 
sample has been collected and 12 hours after morning dose (± 30 min). 
10. Administer AV7909 vaccination #1 after the 12 hr blood sample for doxycycline PK has 
been collected and after the PM dose of doxycycline has been administered. Participants 
should be monitored for at least 30 minutes following vaccine administration for any 
adverse effects especially anaphylaxis.  
11. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature) at 30 ± 5 minutes post-vaccination. 
12. At some point during the day but prior to being discharged from the clinic, the 
participants’ doxycycline supply will be returned to them.  
13. Prior to discharge from the clinic, the participants will be given and trained on the e-diary 
to capture local and systemic reactogenicity events and to record daily for at least seven 
days following each vaccination. If a reaction is not resolved at seven days 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 82 of 139 
 
 
postvaccination, the participant is to continue completing the e-diary daily until they are 
symptom free for two consecutive days. Participantswill be provided an injection site 
reaction measurement tool and shown how to use it to measure the size of certain 
reactogenicity events associated with vaccination, rate the intensity and where to enter 
this information in the e-diary (see Section 8.3.5.1). 
14. When the participants are discharged from the clinic, they will be reminded: 
 about the diet and activity precautions that must be followed when taking 
doxycycline (see Section 5.3).  
 to continue to use the antibiotic e-diary to record the times they take their 
doxycycline doses each day and to use the reactogenicity e-diary to record any 
vaccination reactions, if applicable; as described in Section 8.3.5.1 (Participant e-
diary). 
8.1.4.6. Group 2A: Days 9, 22 and 24 (At home) 
On Days 9, 22 and 24, the participant is to self-administer doxycycline (100 mg po q 12 hr) at 
home (at about the same times [± 30 min] each day).  The participant will continue with the e-
diary as described in Section 8.3.5.1.  
It is required that participants self-administer doxycycline on the day before (morning and 
evening, the day of (evening), and the day after vaccination (morning and evening). The site 
must contact the participant to remind them to begin their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccination date). Any participant who 
needs to shift their vaccine visit must be reminded to start their doxycycline dosing on the 
appropriate day, eg, if the second vaccination shifts to Day 22 then the participant will be 
reminded to start taking doxycycline on the morning and evening of Day 21 in order to meet the 
dosing requirement. 
8.1.4.7. Group 2A: Day 23 (± 1d) – Vaccination # 2 
1. Review e-diary entries with the participant, recording doxycycline dosing, discussing any 
symptoms and if they required any changes in concomitant medications  
2. Review and record AEs including any ongoing since prior visit. 
3. Reassess concomitant medications. 
4. Perform symptom-directed PE, if required. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform a UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of any IP and where conception occurs prior to 12 months 
after last receipt of any IP will be followed to outcome. 
7. Review eligibility for continuing vaccination. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 83 of 139 
 
 
8. Administer AM doxycycline dose; record time of administration in source documents and 
eCRF.  
9. Administer AV7909 vaccination #2; this should occur after doxycycline dosing. 
Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis. 
10. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate, and 
temperature) at 30 ± 5 minutes post-vaccination. 
11. After diary review, participants will be reminded to continue to use the reactogenicity e-
diary and injection site reaction measurement tool to capture reactogenicity events 
associated with vaccination, any use of concomitant medications and to record the dates, 
as well as to use the antibiotic e-diary to record times they take their self-administered 
doxycycline doses; see Section 8.3.5.1 (e-diary). 
12. Prior to discharge on Day 23, participants will be reminded  
 of the precautions in Section 5.3. 
 to continue to take their doxycycline the following day 
 to return to clinic in eight days for the third overnight admission.    
8.1.4.8. Group 2A: Day 31 (+ 1d) – Evening & Overnight Stay # 3 
1. Admit to the clinic for overnight stay #3.  
2. Staff will review e-diary entries with participant, checking doxycycline dosing records to 
document compliance, discuss any t vaccination reactions, as well as the use of 
concomitant medications, and will remind participants about the precautions associated 
with the use of doxycycline.  
8.1.4.9. Group 2A: Day 32 – Post-vaccine Single Dose Doxycycline PK Session 
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.  
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Collect blood sample for doxycycline t=0 concentration determination prior to 
administration of AM dose of doxycycline.  
4. Administer AM dose of doxycycline following blood sample collection for t=0 
concentration determination; ensure the participant remains semi-recumbent for two 
hours after dosing and continues with a light activity level throughout the day. 
5. Blood samples for doxycycline PK assessment are to be collected at the following time 
points:  0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours post-dose (± 5 min 
through hr 4, then ± 15 min thereafter). 
6. Administer doxycycline 100 mg po in the clinic after the final 12-hour doxycycline PK 
sample has been collected and 12 hours after morning dose (± 30 min). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 84 of 139 
 
 
7. Following the PK session, staff will assess and record AEs and changes in concomitant 
medications. 
8. When the participants are discharged from the clinic, they will be reminded to continue to 
use the antibiotic e-diary to record the times they take their doxycycline doses each day 
and to use the reactogenicity e-diary to record any vaccination reactions, if applicable.  
8.1.4.10. Group 2A: Days 33, 34, 35, and 36 – Morning  
1. Review e-diary, confirm compliance with doxycycline dosing to document compliance, 
discuss changes in  any vaccination reactions if still ongoing, as well as the use of 
concomitant medication and remind participants about the dietary and activity 
precautions that must be followed when taking doxycycline (see Section 5.3).  
2. Collect blood samples for determination of doxycycline trough concentrations prior to the 
in-clinic administration of the AM dose of doxycycline on Days 33, 34, 35 and 36; record 
times of administration of doxycycline in source document and eCRF. 
3. On Days 33, 34, 35 and 36, the evening dose (q 12 hr) of doxycycline is to be self-
administered at home (at about the same times [± 30 min] each day). 
8.1.4.11. Group 2A: Day 37 – Blood Draw for TNA 
1. Collect doxycycline supply, review e-diary dosing entries to confirm compliance with 
doxycycline dosing to document compliance, discuss changes in the use of concomitant 
medications, as well as any vaccination reactions, if still ongoing, and remind participants 
about the dietary and activity precautions that must be followed when taking doxycycline 
(see Section 5.3).  
2. Collect blood sample for determination of doxycycline trough concentrations prior to the 
in-clinic administration of the AM dose of doxycycline [100 mg po 12 hours after 
evening dose (± 30 min)]; record time of administration of doxycycline in source 
document and eCRF. 
3. Following doxycycline dose administration, collect blood sample for TNA assessment. 
  
4. Prior to discharge on the morning of Day 37, return doxycycline supply and remind 
participants to return to clinic that evening for the fourth overnight admission.    
8.1.4.12. Group 2A: Day 37 – Evening & Overnight Stay # 4 
1. Admit to clinic for overnight stay #4. 
2. Staff will review the participant’s doxycycline supply and review e-diary entries with 
participant, checking doxycycline dosing records to document compliance, discuss if they 
required the use of concomitant medications, as well as any vaccination reactions if still 
ongoing and will remind participants about the diet and activity precautions that must be 
followed when taking doxycycline (see Section 5.3).  
3. Administer doxycycline 100 mg po 12 hours after morning dose (± 30 min); record time 
of administration of doxycycline in source document and eCRF. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 85 of 139 
 
 
8.1.4.13. Group 2A: Day 38: – Post-vaccine Steady-State Doxycycline PK Session 
1. Provide a non-dairy breakfast 30 to 60 min prior to dosing; provide a light lunch and a 
light dinner/snack over the course of the day.   
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. Collect blood sample for doxycycline t=0 concentration determination prior to 
administration of AM dose of doxycycline. 
4. Administer AM dose of doxycycline (100 mg po) following blood sample collection for 
t=0 concentration determination; ensure the participant remains semi-recumbent for two 
hours after dosing and continues with a light activity level throughout the day. 
5. Blood samples for doxycycline PK assessment are to be collected at the following time 
points: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose (± 5 min 
through hr 4 then ± 15 min).  
6. Record any reported AEs. 
7. Record concomitant medications. 
8. Retain doxycycline supply; dose administered before PK session is the final dose. 
9. When the participants are discharged from the clinic, they will be reminded to return to 
the clinic in seven days (nominally Day 51) for the final study visit. 
10. Participants should also be reminded that they should still avoid strenuous sports and the 
sun and use sunscreens until the Day 51 Final In-clinic Study Visit. 
8.1.4.14. Group 2A: Day 51 (± 1d) – Final In-Clinic Study Visit  
1. Perform complete PE. 
2. Review e-diary entries with participant and collect hand-held device if study provided.  
3. Review and record AEs. 
4. Record concomitant medications. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform a UPT.  Positive UPTs will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participants who receive at least one dose of 
AV7909 or doxycycline and where conception occurs prior to 12 months after last receipt 
of either IP will be followed to outcome. 
7. Collect blood samples for hematology and serum chemistry.  
8. Collect blood samples for TSH and autoantibodies. 
9. Collect urine sample for urinalysis. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 86 of 139 
 
 
8.1.5. 
Group 2B: Doxycycline + AV7909 without Doxycycline PK Sessions 
Shown in Table 8 is a schedule of events for Group 2B participants from screening until the end 
of the study. Following the table are detailed descriptions of the activities that the sites are 
expected to conduct for each of the column headings identified in the table. Note that the detailed 
activities during Screening and Group Assign (Randomization) are covered in Section 8.1.1. 
Table 8: Schedule of Events for Group 2B: Doxycycline + AV7909 without Doxycycline 
PK 
 
Screening Group 
Assign 
At 
Home† 
Vac 
At Home† 
TNA 
Final 
Visit 
Safety 
Calls 
EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
2-7 
8     
23* 
9, 22, 24,  
32-38 
37 
51 
114, 205, 
 296, 388 
NA 
Visit Window ±  
NA 
NA 
 
± 1d 
 
± 1d 
± 1d 
± 14d 
 
Sign, date ICF & assign ID 
X 
 
 
 
 
 
 
 
 
Review eligibility a 
X 
X 
 
X 
 
 
 
 
 
Medical history & demographics 
X 
X 
 
 
 
 
 
 
 
Physical examination b 
X 
 
 
 
 
 
X 
 
X 
ECG c 
X 
 
 
 
 
 
 
 
 
Vital signs d 
X 
X 
 
X 
 
 
X 
 
X 
Pregnancy test e 
X 
X 
 
X 
 
 
X 
 
X 
FSH test e 
X 
 
 
 
 
 
 
 
 
Collect sample for hematology f 
X 
 
 
 
 
 
X 
 
X 
Collect sample for serum chemistry g 
X 
 
 
 
 
 
X 
 
X 
Collect sample for urinalysis h 
X 
 
 
 
 
 
X 
 
X 
Urine drug screen i 
X 
 
 
 
 
 
 
 
 
HIVAb/HBsAg/HCVAb 
X 
 
 
 
 
 
 
 
 
Concomitant medications j 
X 
X 
 
X 
 
X 
X 
X 
X 
Randomize eligible participants 
 
X 
 
 
 
 
 
 
 
Symptom-directed PE k 
 
X 
 
X 
 
 
 
 
 
Blood draws for TNA l 
 
X 
 
 
 
X 
 
 
 
Doxy dosing & compliance m,n 
 
X 
X 
X 
X 
X 
 
 
X 
AV7909 vaccination o 
 
 
 
X 
 
 
 
 
 
Participant e-diary + tools p 
 
X 
X 
X 
X 
X 
X 
 
X 
Staff review of e-diaries q 
 
 
X 
X 
X 
X 
X 
 
X 
AEsr, SAEs & AESIss 
X 
X 
 
X 
 
 
X 
X 
X 
Collect TSH & autoantibody sample t 
 
X 
 
 
 
 
X 
 
X 
For the abbreviations used above please refer to Table 1 of the protocol. *The ± 1 d window applies only to the second 
vaccination on Day 23 (note: the second course of antibiotic treatment will have to shift accordingly). †At Home Days are only 
those days where both doses of doxycycline are taken at home. ‡For EWV occurring within the visit window of Day 37, a blood 
sample for TNA will be drawn. 
a Eligibility will be reviewed before each vaccination, ie, on Day 8 and Day 23. 
b Physical examinations (PE) will be conducted as described in Protocol Section 8.3.3. 
c ECGs will be conducted and interpreted at screening as described in Protocol Section 8.3.3. 
d Vital signs will be administered as described in Protocol Section 8.3.4.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 87 of 139 
 
 
e Pregnancy tests (serum and/or urine) will be administered to all WOCBP as described in Protocol Section 8.3.2. Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP will be required 
before each vaccination. At Screening visit only, FSH test will be performed for postmenopausal women.    
f Hematology will be conducted as described in Protocol Section 8.3.2.   
g Serum chemistry will be conducted as described Protocol Section 8.3.2.   
h Urinalysis will be conducted as described in Protocol Section 8.3.2. 
i Urine drug screens will be conducted as described in Protocol Section 8.3.2. 
j Concomitant medications will be identified and recorded as described in Protocol Section 6.5.   
k Symptom-directed PEs will be conducted as described in Protocol Section 8.3.3. 
l Blood samples for TNA assessment on Day 1 will be collected in the morning following randomization. Those on Day 37 will 
be collected after the morning dose of doxy has been administered. A TNA sample will also be collected if EWV occurs within 
the visit window of Day 37 as described in Protocol Section 8.1.8. 
m Participants receive their first course of doxy following randomization. Format of the doses and distribution of subsequent 
courses will be described in the Pharmacy manual. Self-administration of doxycycline starts the following day (Day 2). 
Doxycycline dose compliance will be managed as described in Protocol Section 6.4.  
n Doxycycline doses (100 mg po q 12 hr) will be administered as described in Protocol Section 6.1.4. 
o Vaccinations with AV7909 will be administered as described Protocol Section 6.1.3. 
p All participants will be provided with an e-diary for post vaccination follow up along with a thermometer and an injection site 
reaction measurement tool. Participants in Group 1 and 2 will be provided with an e-dairy for antibiotic compliance. All 
participants will be trained on the use of these tools and the e-diaries as described in Protocol Section 8.3.5.1. 
q Staff will begin reviewing the e-diaries on Day 3 and will review them on a routine basis thereafter. 
r AEs will be collected at all clinic visits through Day 51/EWV as described in detail in Protocol Section 9. 
s SAEs and potential AESIs will be collected during the Safety Follow-up Telephone Calls (see Protocol Section 8.1.7). 
t Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section 8.3.2 (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination). Additional samples for TSH & 
autoantibody testing may be requested (ie, based on the participant’s report(s) of a potential AESI); blood draws for additional 
TSH and/or autoantibody testing should be performed as part of an unscheduled visit. 
8.1.5.1. Group 2B: Days 2 to 7 (At home) 
1. On Days 2 to 7, the participant will self-administer doxycycline 100 mg po every 12 
hours at home at about the same times (± 30 min) each day.   
2. Participant will use the e-diary to record the date and time of administration of 
doxycycline.  
8.1.5.2. Group 2B: Day 8 – Vaccination #1 
1. Review eligibility. 
2. Staff will review the doxycycline supply and review the e-diary entries, conducting a 
compliance check of the remaining doses compared to the e-diary record. Staff will also 
discuss any changes in the use of concomitant medication.  
3. Review and record AEs. 
4. Conduct a symptom-directed PE, if required. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 or doxycycline and where conception occurs 
prior to 12 months after last receipt of either IP will be followed to outcome. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 88 of 139 
 
 
7. Administer doxycycline 500 mg po in AM prior to vaccination; the evening dose of 
doxycycline 100 mg po will be self-administered at home 12 hours after the AM dose 
[and at approximately the same time (± 30 min) each day]. 
8. Administer AV7909 vaccination #1. Participants should be monitored for at least 30 
minutes following vaccine administration for any adverse effects especially anaphylaxis. 
9. Assess vital signs at 30 ± 5 minutes post-vaccination. 
10. Prior to discharge from the clinic, the participant will be given and trained on an e-diary 
to capture local and systemic reactogenicity events (ie, reactogenicity e-diary) and to 
record daily for at least seven days following each vaccination. If a reaction is not 
resolved at seven days postvaccination, the participant is to continue completing the e-
diary daily until they are symptom free for two consecutive days. Participants will be 
given an injection site reaction measurement tool and shown how to use it to measure the 
size and assess the severity of certain reactogenicity events associated with vaccination. 
See Section 8.3.5.1 (e-diary) and remind participants about the diet and activity 
precautions that must be followed when taking doxycycline (see Section 5.3). 
8.1.5.3. Group 2B: Days 9, 22 and 24 (At home) 
On Days 9, 22 and 24, the participant is to self-administer doxycycline (100 mg po q 12 hr) at 
home (at about the same times [± 30 min) each day]).  The participant will continue with the e-
diary as described in Section 8.3.5.1.  
It is required that participants self-administer doxycycline on the day before (morning and 
evening, the day of (evening), and the day after vaccination (morning and evening). The site 
must contact the participant to remind them to begin their second course of the antibiotics (ie, the 
site should contact the pariticpant within 24 hours of the anticipated start day for the second 
course of antibiotics in relation to the scheduled second vaccination date). Any participant who 
schedules vaccination 2 (on Day 23) to shift within the allowable window (± 1 days) will be 
reminded to start their doxycycline dosing on the appropriate day, eg, if the second vaccination 
shifts to Day 22 then the participant will be reminded to start taking doxycycline on the morning 
and evening of Day 21 in order to meet the dosing requirement. 
8.1.5.4. Group 2B: Day 23 (± 1 day) – Vaccination #2 
1. Staff will review the participant’s doxycycline supply and review e-diary entries, 
conducting a compliance check of the remaining doses compared to the e-diary record. 
Staff will also discuss any changes in the use of concomitant medication as well as any 
vaccination reactions if still ongoing, and reminding the participant of the precautions in 
Section 5.3.  
2. Review and record AEs. 
3. Perform symptom-directed PE, if required. 
4. Record concomitant medications.  
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate, and 
temperature). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 89 of 139 
 
 
6. Review eligibility for continuing vaccination. 
7. For WOCBP, collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of any IP and where conception occurs prior to 12 months 
after last receipt of any IP will be followed to outcome. 
8. Administer doxycycline 100 mg po in AM; the evening dose will be self-administered at 
home. 
9. Administer AV7909 vaccination #2; this should occur after doxycycline dosing. 
Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis.  
10. Following the 30 (± 5) minutes of observation, repeat vital signs (seated/semi-recumbent 
blood pressure, heart rate, respiratory rate, and temperature) measurement. 
11. After diary review, participants will be reminded to continue to use the reactogenicity e-
diary and injection site reaction measurement tool, to capture any use of concomitant 
medications and to record the dates and times they self-administer their doxycycline 
doses on the antibiotic e-diary. See Section 8.3.5.1. 
12. Prior to discharge on Day 23, participants doxycycline supply will be returned, and 
participants will be reminded to return to clinic in two weeks (± 1 day) on Day 37 ± 1d 
for the final blood draws for TNA. Again, participants are to continue dosing with 
doxycycline through the morning of Day 37.  
8.1.5.5. Group 2B: Days 32 to 37 (At home) 
On Days 32 to 37, the participant is to self-administer doxycycline 100 mg po every 12 hours at 
home at about the same times (± 30 min) each day.  The participant will continue with the e-
diary as described in Section 8.3.5.1. The site must contact the participant to remind them to start 
their third course of doxycyline within 24 hours of Day 31.  
8.1.5.6. Group 2B: Day 37 (± 1) – Blood Draw for TNA  
The Day 37 Visit may shift by ± 1 day. If such a shift occurs, the participant must remain on 
doxycycline 100 mg po every 12 hours until the morning before the blood draw.  In the event of 
such a shift, the participant’s required number of doses of doxycycline will vary. The Pharmacy 
Manual will contain a table detailing the dosing options for the final course of doxycycline given 
a one-day shift from Day 37. 
1. Participants will report to the clinic having taken their morning dose of doxycycline at 
home. 
2. Review participant’s doxycycline supply; count the number of remaining doses and 
compare to the e-diary record to document compliance; record total remaining in source 
document. 
3. Review other e-diary entries with participant. Discuss any changes in the use of 
concomitant medication as well as any vaccination reactions if still ongoing. Remind 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 90 of 139 
 
 
participants that they should still use sunscreens and avoid excessive sun exposure and 
strenuous sports until the Day 51 Final Study Visit.  
4. Record concomitant medications. 
5. Collect blood sample for TNA assessment. 
8.1.5.7. Group 2B: Day 51 (± 1d) – Final Study Visit  
1. Perform complete PE.  
2. Review e-diary entries with participant and collect hand-held device if study provided.  
3. Review and record AEs. 
4. Record concomitant medications. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
6. For WOCBP, collect and perform UPT. Positive UPTs will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participants who receive at least one dose of 
AV7909 or doxycycline and where conception occurs prior to 12 months after last receipt 
of either IP will be followed to outcome. 
7. Collect blood sample for hematology. 
8. Collect blood sample for serum chemistry. 
9. Collect blood sample for TSH and autoantibodies.  
10. Collect urine sample for urinalysis. 
8.1.6. 
Group 3: AV7909 Alone 
Shown in Table 9 is a schedule of events for Group 3 participants from screening until the end of 
the study. Following the table are detailed descriptions of the activities that the sites are expected 
to conduct for each of the column headings identified in the table once each participant has 
received his or her group assignment. Note that for Group 3 this detail only includes Days 8 and 
23 as the detailed activities during Screening and Group Assignment (Randomization) were 
covered previously in Section 8.1.1 and the activities for the Day 37 and Day 51 visits, the Safety 
Follow-up Phone calls and the EWVs are handled individually in Section 8.1.6.3, 
Section 8.1.6.4, Section 8.1.7, and Section 8.1.8, respectively.   
Table 9: 
Schedule of Events for Group 3: AV7909 Alone 
 
Screening 
Group 
Assign 
Vac 
TNA 
Final 
Visit 
Safety Calls EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
8  
23* 
37 
51 
114, 205, 
 296, 388 
NA 
Visit Window ±  
NA 
NA 
±1d* 
±1d 
± 1d 
± 14d 
 
Sign, date ICF & assign ID 
X 
 
 
 
 
 
 
Review eligibility a 
X 
X 
X 
 
 
 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 91 of 139 
 
 
 
Screening 
Group 
Assign 
Vac 
TNA 
Final 
Visit 
Safety Calls EWV 
USV‡ 
Study Day(s) 
-28 to -2 
1 
8  
23* 
37 
51 
114, 205, 
 296, 388 
NA 
Visit Window ±  
NA 
NA 
±1d* 
±1d 
± 1d 
± 14d 
 
Medical history & demographics 
X 
X 
 
 
 
 
 
Physical examination b 
X 
 
 
 
X 
 
X 
ECG c 
X 
 
 
 
 
 
 
Vital signs d 
X 
X 
X 
 
X 
 
X 
Pregnancy test e 
X 
X 
X 
 
X 
 
X 
FSH test e 
X 
 
 
 
 
 
 
Collect sample for hematology f 
X 
 
 
 
X 
 
X 
Collect sample for serum chemistry g 
X 
 
 
 
X 
 
X 
Collect sample for urinalysis h 
X 
 
 
 
X 
 
X 
Urine drug screen i 
X 
 
 
 
 
 
 
HIVAb/HBsAg/HCVAb 
X 
 
  
 
 
 
 
Concomitant medications j 
X 
X 
X 
X 
X 
X 
X 
Randomize eligible participants 
 
X 
 
 
 
 
 
Symptom-directed PE k 
 
X 
X 
 
 
 
 
Blood draws for TNA l 
 
X 
 
X 
 
 
 
AV7909 vaccination m 
 
 
X 
 
 
 
 
Participant e-diary + tools n 
 
 
X 
X 
X 
 
X 
AEs o, SAEs & AESIs p 
X 
X 
X 
 
X 
X 
X 
Collect TSH & autoantibody sample q 
 
X 
 
 
X 
 
X 
For the abbreviations used above please refer to Table 1. 
*± 1 d window only applies to the second vaccination (Day 23). ‡For EWV occurring within the visit window of Day 37, a blood 
sample for TNA will be drawn, 
a Elibility will be reviewed before each vaccination, ie, on Day 8 and Day 23. 
b Physical examinations (PE) will be conducted as described in Protocol Section 8.3.3. 
c An ECG will be conducted at screening as described in Protocol Section 8.3.3.  
d Vital signs will be administered as described in Protocol Section 8.3.4.  
e Pregnancy tests (serum and/or urine) will be administered to all WOCBP as described in Protocol Section 8.3.2. Serum 
pregnancy test will be performed at Screening visit for WOCBP, while urine pregnancy tests for WOCBP will be required 
before each vaccination. At Screening visit only, FSH test will be performed for postmenopausal women.    
f Hematology will be conducted as described in Protocol Section 8.3.2.   
g Serum chemistry will be conducted as described Protocol Section 8.3.2.   
h Urinalyses will be conducted as described in Protocol Section 8.3.2.  
i Urine drug screens will be conducted as described in Protocol Section 8.3.2.  
j Concomitant medications will be identified and recorded as described in Protocol Section 6.5.    
k Symptom-directed PEs will be conducted as described in Protocol Section 8.3.3. 
l Blood samples for TNA assessment on Day 1 will be collected in the morning following randomization. Those on Day 37 will 
be collected in the morning. A TNA sample will also be collected if EWV occurs within the visit window of Day 37 as described 
in Protocol Section 8.1.8. 
m Vaccinations with AV7909 will be administered as described in Protocol Section 6.1.3. 
n All participants will be provided with an e-diary for post vaccination follow up along with d  a thermometer and an injection site 
reaction measurement tool and will be trained on the use of these tools and the e-diary as described in Protocol Section 8.3.5.1. 
o AEs will be collected at all clinic visits through Day 51/EWV as described in detail in Protocol Section 9. 
p SAEs and potential AESIs will be collected during the Safety Follow-up Telephone Calls (see Protocol Section 8.1.7). 
q Serum samples for TSH & autoantibody testing will be collected from all participants and tested as described in Protocol 
Section 8.1.6.3 (ie, at Day 1, Day 51, and at EWV if the subject received at least one vaccination). Additional samples for TSH & 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 92 of 139 
 
 
autoantibody testing may be collected based on the safety follow-up phone contact if warranted from participant report(s) of a 
potential AESI); blood draws for additional TSH and/or autoantibody testing should be performed as part of an unscheduled visit. 
8.1.6.1. Group 3: Day 8 – Vaccination #1   
1. Review eligibility. 
2. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
3. For WOCBP, collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 or doxycycline and where conception occurs 
prior to 12 months after last receipt of either IP will be followed to outcome. 
4. Perform symptom-directed PE. 
5. Reassess concomitant medications. 
6. Administer AV7909 vaccination #1. 
7. Participants should be monitored for at least 30 minutes following vaccine administration 
for any adverse effects especially anaphylaxis.  
8. Assess vital signs at 30 ± 5 minutes post-vaccination. 
9.  Before the participant is discharged from the clinic, they will be trained on the use of e-
diary (see Section 8.3.5.1) and given instructions on how the e-diary should be used to 
record daily temperature, and any local and systemic reactogenicity events after 
vaccination. Participants will be instructed to use the e-diary on a daily basis for at least 
seven days postvaccination. If a reaction is not resolved at seven days postvaccination, 
the participant is to continue completing the e-diary daily until they are symptom free for 
two consecutive days.   
10. Participants will also be given an injection site reaction measurement tool and shown 
how to use it to measure the size and rate the intensity of certain reactogenicity events 
associated with vaccination as well as where to enter this in the e-diary.  
Any participant who does not have or who does not wish to use their own personal device to 
access the e-diary will at this time be supplied a hand-held device by the site. 
8.1.6.2. Group 3: Day 23 (± 1 d) Vaccination #2 
1. Review participant e-diary discussing any symptoms and any use of pain medications. 
2. Review and record AEs. 
3. Reassess concomitant medications. 
4. Perform symptom-directed PE. 
5. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate, and 
temperature). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 93 of 139 
 
 
6. For WOCBP, collect and perform UPT (prior to AV7909 vaccination).  Positive UPTs 
will be confirmed with a serum pregnancy test.  All confirmed pregnancies in participants 
who receive at least one dose of AV7909 and where conception occurs prior to 12 
months after last receipt of IP will be followed to outcome. 
7. Review eligibility for continuing vaccination. 
8. Administer AV7909 vaccination #2. Participants should be monitored for at least 30 
minutes following vaccine administration for any adverse effects especially anaphylaxis. 
9. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate, and 
temperature) at 30 ± 5 minutes post-vaccination. 
10. After diary review the participant will be reminded to use the reactogenicity e-diary and 
injection site reaction measurement tool to capture the adverse events associated with 
vaccination, as well as to continue entering their temperatures every day. See 
Section 8.3.5.1 (e-diary). 
11. Prior to discharge following vaccination on Day 23, participants will be reminded to 
return to clinic in two weeks (± 1 day) on Day 37 ± 1d for the final blood draws for TNA.    
8.1.6.3. 
Group 3: Day 37 (± 1 d) – Blood Draw for TNA  
The Day 37 Visit may shift by ± 1 d.  
1. Review e-diary entries with participants, discussing any changes in health status and the 
use of concomitant medication as well as any vaccination reactions if still ongoing.  
2. Review and record AEs. 
3. Record concomitant medications. 
4. Conduct symptom-directed PE (if necessary).  
5. Collect blood sample for TNA assessment. 
8.1.6.4. 
Group 3: Day 51 (± 1 d) – Final In-Clinic Study Visit 
1. Perform complete PE. 
2. Review e-diary entries with participant and collect hand-held device.  
3. Review and record AEs. 
4. Record concomitant medications. 
5. Measure vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate 
and temperature). 
6. For WOCBP, collect and perform UPT.  Positive UPTs will be confirmed with a serum 
pregnancy test. All confirmed pregnancies in participants who receive at least one dose of 
any IP and where conception occurs prior to 12 months after last receipt of any IP will be 
followed to outcome. 
7. Collect blood sample for hematology. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 94 of 139 
 
 
8. Collect blood sample for serum chemistry. 
9. Collect blood sample for TSH & autoantibody determination.  
10. Collect urine sample for urinalysis. 
8.1.7. 
Quarterly Safety Follow-up Phone Calls  
Following the last scheduled vaccination, the site will conduct quarterly safety follow-ups in 
which participants are contacted by phone at 3 months (Day 114 ± 14 d), 6 months (Day 205 ± 14 
d), 9 months (Day 296 ± 14 d) and 12 months (Day 388 ± 14 d).  These phone contacts will be 
scheduled to key off the participant’s actual or, if missed, target Day 23 visit (intended last 
vaccination day) so that all participants (even those failing to receive both vaccinations but who 
are followed for safety only) are contacted 3 months after their target Day 23.  
The following assessments will be performed over the phone at the 3 months (Day 114 ± 14d), 6 
months (Day 205 ± 14 d), 9 months (Day 296 ± 14 d) and 12 months (Day 388 ± 14 d) contacts: 
 Assess and document, AEs, SAEs and potential AESIs (refer to Section 9.3) 
 For WOCBP, confirm continued use of an adequate method of contraception and 
inquire about any possible pregnancies (refer to Section 9.4) 
 If an AE, SAE and/or an AESI is reported, record any associated medications  
 Review the status of ongoing AEs/SAEs/AESIs to update the resolution status 
During the telephone calls, the staff member is to inquire about and record in source 
documentation any AEs and SAEs occurring since either the Day 51 visit or the previous phone 
contact. Any occurrence of SAEs will be reported to Emergent immediately as specified under 
Section 9.3 and followed up per procedures described in Section 9.7.2. If an SAE has occurred, it 
will be recorded on the AE eCRF with any medications taken also recorded on the appropriate 
eCRF. 
During the telephone calls, the staff member will also attempt to elicit and record in source 
documentation any information on AEs of potential autoimmune etiology. If the condition is a 
diagnosed or suspected AESI, the staff member may refer the participant to the PI or designee 
for further phone evaluation if needed; based on initial assessment of potential AESI, the 
participant will be asked to return for an unscheduled clinic visit for evaluation (refer to 
Section 8.1.9) and to provide a blood sample for autoantibody testing and/or TSH assessment (if 
applicable). The PI or designee will obtain records confirming the diagnosis or refer the 
participant to a medical specialist for additional clinical and diagnostic testing and follow up 
until the diagnosis is ascertained.  The potential AESI will be reported to Emergent immediately 
as specified in Section 9.3 and followed up per procedures described in Section 9.7.2. Only after 
the DSMB has assessed the case as a confirmed AESI will the PI or designee record the 
occurrence of the AESI on the AE eCRF with any medications taken also recorded on eCRFs. 
The medical monitor or designee will direct the completion of the AE eCRF when 
communicating the DSMB assessment outcome(s) to the PI or designee. 
In the event the site is unable to reach the participant by telephone at any of the interim safety 
follow-up calls at 3 months (Day 114 ± 14 d), 6 months (Day 205 ± 14 d), 9 months (Day 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 95 of 139 
 
 
296 ± 14 d) and 12 months (Day 388 ± 14 d), at least three phone contact attempts must be made 
before the site documents that the participant was unable to be reached. The contact attempts will 
be spaced at least one week apart. Failure to reach the participant at one of the interim safety 
follow-up time points does not preclude contact attempts at the next scheduled safety follow-up 
time point. Procedures for the final 12-month follow-up call are described in Section 7.4.  
8.1.8. 
Early Withdrawal Visit 
Any participant who withdraws early or is discontinued for any reason will be asked to complete 
an EWV.  
1. For participants in Groups 1 and 2, review the participant’s remaining antibiotic supply 
and count the number of remaining doses to document compliance; record total 
remaining in source document. 
2. Perform complete physical examination. 
3. Assess vital signs (seated/semi-recumbent blood pressure, heart rate, respiratory rate and 
temperature). 
4. For WOCBP, collect and perform serum pregnancy test.   
5. If EWV occurs within the visit window for Day 37, collect blood sample for TNA. 
6. Collect blood sample for hematology.  
7. Collect blood sample for serum chemistry.  
8. Collect urine sample for urinalysis.  
9. For participants who have received at least one vaccination, collect blood sample for TSH 
& autoantibody determination. 
10. Review entries in e-diary with participant. 
11. Review and record AEs. 
12. Record concomitant medications. 
8.1.9. 
Unscheduled Visits 
Unscheduled visits will occur when necessary, in the opinion of the PI or designee, to follow-up 
on an AE or abnormal laboratory test result between scheduled visits. Additionally, participants 
who report a potential autoimmune-related condition at any of the safety follow-up phone calls 
will be requested to return to the clinic for an unscheduled visit to provide a blood sample for 
TSH & autoantibody testing.  
Unscheduled visits occurring before Day 51 will include a symptom-directed PE, measurement 
of vitals, AE (includes SAE/AESI) assessment inclusive of reviewing the status of ongoing AEs 
since the prior visit, updating of medication usage since the last visit, and (if applicable) review 
of e-diary data since the last visit. 
Unscheduled visits occurring after Day 51 will include an AE/SAE/AESI assessment including 
blood draw for TSH and autoantibody testing (if medically indicated) and updating of 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 96 of 139 
 
 
medication usage since the last visit/contact (only if AE/SAE/AESI-related). Other evaluations 
performed by the PI or designee during the unscheduled visit as part of the participant’s medical 
care (eg, vital signs, symptom-directed PE, etc) and recommendations given to the participant 
(eg, referral to the participant’s personal physician or specialist for further diagnosis and/or care, 
prescribed medications) will be documented in the participant’s medical chart at the site. In the 
event of any referrals for further medical care, the PI or designee will follow up with the 
participant and/or personal physician/specialist to ensure the reporting of any SAEs or potential 
AESIs per the protocol (refer to Section 9.7.2).  
8.2. 
Immunogenicity/Efficacy Assessments 
For all participants, blood samples for the determination of TNA titers will be collected on Day 1 
and Day 37 (± 1 d) (2 weeks after the last vaccination). Blood samples will be collected at the 
EWV only if it falls within the visit window for Day 37.  
All immunogenicity laboratory samples will be evaluated using a TNA assay. Specific 
procedures related to collection, processing, storage, and shipment of the samples will be 
provided in a Laboratory Manual. 
The TNA assay being used in this trial has been validated by Battelle Memorial Institute 
(Columbus, Ohio) under National Institute of Allergy and Infectious Diseases sponsorship. The 
assay measures the functional ability of antisera containing anti-PA antibodies to specifically 
protect cells against B. anthracis lethal toxin cytotoxicity {Stinson et al, 2005; Li et al., 2008}. 
The TNA assay results will be reported as the reciprocal of a serum sample dilution that results 
in 50% neutralization of lethal toxin cytotoxicity (50% effective dilution; ED50). To standardize 
assay results, the results are divided by the ED50 of a serum reference standard, and the resulting 
ratio is reported as a 50% neutralization factor, NF50. Reference standard AVR801 will be used. 
8.3. 
Safety Assessments 
8.3.1. 
Adverse Events 
Refer to Section 9, Reporting Adverse Events. 
8.3.2. 
Clinical Laboratory Tests 
All analytes to be tested during screening/safety/autoimmunity clinical laboratory tests are 
specified in Table 10. Instructions for the collection, processing, storage, and shipment of 
screening and safety clinical laboratory test samples are provided separately in the Laboratory 
Manual. All samples will be sent to the central laboratory for analysis, except urine for 
pregnancy testing, which will be performed at the site and results documented in the eCRF. 
It is the responsibility of the PI or designee to review the results of all screening and safety 
laboratory tests (including unscheduled lab tests) as they become available, initially for the 
assessment of study eligibility and subsequently for the continuous safety monitoring of 
participants. Review of the laboratory reports must be documented.  
The following assessments will be performed at Screening only: 
 Urine drug screen (refer to Table 10 for analytes). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 97 of 139 
 
 
 Serologic testing (HIV-1/HIV-2 antibodies, HBV surface antigen, and HCV 
antibody). Confirmatory testing will be performed on any samples that test positive 
for either HIV or HCV; no additional blood/serum will be required for this 
confirmatory testing. 
 FSH test in postmenopausal women; refer to Section 5.1. 
Pregnancy testing will be performed at Screening, immediately following group assignment, 
before each vaccination, and at the Day 51 Final Study Visit or at the EWV. Female participants 
who are surgically sterile or are confirmed at Screening to have an FSH level >30 mIU/mL (ie, 
postmenopausal; refer to Section 5.1) are exempt from pregnancy testing. A serum pregnancy 
test is required at Screening for all other female participants (ie, WOCBP). Post-screening 
pregnancy testing in all women not having an FSH level >30 mIU/mL (ie, WOCBP) will consist 
of a UPT at the above specified visits except for a serum pregnancy test performed at the (if 
applicable) EWV. All UPTs must be performed at the investigational site and documented to be 
negative prior to vaccine administration. For participants with positive UPT results, a 
confirmatory serum pregnancy test will be performed. IP will not be administered to any 
participant who tests positive for pregnancy. If group assignment occurs within four days of a 
negative Screening serum pregnancy test, a UPT does not have to be performed. 
Blood and urine samples for safety clinical laboratory testing (hematology, serum chemistry, 
urinalysis) will be collected at Screening and Day 51 as well as at the EWV if the EWV occurs 
before Day 51. Refer to Table 10 for the list of analytes for hematology, serum chemistry and 
urinalyses. The laboratory test results will be evaluated against the FDA toxicity grading scale 
provided in Table 13 of Appendix A.  
In addition, blood samples for TSH & autoantibody assessment of ANA, RF and anti-dsDNA 
will be taken at Day 1 after randomization, Day 51 or EWV or an unscheduled visit if the 
participant has received at least one dose of vaccine and at the time of safety follow-up phone 
contact(s) if warranted from participant report(s) of a potential AESI (see Table 10 for the list of 
analytes for autoantibody testing). These samples will be shipped to the central laboratory and 
will be banked; testing for TSH and ANA, RF and anti-dsDNA autoantibodies will be performed 
only if medically indicated (as per PI’s discretion based on a report of a potential AESI).  
Instructions for the collection, processing, storage, and shipment of laboratory samples will be 
provided separately in the Laboratory Manual. 
It is the PI’s responsibility to review the results of all screening and safety laboratory tests 
(including unscheduled lab tests) as they become available, initially for the assessment of study 
eligibility and subsequently for the safety monitoring of participants. Review of the laboratory 
report must be documented.  
For each abnormal laboratory test result, the PI needs to ascertain if this is a clinically significant 
change from screening level for that individual participant. This determination, however, does 
not necessarily need to be made the first time an abnormal value is observed. The PI may repeat 
the laboratory test and/or request additional tests to verify the results of the original laboratory 
tests. The PI (or designee) will inform the MM of any unscheduled clinical laboratory testing, 
including but not limited to confirmatory testing of laboratory samples, with the exception that 
notification is not required for confirmatory testing for pregnancy, HCV, and HIV. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 98 of 139 
 
 
Investigational sites will be automatically notified of any Grade 3 or higher laboratory 
abnormalities. For any Grade 3 or higher laboratory result, the test will be repeated as soon as 
possible by the central lab using the same blood sample to confirm the result. The PI or designee 
must request the participant return to the clinic for an unscheduled visit for an assessment of 
clinical status. The decision to redraw laboratory tests will be made by the PI (with notification 
to the MM) and/or MM and will be based on the type and severity of the laboratory abnormality 
and the clinical status of the participant. Any Grade 3 or higher neutropenia or lymphopenia must 
be evaluated with an unscheduled repeat complete blood count (CBC) approximately 72 hours 
after the initial specimen was drawn.  
If the original (retested sample) or repeat laboratory value is Grade 3 or higher or determined by 
the PI to be a clinically significant change from baseline for that participant, this will be 
considered an AE and will be recorded on the AE eCRF. Any other clinical laboratory 
abnormalities must also be reported as AEs if considered by the PI to be a clinically significant 
change from baseline.  If an abnormal laboratory test result is a sign of a disease or syndrome, 
the disease or syndrome will be recorded as the AE/SAE and not the abnormal laboratory result. 
Clinical laboratory abnormalities may trigger individual participant or study halting rules (see 
Section 7.1 and Section 7.3) and may require discontinuation of treatment.  
Table 10: 
Screening/Safety Clinical Laboratory Tests 
Hematology 
-Basophils 
-Eosinophils 
-Hematocrit  
-Hemoglobin 
-Lymphocytes 
-Monocytes 
-Neutrophils 
-Platelets 
-RBC count  
-WBC count  
 
Serum Chemistry 
-ALT 
-AST 
-Bilirubin 
-BUN 
-Creatinine  
-Glucose 
 
Urinalysis 
-Appearance 
-Bilirubin 
-Color 
-Glucose 
-Ketones  
-Leukocyte esterase 
-Nitrite 
-Occult blood 
-pH 
-Protein  
-Specific gravity 
-Urobilinogen 
-Microscopic examination (only if 
protein, nitrite, leukocyte esterase, or 
occult blood results are positive) 
 
Additional Tests 
-FSH (only in postmenopausal women 
at Screening) 
-Serum/UPT (all WOCBP) 
-TSH  
Viral Serology: 
-anti-HCV antibody 
-anti-HIV antibody 
-HBsAg 
 
Urine Drug Screen: 
-Amphetamines 
-Barbiturates  
-Benzodiazepines 
-Cannabinoids 
-Cocaine 
-Opioids 
- 
 
Autoantibodies 
-Rheumatoid factor (RF) 
-Antinuclear antibody 
(ANA) 
-Anti-double stranded 
deoxyribonucleic acid 
(dsDNA) antibodies 
 
For the abbreviations used above refer to Table 1. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 99 of 139 
 
 
8.3.3. 
Physical Examination  
Complete PEs will be performed at screening, the Final Study Visit (Day 51) and early 
withdrawal, if applicable.  The following will be examined: cardiovascular system (including a 
standard 12-lead electrocardiogram at screening only, to be read at the site); lymphatic/ 
hematological, respiratory system; nervous system; skin and appendages; 
abdominal/gastrointestinal system; metabolic/endocrine, musculoskeletal system; and ear, nose, 
and throat. 
Symptom-directed PEs will be performed at all visits except the Screening, Final Study Visits 
and early withdrawal (including any unscheduled visits), only if required (ie, in response to the 
report/collection of AEs/SAEs/potential AESIs).  
Abnormal PE findings are to be recorded as AEs if new or changed in severity any time after the 
first administration of any IP and PE AEs should be assessed for severity and causality.  Grade 3 
(or higher) PE findings could trigger individual or study halting rules if considered associated 
with IP administration (see Section 7).  Physical examination abnormalities are not separately 
reported as AEs if the PE abnormality is part of a symptom complex that is already reported as 
an AE.  
8.3.4. 
Vital Signs 
Vital signs including seated/semi-recumbent systolic and diastolic blood pressure, heart rate, 
respiration rate, and temperature will be obtained at Screening and each subsequent clinic visit 
through Day 51/EWV (except at AM and PM clinic visits for groups 1A and 2A, and at Day 37 
for all groups), including unscheduled visits. Height and weight will only be recorded at 
Screening. On vaccination days (Days 8 and 23), vital signs will be assessed prior to vaccination 
and at 30 ± 5 minutes post-vaccination.  
All vital sign abnormalities determined by the PI or designee to be a clinically significant change 
from baseline for that participant should be recorded as AEs. Grade 3 or higher vital signs will be 
repeated twice to verify that the severity is a Grade 3 or higher. If two of the three assessments 
are Grade 3 or higher, the vital sign should be reported as a Grade 3 or higher abnormality.  Vital 
sign abnormalities may trigger individual participant or study halting rules (refer to Section 7).  
8.3.5. 
Other Safety Assessments 
8.3.5.1. 
E-diary Records 
Participants will be asked to fill out an electronic diary (e-diary) daily for for postvaccination 
reatogenicity events (all groups) and an e-diary for antibiotic compliance (Groups 1 and 2). 
Participants who do not have or don’t want to use their personal electronics to access the web-
enabled e-diary will be provided a hand-held device for purposes of this study. Participants will 
receive instructions on reactrogenicity and/or antibiotic compliance e-diary completion. 
Participants will be asked to complete the reactogenicity e-diary at the same time each day to 
capture observations on the previous 24-hour period. Staff at the clinical site will follow up 
participant’s reactogenicity and/or antibiotic e-diary noncompliance. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 100 of 139 
 
 
There are separate e-diary requirements for this study depending on the treatment group 
assignment: 
 Participants in all three groups will be required to fill out an e-diary to capture 
reactogenicity events after each vaccination. All participants will receive an injection site 
reaction measuring tool and an oral thermometer to support in completing the 
reactogenicity e-diary. 
 Participants in Group 1 and Group 2 will be required to also fill out a separate e-dairy to 
capture antibiotic compliance.  
The e-diary to capture reactogenicity events postvaccination will collect the following 
information: 
 each participant’s daily oral temperature at the same time each day  
 local injection site and systemic reactogenicity events  
 whether they have used any pain medications (eg, acetaminophen, aspirin, ibuprofen)  
Reactogenicity (solicited systemic and local injection site reactions) will be monitored by the site 
for at least 30 minutes after vaccination with special attention being paid to signs and symptom 
of immediate hypersensitivity responses (eg, anaphylaxis, bronchospasm. urticaria, angioedema). 
Thereafter, local injection site and systemic reactogenicity responses will be assessed daily by 
participants in their e-diaries for at least seven days following each vaccination. Information will 
be solicited on the following local injection site reactogenicity reactions: warmth, tenderness, 
itching, pain, arm motion limitation, redness, lump, swelling, and bruising.  In addition, 
information will be solicited on the following systemic reactogenicity reactions:  
tiredness/fatigue, muscle ache, headache, and fever (oral temperature).  Except for oral 
temperature, swelling, and redness, the participant will be prompted to grade each reaction 
according to the grading scale provided below.  
 Grade 0 (Absent):  Symptom not present 
 Grade 1 (Mild):  Symptom present but does not interfere with activities of daily living 
 Grade 2 (Moderate):  Symptom causes some interference with activities of daily living 
 Grade 3 (Severe):  Symptom prevents activities of daily living or requires medical 
intervention 
Participants will also be asked to respond (yes/no) if they have taken pain/fever medications such 
as acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs; eg, ibuprofen) or 
other medication in the past 24 hours. Participants will be directed to not take these types of 
medications 24 hours before or after vaccinations (refer to Table 3). Investigational site staff will 
review participant e-diary entries on a routine basis to assess compliance, need for re-instruction 
and evaluation against individual participant and study halting rules. These reviews will also 
occur on Day 23 (1 ±d) and Day 37 (1 ±d).  
For the assessment of severity of swelling and redness, participants will use the injection site 
reaction measurement tool to measure redness and swelling at the injection site and then grade 
these accordingly. The redness grade will be based on greater of the two perpendicular 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 101 of 139 
 
 
measurements in centimeters, while swelling grade will be based on greater of the two 
perpendicular measurements in centimeters and the functional scale (if applicable); see Table 12.  
Investigator sites will be notified of any Grade 3 or higher severity scores for follow-up and/or 
further assessment of symptoms. The site will record verified Grade 3 or higer e-diary reactions 
as an AE into the AE eCRF.  If these reactions start out as mild in severity on a given day, the 
start date should be recorded as the first date that the reaction is noted as mild in severity.  If 
these reactions end as mild in severity on a given day, the end date should be recorded as the last 
date that the reaction is noted to be mild in severity.  The AE severity will be recorded as the 
highest severity score within the start and stop dates. If severe reactions reappear in the e-diary 
after they were absent for one or more days, a second AE will be recorded on the AE 
eCRF. During follow-up visit(s), the investigator will query the participant about all ongoing e-
diary AEs and document the start and stop date of any Grade 3 or higher AEs on the AE page in 
the eCRF. 
If local injection site or systemic reactions continue beyond seven days, participants will be 
prompted to continue e-diary entries until they are symptom-free for two consecutive days. For 
any type of reactogenicity persisting two weeks or more, the PI or designee will evaluate the 
reaction at the next scheduled visit and/or determine based on the nature and severity if a more 
immediate unscheduled follow-up visit is required to fully assess the reaction. Investigational 
sites will be alerted of any Grade 3 or higher (eg, ER visit or hospitalization) solicited systemic 
reactions, which will require discontinuation of vaccinations upon verification by the PI or 
designee of the Grade 3 or higher status. The PI or designee may require participants reporting 
Grade 3 or higher reactions to return to the clinic for an unscheduled visit to aid in this 
evaluation. 
In addition to any reaction considered an AE by the PI, solicited reactions reported in the e-diary 
will be recorded by the PI or designee on the AE eCRF if they are serious (ie, a solicited reaction 
will be considered ‘serious’ if confirmed by the investigator to be a Grade 4, or a Grade 3 that 
upon the investigator’s assessment meets any of the SAE criteria outlined in Section 9.1.2); 
result in discontinuation of study product or withdrawal from the study; or remain unresolved for 
14 days or more. Solicited systemic reactions may require discontinuation of vaccinations based 
on individual participant halting rules (see Section 7.3). 
The rating scale to be used for reactogenicity events is the same toxicity grading scale provided 
in Appendix A, the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials {CBER, 2007}, where 
symptoms are assessed as Grade 1=mild through Grade 4=potentially life-threatening. 
Additionally, a Grade of 0 will be available in the e-diary in order to allow the participant to 
record “symptom not present.” For most of the reactogenicity events, there is a direct 
corresponding symptom entry in the toxicity grading scale (eg, for systemic reactions: fever, 
headache, fatigue, myalgia; for local reactions: pain, tenderness, erythema/redness, 
induration/swelling) – refer to Table 12.  
For reactogenicity events with no direct corresponding symptom entry in Table 12 (eg, warmth, 
itching, arm motion limitation, bruising), the grading for “illness or clinical AE” will be used to 
rate the symptom severity. The symptom-severity descriptions in Table 12 will be translated to 
lay language in the e-diary instrument to promote participant understanding.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 102 of 139 
 
 
Participants in Groups 1 and 2 will be required to complete e-diary entries to capture their 
compliance to their antibiotic doses of ciprofloxacin or doxycycline respectively. Participants in 
these groups will begin e-diary entries as soon as they receive their first dose of antibiotic. The e-
diary will remind them to self-administer their antibiotic (ciprofloxacin or doxycycline) at 
appropriate times and record those times in the e-diary. For those participants receiving an 
antibiotic, the investigational site staff will review e-diary entries with the participant at every 
visit overlapping with the antibiotic courses. 
8.4. 
Pharmacokinetics Sessions and Trough Concentrations of Antibiotics 
For the participants randomized to Groups 1A or 2A, antibiotic serum concentrations will be 
measured, and PK parameters will be assessed.  
8.4.1. 
Ciprofloxacin  
On days with PK sessions (Days 4, 8, 31 and 35), blood samples for measurement of 
ciprofloxacin concentrations will be collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 
12 hours post dose (± 5 min through hr 4, then ± 15 min thereafter).   
Blood samples for determination of ciprofloxacin pre-dose or trough concentrations will be 
collected on Days 4, 5, 6, 7 and 8 and on 31, 32, 33, 34 and 35 prior to administration of the 
morning ciprofloxacin dose.  
8.4.2. 
Doxycycline  
On days with PK sessions (Days 2, 8, 32 and 38), blood samples for measurement of 
doxycycline concentrations will be collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 
12 hours post dose (± 5 min through hr 4, then ± 15 min thereafter).   
Blood samples for determination of doxycycline pre-dose or trough concentrations will be 
collected on Days 2, 3, 4, 5, 6, 7 and 8 and on 32, 33, 34, 35, 36, 37 and 38 prior to 
administration of the morning doxycycline dose.  
8.4.3. 
Specimen Collection, Preparation, Handling, and Shipping 
Instructions for the collection, preparation, handling, storage, and shipment of the study samples 
will be provided in study-specific laboratory manuals. 
8.5. 
Data Safety Monitoring Board 
Independent safety oversight will be provided by a DSMB which will be notified of significant 
AEs (eg, SAEs, severe AEs recorded on the eCRF, potential AESIs of autoimmune etiology, or 
any other events the medical monitor deems medically relevant) as determined by the medical 
monitor on an ongoing basis, including any that result in study halt based on prespecified 
stopping rules (refer to Section 7.1). The DSMB will consist of at least three voting members, 
one of whom will be an expert in rheumatology/immunology to specifically support the 
evaluation of potential AEs for autoimmune etiology. The DSMB will make recommendations 
regarding the safety of continuing enrollment and dosing.  Study enrollment and dosing may be 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 103 of 139 
 
 
interrupted at the request of the DSMB Chair if it is believed that an AE represents a significant 
safety concern pending full DSMB evaluation.  
The DSMB Chair will receive and evaluate each SAE, each severe AE (reported on the AE 
eCRF), and potential AEs of autoimmune etiology. The DSMB Chair will determine if an ad hoc 
review by the entire DSMB is necessary. An ad hoc review by the entire DSMB, when it occurs, 
may be focused on a single participant or on data for all participants. The operations of the 
DSMB will be detailed in a DSMB Charter to be finalized prior to screening of the first 
participant. 
At least one DSMB member will be an expert in autoimmune disorders (eg, rheumatologist, 
immunologist). This member will review all potential AESIs to assess cases for autoimmune 
etiology, if preexisting or new onset, and relationship to the IP. Details on the recording of 
assessment outcomes will be detailed in the DSMB Charter. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 104 of 139 
 
 
9. 
REPORTING ADVERSE EVENTS 
9.1. 
Definitions 
9.1.1. 
Adverse Event 
An AE is any untoward medical occurrence in a participant administered an investigational 
product regardless of its causal relationship to the study treatment. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product.  
9.1.2. 
Serious Adverse Event  
A serious AE (SAE) is any untoward medical occurrence at any dose that fulfils one or more of 
the following: 
 Results in death 
 Is life-threatening, ie, the participant was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred (does not include an event that, 
had it occurred in a more severe form, might have caused death) 
 Requires inpatient hospitalization or prolongation of existing hospitalization. (Note: a 
prescheduled hospitalization is not considered an SAE.) 
 Results in persistent or significant disability or incapacity 
 Is a congenital anomaly or birth defect 
 Is another medically significant event that, based upon appropriate medical judgment, 
may jeopardize the participant and may require medical or surgical intervention to 
prevent one of the outcomes listed above (eg, allergic bronchospasm requiring 
intensive treatment in an emergency room or home, blood dyscrasias or convulsions 
that do not result in hospitalization, the development of drug dependency or drug 
abuse) 
9.1.3. 
Adverse Events of Special Interest 
For this trial, AESIs are defined as any AE having an autoimmune etiology. Appendix B 
provides a list of AESI terms defined by FDA’s CBER as potentially associated with 
autoimmune disease that might represent a safety signal for vaccine-associated autoimmunity. 
Monitoring for late-onset AESIs, ie, those reported after the final visit on Day 51, will extend 
through 12 months following the last vaccination. Potential AESIs will be evaluated by a 
member of the DSMB having expertise in this area (refer to Section 8.5). Once assessed as 
autoimmune in nature, the event will be considered as a confirmed AESI.  
9.2. 
Eliciting and Reporting Adverse Events 
AEs (including SAEs and potential AESIs) reported spontaneously by the participant and/or in 
response to an open question from the PI or designee or revealed by observation (eg, during PE 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 105 of 139 
 
 
or from a clinical test result) will be recorded on the AE eCRF if they occurred from the time of 
the first administration of any IP (Day 2 for Group 2, Day 4 for Groups 1 or Day 8 for Group 3) 
through Day 51 or EWV, regardless of causal association with the IP. AE reporting is required 
for any new observation presenting after the first receipt of any IP or for a deterioration of 
baseline condition (eg, increased severity/frequency).  From the signing of the ICF until 
immediately before the administration of their first IP, only AEs resulting from a study-related 
procedure will be recorded on the AE eCRF; all other events reported in these time periods will 
be recorded as signs and symptoms on the Medical History eCRF. If there is any doubt as to 
whether a clinical or laboratory observation is an AE, the event will be considered an AE and 
recorded on the AE eCRF. After Day 51 and through the 12-month safety follow-up, AEs, SAEs 
(meeting definition per Section 9.1.2) and AEs assessed by the DSMB to be of autoimmune 
etiology (refer to Section 8.5), ie, AESIs, will be recorded on the AE eCRF. 
Refer to the specific sections on clinical laboratory tests (Section 8.3.2), PEs (Section 8.3.3), 
vital signs (Section 8.3.4), and e-diary reactogenicity (Section 8.3.5.1) for details on AE 
reporting based on participant observation and clinical test results. 
9.2.1. 
Rating the Severity of Adverse Events 
All AEs will be assessed for severity by the PI or designee using the FDA Guidance for Industry: 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials {CBER, 2007 (refer to Appendix A)}.  
The toxicity grading scale has specific grading options for some clinical symptoms, such as 
nausea/vomiting, diarrhea, headache, fatigue, and myalgia. Any AEs not specifically identified in 
the Toxicity Grading Scale will use the scale identified for systemic (general) illness or clinical 
AE. For AEs being reporting from clinical assessments, the PI or designee will refer to the 
specific sections on clinical laboratory tests(Section 8.3.2), PEs (Section 8.3.3), vital signs 
(Section 8.3.4), and e-diary reactogenicity (Section 8.3.5.1) on how and when to report AEs and 
AE severity in applying the toxicity grading scale. 
9.2.2. 
Rating the Causality of Adverse Events 
The PI’s (or designee’s) assessment of an AE's causal relationship to the IP will be documented 
on the AE eCRF. This causality assessment will be performed only by those study personnel 
listed on the Delegation of Authority Log as having both the authority and medical training to 
make such a determination. The following guidelines are provided for this assessment. 
1. Unrelated: there is no relationship between either the vaccine or the antibiotic and the 
reported event. 
2. Possibly related to antibiotic (Groups 1 and 2): the event follows a reasonable temporal 
sequence from the time of antibiotic administration and/or follows a known response 
pattern to the antibiotic, but could also have been produced by other factors. 
3. Possibly related to AV7909 (Groups 1 through 3): the event follows a reasonable 
temporal sequence from the time of vaccine administration and/or follows a known 
response pattern to the vaccine, but could also have been produced by other factors. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 106 of 139 
 
 
4. Probably related to antibiotic (Groups 1 and 2): a reasonable temporal sequence of the 
event with antibiotic administration exists and, based upon the known pharmacological 
action(s) of the antibiotic, known or previously reported adverse reactions to the 
antibiotic or class to which the antibiotic belongs (for ciprofloxacin this would be 
fluoroquinolones and for doxycycline this would be tetracyclines), or the Investigator’s 
clinical judgment, the association of the event with the antibiotic seems likely. 
5. Probably related to AV7909 (Groups 1 through 3): a reasonable temporal sequence of the 
event with vaccine administration exists and, based upon the known action of the 
vaccine, known or previously reported adverse reactions to the vaccine, or the 
Investigator’s clinical judgment, the association of the event with the vaccine seems 
likely. 
6. Definitely related to antibiotic (Groups 1 and 2): a definite causal relationship exists 
between antibiotic administration and the AE, and other conditions (eg, concurrent 
illness, progression/expression of disease state or concurrent medication reaction) do not 
appear to explain the event. 
7. Definitely related to AV7909 (Groups 1 through 3): a definite causal relationship exists 
between vaccine administration and the AE, and other conditions (eg, concurrent illness, 
progression/expression of disease state or concurrent medication reaction) do not appear 
to explain the event. 
If the relationship between the AE and the IP is determined to be “possible” or “probable” or 
“definitely related,” the event will be considered to be related to the IP.  
9.2.3. 
Eliciting Adverse Events from Other Safety Assessments 
Clinical observations during safety evaluations (ie, PEs, vital signs, clinical laboratory tests) 
determined by the PI or designee to be abnormal and to represent a clinically significant change 
from baseline must be reported on the AE eCRF regardless of causal association with the IP. 
This includes any new observation presenting after the dose of IP (either antibiotic or AV7909) 
or deterioration of baseline condition (ie, increased severity/frequency) after the first vaccination 
through Day 51 or EWV. If there is any doubt as to whether a clinical observation is an AE, the 
event will be considered an AE and recorded on the AE eCRF. Additionally, certain types of 
observations must be reported by the PI or designee as AEs, as follows (refer to the listed 
sections below for details on retesting and repeat testing requirements associated with this 
reporting where applicable): 
 Following the dose of any IP, all Grade 3 or higher clinical laboratory abnormalities 
(sample retested and, if needed, test repeated), unless covered under a disease or 
syndrome that is already reported as an AE; refer to Section 8.3.2 for details. 
 Following the first dose of any IP, all vital sign abnormalities found to be Grade 3 or 
higher in two out of three assessments (original plus two repeats); refer to Section 8.3.4 
for details. 
Additionally, while reactogenicity from the e-diary will not be duplicated in AE reporting, the PI 
or designee will record as AEs any e-diary reactogenicity that is serious, results in 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 107 of 139 
 
 
discontinuation of IP or withdrawal from the study, or remains unresolved as of Day 51/EWV 
(refer to Section 8.3.5.1).  
9.3. 
Immediately Reportable Events 
9.3.1. 
Principal Investigator’s Responsibilities 
The following events must be reported via email immediately (ie, within 24 hours of awareness), 
by the site PI or designee to 
:  
 Any SAE regardless of causal association with any IP 
 Any potential AESI, ie, AE of autoimmune etiology (refer to the list of AESI terms in 
Appendix B) regardless of causal association with any IP (ie, ciprofloxacin, 
doxycycline or AV7909) 
 Any pregnancy where conception occurred after first exposure to any IP (ie, 
ciprofloxacin, doxycycline or AV7909) and prior to 12 months after last receipt of 
either IP 
The appropriate form (listed below) will be completed and sent by email to the following 
address: 
 
 
 
   
For SAEs and AESIs, the Serious Adverse Event and/or Adverse Event of Special Interest 
Report Form will be completed (abbreviated hereafter SAE Report Form, AESI Report Form). 
Note that the SAE and AESI Report Form are not the same as the AE eCRF. Accompanying 
these forms will be source documentation or medical records (eg, discharge summary for 
hospitalizations, lab reports) which support a diagnosis. Participant identifiers (eg, individual’s 
name, address, telephone number, social security number, medical record number, or 
hospital/laboratory number) must be redacted from the source documentation.  
All SAEs that are unexpected (eg, adverse drug reactions) must be reported to the IRB/IEC as 
required by ICH GCP E6. 
Confirmed pregnancies where conception occurred after first exposure to any IP, and prior to 12 
months after last receipt of any IP will be reported to Global PV using the Pregnancy 
Notification Form. Although normal pregnancy is not an AE, it will mandate discontinuation of 
IP (refer to Section 9.4).  
9.3.2. 
Sponsor’s Reporting Requirements 
A SUSAR is a suspected adverse reaction that is both serious and unexpected.  As specified in 
21 CFR 312.32, SUSARs will be reported by the Sponsor of the Investigational New Drug 
Application (IND) to the FDA and to all participating PIs in an IND safety report as soon as 
possible, no later than 15 calendar days after the Sponsor becomes aware of the suspected 
adverse reaction (21 CFR 312.32(c)(1)). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 108 of 139 
 
 
In addition, any unexpected fatal or life-threatening suspected adverse reaction will be reported 
to FDA no later than seven calendar days after Emergent’s initial receipt of the information 
(21 CFR 312.32(c)(2)). 
The Sponsor will report AESIs to FDA within 15 calendar days after becoming aware of the 
AESI. 
9.4. 
Pregnancy 
Prior to trial enrollment, female participants must be advised of the importance of avoiding 
pregnancy during trial participation and the risks of an unintentional pregnancy. The participant 
must sign an ICF stating that the risk factors and consequences were communicated. 
To be eligible to enroll in the study, any female participant must certify either that she is 
surgically sterile (ie, had a hysterectomy, bilateral oophorectomy or bilateral salpingectomy), 
postmenopausal (defined as >12 consecutive months without menses and Screening FSH >30 
mIU/mL) or has been using an effective method of birth control for at least one month prior to 
Day 1. Methods of acceptable birth control are listed in Section 5.1. Additionally, WOCBP 
randomized to Groups 1 and 2 must be willing to add a double barrier method of birth control if 
they are not surgically sterile or postmenopausal, and their primary method of birth control is 
hormonal or an IUD.  
All women will have a serum pregnancy test performed at screening and at the EWV, if 
applicable, unless they are postmenopausal (confirmed with FSH >30 mIU/mL at screening) or 
indicate that they are surgically sterile. All WOCBP will also receive a UPT within 24 hours 
prior to each AV7909 vaccination. Vaccinations will not be administered to participants who test 
positive for pregnancy.    
In addition, a UPT will be performed on the Day 51 for WOCBP participants in all groups.  
Positive UPTs will be confirmed with a serum pregnancy test.  Pregnancy is not considered an 
AE in this study.  If a participant’s pregnancy is detected between Randomization and Day 2, no 
IP is to be administered and the participant is to be withdrawn from the study. 
If a participant becomes pregnant at any time after Day 2, (ie, after receipt of at least one dose of 
either IP), and where conception occurs prior to 12 months after last receipt of either IP, the 
pregnancy is to be reported within 24 hours of awareness by completing the Pregnancy 
Notification Form and forwarding it to the Global Pharmacovigilance Department (see 
Section 9.3.1). No further IP will be administered to the participant.  Participants will also be 
encouraged to continue planned safety follow-up in the study. 
All pregnancies occurring after Day 2 (ie, after receipt of at least one dose of either IP), and 
where conception occurs prior to 12 months after last receipt of either IP are to be followed to 
outcome (eg, delivery, spontaneous abortion, or therapeutic abortion), including after the study is 
completed.  When the PI becomes aware of the outcome of the pregnancy, a Pregnancy Outcome 
Form will be completed and forwarded to the Global Pharmacovigilance Department by email 
(see Section 9.3.1) within 24 hours of awareness.  A pregnancy outcome of spontaneous 
miscarriage, congenital anomaly or birth defect is considered an SAE and must be reported 
according to the procedures described in Section 9.3.1 above. As applicable, contact will be 
made when the infant is ~28 days old for a final follow-up. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 109 of 139 
 
 
9.5. 
Reporting of Other Information – Unanticipated Problems 
As outlined by the Office for Human Research Protection (OHRP), unanticipated problems must 
be reported to the IRB according to the requirements of 45 CFR Part 46. Unanticipated problems 
are considered to include any incident, experience, or outcome that meets ALL of the following 
criteria: 
 Unexpected (in terms of nature, severity, or frequency) given: 
o Procedures that are described in the study-related documents, such as the IRB 
approved research protocol and informed consent document. 
o The characteristics of the participant population being entered into the study. 
 Related or possibly related to participation in the study which means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused 
by the sample collection. 
 Suggests that the study places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized. 
An incidence, experience, or outcome that meets the three criteria above generally will warrant 
consideration of substantive changes in the study or informed consent process/document or other 
corrective actions in order to protect the safety, welfare, or rights of participants or others. Only a 
small subset of AEs occurring in human subjects participating in a clinical study will meet these 
three criteria for an unanticipated problem. There are other types of incidents, experiences, and 
outcomes that occur during the conduct of clinical study that represent unanticipated problems 
but are not considered AEs. For example, some unanticipated problems involve social or 
economic harm instead of the physical or psychological harm associated with AEs. In other 
cases, unanticipated problems place participants or others at increased risk of harm, but no harm 
occurs. 
The investigator should promptly notify the IRB when an unanticipated problem involving risks 
to participants or others is identified. Also, the investigator should notify Emergent and CRO of 
unanticipated problem(s). 
9.6. 
Procedure for Breaking the Blind for Individual Participants 
Not applicable to this study. 
9.7. 
Follow-up of Adverse Events 
9.7.1. 
Follow-up of Nonserious Adverse Events 
Nonserious AEs that are identified on or before the last scheduled visit (Day 51 or EWV) must 
be followed through and recorded on the AE eCRF. All nonserious events that are ongoing at 
Day 51 or EWV will be recorded with the current status noted as “Not Recovered/Not Resolved” 
on the AE eCRF. The status of ongoing, previously reported AEs will be reviewed at the Day 
51/EWV to determine if resolved. For participants that continue in the study beyond Day 51, the 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 110 of 139 
 
 
status of ongoing AEs will be queried at the quarterly phone contacts to determine status and 
update the resolution status in the AE eCRF. 
9.7.2. 
Follow-up of Serious Adverse Events or Adverse Events of Special Interest 
Participants experiencing SAEs or AESIs will be followed clinically until their health has 
returned to normal and all parameters have returned to baseline or has otherwise been explained 
or they have been referred to outside care. It is expected that the PI or designee will provide or 
arrange appropriate supportive care for the participant. Withdrawals of participants from 
treatment and/or the trial are at the discretion of the PI or designee, according to the guidance 
provided in Section 7.3. 
All SAEs/AESIs will be followed by the PI or designee until one or the other condition is met: 
 The SAE/AESI is resolved or stable if expected to remain chronic. 
 The participant is referred to a specialist or other physician for treatment and follow-
up. The PI or designee will follow events even if the participant is seen by another 
physician. The PI or designee will follow-up with the participant and the participant’s 
physician to obtain information about the event outcome and any treatments and 
medications administered for the event. 
The following will be considered acceptable reasons for discontinuation of follow-up of ongoing 
SAEs/AESIs: 
 Participant withdraws consent.  
 Participant is referred to appropriate long-term medical care. 
 Participant is considered lost to follow-up (refer to Section 7.4 for description of 
contact attempts before a participant may be deemed lost to follow-up). 
It is expected that the clinical site will obtain supporting medical records from appropriate 
physicians and record this information on the SAE/AESI Report Form (refer to Section 9.3) and 
AE eCRF. Additional information received related to any SAE/AESI must be forwarded within 
24 hours of awareness to the Emergent Global PV Department. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 111 of 139 
 
 
10. 
STATISTICAL ANALYSIS 
10.1. 
Study Endpoints and Statistical Hypotheses 
10.1.1. 
Primary Endpoints 
To assess whether co-administration of AV7909 with antibiotics affects antibiotic PK profiles, 
equivalence tests on the PK parameters (AUC0-12h and Cmax) at steady state pre- and post-
vaccination will be carried out separately for ciprofloxacin and doxycycline using PK data 
collected from subjects from independent study groups (Group 1 for ciprofloxacin, Group 2 for 
doxycycline). 
For each of the primary endpoints (for each of the two antibiotics), the equivalence tests on PK 
parameters (AUC0-12h and Cmax) at steady state pre- and post-vaccination will be performed. 
Therefore, demonstration of non-interference of steady state PK is defined separately for each 
antibiotic and there is only one way to meet the primary endpoint for each antibiotic. 
Specifically, for each antibiotic, the null hypotheses are: 
 AUC0-12h: The geometric mean of the within-participant ratios of post-vaccination 
(Day 35 for ciprofloxacin and Day 38 for doxycycline) over the pre-vaccination 
(Day 8) AUC0-12h will be greater than 1.25 or less than 0.80.  
 Cmax: The geometric mean of the within-participant ratios of the post-vaccination 
(Day 35 for ciprofloxacin and Day 38 doxycycline) over the pre-vaccination (Day 8) 
Cmax will be greater than 1.25 or less than 0.80.  
The null hypothesis will be rejected when the 90% confidence intervals (CIs) of the geometric 
mean of the within-participant ratios is contained entirely within the equivalence bounds of [0.8, 
1.25]. For each antibiotic, to conclude that administration of two-dose regimen of AV7909 does 
not affect the steady state of PK profile, the null hypotheses should be rejected for both 
endpoints AUC0-12h and Cmax.  
10.1.2. 
Secondary Endpoints 
10.1.2.1. Secondary Safety Endpoints 
 Incidences of AEs from the first dose of any IP through the Final Study Visit (Day 
51 ± 1 d) 
 Incidences of serious AEs (SAEs) from the first dose of any IP until the 12-month 
follow up (Day 388 ± 14 d) 
 Incidences of solicited systemic and injection site reactions reported in participant e-
diaries following each vaccination 
 Incidences of AESIs from the first dose of any IP until the 12-month follow up (Day 
388 ± 14 d) 
 Incidences of clinical laboratory abnormalities 
No hypothesis testing is planned for any of the safety endpoints. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 112 of 139 
 
 
10.1.2.2. Secondary Pharmacokinetic Endpoints 
To determine if the single-dose PK values of either ciprofloxacin or doxycycline are affected by 
AV7909 vaccination, separate equivalence tests will be carried out in parallel for each antibiotic 
in the similar manner as the primary PK analyses: 
 AUC0-12h: Geometric mean of within-participant ratios of post-vaccination (Day 31 
for ciprofloxacin and Day 32 for doxycycline) over the pre-vaccination (Day 4 for 
ciprofloxacin and Day 2 for doxycycline) AUC0-12h is greater than 1.25 or less than 
0.8. 
 Cmax: Geometric mean of within-participant ratios of post-vaccination (Day 31 for 
ciprofloxacin and Day 32 for doxycycline) over the pre-vaccination (Day 4 for 
ciprofloxacin and Day 2 for doxycycline) Cmax is greater than 1.25 or less than 0.8. 
No hypothesis testing is planned for the secondary PK endpoints, which will be evaluated and 
reported for information only.   
10.1.2.3. Secondary Immunogenicity Endpoints 
To evaluate whether the co-administration of antibiotics affects the immune response after two 
IM doses of AV7909, a non-inferiority test will be conducted independently for ciprofloxacin 
and doxycycline. Specifically, the null hypotheses are:  
 For ciprofloxacin: the geometric mean ratio of TNA NF50 values at Day 37 for Group 
1 over Group 3 will be less than or equal to 0.5 
 For doxycycline: the geometric mean ratio of TNA NF50 values at Day 37 for Group 2 
over Group 3 will be less than or equal to 0.5 
The null hypothesis will be rejected when the lower bound of the two-sided 95% CI of the 
geometric mean ratio of TNA NF50 values is greater than 0.5. 
For each antibiotic, the formal hypothesis testing for the secondary immunogenicity endpoints 
will only be carried out after the primary PK endpoint has been met for the corresponding 
antibiotic. If the primary PK endpoint for an antibiotic is not met, the corresponding secondary 
immunogenicity endpoints will be provided for information only.  
10.2. 
Sample Size and Power 
The sample size for this study was selected based on both the primary and secondary endpoints. 
The assessment as to whether vaccination with AV7909 affects the PK of either ciprofloxacin or 
doxycycline will be made based on the geometric mean of the within-participant ratios (post-
vaccination over pre-vaccination) of AUC0-12h and Cmax. The equivalence margin for the 
geometric mean ratio is [0.80, 1.25], which will be compared with the 90% CI for the geometric 
mean of within-participant ratios of AUC0-12h and Cmax. Assuming the coefficient of variation 
(CV) is 30% for geometric mean ratio and the true geometric mean ratio is 0.95, 27 participants 
allow for 90% power to reject the null hypothesis at a significance level of 5%. A group size of 
40 participants for Group 1A (AV7909 + ciprofloxacin with PK) or Group 2A (AV7909 + 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 113 of 139 
 
 
doxycycline with PK) is planned to allow for up to 30% of participants being excluded from the 
PK population. 
A sample size of 53 in each of the IP groups (Group 1 = AV7909 + ciprofloxacin, Group 2 = 
AV7909 + doxycycline, Group 3 = AV7909 only) provides 90% power at the 2.5% one-sided 
significance level for the non-inferiority test, defined as the lower bound of the two-sided 95% 
CI of the geometric mean ratio of the AV7909 + antibiotic over the AV7909 only (Group 1 vs. 
Group 3, Group 2 vs. Group 3) greater than 0.5. This assumes that the true geometric mean ratio 
between the two groups is 0.85 and the CV of TNA NF50 values in each group is 100%. A total 
of 70 per IP group is planned to allow for up to 25% of drop-out rate. 
The sample size calculation was performed using SAS 9.4 statistical software. 
10.3. 
Analysis Populations 
There will be four analysis populations for this study: 
The Intent-to-treat (ITT) Population will include all participants who are randomized. Participant 
disposition and baseline demographics will be summarized by IP group (Groups 1, 2 and 3) for 
the ITT population according to the group into which the participant is randomized. 
The Safety Population will include all randomized participants who receive at least one dose of 
either antibiotic or AV7909. All the safety analyses will be conducted with the Safety Population 
according to the treatment they received. 
The PK Population will include all participants in Group 1A and Group 2A who: 
 Received two doses of AV7909 according to the protocol (eg, correct dose no 
temperature excursion, and within the study-specified windows) 
 If in Group 1A, received at least 5 of the 7 in-clinic ciprofloxacin doses between Day 
4 through the morning of Day 8 and between Day 31 through the morning of Day 35; 
or if in Group 2A, received at least 7 of the 9 in-clinic doxycycline doses between 
Day 2 through the morning of Day 8 and between Day 32 through the morning of 
Day 38 
 Have adequate data for PK analysis for the calculation of AUC0-12h and Cmax at the 
Day 8 (both Group 1A and 2A) and Day 35 (Group 1A) or Day 38 (Group 2A) visits,  
 Have no protocol deviations that would affect ciprofloxacin or doxycycline PK 
Exclusion of participants from population will be done on a case-by-case basis at the time of the 
PK parameter analysis. 
The PK Population will be used for all PK analyses. Participants will be included in the 
treatment group (ciprofloxacin or doxycycline) according to the antibiotic they received.  
The Immunogenicity Population will include all randomized participants who meet the 
following criteria: 
 Received two AV7909 vaccinations according to the protocol (eg, correct dose, no 
temperature excursion, and within the study-specified windows) 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 114 of 139 
 
 
 Had a valid immunogenicity (TNA) result at Day 1 (pre-vaccination) showing no 
evidence of previous exposure to anthrax or an anthrax vaccine (ie, TNA below the 
limit of detection)  
 Had a valid immunogenicity (TNA) result at Day 37, within the study specified 
window 
 Participants in Group 1 or 2 should have taken at least 50% of the protocol-specified 
antibiotic doses 
The Immunogenicity Population will be used for the immunogenicity analyses. Participants will 
be included in the IP group (Group 1, 2 and 3) according to the treatment they actually received. 
10.4. 
Handling of Outliers and Missing Data  
Individual serum concentrations or entire serum concentration-time profiles for a participant may 
be excluded from the analysis at the discretion of the pharmacokineticist following a review of 
available documentation (eg, bioanalytical report, validation report, protocol deviation log) and 
communication with the sponsor. Any such exclusion will be clearly listed in the clinical study 
report along with justification for exclusion. Any excluded outlier data should be flagged in the 
individual data listings. 
Missing PK samples or antibiotic concentration values or missing immunogenicity response 
TNA NF50 values will be handled as described in the Statistical Analysis Plan (SAP). Antibiotic 
concentrations reported as below the lower limit of quantification (< LLOQ) will be handled as 
specified in the SAP. Non-missing TNA NF50 values reported as < LLOQ will be handled as 
specified in the SAP. 
10.5. 
Statistical Methods 
10.5.1. 
PK Analyses 
10.5.1.1. Summary of Concentrations and PK Parameters 
Summary statistics for serum concentrations of ciprofloxacin and doxycycline will be tabulated 
by time point and study day. Summary statistics will be provided for trough concentrations of 
ciprofloxacin and doxycycline by study day. The PK parameters shown in Table 11 will be 
derived from the concentration-time data by noncompartmental analysis methods and 
summarized by study day.  
Table 11 
Antibiotic Pharmacokinetic Parameters 
Variable 
Definition 
Cmax 
Maximum observed serum concentration  
tmax 
Time of maximum observed serum concentration  
t1/2 
Elimination half-life (calculated as ln 2/ Kel) 
Kel 
Elimination rate constant 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 115 of 139 
 
 
Variable 
Definition 
AUC0-12h 
Area under the serum concentration-time curve (12 hours) 
AUMC 
Area under the first moment curve 
AUC0-inf 
Area under the serum concentration-time curve extrapolated to infinity 
MRT 
Mean residence time 
10.5.1.2. Equivalence Testing for Primary PK Endpoints 
The goal of the study with the primary PK endpoints is to demonstrate that vaccination with 
AV7909 does not affect the steady-state PK profiles of either ciprofloxacin or doxycycline. The 
equivalence testing will be constructed using paired two one-sided t-tests (TOST) to provide the 
point estimate and 90% CIs for geometric mean of the within-participant ratios of the steady-
state values of AUC0-12h and Cmax post two doses of AV7909 (Day 35 for ciprofloxacin and Day 
38 for doxycycline) vs. pre-vaccination of AV7909 (Day 8 for ciprofloxacin and doxycycline). 
To conclude that AV7909 vaccine has no effect on the steady state PK for ciprofloxacin or 
doxycycline, the 90% CIs should fall entirely within the equivalence range of [0.80, 1.25] for 
both endpoints AUC0-12h and Cmax.  
To demonstrate that antibiotic concentrations have achieved steady state, the trough value 
analysis will be performed using the stepwise testing for linear trend, the application of the 
NOSTASOT (No Statistical Significance Of Trend) methodology proposed by {Maganti et al, 
2008}. The details of the calculation will be provided in the SAP. 
10.5.1.3. Equivalence Testing for Secondary PK Endpoints 
The secondary PK analyses will be performed to evaluate the effect of vaccination with AV7909 
on the single-dose PK profile for either ciprofloxacin or doxycycline. The equivalence tests will 
be conducted in a similar statistical manner as the primary analyses. If the 90% CIs for geometric 
mean of the within-participant ratios of the single-dose values of AUC0-12h and Cmax post two 
doses of AV7909 (Day 31 for ciprofloxacin and Day 32 for doxycycline) vs. pre-vaccination of 
AV7909 (Day 4 for ciprofloxacin and Day 2 for doxycycline) fall entirely within the equivalence 
range of [0.80, 1.25] for both endpoints, AUC0-12h and Cmax, it will be concluded that the 
AV7909 vaccine has no effect on the single dose PK for ciprofloxacin or doxycycline.  
10.5.2. 
Non-Inferiority Testing for Secondary Immunogenicity Endpoints 
Two-sided 95% CIs will be calculated for the geometric mean ratio of TNA NF50 values at Day 
37 between the AV7909 + antibiotic group and the AV7909 only group (Group 1 vs. Group 3, 
Group 2 vs. Group 3). To conclude that ciprofloxacin or doxycycline does not reduce the 
immune response to AV7909, the lower bound of the 95% CI should be greater than the non-
inferiority margin of 0.5. 
10.5.3. 
Exploratory Analysis for Immunogenicity  
To evaluate the possible impact on the immunogenicity endpoints of a population not balanced 
by age and gender, exploratory analyses will be conducted using linear regression to compare the 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 116 of 139 
 
 
immunogenicity response at Day 37 between each AV7909 + antibiotic group and the AV7909 
only group, ie, between Group 1 (AV7909 + ciprofloxacin) and Group 3 (AV7909) and between 
Group 2 (AV7909 + doxycycline) and Group 3 (AV7909). In the linear regression models, the 
stratification factor, study site, will be included in the model as a random effect; participant sex 
and age will be included as fixed factors with age being dichotomized into ≤30 and >30. The 
adjusted GMT ratios for the TNA NF50 values will be provided with 95% CI. 
10.6. 
Safety Analysis 
All safety data will be presented in the form of tabulations and listings, based on the Safety 
Population. Data summaries will be tabulated by treatment group (Ciprofloxacin only, AV7909 
+ ciprofloxacin, Doxycycline only, AV7909 + doxycycline, AV7909 only, and Total, ie, all 
participants receiving any IP) as specified in Section 10.3. Continuous variables will be 
summarized using number of participants (n), mean, standard deviation (SD), median, minimum, 
and maximum. Categorical variables will be summarized by the number (frequency) and 
percentage in each category. No formal hypotheses testing will be conducted for safety data.  
10.6.1. 
Adverse Events 
All AEs will be coded to SOC and PT according to MedDRA. Treatment-emergent adverse 
events (TEAEs) are defined as AEs that present after the initiation of treatment or any AEs 
already present that worsen in either intensity or frequency following treatment. The incidences 
of TEAEs will be presented in tabular form by MedDRA coded terms of SOC and PT, and by 
severity (toxicity grade), seriousness, relationship to IP, and outcome (death, discontinuation of 
IP, study withdrawal) for each treatment group. A tabulation will be provided of TEAE 
incidences by MedDRA PT in decreasing frequency of the “AV7909 Total” column. Separate 
tabulations by MedDRA SOC and PT will be provided for SAEs and AESIs determined to be of 
autoimmune etiology based on decision of the DSMB. Participants having the same TEAE more 
than once will be counted in tabulations once for each PT and once within each SOC at the 
maximum severity and relatedness. The incidences of AEs from the first dose of any IP through 
the Final Study Visit (Day 51 ± 1d), as well as incidences of AEs from the first dose of any IP up 
to 12-month follow-up will be tabulated separately as appropriate. 
10.6.2. 
Clinical Laboratory Data 
Safety clinical laboratory results will be tabulated by visit and group and listed by individual 
participant. Observed values and changes from baseline of continuous laboratory variables 
(hematology, serum chemistry, and selected urinalysis parameters [eg, specific gravity]) will be 
summarized using descriptive statistics (n, mean, median, SD, minimum, and maximum). 
Observed values of categorical laboratory variables (eg, urinary protein), incidences of 
abnormalities by analyte according to laboratory normal ranges and highest toxicity grade (refer 
to Table 13 in Appendix A), and shifts from baseline will be summarized descriptively (number 
and percentage) by visit and treatment group. Shift tables will be produced to reflect shifts from 
baseline values against the lab normal ranges (low, normal, high) as well as against toxicity 
grading criteria (Grade 0, Grade 1, Grade 2, Grade 3, Grade 4). Note: Grade 0 = laboratory value 
within normal range or laboratory value does not meet criteria for toxicity of at least Grade 1 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 117 of 139 
 
 
(refer to Table 13 in Appendix A). Screening (serology, urine drug screen, FSH) and pregnancy 
test results will be listed by individual participant. 
In tabulations, the last measurement before the first IP administration will be used as the baseline 
value. In listings, laboratory values outside of the reference range will be flagged: L=low 
compared to the lower limit of the normal range, H=high compared to the upper limit of the 
normal range. Additionally, laboratory abnormalities associated with a severity grade based on 
the toxicity grading criteria (refer to Table 13 in Appendix A) will be flagged: Grade 1 = Mild, 
Grade 2 = moderate, Grade 3 = severe, and Grade 4 = potentially life-threatening. Grade 3 or 
higher laboratory abnormalities will be summarized in a separate listing. 
10.6.3. 
Physical Examination 
Complete PE and symptom-directed PE data will be tabulated (number of participants with 
normal/abnormal findings by body system and group) and listed by individual participant. 
10.6.4. 
Vital Signs 
Vital signs data will be tabulated by visit and treatment group and listed by individual 
participant. Observed values and changes from baseline in vital signs will be summarized 
descriptively (n, mean, median, standard deviation, minimum, and maximum; incidence of 
abnormality according to highest toxicity grade). Baseline is defined as the last measurement 
before the first IP administration. In listings, vital sign abnormalities associated with a severity 
grade based on the toxicity grading criteria (refer to Table 12 in Appendix A) will be flagged: 
Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, and Grade 4 = potentially life-
threatening. 
10.6.5. 
Prior and Concomitant Medications 
Medications will be coded according to the World Health Organization’s (WHO) WHO Drug 
Global Dictionary and daily dosages normalized. Data will be tabulated and listed by individual 
participant according to study period (prior medications taken before the first IP administration, 
concomitant medications taken after the first IP administration) and treatment group. 
10.6.6. 
Other Safety Variables 
10.6.6.1. Reactogenicity 
In-clinic and e-diary reactogenicity data will be tabulated using descriptive statistics (number and 
percentage of participants reporting a reaction) for any symptom and each individual symptom 
by vaccination, treatment group, and severity grade. During the assessment period post each 
vaccination, when the severity differs across the daily assessments for a symptom, the maximum 
severity will be shown in summary tables.   
10.6.6.2. Autoantibody Testing and TSH Assessment 
Samples taken for TSH assessment and for RF, ANA and anti-ds DNA antibodies will be banked 
and will only be tested if medically indicated (ie, as per PI’s discretion based on a report of 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 118 of 139 
 
 
potential AESI). Results will be tabulated with negative/positive results by study visit and listed 
by individual participant. 
10.7. 
Interim Analysis 
No interim analyses are planned in this study. 
10.8. 
Multiplicity 
In this phase 2 study, multiplicity adjustment is not planned. All the PK and immunogenicity 
endpoints are evaluated in parallel for the two antibiotics, ciprofloxacin and doxycycline.  
The primary PK endpoints for each antibiotic will be met when the 90% CIs of the geometric 
mean of ratios for both AUC0-12h and Cmax are contained entirely within the equivalence bounds 
of [0.8, 1.25]. Since both parameters must satisfy the equivalence condition and each 
equivalence test is conducted at 5% level, the overall type I error rate is controlled at less than 
5%. 
For immunogenicity, non-inferiority is evaluated as a one-sided test at 2.5% level. As a 
secondary endpoint, the test will only be formally evaluated when the corresponding primary PK 
endpoints have been met. Otherwise the results will be provided for information. No adjustment 
for multiplicity is required based on the closed test procedure. 
No other formal hypothesis testing will be carried out. The secondary PK endpoints (single dose) 
will be evaluated and reported for information only. 
 
10.9. 
Final Analysis Plan 
A Statistical Analysis Plan (SAP) will be finalized prior to clinical database lock [to include data 
up to and including last subject’s last in-clinic visit (Day 51; ie, four weeks after second 
vaccination)]. Clinical Study Report (CSR) will be generated with data up to and including last 
subject’s last in-clinic visit (Day 51). All data after Day 51 (ie, data up to and including last 
subject’s 12-month safety follow up telephone call) will be included as an addendum to the CSR. 
Details of the statistical methods and analyses will be provided in the final SAP. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 119 of 139 
 
 
11. 
DATA HANDLING AND RECORD KEEPING 
11.1. 
Source Documents and Access 
Source documents are defined as the records of original observations and activities of a clinical 
investigation. Source documents will include but are not limited to screening logs, progress 
notes, clinical and office charts, hospital records, pharmacy dispensing records, laboratory notes, 
e-diary data, safety laboratory data including both local and central laboratory data, memoranda, 
and recorded data from automated instruments. All source documents pertaining to this trial will 
be maintained by the PI(s) and made available for direct inspection and copying by authorized 
persons. Investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC 
review, and regulatory inspection(s) by providing direct access to source data/documents by 
authorized persons as specified in the ICF. 
11.2. 
Data Management  
A validated, electronic data capture (EDC) system will be used during the trial. The data 
management functions for the study will be outsourced to a CRO. Data management activities to 
be performed for the study will be described in detail in the Data Management Plan documents. 
The standard operating procedures (SOPs) governing data management activities will be 
mutually agreed upon by the CRO and Emergent and documented in these DMP documents. 
Emergent is responsible for the oversight and management of the CRO. 
11.3. 
Data Collection and Discrepancy Management 
Data collected during the study will be recorded in the eCRFs designed for this study. 
Investigational sites will have the responsibility for capturing and maintaining accurate eCRF 
data, records, and relevant source documentation, as well as conforming to procedures 
established by the CRO/Emergent around system access/security and ensuring a data audit/edit 
trail for data corrections. All source documents will be verified by the CRO study monitor for 
accuracy. Information from external sources such as laboratory data, images, etc. as defined in 
this protocol will be collected and maintained outside the EDC and reconciled with the eCRF 
data periodically. As data are entered into the eCRF, automated edit checks will validate data. 
Additionally, manual reviews will be performed for data discrepancy by the CRO and queries 
will be generated into the EDC system. After clinical sites respond to queries and data 
corrections are made and reviewed by the CRO, the PI will review and electronically sign the 
eCRF for each participant. The CRO and Emergent will review data for accuracy, completeness, 
and consistency during the conduct of the study and prior to database lock. 
11.4. 
File Management at the Investigational Site 
The PI will ensure that the trial center file is maintained in accordance with the ICH Guideline 
and as required by applicable local regulations. The PI/institution will take measures to prevent 
accidental or premature destruction of these documents. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 120 of 139 
 
 
11.5. 
Record Retention at the Investigational Site 
Per ICH guidelines, study documents will be retained for one of the following periods: 
 A period of at least two years after the date of the last approval of a marketing 
application in an ICH region until there are no pending or contemplated marketing 
applications; 
 A period of at least two years after Emergent has notified the regulatory authority(ies) 
that clinical investigation with this product is discontinued. 
The PI must not dispose of any records relevant to this trial without either (1) written permission 
from Emergent or (2) provision of an opportunity for Emergent to collect such records. The PI 
will be responsible for maintaining adequate and accurate electronic or hard copy source 
documents of all observations and data generated during this trial, including any data queries 
received from the Sponsor or designee. Such documentation is subject to inspection by Emergent 
and relevant regulatory agencies. If the PI withdraws from the trial (eg, due to relocation or 
retirement), all trial-related records will be transferred to a mutually agreed upon designee within 
an Emergent-specified timeframe. Notice of such transfer will be given to Emergent in writing. 
11.6. 
Protocol Deviations 
The PI or site staff may not deviate from the protocol except, in rare circumstances, as necessary 
to eliminate immediate hazards to the trial participants. In such event, both the Sponsor and 
IRB/IEC will be immediately notified, no more than 24 hours after the deviation is implemented. 
It is the responsibility of the PI to comply with the protocol. A deviation occurs when site 
personnel or a participant does not adhere to the protocol’s stipulated requirements, whether 
inadvertently or planned. The occurrence of protocol deviations will be routinely monitored by 
the CRO and Sponsor for evaluation of PI compliance with the protocol, GCP, and regulatory 
requirements. The PI or designee will inform the IRB/IEC of all protocol deviations according to 
the requirements of each IRB/IEC. Deviations may be identified during the course of the study 
by the PI or site staff, study monitor during routine or directed monitoring visits (recorded in 
monitoring reports), and Sponsor or BARDA personnel. In compliance with GCP, all identified 
protocol deviations will be documented – entered in the CRO’s Clinical Trial Management 
System or equivalent – and classified according to procedures outlined in the protocol deviation 
plan. Deviations will be assessed by the CRO and Sponsor to identify appropriate corrective and 
preventive actions and followed up to ensure renewed understanding and proper execution of the 
protocol. 
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg, violation of informed consent process, participant dosing error, treatment 
assignment error, participant enrolled in violation of eligibility criteria, violation of concomitant 
medication use restriction), the PI or designee will contact the MM at the earliest possible time 
by telephone, or the reverse as applicable. The PI and MM will come as quickly as possible to a 
joint decision regarding the participant’s continuation in the trial. This decision will be 
documented by the PI and MM and reviewed by the site monitor.  
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 121 of 139 
 
 
Continued protocol deviations despite re-education of investigational site personnel, or persistent 
protocol deviations that are reportable to regulatory agencies may result in discontinued 
shipment of IP and termination of further enrollment at the investigational site, or termination of 
the investigational site from the study. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 122 of 139 
 
 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE 
12.1. 
Monitoring 
The site will be monitored at regular intervals using a risk-based monitoring approach to ensure 
compliance with the protocol, ICH GCP, applicable regulatory requirements, and current SOPs 
of the CRO and Emergent. Sites will be monitored both remotely and in-person to ensure the 
integrity of the data collection and the safety of study participants. A medical monitoring plan 
will be established, and data will be reviewed on a monthly basis.  A Monitoring Plan, 
containing the frequency on-site and remote monitoring visits conducted by the CRO study 
monitors as well as monitoring requirements and contact details of the CRO study monitors will 
be developed and followed throughout the study. 
As a representative of Emergent, the CRO study monitors will visit the site periodically. In 
addition, the CRO study monitors will be available between visits via telephone and email as 
needed. The CRO study monitors will perform the following functions: 
 Provide information and support to the PI(s) and study site 
 Confirm the facility(-ies) are satisfactory to continue study conduct 
 Confirm the site is adhering to the protocol, data are being accurately recorded in the 
eCRFs, and IP accountability checks are being performed 
 Confirm that the study site staff are routinely reviewing the participants e-diary 
records 
 Perform source data verification including a comparison of eCRF data with the 
participant’s clinic records and other records relevant to the study. This will require 
direct access to all original records for each participant (eg, clinic charts) 
 Record and report any protocol deviations not previously sent to Emergent 
 Confirm AEs, AESIs, and SAEs have been properly documented on eCRFs; SAE, 
AESI, and pregnancy reports where conception occurred after first exposure to the IP 
and (ie, after receipt of at least one dose of either IP), and prior to 12 months after last 
receipt of either IP have been sent to Emergent; and SAEs and potential AESIs 
meeting the criteria for reporting have been sent to the IRB/IEC 
 Confirm all pregnancies where conception occurred after first exposure to the IP (ie, 
after receipt of at least one dose of either IP), and prior to 12 months after receipt of 
either IP are followed properly and that the post-birth follow-up occurs 
The CRO study monitors may inspect all documents and required records that are maintained by 
the PI, including medical records (office, clinic, or hospital) for the participants in this trial. The 
PIs will permit unrestricted access to all source documents.  Source documentation must be 
available to substantiate proper informed consent procedures, adherence to protocol procedures, 
adequate reporting and follow-up of AEs, accuracy of data collected on eCRFs, and device 
procedure information. A monitoring visit sign-in log will be maintained at the site. The PI and 
investigational site staff will be available for monitoring visits. It is expected that the PI will 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 123 of 139 
 
 
provide the CRO study monitors with a suitable working environment for review of study-related 
documents and internet access. 
12.2. 
Auditing 
Emergent’s Quality Assurance Department (or designee[s]) may conduct investigational site 
audits before trial initiation, during the trial, or after trial completion, as documented in the 
Clinical Quality Oversight Plan. Audits will include, but are not limited to, review of drug 
supply, presence of required documents, informed consent process, and comparison of eCRFs 
with source documents. The PI agrees to participate in site audits and assist in the prompt 
resolution of any issues found during audits. 
Regulatory authorities or the IRB/IEC may inspect the investigational site during or after the 
trial. The PI will cooperate with such inspections and will contact Emergent immediately if such 
an inspection occurs. 
In the event the PI is contacted by a regulatory agency in relation to this study, the PI and 
investigational site staff must be available to respond to reasonable requests and inspection 
queries made during the inspection process. The PI must provide Emergent with copies of all 
correspondence that may affect the review of the current study (eg, Form FDA 483, inspectional 
observations, warning letters). Emergent may provide any needed assistance in responding to 
regulatory inspections. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 124 of 139 
 
 
13. 
ETHICS 
This trial must be conducted in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and in compliance with the protocol, ICH E6 GCP Guideline, FDA 
regulations, and all other applicable local laws and regulatory requirements. Each investigational 
site will seek approval by an IRB/IEC according to regional requirements. The IRB/IEC will 
evaluate the ethical, scientific and medical appropriateness of the trial. Further, in collecting and 
handling participant data and completing eCRFs, the PI and investigational site staff will take 
measures to ensure adequate care in protecting participant privacy. To this end, a subject ID 
number will be used to identify each participant. 
13.1. 
Informed Consent 
The Principal Investigator (PI) or designee at each site will ensure the participant is given full 
and adequate oral and written information about the nature, purpose, and possible risks and 
benefits of the trial. Written informed consent will be obtained from all participants and 
documented on a written ICF. The ICF will be approved by the same institutional review board/ 
independent ethics committee (IRB/IEC) that approves this protocol. Each ICF will comply with 
the FDA regulations in 21 CFR Part 50, ICH guidelines and local regulatory requirements.  
Investigators may discuss trial availability and the possibility for entry with a potential 
participant without first obtaining consent. However, informed consent must be obtained and 
documented prior to initiation of any procedures that are performed solely for the purpose of 
determining eligibility for this trial. 
Once appropriate essential information has been provided and fully explained in layman’s 
language to the participant by the PI or a qualified designee (and source documented at the site), 
the IRB/IEC approved written ICF will be signed and dated by both the participant and the 
person obtaining consent (PI or designee), as well as by any other parties required by the 
IRB/IEC. The participant will receive a copy of the signed/dated ICF; the original shall be kept 
on file by the PI. 
13.2. 
Institutional Review Board 
The final study protocol, associated ICF, and any recruitment materials must be reviewed and 
approved by the IRB/IEC at each investigational site. The potential benefits and risks for 
participants will be considered as will the benefits to the knowledge gained through the conduct 
of the proposed study. The PI or designee must submit written approval from the IRB/IEC to 
Emergent before any participants can be screened for the study. 
The PI or designee is responsible for informing the IRB/IEC of any amendment to the protocol 
or ICF in accordance with local requirements. The protocol must be re-approved by the IRB/IEC 
upon receipt of amendments and annually, as required by local regulations. 
The PI or designee is also responsible for providing the IRB/IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the IP, if required by the 
IRB/IEC. Emergent will provide this information to the PI. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 125 of 139 
 
 
Progress reports and notifications of serious adverse drug reactions will be provided to the 
IRB/IEC according to local regulations and guidelines, if required. 
Additionally, the PI or designee will provide an IRB/IEC membership list or assurance number 
to Emergent annually. Initial IRB/IEC approval, and all materials approved by the IRB/IEC for 
the study including the ICF and recruitment materials, must be maintained by the PI and made 
available for inspection. 
13.3. 
Future Use of Stored Specimens 
Any remnant (leftover) blood samples collected for the TNA analysis will be stored frozen at a 
long-term storage facility for possible later retesting for anthrax research. Specimens will be 
identified by subject ID numbers, thereby maintaining confidentiality while in storage. 
Participants will be asked to consent to the future use of these samples as part of the informed 
consent process.  
Samples may be retained until at least 2 years after the last approval of a marketing application 
in an ICH region and until there are no pending or contemplated marketing applications in an 
ICH region or at least 2 years have elapsed since the formal discontinuation of clinical 
development of the vaccine. They may be retained for a longer period, however, if required by 
the applicable regulatory requirements. 
13.4. 
Confidentiality 
Participant confidentiality must be strictly held in trust by the participating PIs, their staff, and 
Emergent and its agents. This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Participants will be identified only by 
their subject ID or other de-identifying information, on the eCRF or any other study documents 
provided to Emergent or designate(s).  
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study, or the data will be released to any 
unauthorized third party without prior written approval of Emergent. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 126 of 139 
 
 
14. 
AMENDMENT POLICY 
The PI will not make any changes to this protocol. Any permanent change to the protocol, 
whether it be an overall change or a change for specific investigational site(s), must be handled 
as a protocol amendment. Any amendment will be initiated/written by Emergent. Each 
amendment will be submitted to the IRB/IEC. Except for non-substantial, in other words, 
administrative, amendments, PIs will wait for IRB/IEC approval of the amended protocol before 
implementing the change(s). Administrative amendments are defined as having no effect on the 
safety or physical or mental integrity of participants, the conduct or management of the trial, the 
scientific value of the trial or the quality or safety of IP(s) used in the trial. However, a protocol 
change intended to eliminate an apparent immediate hazard to participants should be 
implemented immediately, followed by IRB/IEC notification within 5 working days. Emergent 
will submit protocol amendments to the FDA or other regulatory agencies. 
When the IRB/IEC, PIs, and/or Emergent conclude that the protocol amendment substantially 
alters the trial design and/or increases the potential risk to the participant, the currently approved 
written ICF will require similar modification. In such cases, after approval of the new ICF by the 
IRB/IEC, repeat informed consent will be obtained from participants in a timely manner before 
expecting continued participation in the trial. 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 127 of 139 
 
 
15. 
PUBLICATION POLICY 
Following the completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, Emergent will be responsible for 
these activities and may work with the PI(s) to determine how the manuscript is written and 
edited, the number and order of authors, the publication to which it will be submitted and other 
related issues. Emergent has final approval authority over all such issues.  
Any proposed publication will be subject to review conditions and timelines agreed between 
Emergent and the site PI and detailed in the agreements with these parties prior to the start of the 
study. Emergent will also post the results of the clinical trial on ClinicalTrial.gov in a period no 
greater than 12 months from the completion of the study, defined as the time the final participant 
was examined or received an intervention for purposes of final collection of data for one of the 
primary endpoints. 
Data are the property of Emergent and cannot be published without prior authorization from 
Emergent, but data and publication thereof will not be unduly withheld. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 128 of 139 
 
 
16. 
LIST OF REFERENCES 
Athenahealth, Inc [US] 2019a [Internet] Epocrates Monograph Ciprofloxacin available at:  
https://online.epocrates.com/drugs/50110/ciprofloxacin/Monograph  Accessed 21 Mar 2019 
Athenahealth, Inc [US] 2019b [Internet] Epocrates Monograph Doxycycline available at: 
https://online.epocrates.com/drugs/20310/doxycycline/Monograph  Accessed 21 March 2019 
BioThrax.com [Internet]. 
 c2016 [updated 2016; cited 
5April 2017]. What is BioThrax. Who Should be Immunized; [about 1 screen]. Available from: 
http://biothrax.com/whoshouldbeimmunized.aspx. 
Brachman PS, Friedlander AM, Grabenstein JD. 2008. Anthrax. In: Plotkin SA, Orenstein WA, 
Offit PA, eds. Vaccines, 5th ed. Philadelphia, Pa.: W. B. Saunders Co. Pp. 111–1267. 
CBER, Center for Biologics Evaluation and Research [Internet]. Guidance for Industry: Toxicity 
Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials. September 2007. Accessed 19 Jun 2018: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977. 
CDC, Centers for Disease Control and Prevention.  Use of Anthrax Vaccine in the United States 
Recommendations of the Advisory Committee on Immunization Practices.  MMWR 2000; 
49(RR-15):1-20. 
CDC, Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related 
anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep. 
2001; Nov 9;50 (44):973-6.  
CDC, Centers for Disease Control and Prevention.  Use of Anthrax Vaccine in Response to 
Terrorism: Supplemental Recommendations of the Advisory Committee on Immunization 
Practices.  MMWR 2002; 51:1024-1026. 
CDC Centers for Disease Control and Prevention, Department of Health and Human Services. 
Anthrax Bioterrorism Threat. Atlanta, GA 2014 updated 01Aug 2014; cited 04Jun2017 
https://www.cdc.gov/anthrax/bioterrorism/threat.html 
Coley Pharmaceutical Group, Inc., V011 study report ‘Phase 1/2, proof of concept, double-blind, 
randomized, controlled trial assessing the immunogenicity and safety of AVA (BioThrax®) 
combined with CPG 7909 (VaxImmune™) in normal volunteers.  Final Clinical Study Report. 
Issued 31 July 2006. 
Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote 
J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to 
Engerix-B® HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 
2004;24:693-701. 
 A Study of the Effects of Co-
Administering Ciprofloxacin and Biothrax on the Pharmacokinetics of Ciprofloxacin in Healthy 
Adults (EBS.AVA.009) Final Clinical Study Report. Issued 14 March 2014 BLA 103821; 
Sequence 0110. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 129 of 139 
 
 
Emergent BioSolutions [Internet]. BioThrax® (Anthrax Vaccine Adsorbed), Emergent 
BioSolutions, Prescribing information, [Updated November 2015]. Available from: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProduc
ts/LicensedProductsBLAs/UCM074923.pdf. Accessed 03 May 2017 
Hopkins RJ, Daczkowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C, et al. Randomized, 
double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of anthrax 
vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine 2013; 31(30): 
3051-8. 
Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, et al. 
Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of 
three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure 
prophylaxis in healthy adults. Vaccine. 2016 34(18):2096-105. 
Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, et al. Investigation 
of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerging 
infectious diseases. 2002;8(10):1019-28. 
Kaminski MM, Sauer SW, Klemke CD, Suss D, Okun JG, Krammer PH, Gulow K, 
Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 
expression: mechanism of ciprofloxacin-mediated immunosuppression. Journal of Immunology 
2010;184(9):4827-41. 
Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO. Comparison of the effect 
of different immunological adjuvants on the antibody and T-cell response to immunization with 
MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine. 1999; 18:597-603. 
Krieg A. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends 
Microbiol. 1996; 4:73-84. 
Longstreth J, Blumenau J, Ervin J, Essink B, Hunter-Stitt E, Fleming A, Montalvo-Lugo VM, 
Pentikis H, Sweeney D, Hopkins RJ. Co-administration of BioThrax Vaccine and Ciprofloxacin 
as Would be Required for Post-exposure Prophylaxis of Anthrax Shows No Interactive Effects 
presented at ECMIDD, Madrid Spain 21 - 24 April 2018. 
Li H, Soroka SD, Taylor TH Jr, Stamey KL, Stinson KW, Freeman AE, et al. Standardized 
mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J 
Immunol Methods. 2008 Apr 11; 333(1-2): 89-106. 
MacDougall C. Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for 
Urinary Tract Infections. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & 
Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York. McGraw-Hill 
Medical Division; c2018. p. 1011-1021. 
Maganti L, Panebianco D, Maes A, Evaluation of methods for estimating time to steady state 
with examples from Phase 1 studies. The AAPS Journal. 2008 10(1):141–147. 
Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, 
Moretz S, Zhou H, Long CA, Miller LH, Treanor J. Phase 1 trial of AMA1-C1/Alhydrogel plus 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 130 of 139 
 
 
CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One. 2008 
Aug 13;3(8):e2940.  
Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity. 1996; 5: 303-
309. 
Pomorska-Mól M, Kwit K, Markowska-Daniel I, Pejsak Z. The effect of doxycycline treatment 
on the postvaccinal immune response in pigs. Toxicology and applied pharmacology. 2014 Jul 
1;278(1):31-8. 
Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, et al. Marked enhancement 
of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 
7909 in healthy volunteers.  Vaccine.  2011; 29(37):6313-6320.  
Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, Sissoko MS, Fay MP, Guindo 
MA, Kante O, Saye R, Miura K, Long C, Mullen GE, Pierce M, Martin LB, Rausch K, Dolo A, 
Diallo DA, Miller LH, Doumbo OK. A randomized and controlled Phase 1 study of the safety 
and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium 
falciparum malaria in semi-immune Malian adults. Vaccine. 2009 Dec 9;27(52):7292-8. 
Segal BM, Chang JT, Shevach EM. CpG oligonucleotides are potent adjuvants for the activation 
of autoreactive encephalitogenic T cells in vivo. J Immunol. 2000; 164(11): 5683-5688.  
Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al CDC 
Adverse Events Working Group. Antimicrobial post-exposure prophylaxis for anthrax: adverse 
events and adherence. Emerg Infect Dis. 2002; 2002 8(10):1124-32. 
Stewart VA, McGrath S, Krieg AM, Larson NS, Angov E, Smith CL, et al.  Activation of innate 
immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 
7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques.  Clin 
Vaccine Immunol.  2008; 15(2):221-226. 
Stinson KW, Freeman A, Li H. CDC SSP AVRP-0002, An In Vitro MTT Cytotoxicity Assay for 
Quantification of Neutralizing Antibodies to Bacillus anthracis Lethal Toxin, 2005. 
Takahashi HK, Iwagaki H, Xue D, Katsuno G, Sugita S, Mizuno K, Mori S, Saito S, Yoshino T, 
Tanaka N, Nishibori M. Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18-
treated monocytes. Antimicrobial agents and chemotherapy. 2005;49(8):3228-33.  
Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, et al Serious 
adverse events among participants in the Centers for Disease Control and Prevention's Anthrax 
Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related 
inhalational anthrax. Clin Infec Dis. 2003;37(7):905-11. 
WHO. Anthrax in Humans and Animals 2008. Available from: 
http://apps.who.int/iris/bitstream/10665/97503/1/9789241547536_eng.pdf. 
Woo PC, Tsoi HW, Wong LP, Leung HC, Yuen KY. Antibiotics modulate vaccine-induced 
humoral immune response. Clinical and diagnostic laboratory immunology. 1999 Nov 
1;6(6):832-7. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 131 of 139 
 
 
Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States: 
recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 
2010;59(RR-6):1-30. 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 132 of 139 
 
 
17. 
APPENDICES 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 133 of 139 
 
 
APPENDIX A. 
TOXICITY GRADING SCALE FOR HEALTHY ADULT 
AND ADOLESCENT VOLUNTEERS ENROLLED IN 
PREVENTIVE VACCINE CLINICAL TRIALS 
The toxicity grading scales that will be used to rate the severity of local reaction to injectable 
product, vital signs, and general systemic condition related to clinical abnormality and laboratory 
abnormality are presented in Table 12 and Table 13, respectively. 
Table 12: 
Toxicity Grading Scale for Clinical Abnormalities in Healthy Adult and 
Adolescent Volunteers 
Toxicity 
Grade 1 
(Mild) 
Grade 2 
(Moderate) 
Grade 3 
(Severe) 
Grade 4 
(Potential Life-
Threatening) 
Local Reaction to Injectable Product 
Pain 
Does not interfere 
with activity 
Repeated use of  
non-narcotic pain 
reliever >24 hours or 
interferes with activity 
Any use of narcotic 
pain reliever or 
prevents daily activity 
ER visit or 
hospitalization 
Tenderness 
Mild discomfort to 
touch 
Discomfort with 
movement 
Significant discomfort 
at rest 
ER visit or 
hospitalization 
Erythema/rednessa 
2.5–5 cm 
5.1–10 cm 
>10 cm 
Necrosis or 
exfoliative 
dermatitis 
Induration/swellingb 
2.5–5 cm and does 
not interfere with 
activity 
5.1–10 cm or interferes 
with activity 
>10 cm or prevents 
daily activity 
Necrosis 
Vital Signsc 
Fever (°C) (°F)d 
38.0–38.4 
100.4–101.1 
38.5–38.9 
101.2–102.0 
39.0–40 
102.1–104 
>40 
>104 
Tachycardia 
(beats/minute) 
101–115 
116–130 
>130 
ER visit or 
hospitalization for 
arrhythmia 
Bradycardiae 
(beats/min) 
50–54 
45–49 
<45 
ER visit or 
hospitalization for 
arrhythmia 
Hypertension –
systolic (mmHg) 
141–150 
151–155 
>155 
ER visit or 
hospitalization for 
malignant 
hypertension 
Hypertension –
diastolic (mmHg) 
91–95 
96–100 
>100 
ER visit or 
hospitalization for 
malignant 
hypertension 
Hypotension – 
systolic (mmHg) 
85–89 
80–84 
<80 
ER visit or 
hospitalization for 
hypotensive shock 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 134 of 139 
 
 
Toxicity 
Grade 1 
(Mild) 
Grade 2 
(Moderate) 
Grade 3 
(Severe) 
Grade 4 
(Potential Life-
Threatening) 
Respiratory rate 
(breaths/minute) 
17–20 
21–25 
>25 
Intubation 
Systemic (General) 
Nausea/vomiting 
No interference with 
activity or 1-2 
episodes/24 hours 
Some interference with 
activity or >2 
episodes/24 hours 
Prevents daily activity, 
requires outpatient IV 
hydration 
ER visit or 
hospitalization for 
hypotensive shock 
Diarrhea 
2–3 loose stools or 
<400 g/24 hours 
4–5 stools or 400–800 
g/24 hours 
≥ 6 watery stools or 
>800 g/24 hours or 
requires outpatient IV 
hydration 
ER visit or 
hospitalization 
Headache 
No interference with 
activity 
Repeated use of non-
narcotic pain reliever 
>24 hours or some 
interference with 
activity 
Significant; any use of 
narcotic pain reliever 
or prevents daily 
activity 
ER visit or 
hospitalization 
Fatigue 
No interference with 
activity 
Some interference with 
activity 
Significant; prevents 
daily activity 
ER visit or 
hospitalization 
Myalgia 
No interference with 
activity 
Some interference with 
activity 
Significant; prevents 
daily activity 
ER visit or 
hospitalization 
Illness or clinical 
AEf 
No interference with 
activity 
Some interference with 
activity not requiring 
medical intervention 
Prevents daily activity 
and requires medical 
intervention 
ER visit or 
hospitalization 
AE = adverse event; ER = emergency room; gm = grams; IV = intravenous 
a In addition to grading the measured local reaction at the greatest single diameter, the measurement is recorded as a continuous 
variable. 
b Induration/swelling is evaluated and graded using the functional scale as well as the actual measurement. 
c Participant will be at rest for all vital sign measurements. 
d Oral temperature; no recent hot or cold beverages or smoking. 
e When resting heart rate is between 60-100 beats per minuteclinical judgment will be used when characterizing bradycardia 
among some healthy participant populations, for example, conditioned athletes. 
f Adverse event defined according to applicable regulations. 
 
 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 135 of 139 
 
 
Table 13: 
Toxicity Grading of Laboratory Abnormalities 
Panel and Analytea 
Mild (Grade 1) 
Moderate (Grade 
2) 
Severe (Grade 3) 
Potentially Life 
Threatening  
(Grade 4)b 
Serum Chemistry 
Glucose – 
hypoglycemia 
mg/dL  
65–69 
55–64 
45–54 
< 45 
Glucose – 
hyperglycemia  
Fasting (mg/dL)  
Random (mg/dL)  
 
 
100–110 
110–125 
 
 
111–125 
126–200 
 
 
>125 
>200 
 
 
Insulin requirements or 
hyperosmolar coma 
Blood Urea 
Nitrogen (mg/dL) – 
mg/dL  
23–26 
27–31 
> 31 
Requires dialysis 
Creatinine (mg/dL)  
1.5–1.7 
1.8–2.0 
2.1–2.5 
> 2.5 or requires dialysis 
Alkaline phosphate 
increase by factor  
1.1–2.0 x ULN 
2.1–3.0 x ULN 
3.1–10 x ULN 
> 10 x ULN 
Liver Function 
Tests: ALT, AST 
increase by factor  
1.1–2.5 x ULN 
2.6–5.0 x ULN 
5.1–10 x ULN 
> 10 x ULN 
Bilirubin (when 
accompanied by any 
increase in Liver 
Function Test) 
increase by factor  
1.1–1.25 x ULN 
1.26–1.5 x ULN 
1.51–1.75 x ULN 
> 1.75 x ULN 
Bilirubin (when 
Liver Function Test 
is normal) 
increase by factor  
1.1–1.5 x ULN 
1.6–2.0 x ULN 
2.0–3.0 x ULN 
> 3.0 x ULN 
Hematology 
Hemoglobin, female 
(g/dL)  
11.0–12.0 
9.5–10.9 
8.0–9.4 
<8.0 
Hemoglobin 
decrease from 
baseline value, 
female (g/dL) 
Any decrease–
1.5 
1.6–2.0 
2.1–5.0 
>5.0 
Hemoglobin, male 
(g/dL)  
12.5–13.5 
10.5–12.4 
8.5–10.4 
<8.5 
Hemoglobin 
decrease from 
baseline value, male 
(g/dL) 
Any decrease–
1.5 
1.6–2.0 
2.1–5.0 
>5.0 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 136 of 139 
 
 
Panel and Analytea 
Mild (Grade 1) 
Moderate (Grade 
2) 
Severe (Grade 3) 
Potentially Life 
Threatening  
(Grade 4)b 
WBC increase 
(cell/mm3) 
10,800–15,000 
15,001–20,000 
20,001–25,000 
>25,000 
WBC decrease 
(cell/mm3) 
2,500–3,500 
1,500–2,499 
1,000–1,499 
<1,000 
Lymphocyte 
decrease (cell/mm3) 
750–1,000 
500–749 
250–499 
<250 
Neutrophil decrease 
(cell/mm3) 
1,500–2,000 
1,000–1,499 
500–999 
<500 
Eosinophils 
(cell/mm3) 
650–1,500 
1,501–5,000 
>5,000 
Hypereosinophilic 
Platelets decrease 
(cell/mm3) 
125,000–
140,000 
100,000–124,000 
25,000–99,000 
<25,000 
Urine 
Protein  
Trace 
1+ 
2+ 
Hospitalization or 
dialysis  
Glucose  
Trace 
1+ 
2+ 
Hospitalization for 
hyperglycemia  
Blood (microscopic) 
(RBC/hpf)  
1–10 
11–50 
>50 and/or gross 
blood 
Hospitalization or 
PRBC transfusion  
ALT = alanine aminotransferase; AST = aspartate aminotransferase; HPF = high power field); PRBC = packed red blood cells; 
RBC = red blood cells; ULN = upper limit of normal range; WBC = white blood cell. 
a Laboratory normal reference ranges have not been taken into consideration for the toxicity grading scale. 
b The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory 
abnormalities as Potentially Life Threatening (Grade 4). For example, a low sodium value that falls within a Grade 3 parameter 
(125-129 mE/L) will be recorded as a Grade 4 hyponatremia event if the participant had a new seizure associated with the low 
sodium value. 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 137 of 139 
 
 
APPENDIX B.       ADVERSE EVENTS OF SPECIAL INTEREST 
Note: These listed AEs (Version 3, provided to Emergent by CBER on 24 October 2017), may 
indicate diseases with autoimmune etiology and will be immediately reported to Emergent. 
 
Table 14: 
List of Adverse Events of Special Interest* 
Gastrointestinal Disorders 
 
Celiac disease 
 
Crohn’s disease 
 
Ulcerative colitis 
 
Ulcerative proctitis 
Liver Disorders 
 
Autoimmune cholangitis 
 
Autoimmune hepatitis 
 
Primary biliary cirrhosis 
 
Primary sclerosing cholangitis 
Metabolic Diseases 
 
Addison’s disease 
 
Autoimmune thyroiditis (including Hashimoto thyroiditis) 
 
Diabetes mellitus type I 
 
Graves’ or Basedow’s disease 
Musculoskeletal Disorders 
 
Antisynthetase syndrome 
 
Dermatomyositis 
 
Juvenile chronic arthritis (including Still’s disease) 
 
Mixed connective tissue disorder 
 
Polymyalgia rheumatic 
 
Polymyositis 
 
Psoriatic arthropathy 
 
Relapsing polychondritis 
 
Rheumatoid arthritis 
 
Scleroderma, including diffuse systemic form and CREST syndrome 
 
Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter's Syndrome) and 
undifferentiated spondyloarthritis 
 
Systemic lupus erythematosus 
 
Systemic sclerosis 
Neuroinflammatory Disorders 
 
Acute disseminated encephalomyelitis, including site specific variants (eg, non-infectious encephalitis, 
encephalomyelitis, myelitis, radiculomyelitis) 
 
Cranial nerve disorders, including paralyses/paresis (eg, Bell’s palsy) 
 
Guillain-Barré syndrome, including Miller Fisher syndrome and other variants 
 
Immune-mediated peripheral neuropathies and plexopathies, including chronic inflammatory 
demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associated with 
monoclonal gammopathy 
 
Multiple sclerosis 
 
Narcolepsy 
 
Optic neuritis 
 
Transverse Myelitis 
 
Myasthenia gravis, including Eaton-Lambert syndrome 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 138 of 139 
 
 
Skin Disorders 
 
Alopecia areata  
 
Autoimmune bullous skin diseases, including pemphigus, pemphigoid and dermatitis herpetiformis  
 
Cutaneous lupus erythematosus  
 
Erythema nodosum  
 
Erythema multiforme 
 
Morphoea  
 
Lichen planus  
 
Psoriasis  
 
Rosacea 
 
Sweet’s syndrome  
 
Vitiligo 
Vasculitides 
 
Large vessels vasculitis including: giant cell arteritis such as Takayasu's arteritis and temporal arteritis 
 
Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, Kawasaki's disease, 
microscopic polyangiitis, Wegener's granulomatosis, Churg–Strauss syndrome (allergic granulomatous 
angiitis), Buerger’s disease thromboangiitis obliterans, necrotizing vasculitis and anti-neutrophil 
cytoplasmic antibody (ANCA) positive vasculitis (type unspecified), Henoch- Schonlein purpura, 
Behcet's syndrome, leukocytoclastic vasculitis 
Others 
 
Antiphospholipid syndrome 
 
Autoimmune hemolytic anemia 
 
Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapidly progressive, 
membranous glomerulonephritis, membranoproliferative glomerulonephritis, and mesangioproliferative 
glomerulonephritis) 
 
Autoimmune myocarditis/cardiomyopathy 
 
Autoimmune thrombocytopenia 
 
Goodpasture syndrome 
 
Idiopathic pulmonary fibrosis 
 
Pernicious anemia 
 
Raynaud’s phenomenon 
 
Sarcoidosis 
 
Sjögren’s syndrome 
 
Stevens-Johnson syndrome 
 
Uveitis 
*Emergent added erythema multiforme. 
 
 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


AV7909 Anthrax Vaccine 
IND 014451 
Protocol EBS.AVA.210, Version 3.0 (28 October 2019)  
 
 
Confidential & Proprietary  
Page 139 of 139 
 
 
APPENDIX C. 
SPONSOR’S GUIDANCE ON CHRONIC CONDITIONS 
FOR INVESTIGATORS  
The Sponsor’s guidance on the interpretation of stability or seriousness of chronic conditions for 
study eligibility purposes is outlined below. 
A chronic illness is NOT exclusionary IF the following three conditions are met:  
 The condition is not serious (no history of ER visit, hospitalization, or other urgent 
medical intervention for the condition)  
 The condition is stable (no clinical or medication changes in the last six months)  
 The condition does not require treatment with any prohibited medication (protocol 
Section 6.5, Table 3) or medication that would appear on the urine drug screen.  
This guidance would apply to conditions such as: 
 Insomnia 
 Migraine 
 Seasonal allergy 
 Asthma 
 Gastroesophageal reflux disease (GERD) 
 Anxiety 
 Attention-deficit/hyperactivity disorder (ADHD) 
 Depression 
 Scoliosis 
 Fibromyalgia 
 Osteoarthritis (NOT rheumatoid arthritis or reactive arthritis, which are AESIs as per 
Appendix B of the protocol) 
Specifically, for Type 2 diabetes mellitus (DM) and hypercholesterolemia:  
 The condition is not serious (no history of ER visit, hospitalization, or other urgent 
medical intervention for the condition) 
 The condition is stable (no clinical or medication changes in the last six months) AND is 
within relevant treatment guidelines 
o For Type 2 DM: Standards of Medical Care in Diabetes – 2019 
o For hypercholesterolemia: American College of Cardiology/American Heart 
Association (AHA/ACC) Guideline on the Management of Blood Cholesterol 
– 2018 
 The condition, if treated, requires only a single agent that is not a prohibited medication 
(Section 6.5, Table 3) or medication that would appear on the urine drug screen.  
Please note that Exclusion criterion #22 states that a serious chronic illness is exclusionary (not 
just cancer/malignancies). 
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019


Document Approvals
Approved Date: 10/28/2019
Approval Task
Verdict:  Approve
28-Oct-2019 13:52:34 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 14:11:57 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 14:42:07 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 15:23:09 GMT+0000
Approval Task
Verdict:  Approve
28-Oct-2019 16:48:16 GMT+0000
Number: CLIN040043  Version: 3.0                    Effective Date: 28 Oct 2019

SAP_001.pdf: 
 
 
 
 
 
AV7909 
 
A Phase 2 Drug-Vaccine Interaction Study to Examine Whether Co- 
administering AV7909 with Ciprofloxacin or Doxycycline Affects 
Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy 
Adults 
 
Clinical Protocol EBS.AVA.210 
 
 
 
  
Protocol Version
 Date 
3.0
 28-October-2019 
  
  
SAP Version
 Date 
1.0
 01-June-2020 
 
 
 
 
 
 
 


 
 
Confidential and Proprietary 
Page 2 of 43
Version 1.0, 01 June 2020 
 
 
Study Statistician 
 
 
 
Wanrong Yin, MS 
Principal Statistician  
Emergent Product Development Gaithersburg Inc. 
 
 
 
Date (DD MMM YYYY) 
 
Reviewed and Approved by Emergent: 
 
 
Statistical Reviewer 
 
 
 
Na (Michael) Li, PhD 
Director, Biostatistics and Data Management 
Emergent Product Development Gaithersburg Inc. 
 
 
Date (DD MMM YYYY) 
 
Sponsor Representatives  
 
 
 
Paul-André de Lame, MD  
VP, Clinical Development  
Emergent Product Development Gaithersburg Inc. 
 
 
Date (DD MMM YYYY) 
 
Clinical Project Manager 
 
 
 
Daphne Papanicolaou 
Senior Clinical Project Manager  
Emergent Product Development Gaithersburg Inc. 
 
 
 
         
Date (DD MMM YYYY) 


 
 
Confidential and Proprietary 
Page 3 of 43
Version 1.0, 01 June 2020 
 
Reviewed by 
: 
 
Statistical Team Lead 
 
 
 
Asmita Modak, MS 
Sr. Biostatistician 
IQVIA  
 
 
 
Date (DD MMM YYYY) 
PK Scientist 
 
 
Kathleen Koeck, PhD 
Research Pharmacokinetics Director 
IQVIA 
 
Date (DD MMM YYYY) 
 
PK Biostatistician 
 
 
 
 
 
Ashutosh Ranjan 
Biostatistician 2 
IQVIA 
 
Date (DD MMM YYYY) 
 
 


 
 
Confidential and Proprietary 
Page 4 of 43
Version 1.0, 01 June 2020 
 
1 
INTRODUCTION ........................................................................................................ 11 
2 
PROTOCOL SUMMARY ........................................................................................... 11 
2.1. 
Study Objectives .................................................................................................. 11 
2.1.1 
Primary Objective ............................................................................................... 11 
2.1.2 
Secondary Objectives ......................................................................................... 11 
2.2 
Study Design and Conduct ................................................................................. 11 
2.2.1 
Overall Study Design ......................................................................................... 11 
2.2.2 
PK Sampling ....................................................................................................... 15 
2.2.3 
Immunogenicity Assessment .............................................................................. 15 
2.2.4 
Safety Assessments ............................................................................................ 15 
2.3 
Study Endpoints and Statistical Hypotheses..................................................... 17 
2.3.1 
Primary Endpoints .............................................................................................. 17 
2.3.2 
Secondary Endpoints .......................................................................................... 18 
2.4 
Sample Size and Power Considerations ............................................................ 19 
2.5 
Randomization and Blinding .............................................................................. 19 
2.5.1 
Randomization .................................................................................................... 19 
2.5.2 
Blinding .............................................................................................................. 20 
3 
DATA CONSIDERATIONS ....................................................................................... 20 
3.1 
Protocol Deviations .............................................................................................. 20 
3.2 
Analysis Populations ........................................................................................... 20 
3.3 
Multicenter Study ................................................................................................ 21 
3.4 
Analysis Time Points ........................................................................................... 21 
3.5 
Definition of Baseline .......................................................................................... 22 
3.6 
Selection of Data in the Event of Multiple Records in an Analysis Window . 22 
3.7 
Coding Dictionaries ............................................................................................. 22 
3.8 
Toxicity and Severity Grading Scales ................................................................ 23 
4 
STATISTICAL ANALYSIS ........................................................................................ 23 
4.1 
General Considerations ...................................................................................... 23 
4.2 
Precision ............................................................................................................... 23 
4.3 
Derived Variables ................................................................................................ 24 
4.4 
Handling of Missing Data ................................................................................... 24 
4.5 
Diary Data Issue Handling ................................................................................. 25 
4.5.1 
Oral Temperature Data Errors ............................................................................ 25 
4.5.2 
Antibiotic Dosing Data Errors ............................................................................ 25 
4.6 
Adjustment for Covariates ................................................................................. 25 
4.7 
Subgroup Analysis ............................................................................................... 25 
4.8 
Multiplicity Adjustment ...................................................................................... 25 
5 
STUDY POPULATION CHARACTERISTICS ....................................................... 26 
5.1 
Subject Disposition .............................................................................................. 26 
5.2 
Protocol Deviations .............................................................................................. 26 


 
 
Confidential and Proprietary 
Page 5 of 43
Version 1.0, 01 June 2020 
 
5.3 
Demographics and Baseline Characteristics ..................................................... 27 
5.3.1 
Demographics ..................................................................................................... 27 
5.3.2 
Medical History .................................................................................................. 27 
5.4 
Treatment Compliance and Exposure to Study Drugs .................................... 27 
5.4.1 
Compliance of Ciprofloxacin and Doxycycline ................................................. 27 
5.4.2 
AV7909 Compliance and Exposure ................................................................... 28 
6 
PK ASSESSSMENT ..................................................................................................... 28 
6.1 
Serum Concentration Data ................................................................................. 28 
6.2 
Exclusion of Outliers ........................................................................................... 28 
6.3 
Non-Quantifiable and Missing Concentrations ................................................ 29 
6.4 
PK Parameters ..................................................................................................... 29 
6.5 
PK Analyses ......................................................................................................... 30 
6.5.1 
Equivalence Testing for Primary PK Endpoints ................................................ 31 
6.5.2 
Equivalence Testing for Secondary PK Endpoints ............................................ 31 
6.5.3 
Time to Steady State Assessment Using Trough Concentrations ...................... 32 
7 
IMMUNOGENICITY ANALYSIS............................................................................. 32 
7.1 
Summary of Immunogenicity Data .................................................................... 32 
7.2 
Secondary Immunogenicity Endpoints ............................................................. 33 
7.2.1 
Exploratory Analysis for Immunogenicity ......................................................... 33 
8 
SAFETY ANALYSIS ................................................................................................... 33 
8.1 
Adverse Events .................................................................................................... 33 
8.1.1 
Overall Summary of TEAEs .............................................................................. 34 
8.1.2 
All TEAEs .......................................................................................................... 34 
8.1.3 
Drug/Vaccine Related TEAEs ............................................................................ 35 
8.1.4 
Serious TEAEs ................................................................................................... 35 
8.1.5 
Adverse Events of Special Interest (AESI) ........................................................ 35 
8.1.6 
TEAEs Leading to Discontinuation of Study Treatment, and Study 
Withdrawal ......................................................................................................... 35 
8.1.7 
Deaths ................................................................................................................. 35 
8.2 
Clinical Laboratory Tests ................................................................................... 35 
8.3 
Vital Signs ............................................................................................................ 36 
8.4 
Physical Examinations ........................................................................................ 36 
8.5 
Prior and Concomitant Medications ................................................................. 36 
8.6 
Other Safety Analyses ......................................................................................... 37 
8.6.1 
E-diary Reactogenicity ....................................................................................... 37 
8.6.2 
In-clinical Reactogenicity ................................................................................... 37 
8.6.3 
E-diary Compliance ............................................................................................ 37 
8.6.4 
Auto-antibody Testing ........................................................................................ 38 
8.6.5 
Pregnancy ........................................................................................................... 38 
8.6.6 
Urine Drug Screening and Viral Serology Testing ............................................ 38 
9 
INTERIM ANALYSES ................................................................................................ 38 
10 
FINAL ANALYSIS PLAN .......................................................................................... 38 


 
 
Confidential and Proprietary 
Page 6 of 43
Version 1.0, 01 June 2020 
 
11 
REFERENCES ............................................................................................................. 38 
12 
APPENDICES .............................................................................................................. 40 
 
APPENDIX I 
TABLE/LISTING/FIGURE TEMPLATE GUIDANCE ....................... 40 
 
 


 
 
Confidential and Proprietary 
Page 7 of 43
Version 1.0, 01 June 2020 
 
Table 1 
Study Groups ...................................................................................................... 12 
Table 2 
Analysis Windows for Vaccination, Immunogenicity (TNA) Testing, Clinical 
Laboratory Data, Vital Signs, and Physical Examinations ................................ 22 
Table 3 
Ciprofloxacin and Doxycycline PK Parameters ................................................. 30 
 
Figure 1 
Study Design for EBS.AVA.210 ........................................................................ 13 
Figure 2 
Event Schematic for EBS.AVA.210 Groups 1 to 3 ........................................... 14 
 
 
 
 


 
 
Confidential and Proprietary 
Page 8 of 43
Version 1.0, 01 June 2020 
 
AE 
Adverse Event 
AESI 
Adverse event of special interest 
ANA 
Antinuclear antibody 
ATC 
Anatomical therapeutic chemical 
AUC0-12h 
Area under the serum concentration-time curve (12 hours) 
AUC0-inf 
Area under the serum concentration-time curve extrapolated to infinity 
AUC0-t 
Area under the concentration-time curve from time 0 to last measurable concentration 
AUMC 
Area under the first moment curve 
AVA 
Anthrax vaccine adsorbed, BioThrax  
BMI 
Body mass index 
CBER 
Center for Biologics Evaluation and Research  
CI 
Confidence interval  
cm 
Centimeter 
Cmax 
Maximum observed serum concentration 
CRO 
Contract research organization  
CSR 
Clinical study report  
Ct 
Last measurable concentration  
CV 
Coefficient of variation 
d 
Day(s) 
dsDNA 
Double-stranded deoxyribonucleic acid 
DSMB 
Data Safety Monitoring Board 
 
 
ECG 
Electrocardiogram 
eCRF  
Electronic case report form  
EDC 
Electronic data capture  
e-diary 
Electronic diary 
ED50 
50% effective dilution 
EWV 
Early withdrawal visit  
FDA 
Food and Drug Administration  
FSH 
Follicle-stimulating hormone 


 
 
Confidential and Proprietary 
Page 9 of 43
Version 1.0, 01 June 2020 
 
GCP 
Good Clinical Practice  
GMT 
Geometric mean titer  
HBV 
Hepatitis B virus 
HCV 
Hepatitis C virus 
HIV 
Human immunodeficiency virus 
hr 
Hour 
ICF 
Informed consent form  
ICH 
International Conference on Harmonisation  
ID 
Identification, as in subject identification (number) 
IM 
Intramuscular  
IP 
Investigational product 
IRB 
Institutional Review Board  
ITT 
Intent-to-treat  
Kel 
Apparent elimination rate constant 
kg 
Kilogram 
LLOQ 
Lower limit of quantification  
LOD  
Limit of detection 
MedDRA 
Medical Dictionary for Regulatory Activities  
min 
Minute 
MRT 
Mean residence time 
NF50 
50% neutralization factor  
NOSTASOT 
No Statistical Significance Of Trend 
PE 
Physical examination  
PI 
Principal Investigator 
PK 
Pharmacokinetic(s) 
po 
Per os (orally) 
q 12 hr 
Every 12 hours 
RF 
Rheumatoid factor  
SAE 
Serious adverse event  
SAP 
Statistical analysis plan  
SC 
Subcutaneous 


 
 
Confidential and Proprietary 
Page 10 of 43
Version 1.0, 01 June 2020 
 
SD 
Standard deviation  
SOC 
 
System organ class 
t1/2 
Half-life 
TEAE 
Treatment emergent adverse event 
TLF 
Tables, listings, and figures 
tmax 
Time to maximum observed serum concentration 
TNA 
Toxin neutralizing antibody  
TOST 
Two one-sided t-tests  
TSH 
Thyroid stimulating hormone 
UPT 
Urine pregnancy test 
US 
United States 
WHO 
World Health Organization  


 
 
Confidential and Proprietary 
Page 11 of 43
Version 1.0, 01 June 2020 
 
1 
INTRODUCTION 
This Statistical Analysis Plan (SAP) is based on Protocol EBS.AVA.210 A Phase 2 Drug-
Vaccine Interaction Study to Examine Whether Co-administering AV7909 with Ciprofloxacin 
or Doxycycline Affects Antibiotic Pharmacokinetics or AV7909 Immunogenicity in Healthy 
Adults
Version 3.0, 28 October 2019). This document specifies details of the definitions of 
the derived variables, analysis methods, assumptions and data handling conventions for the 
analyses of pharmacokinetics, immunogenicity and safety to be included in the clinical study 
report (CSR). 
2 
PROTOCOL SUMMARY 
2.1. 
Study Objectives  
2.1.1 Primary Objective 
To evaluate the pharmacokinetic (PK) profiles of ciprofloxacin or doxycycline when 
administered orally, prior to, and following, the intramuscular (IM) administration of a two-
dose schedule of AV7909 administered two weeks apart. 
2.1.2 Secondary Objectives 
To assess the safety of concurrent administration of oral ciprofloxacin or doxycycline 
and two doses of AV7909 administered IM.  
To evaluate the Day 37 immune response using the toxin neutralizing antibody (TNA) 
assay following two IM doses of AV7909 with and without the concurrent oral 
administration of ciprofloxacin or doxycycline. 
2.2 
Study Design and Conduct 
2.2.1 Overall Study Design 
This is a randomized, open-label, phase 2, multicenter trial to investigate the potential 
interactions of AV7909 and ciprofloxacin or doxycycline when administered concomitantly.   
Healthy males and females 18 to 45 years of age, inclusive, will read, sign and date an informed 
consent form (ICF) and then be screened (2 to 28 days prior to randomization) for eligibility to 
participate in the study. Participants (N=210) meeting the entry criteria will be evenly 
randomized 1:1:1 to one of the three investigational product (IP) groups shown in Table 1. 
Approximately the first 40 participants who are randomized for either IP Groups 1 and 2 will be 
assigned to Treatment Groups 1A or 2A while the remaining 30 participants randomized into IP 
Groups 1 and 2 thereafter will be assigned to Treatment Groups 1B or 2B.  
Randomization will be stratified by site. A representative racial distribution will be sought 
among participants and sites will be asked to recruit populations that are gender- and age-
balanced (i.e., between 40-60% male with 40-60% of participants in the two age ranges of 18 to 
30 years of age and 31 to 45 years of age). 


 
 
Confidential and Proprietary 
Page 12 of 43
Version 1.0, 01 June 2020 
 
Table 1 
Study Groups 
IP Group 
Treatment 
Group 
Treatment 
Sample Size 
(N) 
1 Cipro 
1A 
AV7909 + ciprofloxacin (with PK assessment) 
40 
70 
1B 
AV7909 + ciprofloxacin (without PK assessment) 
30 
2 Doxy 
2A 
AV7909 + doxycycline (with PK assessment) 
40 
70 
2B 
AV7909 + doxycycline (without PK assessment) 
30 
3 AV7909 
3 
AV7909 only 
70 
 
 
TOTAL 
210 
 
Figure 1 shows the design for this study.  
Ciprofloxacin (500 mg by mouth [per os] every 12 hours [q 12 hr]) will be administered to 
Group 1 on Days 4-9, Days 22-24 and Days 31-37, and doxycycline (100 mg by mouth [per os] 
every 12 hours [po q 12 hr]) will be administered to Group 2 on Days 2-9, Days 22-24, and 
Days 32-38. 
All participants, including the 70 participants in Group 3, will receive AV7909 (0.5 mL) IM in 
the deltoid muscle on Days 8 and 23.  For Groups 1A and 2A, the first vaccination will occur 
following completion of the PK sessions and after administration of the evening antibiotic 
(ciprofloxacin or doxycycline) dose.  
An event schematic for this study is provided in Figure 2. 
 
 


 
 
Confidential and Proprietary 
Page 13 of 43
Version 1.0, 01 June 2020 
 
Figure 1 
Study Design for EBS.AVA.210 
 
 
 


 
 
Confidential and Proprietary 
Page 14 of 43
Version 1.0, 01 June 2020 
 
Figure 2 
Event Schematic for EBS.AVA.210 Groups 1 to 3 
 


 
 
Confidential and Proprietary 
Page 15 of 43
Version 1.0, 01 June 2020 
 
2.2.2 PK Sampling  
Serial PK assessments will be conducted on the following days: 
Group 1A (ciprofloxacin): Days 4, 8, 31, and 35; 
Group 2A (doxycycline): Days 2, 8, 32, and 38.  
On these serial PK assessment days, blood samples for measurement of drug concentrations 
will be collected at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post dose (± 5 
min through hr 4 then ± 15 min).  
In addition, antibiotic pre-dose or trough values will be measured prior to the 
morning doses on the following days: 
Group 1A (ciprofloxacin): Days 4, 5, 6, 7, and 8, and on Days 31, 32, 33, 34, and 35; 
Group 2A (doxycycline): Days 2, 3, 4, 5, 6, 7, and 8, and on Days 32, 33, 34, 35, 36, 37, 
and 38. 
2.2.3 Immunogenicity Assessment  
For all participants, blood draws for TNA assessments will be done at randomization (Day 1) 
and on Day 37 (± 1 day) (2 weeks following the final dose of a two-dose vaccination series). All 
immunogenicity laboratory samples will be evaluated using a validated TNA assay by Battelle 
Memorial Institute (Columbus, Ohio). Specific procedures related to collection, processing 
storage, and shipment of the samples will be provided in study-specific Laboratory Manual. 
2.2.4 Safety Assessments  
2.2.4.1 
Adverse Events 
AEs (including SAEs and potential AESIs) will be recorded on the AE eCRF if they occurred 
from the time of the first administration of any study treatment (Day 2 for Group 2, Day 4 for 
Groups 1 or Day 8 for Group 3) through Day 51 or EWV. From the signing of the ICF until 
immediately before the administration of their first study treatment, only AEs resulting from a 
study-related procedure will be recorded on the AE eCRF. After Day 51 and through the 12-
month safety follow-up, AEs, SAEs and AEs assessed by the DSMB to be of autoimmune 
etiology, i.e., AESIs, will be recorded on the AE eCRF. 
Safety follow-up phone contacts to collect information on AEs, SAEs and AESIs will occur at 3 
months (Day 114 ± 14 days), 6 months (Day 205 ± 14 days), 9 months (Day 296 ± 14 days), 
and 12 months (Day 388 ± 14 days) after the last scheduled vaccination. 
Refer to Protocol EBS.AVA.210, Section 9.2 for reporting adverse events. 
2.2.4.2 
Clinical Laboratory Tests 
All analytes to be tested during screening/safety/autoimmunity clinical laboratory tests are 
specified in Protocol EBS.AVA.210, Table 10.  
The following assessments will be performed at Screening only: 


 
 
Confidential and Proprietary 
Page 16 of 43
Version 1.0, 01 June 2020 
 
Urine drug screen 
Serologic testing (HIV-1/HIV-2 antibodies, HBV surface antigen, and HCV antibody).  
Follicle-stimulating hormone (FSH) test in postmenopausal women. 
Pregnancy testing will be performed at Screening, immediately following group assignment, 
before each vaccination, and at the Day 51 Final Study Visit or the EWV.  
Blood and urine samples for safety clinical laboratory testing (hematology, serum chemistry, 
urinalysis) will be collected at Screening and Day 51 as well as at the EWV if the EWV occurs 
before Day 51.  
Blood samples for TSH & autoantibody assessment of ANA, RF and anti-dsDNA will be taken 
at Day 1 after randomization, Day 51 or EWV or an unscheduled visit if the participant has 
received at least one dose of vaccine, and at the time of safety follow-up phone contact(s) if 
warranted from participant report(s) of a potential AESI. These samples will be shipped to the 
central laboratory and will be banked; testing for TSH and ANA, RF and anti-dsDNA 
 
All samples for testing will be sent to the central laboratory for analysis, except urine for 
pregnancy testing, which will be performed at the site and results documented in the eCRF.  
Refer to Protocol EBS.AVA.210, Section 8.3.2 for details on clinical laboratory tests. 
2.2.4.3 
Physical Examination (PE)  
Complete PEs will be performed at Screening, the Final Study Visit (Day 51) and EWV, if 
applicable.  
Symptom-directed PEs will be performed at all visits except the Screening and Final Study Visit 
and early withdrawal (including any unscheduled visits), only if required (ie, in response to the 
report/collection of AEs/SAEs/potential AESIs.) 
Refer to Protocol EBS.AVA.210, Section 8.3.3 for details on physical exams. 
2.2.4.4 
Vital Signs 
Vital signs including seated/semi-recumbent systolic and diastolic blood pressure, heart rate, 
respiration rate, and temperature will be obtained at Screening and each subsequent clinic visit 
through Day 51/EWV(except at AM and PM clinic visits for groups 1A and 2A, and at Day 37 
for all groups), including unscheduled visits. Height and weight will only be recorded at 
Screening. On vaccination days (Days 8 and 23), vital signs will be assessed prior to 
vaccination and at 30 ± 5 minutes post-vaccination. 
Refer to Protocol EBS.AVA.210, Section 8.3.4 for details on vital signs. 
2.2.4.5 
E-diary 
Participants will be asked to fill out an electronic diary (e-diary) daily for postvaccination 
reactogenicity events (all groups) and an e-diary for antibiotic compliance (Groups 1 and 2). 
There are separate e-diary requirements for this study depending on the treatment group: 


 
 
Confidential and Proprietary 
Page 17 of 43
Version 1.0, 01 June 2020 
 
Participants in all three groups will be required to fill out e-diary to capture 
reactogenicity events after each vaccination.  
Participants in Group 1 and Group 2 will be required to also fill out a separate e-
diary to capture antibiotic compliance.  
The e-diary to capture reactogenicity events post vaccination will collect the following 
information: 
 
local injection site and systemic reactogenicity responses  
whether they have use of any medications (e.g., acetaminophen, aspirin, ibuprofen)  
Refer to Protocol EBS.AVA.210, Section 8.3.5.1 for details on the e-diary and severity grading 
of reactogenicity responses. 
2.2.4.6 
Concomitant Medications 
Prior and concomitant medication information (medications used 30 days prior to Screening or 
medications used since the last study visit) will be recorded at screening, randomization and at 
each study visit in the eCRF. Participants will also record concomitant medications taken in 
their e-diaries and site staff will review this information on a routine basis and with the 
participant at each study visit, transferring information to the concomitant medications eCRF 
page as appropriate intervals. 
For the purposes of this trial, concomitant medications include prescription drugs and biologics, 
over-the-counter drugs as well as herbal and nutritional supplements. 
2.3 
Study Endpoints and Statistical Hypotheses  
2.3.1 Primary Endpoints 
The two primary endpoints in this study, whether co-administration of AV7909 with antibiotics 
affects antibiotic PK profiles for ciprofloxacin or doxycycline, are evaluated separately with 
independent study subjects (Group 1A for ciprofloxacin, Group 2A for doxycycline). 
For each of the primary endpoints, the equivalence tests on PK parameters (AUC0-12h and Cmax) 
at steady state pre- and post-vaccination will be performed.  
Specifically, for each antibiotic, the null hypotheses are: 
AUC0-12h: The geometric mean of the within-participant ratios of post-vaccination (Day 
35 for ciprofloxacin and Day 38 for doxycycline) over the pre-vaccination (Day 8)     
AUC0-12h is greater than 1.25 or less than 0.80. 
Cmax: The geometric mean of the within-participant ratios of post-vaccination (Day 35 
for ciprofloxacin and Day 38 for doxycycline) over the pre-vaccination (Day 8) Cmax is 
greater than 1.25 or less than 0.80.  
The null hypothesis will be rejected when the 90% CIs of the geometric mean of the within-
participant ratios is contained entirely within the equivalence bounds of [0.80, 1.25]. For each 


 
 
Confidential and Proprietary 
Page 18 of 43
Version 1.0, 01 June 2020 
 
antibiotic, to conclude that administration of two-dose regimen of AV7909 does not affect the 
steady-state PK profile, the null hypotheses should be rejected for both PK parameters AUC0-12h
and Cmax. 
2.3.2 Secondary Endpoints 
2.3.2.1 
Secondary Safety Endpoints 
Incidences of AEs from the first dose of any IP through the Final Study Visit (Day 
51) 
Incidences of serious AEs (SAEs) from the first dose of any IP until the 12-month 
follow-up (Day 388) 
Incidences of solicited systemic and injection site reactions reported in participant e-
diaries following each vaccination 
Incidences of AESIs from the first dose of any IP until the 12-month follow-up (Day 
388) 
Incidences of clinical laboratory abnormalities 
No hypothesis testing is planned for any of the safety endpoints. 
2.3.2.2 
Secondary Pharmacokinetic Endpoints 
For each antibiotic, to determine if the single-dose PK parameters are affected by AV7909 
vaccination, the equivalence tests will be performed in the similar manner as those performed 
for the primary PK analyses. 
Specifically, for each antibiotic, the null hypotheses are: 
AUC0-12h: Geometric mean of within-participant ratios of post-vaccination (Day 31 for 
ciprofloxacin and Day 32 for doxycycline) over the pre-vaccination (Day 4 for 
ciprofloxacin and Day 2 for doxycycline) AUC0-12h is greater than 1.25 or less than 0.80. 
Cmax: Geometric mean of within-participant ratios of post-vaccination (Day 31 for 
ciprofloxacin and Day 32 for doxycycline) over the pre-vaccination (Day 4 for 
ciprofloxacin and Day 2 for doxycycline) Cmax is greater than 1.25 or less than 0.80.  
No hypothesis testing is planned for the secondary PK endpoints, which will be evaluated and 
reported for information only. 
2.3.2.3 
Secondary Immunogenicity Endpoints 
For each antibiotic, to evaluate whether the co-administration of the antibiotic affects the 
immune response after two IM doses of AV7909, a non-inferiority test will be conducted. 
Specifically, the null hypotheses are: 
For ciprofloxacin: the geometric mean ratio of TNA NF50 values at Day 37 for Group 1 
over Group 3 is less than or equal to 0.5 


 
 
Confidential and Proprietary 
Page 19 of 43
Version 1.0, 01 June 2020 
 
For doxycycline: the geometric mean ratio of TNA NF50 values at Day 37 for Group 2 
over Group 3 is less than or equal to 0.5 
The null hypothesis is rejected when the lower bound of the two-sided 95% CI of the geometric 
mean ratio of TNA NF50 values is greater than 0.5.  
For each antibiotic, the formal hypothesis testing for the secondary immunogenicity endpoints 
will only be carried out after the primary PK endpoint has been met for the corresponding 
antibiotic. If the primary PK endpoint for an antibiotic is not met, the corresponding secondary 
immunogenicity endpoints will be provided for information only.  
2.4 
Sample Size and Power Considerations 
The sample size for this study was selected based on both the primary and secondary endpoints. 
Assessment as to whether vaccination with AV7909 affects the PK of either ciprofloxacin or 
doxycycline will be made based on the geometric mean of the within-participant ratios (post-
vaccination over pre-vaccination) of AUC0-12h and Cmax. The equivalence margin for the 
geometric mean ratio is [0.80, 1.25], which will be compared with the 90% confidence interval 
(CI) for the geometric mean of with-participant ratios of AUC0-12h and Cmax. Assuming the 
coefficient of variation (CV) is 30% for the geometric mean ratio and the true geometric mean 
ratio is 0.95, 27 participants allow for 90% power to reject the null hypothesis at a significance 
level of 5%. A group size of 40 participants for Group 1A (AV7909 + ciprofloxacin with PK) or 
Group 2A (AV7909 + doxycycline with PK) is planned to allow for up to 30% of participants 
being excluded from the PK Population. 
A sample size of 53 in each of the IP groups (Group 1 = AV7909 + ciprofloxacin, Group 2 = 
AV7909 + doxycycline, and Group 3 = AV7909 only) provides 90% power at 2.5% one-sided 
significance level for the non-inferiority test, defined as the lower bound of the two-sided 95% 
CI of the geometric mean ratio of the AV7909 + antibiotic over AV7909 only (Group 1 vs. 
Group 3, Group 2 vs. Group 3) greater than 0.5. This assumes that the true ratio of the 
geometric means between two groups is 0.85 and the CV of TNA NF50 values in each group is 
100%. A total of 70 per IP group is planned to allow for up to 25% of drop-out rate. 
2.5 
Randomization and Blinding 
2.5.1 Randomization 
At the Randomization visit (Day 1), after the PI has confirmed that the participant meets all the 
inclusion criteria and none of the exclusion criteria, a central randomization process will be used 
to assign each participant to one of the three open-label IP groups with the ratio of 1:1:1 (block 
size of 3). Approximately the first 40 participants who are randomized into IP Groups 1 and 2 
will be assigned to Treatment Groups 1A or 2A while the remaining 30 participants randomized 
into IP Groups 1 and 2 thereafter will be assigned to Treatment Groups 1B or 2B.  
Randomization will be stratified by site. The sites will be asked to the extent possible to execute 
a recruitment process that achieves a representative racial/ethnic distribution in populations that 
are reasonably gender- and age-balanced (i.e., at least 40% male with 40% of participants in the 
two age ranges of 18 to 30 years of age and 31 to 45 years of age).  


 
 
Confidential and Proprietary 
Page 20 of 43
Version 1.0, 01 June 2020 
 
A randomization plan will be prepared and finalized prior to randomization of the first 
participant. The specific instructions for randomizing participants will be provided in the 
Pharmacy Manual. 
A screen failure is a participant from whom informed consent is obtained and documented in 
writing, but who is not subsequently randomized to study treatment. Reasons for screen failure 
are to be recorded on the electronic case report forms (eCRFs). 
Participants who are screen failures are permitted to be rescreened one time (only) according to 
 If a participant is rescreened, a new subject ID will be assigned. To link 
eCRF along with the new subject ID. Participants who complete the rescreening and are 
randomized in the study will not be considered as screen failures. 
2.5.2 Blinding 
Not applicable; this is an open-label study. 
3 
DATA CONSIDERATIONS 
3.1 
Protocol Deviations 
stipulated requirements, whether inadvertently or planned. All identified protocol deviations 
will be documented (
), 
classified, and reviewed on an ongoing basis through out the study according to procedures 
outlined in the Protocol Deviations Management Plan (PDMP). The final protocol deviation 
data will be reviewed and locked prior to database lock and incorporated into Study Data 
Tabulation Model (SDTM). 
3.2 
Analysis Populations 
There will be four analysis populations for this study: 
The Intent-to-treat (ITT) Population will include all participants who are randomized. 
Participant disposition and baseline demographics will be summarized by IP group (Group 1, 2, 
and 3) and overall for the ITT population according to the group which the participant is 
randomized to. 
The Safety Population will include all randomized participants who receive at least one dose of 
either antibiotic or AV7909.  Participants will be included in the IP group (Group 1, 2, and 3) 
according to the treatment they received. 
The PK Population will include all participants in Group 1A and Group 2A who: 
Received two doses of AV7909 according to the protocol (e.g., correct dose, no 
temperature excursion, and within the study-specified windows). 
If in Group 1A, received at least 5 of the 7 in-clinic ciprofloxacin doses between Day 
4 through the morning of Day 8 and between Day 31 through the morning of Day 


 
 
Confidential and Proprietary 
Page 21 of 43
Version 1.0, 01 June 2020 
 
35; or if in Group 2A, received at least 7 of the 9 in-clinic doxycycline doses 
between Day 2 through the morning of Day 8 and between Day 32 through the 
morning of Day 38. 
Have adequate data for calculation of the PK parameters (AUC0-12h and Cmax) at the 
Day 8 (both Group 1A and 2A) and Day 35 (Group 1A) or Day 38 (Group 2A) 
visits. 
Have no protocol deviations/events that would affect ciprofloxacin or doxycycline 
steady state PK assessment or immunogenicity results.  
Exclusion of participants from population will be done on a case-by-case basis at the time of the 
PK parameter analysis. 
The PK Population will be used for all PK analyses. Participants will be included in the 
treatment group (Group 1A or Group 2A) according to the antibiotic received. 
The Immunogenicity Population will include all randomized participants who: 
Received two doses of AV7909 according to the protocol (e.g., correct dose, no 
temperature excursion, and within the study-specified windows). 
Had a valid immunogenicity (TNA) result at Day 1 (pre-vaccination) with no 
evidence of previous exposure to anthrax or an anthrax vaccine (i.e., TNA below the 
limit of detection of 0.059). 
Had a valid immunogenicity (TNA) result at Day 37, within the study-specified 
window. 
Participants in Group 1 or Group 2 should have taken at least 50% of the protocol-
specified antibiotic doses. 
The Immunogenicity Population will be used for the immunogenicity analyses. Participants will 
be included in the IP group (Group 1, 2, and 3) according to the treatment they received.  
3.3 
Multicenter Study 
This study is expected to enroll 210 participants at approximately 4 sites in the United States. 
Subject randomization and protocol deviations will be summarized by site and treatment group. 
3.4 
Analysis Time Points 
Participant visits occur on protocol-specified days with associated visit windows. The schedule 
may shift by ± 1 day at the following visits: 
Day 23 visit of the second vaccination for all participants. 
Day 37 visit of TNA assessment for Group 1, 2B, and 3. There is no shifting 
flexibility for Group 2A at this visit as PK assessment schedule at Day 38. 
Day 51 of final study visit for all participants. 
If not otherwise specified, for the purposes of analysis, the analysis visits will be assigned as 
provided in Table 2 for vaccination, immunogenicity (TNA) testing, clinical laboratory data, 


 
 
Confidential and Proprietary 
Page 22 of 43
Version 1.0, 01 June 2020 
 
vital signs, and physical examinations. Data at unscheduled visits will not be presented in the 
by-visit summary analyses but will be included in the summary tables by maximum toxicity 
grade or abnormality when applicable, and in data listings. 
Table 2 
Analysis Windows for Vaccination, Immunogenicity (TNA) Testing, Clinical Laboratory 
Data, Vital Signs, and Physical Examinations 
3.5 
Definition of Baseline 
For all analyses, the baseline value is defined as the last non-missing value prior to the first dose 
of any study treatment. 
3.6 
Selection of Data in the Event of Multiple Records in an Analysis Window 
For clinical laboratory data, vital signs, and physical examinations, if multiple valid non-
missing observations exist in an analysis window for a specific visit, a single value will be 
chosen in the by-visit summary analyses based on the following rules: 
For baseline, the last available record prior to the date and time of the first vaccination 
will be selected.  
For post baseline visits,  
o
if the analysis values are numeric and the toxicity grades are available, the record 
with the highest toxicity grade will be selected; 
o
if the analysis values are numeric and the toxicity grades are identical or not 
available, the average (arithmetic mean) will be used; 
o
if the analysis values are categorical, the most conservative value will be selected 
(e.g., abnormal will be selected over normal). 
3.7 
Coding Dictionaries 
Medical history and AEs will be coded to system organ class and preferred terms using Medical 
Dictionary for Regulatory Activities (MedDRA) dictionary version 22.0.  
Medications will be coded according to the latest version of the World Health Organization
(WHO) WHODrug Global Dictionary version prior to the database lock. 
Analysis Visit 
Nominal Day 
Lower Limit of Study Day 
Upper Limit of Study Day 
Baseline 
NA 
-28 
Prior to the first exposure to 
any study treatment 
Day 1 
1 
1 
1 
Day 8 
8 
8 
8 
Day 23 
23 
22 
24 
Day 37 
37 
36 for Group 1, 2B, and 3, 
37 for Group 2A 
38 for Group 1, 2B, and 3, 37 
for Group 2A 
Day 51 
51 
50 
52 


 
 
Confidential and Proprietary 
Page 23 of 43
Version 1.0, 01 June 2020 
 
3.8 
Toxicity and Severity Grading Scales 
The toxicity grading scales (Grade 1 to 4) that will be used for safety assessment in this study 
are presented in Protocol EBS.AVA.210, Appendix A (Table 12 and Table 13), based on the 
FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventative Vaccine Clinical Trials (CBER, 2007). The severity of 
AEs, vital signs, and reactogenicity events will be assessed by the PI or the designee. Selected 
clinical laboratory results will be graded by the central laboratory for analytes appearing in 
Protocol EBS.AVA.210, Table 13 and reviewed by the PI or the designee. The toxicity grading 
scale has specific grading options for some clinical symptoms, such as nausea/vomiting, 
diarrhea, headache, fatigue, and myalgia. For symptoms not appearing on the grading scale, the 
Protocol EBS.AVA.210, Table 
12). For reactogenicity assessment, a Grade of 0 will be available in the e-diary to record 
.  
4 
STATISTICAL ANALYSIS 
4.1 
General Considerations 
Data summaries will be tabulated by appropriate grouping for each analysis population as 
specified in Section 3.2. Continuous variables will be summarized by descriptive statistics 
including number of non-missing observations (n), mean, standard deviation (SD), median, 
minimum and maximum. Categorical variables will be summarized by the frequency count (n) 
and the percentage of participants (%) in each category. Logarithm transformation will be used 
when appropriate. 
All clinical laboratory data and vital sign data will be reported using standard international 
units, if applicable. The immunogenicity response TNA NF50 is a unitless quantitative result as 
it is derived from ED50 divided by the reference standard of ED50. 
The reporting conventions in Appendix I will be applied to all tables, listings, and figures. All 
derivations, statistical analyses, summaries, and listings will be generated using SAS Version 
9.4 or higher (SAS Institute, Inc., Cary, North Carolina, United States). 
4.2 
Precision 
Safety variables (i.e., clinical laboratory values, vital signs) including derivations thereof will be 
reported to the same precision as the source data. The immunogenicity response TNA NF50 will 
be reported with one decimal place or two significant digits (e.g., 0.032, 18.0). 
All PK concentrations will be reported and analyzed with the same precision as the source data 
provided by the bio-analytical laboratory regardless of how many significant figures or decimals 
the data carry.  Derived PK parameters will be rounded for reporting purposes in by-subject 
listings.  The unrounded derived PK data will be considered the source data for the calculation 
of descriptive statistics and the statistical analysis.  For most derived PK parameters, 3 
significant digits will be used as the standard rounding procedure, with the following 
exceptions: 


 
 
Confidential and Proprietary 
Page 24 of 43
Version 1.0, 01 June 2020 
 
Parameters directly derived from source data (e.g., Cmax) will be reported and 
analyzed with the same precision as the source data.
Parameters derived from actual elapsed sample collection times (e.g., tmax) will be 
reported with the same precision as the actual elapsed sampling time value of the 
source data. Actual elapsed time from dosing will be rounded to 2 decimal places. 
Coefficient of variation will be reported to 1 decimal place. Ratios of means for 
pharmacokinetic parameters will be presented with two decimal places. 
4.3 
Derived Variables 
In all data listings, study day(s) relative to Study Day 1 (date of randomization) will be 
presented. The day prior to the date of randomization is Study Day -1. There is no Study Day 0. 
Study day relative to Study Day 1 will be calculated as:  
Study day = (assessment date  date of randomization) if the assessment is before the 
date of randomization. 
Study day = (assessment date  date of randomization + 1) if the assessment is on or 
after the date of randomization. 
If the study day is missing due to missing dates, it will remain as missing unless specified 
otherwise. 
4.4 
Handling of Missing Data  
Descriptive safety data summary will be based on observed cases. For imputation of completely 
and partially missing dates of AEs or prior and concomitant medications, if appropriate, the 
following conventions will be used: 
For the start date missing completely, impute the date of the first exposure to any study 
treatment. 
For the start date with missing day only, impute the 1st of the month unless month is 
same as month of the first exposure to any study treatment then impute the date of first 
exposure to any study treatment. 
For the start date with missing month and day, impute 1st January unless year is the same 
as the date of the first exposure to any study treatment then impute the date of first 
exposure to any study treatment. 
If the stop date is not missing and the start date is after the stop date after missing value 
calculation, the stop date will be used for the start date.  
For the stop date missing completely, impute date of last contact. 
For the stop date with missing day only, impute the last day of the month. If the month 
of the stop date is same as month of last contact then impute the date of last contact. 
For the stop date with missing month and day, impute 31st December or date of last 
contact, whichever is earlier. 


 
 
Confidential and Proprietary 
Page 25 of 43
Version 1.0, 01 June 2020 
 
An AE completely missing both start and stop dates, or with the start date missing and 
stop date later than the first dose date of study drug, will be considered to be 
treatment emergent. 
Missing start/stop dates will remain as missing in the participant data listings but will be 
imputed to permit proper tabulation of AE and concomitant medications data. 
Missing PK concentrations and missing PK sampling time will be handled as described in 
Section 6.3 and 6.4. 
Unless specified above, no other imputation will be made for missing data. 
4.5 
Diary Data Issue Handling  
4.5.1 Oral Temperature Data Errors   
Oral temperatures are reported by participants in the e-diary for post vaccination reactogenicity. 
The numeric temperature values and the associated toxicity grades with temperatures less than 
90 °F or greater than 110 °F will be set to null in the analysis. 
4.5.2 Antibiotic Dosing Data Errors 
Antibiotic self-administered at home will be reported by participants in the antibiotic e-diary. 
Issues related to entry of information into antibiotic e-diary will be manually reviewed by 
monitors and resolutions will be performed on a case-by-case basis.  
4.6 
Adjustment for Covariates 
An exploratory immunogenicity linear regression analysis will be conducted with adjustment 
for site, and covariates age and sex, as specified in Section 7.2.1.  
4.7 
Subgroup Analysis 
For immunogenicity analysis, TNA NF50 values will be summarized by treatment group and 
each of the following classification variables (categories are defined in the parentheses): 
Age (18 - 30, 31 - 45) 
Sex (Male, Female) 
No statistical testing will be performed for subgroup analyses.  
4.8 
Multiplicity Adjustment 
 
There is a single primary endpoint for each of the two antibiotics, which will be evaluated 
separately with independent study participants (Group 1 for ciprofloxacin, Group 2 for 
doxycycline). Demonstration of non
interference of steady state PK is defined separately and 
there is only one way to meet the primary endpoint for each antibiotic. Success is therefore 
defined per antibiotic only, not at the study level, and type I error is controlled for each 


 
 
Confidential and Proprietary 
Page 26 of 43
Version 1.0, 01 June 2020 
 
antibiotic. As such, multiplicity adjustment is not needed between the endpoints across the two 
antibiotics.
For the assessment of the steady state PK as the primary endpoint, there are two parameters, 
AUC0-12h and Cmax. To conclude that administration of two-dose regimen of AV7909 does not 
affect the steady state PK of each antibiotic, the null hypotheses should be rejected for both 
parameters of the corresponding antibiotic. For each parameter, the type I error rate is controlled 
at 5% and there is no need to adjust for multiple testing when the criteria for both parameters 
must be met. 
Of the secondary endpoints for each antibiotic, formal hypothesis testing will only be carried 
out for the immunogenicity endpoints and only after the primary PK endpoint has been met for 
the corresponding antibiotic. If the primary PK endpoint for an antibiotic is not met, the 
corresponding secondary immunogenicity endpoint will be provided for information only. Non-
inferiority of the secondary immunogenicity endpoint is evaluated with a one-sided alpha of 
0.025. This pre-specified hierarchical order of hypotheses testing preserves the type I error rate 
without the need for further adjustment.   
No other formal hypothesis testing will be carried out. The secondary PK endpoints (single dose 
antibiotic PK values) and all safety endpoints will be evaluated and reported for information 
only. Thus no multiplicity adjustment is needed. 
5 
STUDY POPULATION CHARACTERISTICS 
5.1 
Subject Disposition 
Subject disposition will be displayed in form of tabulation and listing for all participants who 
signed and dated the ICF. Tabulations will include the number of participants screened, 
randomized, treated with any study treatment, completed the study, discontinued study 
treatment, and study withdrawal. Reasons for discontinuation of treatment and study withdrawal 
will be summarized.  
The participant last study visit will be summarized by treatment group and overall for all 
randomized participants. The number and percentage of participants randomized by site will be 
provided by treatment group and overall based on the ITT population. Reasons for screen 
failure and reasons for exclusion from PK Population and Immunogenicity Population will be 
summarized.  
Listings of participants excluded from the PK Population and Immunogenicity Population with 
reasons will be provided. 
5.2 
Protocol Deviations 
Protocol deviations defined in Section 3.1 will be summarized by deviation category, severity, 
and treatment group for each site and overall based on the ITT Population. 
A listing of protocol deviations will be provided.  


 
 
Confidential and Proprietary 
Page 27 of 43
Version 1.0, 01 June 2020 
 
5.3 
Demographics and Baseline Characteristics 
5.3.1 Demographics 
The following demographics and baseline characteristics will be summarized as continuous 
variables using descriptive statistics (n, mean, SD, median, minimum, and maximum) by 
IP/treatment group and overall for all participants in the Safety, ITT, PK, and Immunogenicity 
populations:  
Age (years) 
Baseline weight (kg) 
Baseline height (cm)  
Baseline BMI 
The following demographics and baseline characteristics will be summarized as categorical 
variables with counts and percentages by IP/treatment group and overall for ITT, Safety, PK, 
and Immunogenicity populations: 
Age (18  30, 31  45 years) 
Sex (Female, Male) 
Race (American Indian or Alaska Native, Asian, Black or African American, Native 
Hawaiian or Other Pacific Islander, White, More than one Race, and Other) 
Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown) 
Subject demographics and baseline characteristics data listing will be provided. 
5.3.2 Medical History 
Medical history will be coded to system organ class (SOC) and preferred term (PT), according 
to the Medical Dictionary for Regulatory Activities (MedDRA).  A summary table and a listing 
of medical history will be provided. 
5.4 
Treatment Compliance and Exposure to Study Drugs 
5.4.1 Compliance of Ciprofloxacin and Doxycycline 
The compliance rate of ciprofloxacin and doxycycline will be computed for each participant 
who takes at least one dose of antibiotic as 100 times the total number of tablets taken 
(administered in-clinic and reported in the CRF by staff and self-administered by participants at 
home and reported to the e-diary) divided by the required total number of tablets that should 
have been taken as specified in Figure 2. The compliance will be summarized as follows by 
appropriate treatment group: 
Number of participants taking at least 50% of protocol specified doses 


 
 
Confidential and Proprietary 
Page 28 of 43
Version 1.0, 01 June 2020 
 
Number of participants in Group 1A taking at least 5 of 7 in-clinic ciprofloxacin doses 
or in Group 2A taking at least 7 of 9 in-clinic doxycycline doses prior to each PK 
assessment.  
The subject listing of antibiotic administration will be provided. 
5.4.2 AV7909 Compliance and Exposure 
AV7909 will be administered to all participants in all IP groups as a 0.5 mL IM vaccination in 
alternate arms on Days 8 and 23. Vaccinations will be administered in the clinic by authorized 
personnel in a controlled, clinical environment. 
AV7909 exposure will be tabulated as the number and percentage of participants receiving each 
vaccination by treatment group for all vaccinations administered and for per-protocol 
vaccinations which are administered without any administration issues, e.g., incorrect product 
administered, incorrect dose of IP, incorrect route, missing previous dose, and outside the 
acceptable visit windows on Days 8 and 23(± 1 day). Shift of the first vaccination at Day 8 in 
Group 3 may be acceptable with consideration of subject overall vaccination and assessment 
schedules. 
The subject listing of AV7909 vaccinations will be provided. 
6 
PK ASSESSSMENT 
6.1 
Serum Concentration Data 
Subjects with partial data will be evaluated on a case-by-case basis to determine if sufficient 
data are available for reliable estimation of PK parameters. 
A listing of PK blood sample collection times as well as derived sampling time deviations will 
be provided. 
6.2 
Exclusion of Outliers 
Individual serum concentrations may be excluded from the analysis because they are erroneous 
or abnormal at the discretion of the pharmacokineticist following a review of available 
documentation (e.g., bioanalytical report, validation report) and communication with the 
sponsor. Any such exclusion will be clearly listed in the study report along with justification for 
exclusion. 
Entire serum concentration-time profiles for a participant may be excluded following review of 
available documentation (e.g., bioanalytical report, validation report, and protocol deviation 
log) and communication with the sponsor. However, results of analysis with and without the 
excluded profiles may be presented in the study report. Any such exclusion will be clearly listed 
in the study report along with justification for exclusion. 
Any excluded data will be flagged in the individual data listings. 


 
 
Confidential and Proprietary 
Page 29 of 43
Version 1.0, 01 June 2020 
 
6.3 
Non-Quantifiable and Missing Concentrations 
If a concentration value is below the lower limit of quantification (<LLOQ), which is 10 ng/mL 
for the ciprofloxacin assay and 100 ng/mL for the doxycycline assay: 
Individual concentration listings in the CSR should list these concentrations as 
 
For the calculation of concentration summaries and plotting mean and individual 
concentration-time profiles, concentration values <LLOQ are treated as zero . 
For purpose of calculating PK parameters, pre-dose concentrations <LLOQ, missing pre-dose 
values (Day 4 Group 1A and Day 2 Group 2A, only), and concentrations prior to the first 
. A value <LLOQ occurring after 
Cmax, that is embedded between two quantifiable points will be treated as missing for PK 
parameter calculation. Values <LLOQ occurring at the end of the collection interval (after the 
ulation of AUC0-12h. 
For calculation of AUC0-inf, trailing zero values are treated as missing by Phoenix WinNonlin. If 
there are more than two consecutive <LLOQ concentrations after Cmax, all concentrations after 
that may be treated as missing after pharmacokineticist review of available documentation (e.g., 
bioanalytical report, validation report). 
For Handling of missing data for AUC0-inf and AUC0-12h calculation is described below in 
Section 6.4. 
6.4 
PK Parameters 
Where possible, the PK parameters in Table 3 for ciprofloxacin and doxycycline will be 
derived from the concentration-time data by non-compartmental techniques using actual elapsed 
time from dosing. If the actual PK sampling time is missing, but a valid concentration value has 
been measured, the scheduled protocol time may be used for the calculation of derived PK 
parameters. 
Any anomalous concentration values observed at predose for single dose PK days will be 
identified in the clinical study report and used for the computation of PK parameters.  
Pharmacokinetic parameters will be computed irrespective to whether the anomalous 
concentration exceeds 5% of the observed maximum concentration (Cmax). If the anomalous 
predose concentration is greater than 5% of Cmax, the PK parameters for the affected subject 
profile will be calculated and reported in the listing but excluded from statistical summaries and 
analyses. Similarly, PK concentrations for the affected profile will be excluded from statistical 
summaries.  
Non-compartmental PK parameter calculations will be performed using Phoenix® WinNonlin® 
8.0 or higher (Certara Company, Princeton, New Jersey, United States) or SAS version 9.4 or 
higher. Graphics may be prepared using the same versions of SAS, or Phoenix WinNonlin, or 
with SigmaPlot 12.5, or higher (Systat Software, Inc., San Jose, California, United States).  


 
 
Confidential and Proprietary 
Page 30 of 43
Version 1.0, 01 June 2020 
 
Table 3 
Ciprofloxacin and Doxycycline PK Parameters 
Variable 
Definition 
Cmax 
Maximum observed serum concentration  
tmax 
Time of maximum observed serum concentration  
t1/2 
Half-life (calculated as ln 2/ Kel) 
Kel 
Apparent elimination rate constant; a minimum of 3 data points in the regression interval will 
be required for determination 
AUC0-12h 
Area under the serum concentration-time curve (12 hours) 
AUMC 
Area under the first moment curve 
AUC0-inf 
Area under the serum concentration-time curve extrapolated to infinity 
MRT 
Mean residence time 
 
The linear-up/log-down trapezoidal summation will be used for calculation of AUC parameters. 
AUC0-inf will only be calculated if Kel can be estimated. If Kel cannot be estimated due to 
missing data or an undetermined terminal phase, AUC0-inf will not be calculated. The reliability 
of estimation of Kel and hence the PK parameters AUC0-inf and t1/2 will be also be evaluated 
using diagnostic parameters (adjusted Rsq, time interval of the log-linear regression to 
determine Kel, percentage of AUC0-inf obtained by extrapolation). If the adjusted Rsq is <0.800, 
then the Kel-related parameters AUC0-inf and t1/2 will only be listed but not included in summary 
statistics. Any exclusions will be documented in the clinical study report.  
AUC0-inf will only be calculated for single-dose serial PK days; for steady-state, only AUC0-12h 
(i.e., AUC0-tau) will be reported.  
For calculation of AUC0-12h, if the t=12h sample is missing or collected outside of the protocol-
specified window of ±15 min, AUC0-12h will be determined to a nominal time point of 12 hours 
using interpolation or extrapolation (if Kel can be estimated; trailing BLQ values are to be set to 
missing in that case). For extrapolation, if Kel cannot be estimated due to missing data or an 
undetermined terminal phase, AUC0-12h will not be calculated. Interpolation will not be 
performed if the subsequent concentration is <LLOQ and AUC0-12h will not be calculated.  
For multiple-dose profiles, if the concentration at time of dosing is missing then the 
concentration will be set to equal the concentration at the end of the dosing interval (assuming 
linear PK and steady-state conditions). For multiple-dose profiles with missing data at the end 
of the dosing interval for which interpolation/extrapolation is not possible, the missing 
concentration will be set to the pre-dose value to allow for calculation of AUC0-12h. 
6.5 
PK Analyses 
All PK analyses will be conducted based on the PK Population. All PK data listings will be 
presented based on the Safety Population. 
PK concentration data will be summarized by study day and nominal time. The trough 
concentrations will be summarized by study day. The summary statistics for concentration data 
will include n, arithmetic mean, SD, median, minimum, maximum, and coefficient of variation 
(CV%). 


 
 
Confidential and Proprietary 
Page 31 of 43
Version 1.0, 01 June 2020 
 
PK parameters in Table 3 will be summarized by study day. Summary of tmax will include n, 
median, minimum, and maximum only. For other PK parameters, n, arithmetic mean, SD, 
median, minimum, maximum, coefficient of variation (CV%), geometric mean, and geometric 
CV% will be presented.  
The CV% is computed as:  
CV% = 100x(SD/Mean).  
The geometric mean is computed as:  
Geometric mean = exp(arithmetic mean of log transformed data). 
The geometric CV% is computed as:  
CV% geometric mean = (sqrt (exp (variance for log transformed data)-1))x100. 
Individual as well as arithmetic mean concentration-time profile plots for serum concentration 
and trough concentrations will be presented in linear and semi-logarithmic scale.  
The scatter plots of individual and geometric mean values for AUC0-12h and Cmax for 
ciprofloxacin and doxycycline will be presented for single dose and steady state profiles. The 
scatter plots of individual and geometric mean values for the ratio of AUC0-12h and Cmax will be 
presented for single dose and steady state profiles. 
6.5.1 Equivalence Testing for Primary PK Endpoints 
For each of the two antibiotics, the goal with the primary PK endpoint is to demonstrate that 
vaccination with AV7909 does not affect the steady-state PK profile. The equivalence testing 
will be constructed using paired two one-sided t-tests (TOST) to provide the point estimate and 
90% CIs for geometric mean of the within-participant ratios of the steady-state values of AUC0-
12h and Cmax post two doses of AV7909 (Day 35 for ciprofloxacin and Day 38 for doxycycline) 
vs. pre-vaccination of AV7909 (Day 8 for ciprofloxacin and doxycycline). The analyses will be 
conducted with natural log transformation of PK parameters. Results obtained from transformed 
analyses will be back-transformed by exponentiation for presentation. To conclude that AV7909 
vaccine has no effect on the steady-state PK of ciprofloxacin or doxycycline, the 90% CIs 
should fall entirely within the equivalence range of [0.80, 1.25] for both AUC0-12h and Cmax.  
6.5.2 Equivalence Testing for Secondary PK Endpoints 
For each antibiotic, the secondary PK analyses will be performed to evaluate the effect of 
vaccination with AV7909 on the single-dose PK profile. The equivalence tests will be 
conducted in the similar statistical manner as the primary analyses. If the 90% CIs for geometric 
mean of the within-participant ratios of the single-dose values of  AUC0- 12h and Cmax post two 
doses of AV7909 (Day 31 for ciprofloxacin and Day 32 for doxycycline) vs. pre-vaccination of 
AV7909 (Day 4 for ciprofloxacin and Day 2 for doxycycline) fall entirely within the 
equivalence range of [0.80, 1.25] for both AUC0-12h and Cmax, it is concluded that AV7909 
vaccine has no effect on the single-dose PK for ciprofloxacin or doxycycline.  


 
 
Confidential and Proprietary 
Page 32 of 43
Version 1.0, 01 June 2020 
 
6.5.3 Time to Steady State Assessment Using Trough Concentrations 
To evaluate time to steady state before and after AV7909 vaccination, the trough levels of 
ciprofloxacin will be analyzed by comparing values on Days 4, 5, 6, 7, and 8 and on Days 31, 
32, 33, 34 and 35; the trough levels of doxycycline will be analyzed by comparing values on 
Days 2, 3, 4, 5, 6, 7, and 8 and on Days 32, 33, 34, 35, 36, 37 and 38.  
Stepwise testing for linear trend, the application of the NOSTASOT (No Statistical Significance 
Of Trend) methodology to trough concentrations proposed by Maganit et al., 2008 involves 
straight line approximations to the aggregate plasma concentration curve over specified time 
intervals; therefore, the null hypothesis is that there is no linear trend, i.e., the slope of the 
regression line equals zero. The alternative is that there is a linear trend (slope not equal to 
zero). The first linear contrast uses the entire range of time points included in the model. If the 
contrast is significantly different from zero at alpha=0.05, a new linear contrast is tested, this 
time excluding the earliest time point. This testing continues, based on contrasts successively 
excluding the next earliest time point from the start of the study, until the contrast is no longer 
significantly different from zero or until only three timepoints remain in the contrast. If the final 
contrast is not statistically significant, then the first timepoint included in that contrast is 
considered to be the time point at which steady state is attained. If the final contrast includes 
three timepoints and is still statistically significant, then steady state is considered not to have 
been attained by the end of the study. 
The repeated measures ANOVA model will be conducted with natural log transformed trough 
level as response and study day as fixed factor. The slope estimates along with the 90% 
confidence intervals for the slope will be presented as results.  
7 
IMMUNOGENICITY ANALYSIS 
All the immunogenicity analyses presented in the tabulations and figures will be performed 
based on the Immunogenicity Population as defined in Section 3.2. The immunogenicity data 
listing will be presented based on the Safety Population.  
Immunogenicity is assessed with TNA NF50. In the tabulations and figure, the non-missing 
TNA NF50 values which are below the LLOQ will be imputed with 0.032, which is ½ the LLOQ 
of the assay (BBRC Study Report 762-G004690). In the data listing, TNA NF50 values which 
are below the LLOQ will be presented in the original values. 
7.1 
Summary of Immunogenicity Data 
The summary of immunogenicity response TNA NF50 at Day 37 and IP group (Group 1, 2, 3, 
and Total) will include: 
Descriptive summaries (n, mean, median, standard deviation, minimum, and 
maximum) of TNA NF50 values 
Geometric mean titer (GMT) and corresponding 95% CIs for TNA NF50  
Subject data listing with TNA assessments at baseline (prior to administration of ciprofloxacin 
or doxycycline on Day 1) and at Day 37 (2 weeks following the final dose of a two-dose 
vaccination series) will be presented.  


 
 
Confidential and Proprietary 
Page 33 of 43
Version 1.0, 01 June 2020 
 
The scatter plot of estimated GMTs and associated 95% CIs for TNA NF50 at Day 37 by 
treatment group will be provided. In addition, scatter plots of estimated GMTs and associated 
95% CIs for TNA NF50 at Day 37 will be presented by each subgroup (age group and sex) in 
each treatment group. 
7.2 
Secondary Immunogenicity Endpoints 
The secondary immunogenicity analysis is aimed to assess whether the immunogenicity of 
AV7909 two weeks following the final dose of a two-dose vaccination series is affected by 
concomitant dosing with oral ciprofloxacin or doxycycline.  
Non-inferiority test will be constructed using the GMT ratio of TNA NF50 (Group 1/Group 3 or 
Group 2/Group 3) between IP group with participants that received both AV7909 and 
ciprofloxacin or doxycycline (Group 1 or 2) and the IP group with participants that received 
AV7909 only (Group 3). Point estimate and the 95% CI for the GMT ratio will be estimated 
using the linear regression based on log 10 transformed TNA NF50 with equal variance. If the 
lower bound of the two-sided 95% CI of geometric mean ratio is greater than the non-inferiority 
margin of 0.5, it is concluded that the immune response in the group who received AV7909 plus 
either ciprofloxacin or doxycycline is non-inferior to the group which received AV7909 alone 
and thus that either ciprofloxacin or doxycycline did not demonstrably affect the 
immunogenicity of AV7909. 
7.2.1 Exploratory Analysis for Immunogenicity  
To evaluate the possible impact of imbalance in sex and age on the immunogenicity endpoints, 
exploratory analyses will be conducted using linear regression to compare the immunogenicity 
response at Day 37 between each AV7909 + antibiotic group and the AV7909 only group, i.e., 
between Group 1 (AV7909 + ciprofloxacin) and Group 3 (AV7909) and between Group 2 
(AV7909 + doxycycline) and Group 3 (AV7909). In the linear regression models, the 
stratification factor, study site, will be included in the model as a random effect; treatment 
group, participant sex and age will be included as fixed factors with age being dichotomized 
into 30 years and >30 years. The adjusted GMT ratio for TNA NF50 will be provided with 95% 
confidence interval. Any differences between the exploratory (adjusted) and the primary 
(unadjusted) analyses will be discussed in the final CSR. 
8 
SAFETY ANALYSIS 
All safety data will be presented in the form of tabulations and listings, based on the Safety 
Population. Data summaries will be tabulated by treatment group as specified in Section 3.2.  
8.1 
Adverse Events 
AEs will be coded to system organ class (SOC) and preferred term (PT) according to the 
Medical Dictionary for Regulatory Activities (MedDRA). A subject data listing of all AEs 
(including treatment-emergent AEs (TEAEs) and non-TEAEs) sorted by treatment group, 
subject ID and AE start date/time will be provided based on the Safety Population. This listing 


 
 
Confidential and Proprietary 
Page 34 of 43
Version 1.0, 01 June 2020 
 
-treatment-
be included in the AE summaries described below.
8.1.1 Overall Summary of TEAEs 
A treatment emergent adverse event (TEAE) is defined as an AE that presents after the initiation 
of treatment or any AEs already present that worsen in either intensity or frequency following 
treatment. For programming purpose, any AEs with start date on or after the date of first 
exposure of any study treatment will be counted as treatment emergent. AEs with missing start 
dates, but with stop dates overlapping into the treatment period will also be counted as treatment 
emergent. 
An overall summary of the following TEAE categories will be provided: 
TEAEs 
TEAEs related to any study treatment 
Grade 3/4 TEAEs 
Grade 3/4 TEAEs related to any study treatment 
Serious TEAEs 
Serious TEAEs related to any study treatment 
TEAEs leading to death 
TEAEs leading to discontinuation of any study treatment 
TEAEs leading to study withdrawal 
AESIs 
AESIs related to study vaccine 
8.1.2 All TEAEs 
All TEAEs will be tabulated by SOC and PT (in descending order of participant incidence in 
Total  column).  
TEAEs with 5% or more for a PT term in any treatment group will be tabulated by SOC and PT.  
All TEAEs will be summarized by SOC, PT, severity, and treatment group. The severity of AEs 
will be assessed by the PI or designee using toxicity grading (Grade 1 to 4) according to 
Protocol EBS.AVA.210, Appendix A. All TEAEs will also be summarized by SOC, PT, 
relationship to study treatment, and treatment group. Participants having the same TEAE more 
than once will be counted once for each PT and once within each SOC at the maximum severity 
and relatedness. If the severity/relatedness is missing for one or more of the occurrences, the 
maximum severity/relatedness of the remaining occurrences will be used. 
TEAE summaries will be provided for TEAEs through the Final Study Visit (Day 51) and for 
all TEAEs through the 12-month follow up , respectively. 


 
 
Confidential and Proprietary 
Page 35 of 43
Version 1.0, 01 June 2020 
 
8.1.3 Drug/Vaccine Related TEAEs 
Adverse event causal relationship to the study treatment will be assessed by the PI or designee 
using terms and scales 
nrelated , 
ossibly related , 
robably related , and 
efinitely 
related . If the relationship between the AE and the study treatment is determined to be 
Possibly
Probably
 Definitely related , the event will be considered as related to the 
IP.  
To assess the causality between AEs and the study treatment ciprofloxacin, doxycycline, and 
AV7909, TEAEs will be tabulated with the structures as follows: 
TEAEs by SOC, PT, and Relationship to Study Vaccine. 
TEAEs by SOC, PT, and Relationship to Antibiotics. 
TEAEs onset prior to the first vaccination by SOC, PT, and relationship to ciprofloxacin 
or Doxycycline. 
8.1.4 Serious TEAEs 
Serious TEAEs will be tabulated using the MedDRA coded terms of SOC and PT by 
relationship to study treatment (ciprofloxacin, doxycycline, AV7909). A subject data listing of 
all serious TEAEs will be provided. 
8.1.5 Adverse Events of Special Interest (AESI) 
Treatment-emergent AESIs determined to be of autoimmune etiology based on decision of the 
DSMB will be tabulated by SOC, PT, and relationship with AV7909. A subject data listing of 
all AESIs will be provided. 
8.1.6 TEAEs Leading to Discontinuation of Study Treatment, and Study Withdrawal 
Separate tabulations will be displayed for TEAEs leading to discontinuation of antibiotic or 
vaccination, and withdrawal from the study. 
8.1.7 Deaths 
A large number of deaths is not expected in this study with healthy participants. A tabulation 
and subject data listing of all deaths will be provided as appropriate. 
8.2 
Clinical Laboratory Tests 
Clinical laboratory results for the lab analytes that appear in Protocol EBS.AVA.210, Table 13 
will be assigned by the central laboratory a toxicity grade (Grade 1=mild through Grade 
4=potentially life-threatening).  
Central laboratory measurements will be tabulated by treatment group as follows: 
Observed values and changes from baseline of continuous laboratory variables 
(hematology, serum chemistry, and selected urinalysis parameters [e.g., specific 


 
 
Confidential and Proprietary 
Page 36 of 43
Version 1.0, 01 June 2020 
 
gravity]) will be summarized using descriptive statistics (n, mean, SD, median, 
minimum, and maximum) by study visit and treatment group.
Observed values of categorical laboratory analytes (e.g., urinary protein) and shifts from 
baseline (number and percentage) will be summarized by study visit and treatment 
group. 
Shift from baseline 
 will be summarized (number and percentage) by study visit and treatment 
group. 
Shift from baseline according to toxicity grading criteria grade (Grade 0, Grade 1-4) will 
be summarized (number and percentages) by study visit for analytes that appear in 
Protocol EBS.AVA.210, Table 13. Grade 0 includes all values within normal range or 
value not meeting criteria for toxicity of at least Grade 1.  
Frequency and percentage of participants with the highest grade of post baseline 
abnormal laboratory values according to toxicity grading criteria grade (Grade 1- 4). 
Post baseline abnormal laboratory results with Grade 3 or higher 
All laboratory records will be provided in the subject data listings. This listing will include all 
test results that are collected throughout the study for the analyte of interest, with all applicable 
severity grades or abnormal flags displayed.  
8.3 
Vital Signs 
Vital sign data will be assigned a toxicity grade (Grade 1=mild through Grade 4=potentially 
life-threatening) according to Protocol EBS.AVA.210, Table 12.  
Vital signs data will be summarized as follows: 
Observed values and changes from baseline by study visit and treatment group. 
Shift from baseline according to toxicity grading criteria grade (Grade 0, Grade 1-4) 
(number and percentages) by study visit and treatment group. Grade 0 includes all 
values not meeting criteria for toxicity of at least Grade 1.  
All vital sign records will be provided in the subject data listings. This listing will include all 
results that are collected throughout the study for the analyte of interest, with all applicable 
severity grades displayed.  
8.4 
Physical Examinations  
Complete and symptom-directed PE findings will be tabulated including number of participants 
with normal/abnormal PE findings by study visit, body system, and treatment groups. Listings 
will be provided. 
8.5 
Prior and Concomitant Medications 
Prior and concomitant medication information will be coded according to the World Health 
Organization
 Data will be tabulated by Anatomical 


 
 
Confidential and Proprietary 
Page 37 of 43
Version 1.0, 01 June 2020 
 
Therapeutic Chemical (ATC) classification level 4, medication preferred term, and treatment 
group. A subject data listing of all medications will be provided.
Prior medications are those used from within 30 days before screening through the start of the 
first study treatment (ciprofloxacin, doxycycline, or AV7909), while concomitant medications 
are those used since the start of the first IP. For purposes of analysis, any medication with a stop 
date between 30 days before date of screening and prior to the start date of the first study 
treatment will be categorized as prior; Any medication which is ongoing or with a stop date that 
is on or after the start date of the first study treatment will be categorized as a concomitant 
medication. Partial dates will be imputed according to Section 4.4. In the tabulation, ATC levels 
and standardized names within each ATC level are sorted in descending order of percentage in 
the Total column. A subject data listing of all medications will be provided. 
8.6 
Other Safety Analyses 
8.6.1 E-diary Reactogenicity 
E-diary reactogenicity data will be summarized with number and percentage of participants with 
the highest severity grade for each symptom of solicited systemic reactions (tiredness, muscle 
ache, headache, and fever) and injection site reactions (warmth, tenderness, itching, pain, arm 
motion limitation, redness, induration, swelling, and bruising) by severity grade and treatment 
group post each vaccination. Severity of fever will be attributed programmatically using oral 
temperature measurement reported in the e-diary according to the grading scale for fever in 
Protocol EBS.AVA.210, Table 12. 
Participant listings of e-diary reactogenicity will be provided for each symptom of systemic and 
injection site reactions. 
8.6.2 In-clinical Reactogenicity 
In-clinical reactogenicity data will be summarized in the similar manner as those for e-diary 
reactogenicity, except for fever (oral temperature) which will be reported and presented as vital 
sign observations at 30 minutes post vaccinations.  
All in-clinical reactogenicity data will be provided in the data listings.  
8.6.3 E-diary Compliance 
The compliance of reactogenicity e-diary will be summarized by vaccination and treatment 
group. Degree of compliance for a participant and vaccination will be calculated based on the 
expected total number of diary days, including extra days if there was an ongoing reaction, 
times the number of questions per day. The subject-level compliance percentage will be 
calculated for each vaccination, and then summarized with the following categories: Did not 
enter any diary, < 50%, 50-75%, and >75%. 
Participants in Groups 1 and 2 are required to complete antibiotic e-diary entries to record the 
time of their antibiotic self-administrations. The compliance of antibiotic e-diary will be 
calculated for each course and overall based on the dosing schedule of self-administered 


 
 
Confidential and Proprietary 
Page 38 of 43
Version 1.0, 01 June 2020 
 
ciprofloxacin and doxycycline as specified in Figure 2. The compliance will be summarized 
with the following categories: Did not enter any diary, < 50%, 50-75%, and >75%.
8.6.4 Auto-antibody Testing 
Samples taken for testing for RF, ANA and anti-dsDNA antibodies and TSH assessment will be 
held and only be tested if medically indicated (e.g., in the event of a reported potential AESI). 
All test results will be provided in the data listings. 
8.6.5 Pregnancy 
Participant listing of FSH, and pregnancy test results (serum and urine) will be provided.  
8.6.6 Urine Drug Screening and Viral Serology Testing  
Urine drug screening and viral serology testing results will be provided in the participant listing.  
9 
INTERIM ANALYSES 
No interim analysis is planned for the study. 
10 FINAL ANALYSIS PLAN 
A Statistical Analysis Plan (SAP) will be finalized prior to clinical database lock [to include 
data 
-clinic visit (Day 51; ie, four weeks after second 
vaccination)]. Clinical Study Report (CSR) will be generated with data up to and including last 
-clinic visit (Day 51). All data after Day 51 (i.e., data up to and including last 
-month safety follow up telephone call) will be included as an addendum to the 
CSR.   
11 REFERENCES 
1.
CBER, Center for Biologics Evaluation and Research [Internet]. Guidance for Industry: 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials. September 2007. Accessed 19 Jun 2018: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977. 
2.
Maganti, L., Panebianco, D., Maes, A. Evaluation of Methods for Estimating Time to 
Steady State with Examples from Phase 1 Studies. The AAPS Journal. March 2008, 
Volume 10, Issue 1, pp 141 147. 
3.
Marcus, R., Peritz, E., Gabriel, K.R. On Closed Testing Procedures with Special Reference 
to Ordered Analysis of Variance. Biometrika (1976), 63, 3, pp. 655-60. 
4.
BBRC Study 762-
Neutralization Assay (htpTNA) Conducted in Conjunction with Validation Protocol 
VP2007-
 


 
 
Confidential and Proprietary 
Page 39 of 43
Version 1.0, 01 June 2020 
 
5.
Emergent global standard operating procedure, Production and Control of Statistical 
Analysis Plan (SAP) and SAP Amendments. SOP003107, version 3.0, effective on 02 Feb 
2017. 
6.
Emergent global standard operating procedure, Statistical Oversight of Clinical Studies. 
SOP041684, version 2.0, effective on 18 Sep 2018. 
7.
Emergent global standard operating procedure, Database Lock. SOP002988, version 3.0, 
effective on 12 Jun 2017. 
8.
Emergent global standard operating procedure, Production of Tables, Listings and Figures 
for Clinical Study Reports and Regulatory Submissions. SOP041908, version 0.3, Ready 
for Approval. 
9.
IQVIA Operating Procedure, Statistical Principles. CS_OP_BS001 Revision 11, effective 
on 15 Mar 2018. 
10.
IQVIA Operating Procedure, Ensuring Quality in Biostatistical Deliverables. 
CS_OP_BS0216 Revision 2, effective on 1 Aug 2016. 
 
 


 
 
Confidential and Proprietary 
Page 40 of 43
Version 1.0, 01 June 2020 
 
12 APPENDICES 
APPENDIX I 
TABLE/LISTING/FIGURE TEMPLATE GUIDANCE 
Convention for All Outputs 
Unless otherwise specified, all computer-generated table/listing/figure (TLF) outputs 
should be produced in landscape mode. Required margins: 1inches on top and 
bottom and 1 inch on the left and right; required font: Courier New; and required 
font size: 8, at the minimal.  
Single line space is the standard for all TLFs.  
All output should have the following header at the top of the page: 
            
 < left adjusted>            Page x of y < right adjusted> 
            Protocol EBS.AVA.210 < left adjusted> 
TLFs should be internally paginated in relation to total length (i.e., page number 
should appear sequentially as page x of y, where y is the total number of pages in 
each table, listing, and figure). 
Each output should be identified by a numeral, and the output designation (e.g., 
Table 1) should be listed on the same line, before the title. A decimal system (x.y 
and x.y.z) should be used to identify tables and listings with related contents. The 
title is centered in initial capital characters.  
Table <Table No> Table Title 
(Study Population) 
The study population should be identified immediately following the title. Insert a 
blank line after the last title and before the body of the TLF content. 
Footnotes should be single spaced but separated by at least a double space from the 
bottom line of the table. The notes are aligned vertically by the left vertical border of 
the table. Footnote should be ordered as follows, if appropriate: 
Footnote 1: source listing and/or Dictionary version, if needed 
Footnote 2: treatment group(s)  
Footnote 3: abbreviation footnotes (if needed): Separated by semi-colon, ended 
 
Add other notes if needed 
Last footnote: output name, programme name, TLF version, production 
date/time. Insert a blank line before the last footnote. 
Column headings should be in initial upper-case characters. For numeric variables, 
 
For the text within the table body and not directly from the data, only capitalize the 
first letter of the first word as in a sentence, and do not capitalize the first letter of 
each word. 


 
 
Confidential and Proprietary 
Page 41 of 43
Version 1.0, 01 June 2020 
 
Table Convention 
Decimal Places for numeric results:  
For numeric value, display mean, median, STD, minimum, and maximum the 
same decimal places as reported value. 
For TNA NF50, display mean, median, STD, minimum, and maximum with one 
decimal point or two significant digits (e.g., min 0.032 max 18.0).  
Geometric mean ratio will be formatted with two decimal places. 
Unless otherwise specified, CIs are two-sided with 95% confidence.  
 For numerical variable data summary, align decimal point of each statistics across 
 
 
 
 
 
 
For categorical variables, the number and percentage of responses will be presented 
in the form XX (XX.X), where the percentage is in the parentheses. Percentages will 
be calculated using a denominator of all participants in a specified analysis 
population (and present at the analyzed visit in by-visit summaries). The 
denominator will be specified in a footnote to the tables for clarification where 
necessary. All percentages will be rounded to one decimal place. Unless otherwise 
s
participants in that group, and all percentages below will be based on this number. 
Align count (integer) and first parenthesis across each row. Align decimal place of 
percentages, with the exception of 100% (no decimal) and zero frequencies (present 
as 0, no percentage). 
 
 
 
 
 
 
Each level of indentation within a table takes a space of 2 characters. 
 
 
 
 
Group 1 
Group 2 
Group 3 
 
(N=xxx) 
(N=xxx) 
(N=xxx) 
 
 
 
 
Parameter 1 
 
 
 
  n 
     xx 
     xx 
     xx 
  Mean  
     xx.x 
     xx.x 
     xx.x 
  SD 
     xx.x 
     xx.x 
     xx.x 
  Median 
     xx.x 
     xx.x 
     xx.x 
  Min, Max 
   xx.x, xx.x 
   xx.x, xx.x 
   xx.x, xx.x 
Group 1 
Group 2 
Group 3 
(N=xxx) 
(N=xxx) 
(N=xxx) 
n (%)  
n (%) 
n (%) 
 
 
 
 
 
 
   xx (100) 
   xx (100) 
   xx (100) 
    0 
   xx ( xx.x) 
    x (  x.x) 
   xx ( xx.x) 
    0 
   xx ( xx.x) 
   xx (  x.x) 
    x (  x.x) 
   xx ( xx.x) 
    x (  x.x) 
    x (  x.x) 
    0 


 
 
Confidential and Proprietary 
Page 42 of 43
Version 1.0, 01 June 2020 
 
Listing Convention 
Listings should be sorted by treatment group and subject numbers. 
In a listing, the subject number should be displayed only once for the subject with 
number once for every page. 
Missing data should be represented on subject lis
-
- 
 
Missing portions of dates should be represented on subject listings as dashes (--
JUL2000). Dates that are missing because they are not applicable for the subject are 
 
 17:30). Missing 
portions of time should be represented on subject listings as dashes (--:30). Times 
unless otherwise specified. 
a. Graphic Convention 
Each container document will be in MS Word format. 
 Graphic object output will be in <PDF, CGM, WMF, EPS, or EMF > format. 
Same plot produced for each treatment group will have same axis ranges.  
Define line and symbol types as below: 
 
 


 
 
Confidential and Proprietary 
Page 43 of 43
Version 1.0, 01 June 2020 
 
Table I:1 
Line and Symbol Types in Graph 
 
 
 
Attribute 
Parameter 
Value/Line 
Line 
< Treatment group 1 > 
Line Type = 1 
 
< Treatment group 2 > 
Line Type = 2 
 
< Treatment group 3 > 
Line Type = 3 
 
< Treatment group 4> 
Line Type = 4 
Symbol 
< Treatment group 1 > 
Symbol = circle 
 
< Treatment group 2 > 
Symbol = triangle 
 
< Treatment group 3 > 
Symbol = square 
 
< Treatment group 4 > 
Symbol = empty circle